```
=> d his

     (FILE 'HOME' ENTERED AT 14:18:59 ON 09 JAN 2006)

     FILE 'REGISTRY' ENTERED AT 14:19:08 ON 09 JAN 2006
L1             STRUCTURE UPLOADED
L2              50 S L1
L3            9180 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 14:20:12 ON 09 JAN 2006
L4             490 S L3
L5             366 S L4 AND PY<2003
L6               0 S L5 AND (NITRIC OXIDE)
L7             211 S L5 AND PATENT/DT

=> d que l7 stat
L1             STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L3            9180 SEA FILE=REGISTRY SSS FUL L1
L4             490 SEA FILE=CAPLUS ABB=ON  PLU=ON  L3
L5             366 SEA FILE=CAPLUS ABB=ON  PLU=ON  L4 AND PY<2003
L7             211 SEA FILE=CAPLUS ABB=ON  PLU=ON  L5 AND PATENT/DT


=> d 1-211 bib abs hitstr
```

L7 ANSWER 1 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:533982 CAPLUS
DN 141:89085
TI Preparation of indazole derivatives as JNK enzyme inhibitors
IN Bhagwat, Shripad S.; Satoh, Yoshitaka; Sakata, Steven T.; Buhr, Chris A.; Albers, Ronald; Sapienza, John; Plantevin, Veronique; Chao, Qi; Sahasrabudhe, Kiran; Ferri, Rachel
PA USA
SO U.S. Pat. Appl. Publ., 275 pp., Cont.-in-part of U.S. Ser. No. 910,950.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004127536	A1	20040701	US 2003-414839	20030416
	US 2002103229	A1	20020801	US 2001-910950	20010723
<--					
	US 6897231	B2	20050524		
	US 2004077877	A1	20040422	US 2003-673121	20030926
	US 2005009876	A1	20050113	US 2003-718185	20031119
	CA 2522682	AA	20041104	CA 2004-2522682	20040416
	WO 2004094388	A2	20041104	WO 2004-US11958	20040416
	WO 2004094388	A3	20041209		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005107457	A1	20050519	US 2004-462	20041130
PRAI	US 2000-221799P	P	20000731		
	US 2001-910950	A2	20010723		
	US 2003-414839	A2	20030416		
	WO 2004-US11958	W	20040416		

OS MARPAT 141:89085
GI



I

AB Indazole derivs. I [A = a bond, (CH2)a, (CH2)bCH:CH(CH2)c, (CH2)bC.tplbond.C(CH2)c; R1 = (un)substituted aryl, heteroaryl or heterocycle fused to Ph; R2 = R3, R4, (CH2)bC(O)R5, (CH2)bC(:O)OR5, (CH2)bC(O)NR5R6, (CH2)bC(O)NR5(CH2)cC(O)R6, (CH2)bNR5C(O)R6,

L7 ANSWER 1 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(CH2)bNR5C(O)NR6R7, (CH2)bNR5R6, (CH2)bOR5, (CH2)bSOdR5 or (CH2)bSO2NR5R6;
a = 1-6; b, c = 0-4; d = 0-2; R3 = halo, OH, CO2H, carboxy, etc.; R4 = (un)substituted alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, or R4 = halo or OH; R5-R7 = H, (un)substituted alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl; with the provisos] having activity as selective inhibitors of JNK, are disclosed. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. contg. one or more compds. of the above compds. Many of the claimed compds. have IC50 values ≤0.5 μM in the JNK2 assay, e.g. 5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole. Although the methods of prepn. are not claimed, >400 example prepns. are included.
IT 716321-40-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indazole derivs. as JNK enzyme inhibitors)
RN 716321-40-3 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)



L7 ANSWER 2 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:551181 CAPLUS
DN 139:117339
TI Preparation of substituted arylamine derivatives as antitumor agents
IN Elbaum, Daniel; Askew, Benny; Booker, Shon; Germain, Julie; Habgood, Gregory; Handley, Michael; Kim, Tae-Seong; Li, Aiwen; Nishimura, Nobuko; Patel, Vinod F.; Yuan, Chester Chenguang; Kim, Joseph L.
PA Amgen Inc., USA
SO U.S. Pat. Appl. Publ., 106 pp., Cont.-in-part of U.S. Ser. No. 46,526.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003134836	A1	20030717	US 2002-197960	20020717
	US 2002147198	A1	20021010	US 2002-46526	20020110
<--					
	CA 2492164	AA	20040122	CA 2003-2492164	20030715
	WO 2004007457	A2	20040122	WO 2003-US22276	20030715
	WO 2004007457	A3	20050804		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1583744	A2	20051012	EP 2003-764756	20030715
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2004204437	A1	20041014	US 2004-823809	20040412
	US 2005153960	A1	20050714	US 2004-996035	20041122
PRAI	US 2001-261360P	P	20010112		
	US 2001-323686P	P	20010919		
	US 2002-46526	A2	20020110		
	US 2002-197960	A	20020717		
	WO 2003-US22276	W	20030715		
	US 2004-823809	A1	20040412		

OS MARPAT 139:117339
GI

L7 ANSWER 2 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I II

AB The title compds. I [R2 = (un)substituted Ph, 9-10 membered bicyclic and 11-14 membered tricyclic (un)saturated heterocyclyl; R8 = halo, NH2, NO2, etc.], and their pharmaceutically acceptable derivs., are prepared and disclosed as agents effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. E.g., a multi-step synthesis of II, starting from 1-dimethylamino-2-propyne and 3-bromo-5-trifluoromethylaniline, was given. Selected compds. of the invention, e.g., II, inhibited VEGF-stimulated cell proliferation at a level below 50 nM. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.
IT 442846-39-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of substituted aminopyridines as antitumor agents)
RN 442846-39-1 CAPLUS
CN 3-Pyridinecarboxamide, N-2-benzothiazolyl-2-[[[3-(hydroxymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



L7 ANSWER 2 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L7 ANSWER 3 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
347170-88-1P 347171-92-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted 1-cyclohexyl-2-phenylbenzimidazole-5-carboxylic acids as remedies for hepatitis C)
RN 347169-99-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(2-benzothiazolylamino)carbonyl] phenyl]-1-cyclopentyl- (9CI) (CA INDEX NAME)



RN 347170-23-4 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[3-[(2-benzothiazolylamino)carbonyl] phenyl]-1-cyclopentyl- (9CI) (CA INDEX NAME)



RN 347170-74-5 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[(4-chloro-2-benzothiazolyl)amino]carbonyl]phenyl]-1-cyclopentyl- (9CI) (CA INDEX NAME)



RN 347170-88-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(2-benzothiazolylamino)carbonyl]

L7 ANSWER 3 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:203407 CAPLUS
DN 138:238181
TI Preparation of substituted 1-cyclohexyl-2-phenylbenzimidazole-5-carboxylic acids as remedies for hepatitis C
IN Hashimoto, Hiromasa; Mizutani, Kenji; Yoshida, Atsuhito
PA Japan Tobacco Inc., Japan
SO U.S. Pat. Appl. Publ., 406 pp., Cont.-in-part of Appl. No. PCT/JP00/09181.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003050320	A1	20030313	US 2001-939374	20010824
	US 6770666	B2	20040803		
	WO 2001047883	A1	20010705	WO 2000-JP9181	20001222

<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	JP 2001247550	A2	20010911	JP 2000-391904	20001225

<--

	ZA 2003001393	A	20040715	ZA 2003-1393	20020626
	US 2004097438	A1	20040520	US 2003-615329	20030708
PRAI	JP 1999-369008	A	19991227		
	WO 2000-JP9181	A2	20001222		
	JP 2000-391904	A	20001225		
	JP 2001-193786	A	20010626		
	US 2001-939374	A3	20010824		

OS MARPAT 138:238181
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [the dotted line in rings B1 and B2 indicates a single or double bond; G1 = N, CR1; G2 = N, CR2, G3 = N, CR3; G4 = N, CR4; G5, G6, G8, G9 = C, N; G7 = O, S, CR7, etc.; R1-R4 = H, NO2, etc.; ring Cy = (un)substituted cycloalkyl ring, etc.; ring A = Ph, cycloalkyl, etc. R5, R6 = H, halo, etc.; X = H, CN, etc.; R7 = H, alkyl] are prepared and formulated. Compds. I showed HCV polymerase inhibitory activity (data given). E.g., a multi-step synthesis of II.HCl, starting from 2-bromo-5-nitrotoluene and Me 2-(2-fluoro-4-hydroxyphenyl)-1-cyclohexylbenzimidazole-5-carboxylate, was given.
IT 347169-99-7P 347170-23-4P 347170-74-5P

L7 ANSWER 3 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
phenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)



RN 347171-92-0 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[3-[(2-benzothiazolylamino)carbonyl] phenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:947029 CAPLUS
DN 138:24705
TI Preparation of spiroisoindolinepiperidinecarboxamides, spirocyclohexaneisobenzofurancarboxamides, spiroazaisobenzofurancyclohexanecarboxamides, and related compounds as neuropeptide Y antagonists.
IN Fukami, Takehiro; Kanatani, Akio; Ishihara, Akane; Ishii, Yasuyuki; Takahashi, Toshiyuki; Haga, Yuji; Sakamoto, Toshihiro; Itoh, Takahiro
PA Banyu Pharmaceutical Co., Ltd., Japan
SO U.S. Pat. Appl. Publ., 53 pp., Cont.-in-part of U.S. Pat. Appl. 2002 52,371.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002188124	A1	20021212	US 2002-92549	20020308
<--					
	US 6803372	B2	20041012		
	US 6326375	B1	20011204	US 2000-640784	20000818
<--					
	US 6335345	B1	20020101	US 2001-928431	20010814
<--					
	US 2002052371	A1	20020502	US 2001-983598	20011025
<--					
	US 6388077	B2	20020514		
	ZA 2002000734	A	20030128	ZA 2002-734	20020128
	US 6462053	B2	20021008	US 2002-101221	20020320
<--					
	US 2002165391	A1	20021107		
	US 2003055251	A1	20030320	US 2002-226225	20020823
	US 6649624	B2	20031118		
	JP 2003104884	A2	20030409	JP 2002-271261	20020918
	JP 3553560	B2	20040811		
	CA 2482191	AA	20030918	CA 2003-2482191	20030305
	WO 2003076443	A1	20030918	WO 2003-JP2611	20030305
	WO 2003076443	C2	20050120		
	W: AE, AG, AL, AM, AU, AZ, BA, BB, BR, BY, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GH, HR, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, RU, SC, SG, TJ, TM, TN, TT, UA, US, UZ, VC, VN, YU, ZA				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1483266	A1	20041208	EP 2003-710252	20030305
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005519955	T2	20050707	JP 2003-574660	20030305
	US 2003220499	A1	20031127	US 2003-453737	20030604
	US 6723847	B2	20040420		
	US 2005032820	A1	20050210	US 2004-922869	20040823
PRAI	JP 1999-233573	A	19990820		
	JP 2000-137692	A	20000510		
	US 2000-640784	A3	20000818		

L7 ANSWER 4 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

	US 2001-983598	A2	20011025	
	JP 2000-247145	A3	20000817	
	US 2002-92549	A	20020308	
	US 2002-101221	A3	20020320	
	US 2002-226225	A3	20020823	
	WO 2003-JP2611	W	20030305	

OS MARPAT 138:24705
GI



AB Title compds. [I; Ar1 = (substituted) aryl, heteroaryl, QAr2; Ar2 = (substituted) aryl, heteroaryl; Q = bond, CO; T, U, V, W = N, (substituted) CH; X = CH, CH(OH); Y = (substituted) imino, O], were prepared
Thus, N-tert-butoxycarbonyl-4-piperidone was refluxed 3 h with PhCH2NH2 in
PhMe to give a residue which was stirred with o-iodobenzoyl chloride and Et3N in PhMe at 80° for 2 h to give N-benzyl-N-(1-tert-butoxycarbonyl-1,2,3,6-tetrahydropyridin-4-yl)-2-iodobenzamide. The latter was heated with Pd(OAc)2, Ph3P, K2CO3, and Et4NCl in MeCN at 80° for 6 h to give 2-benzyl-1'-tert-butoxycarbonyl-1',6'-dihydrospiro[1H-isoindole-1,4'(5'H)-pyridine]-3(2H)-one. This was converted to N-(4-benzoylphenyl)-3-oxospiro[isoindoline-1,4'-piperidine]-1'-carboxamide (II), which inhibited [125I]neuropeptide Y binding to NPY Y5 receptors with IC50 = 1.2 nM. II drug formulations are given.
IT 478014-43-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of spiroisoindolinepiperidinecarboxamides, spirocyclohexaneisobenzofurancarboxamides, spiroazaisobenzofurancyclohexanecarboxamides, and related compds. as neuropeptide Y antagonists)
RN 478014-43-6 CAPLUS
CN Spiro[isoquinoline-1(2H),4'-piperidine]-1'-carboxamide, 3,4-dihydro-N-(4-methyl-2-benzothiazolyl)-3-oxo- (9CI) (CA INDEX NAME)

L7 ANSWER 5 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:900736 CAPLUS
DN 138:4612
TI Preparation of 2-heterocyclyl-4-aminopyrimidine-5-carboxamide and 5-heterocyclyl-3-aminopyrazine-2-carboxamide derivatives as selective inhibitors of phosphodiesterase IV
IN Yamada, Koichiro; Matsumoto, Kenji; Omori, Kenji; Yoshikawa, Kohei
PA Tanabe Seiyaku Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 53 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2002338466	A2	20021127	JP 2002-61580	20020307
<--					
PRAI	JP 2001-73385	A	20010315		

OS MARPAT 138:4612
GI



AB Disclosed is a pharmaceutical composition containing the title compound [I; the ring
A = (un)substituted N-containing heterocyclyl; R1 = (un)substituted lower alkyl, NH-Q-R3, NH-R4; wherein R3 = (un)substituted N-containing heterocyclyl;
Q = a single bond, lower alkylene; R4 = (un)substituted cycloalkyl; R2 = (un)substituted aryl; one of Y and Z is CH and the other is N] or pharmacol. acceptable salt thereof as the active ingredient for the prevention and/or treatment of impotence, pulmonary hypertension, or diabetic stomach failure or paralysis. Thus, a solution of 2.057 g 2-methylthio-4-(3-chloro-4-methoxybenzylamino)-5-formylpyrimidine was treated with 1.468 g m-chloroperbenzoic acid (80%) at 0° for 30 min, followed by successively adding 0.901 g L-prolinol and 1.33 mL Et3N, and the resulting mixture was allowed to react at 0° for 1 h to give 2.00 g (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-formylpyrimidine (II). A solution of 91.0 mg II in 20
mL THF was reacted with 1.1 mL 1.10 M MeLi/Et2O at -78° for 10 min to give, after treatment with aqueous NaHCO3 and extraction with EtOAc, an EtOAc
solution of crude (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-(1-hydroxyethyl)pyrimidine which was stirred with 0.5 g MnO2 at room temperature overnight and then at refluxing temperature for 5 h to
give (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-acetylpyrimidine (III). III and inhibitors N-(2-pyridylmethyl)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine-5-carboxamide showed IC50 of 5.18 and 0.0859

L7 ANSWER 5 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
μM, resp., against PDE IV isolated from a dog lung. III in vitro exhibited the relaxant activity on rabbit corpus cavernosum with ED50 of 1
nM.
IT **330785-26-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclylaminopyrimidinecarboxamide and heterocyclylaminopyrazinecarboxamide derivs. as selective inhibitors of
phosphodiesterase IV for prevention and/or treatment of diseases)
RN 330785-26-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-[[[3-chloro-4-methoxyphenyl]methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(6-methoxy-2-benzothiazolyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 6 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:849613 CAPLUS
DN 137:353066
TI Preparation of nitrogenous fused-ring compound having pyrazolyl group as substituents as inhibitors of activation of signal transduction and activation of transcription (STAT6) protein
IN Yoshida, Ichiro; Yoneda, Naoki; Ohashi, Yoshiaki; Suzuki, Shuichi; Miyamoto, Mitsuaki; Miyazaki, Futoshi; Seshimo, Hidenori; Kamata, Junichi;
Takase, Yasutaka; Shirato, Manabu; Shimokubo, Daiya; Sakuma, Yoshinori; Yokohama, Hiromitsu
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 1006 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002088107	A1	20021107	WO 2002-JP4156	20020425

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1382603	A1	20040121	EP 2002-722791	20020425

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRAI JP 2001-129959	A	20010426	
WO 2002-JP4156	W	20020425	

OS MARPAT 137:353066
GI



I

AB The 4-(N-containing fused aromatic heterocyclyl)pyrazoles (I) or salts thereof,
or hydrates of either {X = a nitrogenous fused aromatic heterocyclic group,

L7 ANSWER 6 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
e.g., imidazo[1,2-a]pyridine, having (R4)n as a substituent; wherein n = an integer of 0-3; R4 = H, halo, cyano, OH, NH2, C1-6 alkyl, halo-C1-6 alkyl, C2-6 alkenyl, C1-6 alkylsulfonyl, C1-6 alkylsulfonylamino, C1-6 alkylsulfinyl, N-mono, or N,N-di(C1-6 alkyl)amino, C1-6 alkoxy, C1-6 alkylsulfanyl, CONH2, etc.; Y = C3-8 cycloalkyl, C4-8 cycloalkenyl, 5- to 14-membered nonarom. or arom. heterocyclyl, C6-14 arom. hydrocarbyl, benzene- or 5- or 6-membered arom. heterocycle-fused 5- to 7-membered nonarom. ring group; Z = H, NH2, halo, HO, NO2, cyano, N3, CHO, HONH, SO2NH2, guanidino, oxo, C2-6 alkenyl, C1-6 alkoxy, etc.; R1 = H, halo, HO,
NO2, cyano, halo-C1-6 alkyl, hydroxy- or cyano-C1-6 alkyl, C2-6 alkenyl, etc.; R2 = H, pyrazolyl; R3 = H, halo, cyano, NH2, C1-4 alkyl, halo-C1-4 alkyl] are prepd. These compds. are inhibitors of STAT6 protein activation and IL-4 and/or IL-13 signal transduction and are useful for prevention and/or treatment of diseases on which the inhibition of STAT6 activation and/or IL-4 and/or IL-13 signal transduction is effective. The
diseases include allergy, allergic rhinitis, bronchial asthma, atopic dermatitis, pollinosis, digestive tract allergy, urticaria, hypersensitivity pneumonia, lung aspergillosis, eosinophil leukemia, parasite infection, eosinophilia, eosinophil pneumonia, eosinophil gastroenteritis, autoimmune disease, systemic lupus erythematosus, virus infection, bacteria infection, obesity, overeating (hyperphagia), malignant tumor, and acquired immunodeficiency syndrome (AIDS). Thus, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile was coupled with 6-[3-(4-fluorophenyl)-1-trityl-1H-pyrazolyl]-3-iodoimidazo[1,2-a]pyridine in the presence of tetrakis(triphenylphosphine)palladium and K3PO4 in DMF at 75° for 3 h followed by treating a soln. of the coupling product in THF and MeOH with 5 N aq. HCl to give 4-[6-[3-(4-fluorophenyl)-1H-4-pyrazolyl]imidazo[1,2-a]pyridin-3-yl]benzonitrile dihydrochloride (II). II showed IC50 of <10 nM for inhibiting the IL-4-induced induction of alkali phosphatase in human embryonic kidney cell transfected with STAT gene and STAT reporter gene.
IT **474700-88-4P 474701-11-6P 474701-12-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (N-containing heterocyclyl)pyrazole as inhibitors of activation
of STAT6 protein and/or IL-4 and/or IL-13 signal transduction as preventives and/or remedies of diseases)
RN 474700-88-4 CAPLUS
CN Benzamide, 2-fluoro-4-[6-(3-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl]-N-[6-(methylsulfonyl)-2-benzothiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L7 ANSWER 6 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 474701-11-6 CAPLUS
CN Benzamide, 2-fluoro-N-(6-fluoro-2-benzothiazolyl)-4-[6-(1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 474701-12-7 CAPLUS
CN Benzamide, 2-fluoro-4-[6-(1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl]-N-[6-(trifluoromethoxy)-2-benzothiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

IT **474699-25-7P 474699-26-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (N-containing heterocyclyl)pyrazole as inhibitors of activation
of STAT6 protein and/or IL-4 and/or IL-13 signal transduction as preventives and/or remedies of diseases)
RN 474699-25-7 CAPLUS
CN Benzamide, 2-fluoro-N-(6-fluoro-2-benzothiazolyl)-4-[6-[1-(triphenylmethyl)-1H-pyrazol-4-yl]imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 474699-26-8 CAPLUS
CN Benzamide, 2-fluoro-N-[6-(trifluoromethoxy)-2-benzothiazolyl]-4-[6-[1-

L7 ANSWER 6 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(triphenylmethyl)-1H-pyrazol-4-yl]imidazo[1,2-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:849446 CAPLUS
DN 137:370100
TI Preparation of pyridopyrimidine derivatives as inhibitors of drug efflux pump of microorganisms
IN Nakayama, Kiyoshi; Ohtsuka, Masami; Kawato, Haruko; Okumura, Ryo; Hoshino,
Kazuki; Watkins, William; Zhang, Jason; Palme, Monica; Cho, Aesop
PA Daiichi Pharmaceutical Co., Ltd., Japan; Essential Therapeutics, Inc.
SO PCT Int. Appl., 545 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002087589	A1	20021107	WO 2002-JP4087	20020424
<--					
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003092720	A1	20030515	US 2001-842234	20010426
	CA 2445697	AA	20021107	CA 2002-2445697	20020424
<--					
	EP 1389463	A1	20040218	EP 2002-722752	20020424
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2005009843	A1	20050113	US 2004-475091	20040628
PRAI	US 2001-842234	A	20010426		
	JP 2002-33133	A	20020208		
	WO 2002-JP4087	W	20020424		

OS MARPAT 137:370100
GI



AB The title compds. I [R1 and R2 each represent hydrogen, a halogen atom, a hydroxyl group or the like; W1 represents CH:CH, CH2O, CH2CH2 or the like;
R3 represents hydrogen, a halogen atom, a hydroxyl group or an amino

L7 ANSWER 7 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
group; R4 represents hydrogen, OZ0-4R5 (where Z0-4 represents an alkylene group or a fluorine-substituted alkylene group or a single bond and R5 represents a cyclic alkyl group, an aryl group or the like) or the like; W2 represents a single bond or C(R8):C(R9) (where R8 and R9 each represent
hydrogen, a halogen atom, a lower alkyl group or the like) and Q represents an acidic group; a proviso is given} are prepd. A method for screening inhibitors of drug efflux pump of microorganisms is disclosed. Compds. of this invention in vitro enhanced the antibacterial activity of levofloxacin against P. aeruginosa PAM 1723.
IT 475057-21-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridopyrimidine derivs. as inhibitors of drug efflux pump
of microorganisms)
RN 475057-21-7 CAPLUS
CN 4H-Pyrido[1,2-a]pyrimidine-8-carboxamide, N-2-benzothiazolyl-4-oxo-3-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:814117 CAPLUS
DN 137:325410
TI Broad-spectrum 2-(substituted-amino)-benzothiazolesulfonamide HIV protease
inhibitors
IN Surleraux, Dominique Louis Nestor Ghislain; Wigerinck, Piet Tom Bert Paul;
Getman, Daniel; Verschueren, Wim Gaston; Vendeville, Sandrine; De Bethune,
Marie-Pierre; De Kerpel, Jan Octaaf Antoon; Moors, Samuel Leo Christiaan;
De Kock, Herman Augustinus; Voets, Marieke Christiane Johanna
PA Tibotec Pharmaceuticals Ltd., Ire.
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002083657	A2	20021024	WO 2002-EP1788	20020214
<--					
	WO 2002083657	A3	20030213		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2438304	AA	20021024	CA 2002-2438304	20020214
<--					
	EE 200300381	A	20031215	EE 2003-381	20020214
	EP 1370543	A2	20031217	EP 2002-729930	20020214
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002007862	A	20040622	BR 2002-7862	20020214
	JP 2004518767	T2	20040624	JP 2002-581413	20020214
	CN 1525962	A	20040901	CN 2002-804982	20020214
	NZ 527391	A	20050429	NZ 2002-527391	20020214
	ZA 2003006086	A	20041108	ZA 2003-6086	20030806
	US 2004116485	A1	20040617	US 2003-467609	20030807
	NO 2003003584	A	20031014	NO 2003-3584	20030813
	BG 108143	A	20040730	BG 2003-108143	20030901
PRAI	EP 2001-200529	A	20010214		
	US 2001-287758P	P	20010502		
	WO 2002-EP1788	W	20020214		

OS MARPAT 137:325410
GI

L7 ANSWER 8 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Title compds. I [R1, R8 = H, (un)substituted alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heterocyclylalkyl; R2 = H, alkyl; L = CO, O2C, (un)substituted NHCO, oxoalkylcarbonyl, aminoalkylcarbonyl, SO2, O3S, NHSO2; R3 = alkyl, aryl, cycloalkyl, cycloalkylalkyl, aralkyl; R4 = H, alkoxycarbonyl, carboxy, (un)substituted CONH2, cycloalkyl, alkenyl, alkynyl (un)substituted alkyl; A = alkanediyl, CO, CS, SO2, oxoalkanediyl, thioalkanediyl, alkanediylsulfonyl; R5 = H, OH, alkyl, heterocyclylalkyl, (un)substituted aminoalkyl; R6 = alkoxy, heterocyclyl, heterocycloxy, aryl, aryloxy, alkoxycarbonylamino, amino; and when A is other than alkanediyl then R6 may also be alkyl, heterocyclylalkyl, heterocycloxyalkyl, aralkyl, aryloxyalkyl, (un)substituted aminoalkyl; R5NAR6 = heterocyclic] their N-oxides, salts, stereoisomeric forms, racemic mixts., prodrugs, esters and metabolites were prepared I are useful as broad-spectrum HIV protease inhibitors, and may be formulated in diagnostic kits.. Thus, the sulfonamide II, prepared in several steps from the benzothiazolecarbamate, showed activity against a number of resistant mutants of HIV-1 strain LAI.

IT 473737-87-0P 473738-16-8P 473738-17-9P
473738-18-0P 473738-19-1P 473738-21-5P
473738-22-6P 473738-30-6P 473738-32-8P
473738-33-9P 473738-46-4P 473738-51-1P
473738-74-8P 473738-77-1P 473738-78-2P
473738-79-3P 473738-81-7P 473738-83-9P
473738-85-1P 473738-89-5P 473738-94-2P
473738-96-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(broad-spectrum 2-aminobenzothiazolesulfonamide HIV protease inhibitors)

L7 ANSWER 8 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 473737-87-0 CAPLUS
CN Benzamide, 3-fluoro-N-[(1S,2R)-3-[[[2-[(3-fluoro-2-methylbenzoyl)amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 473738-16-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[6-[[[(2R,3S)-3-[[(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 473738-17-9 CAPLUS

L7 ANSWER 8 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Pyridinecarboxamide, N-[6-[[[(2R,3S)-3-[[(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 473738-18-0 CAPLUS
CN Benzamide, N-[6-[[[(2R,3S)-3-[[(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-2-benzothiazolyl]-3,5-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 473738-19-1 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-[6-[[[(2R,3S)-3-[[(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenylbutyl](2-

L7 ANSWER 8 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
methylpropyl)amino]sulfonyl]-2-benzothiazolyl]-1-(2-furanylmethyl)-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 473738-21-5 CAPLUS
CN Benzamide, N-[6-[[[(2R,3S)-3-[[(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-2-benzothiazolyl]-4-hydroxy-3,5-dimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 8 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B



RN 473738-22-6 CAPLUS
CN Benzamide, N-[6-[[[(2R,3S)-3-[[(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-2-benzothiazolyl]-3-hydroxy-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 473738-30-6 CAPLUS
CN 4-Pyridinecarboxamide, N-[6-[[[(2R,3S)-3-[[(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 8 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 473738-46-4 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[(2-pyridinylcarbonyl)amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

L7 ANSWER 8 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

RN 473738-32-8 CAPLUS
CN 4-Piperidinecarboxamide, N-[6-[[[(2R,3S)-3-[[(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-2-benzothiazolyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 473738-33-9 CAPLUS
CN 3-Piperidinecarboxamide, N-[6-[[[(2R,3S)-3-[[(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenylbutyl](2-methylpropyl)amino]sulfonyl]-2-benzothiazolyl]-1-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 8 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 473738-51-1 CAPLUS
CN 4-Pyridinecarboxylic acid, (1R,2S)-2-[[(2,6-dimethylphenoxy)acetyl]amino]-1-[[(2-methylpropyl)[[2-[(4-pyridinylcarbonyl)amino]-6-benzothiazolyl]sulfonyl]amino]methyl]-3-phenylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 473738-74-8 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[[(5-oxo-2-pyrrolidinyl)carbonyl]amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, 5-thiazolylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 8 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B



RN 473738-77-1 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[2-[(3,5-dihydroxybenzoyl)amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, 5-thiazolylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 473738-78-2 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[(3-pyridinylcarbonyl)amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, 5-thiazolylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 8 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 473738-79-3 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[[2-[(3-furanylcarbonyl)amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, 5-thiazolylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473738-81-7 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[(2-pyridinylcarbonyl)amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, 5-thiazolylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473738-83-9 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[[[(2S)-1-methyl-2-pyrrolidinyl]carbonyl]amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, 5-thiazolylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 8 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 473738-85-1 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[(4-pyridinylcarbonyl)amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, 5-thiazolylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473738-89-5 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[[[2-[(5-isoxazolylcarbonyl)amino]-6-benzothiazolyl]sulfonyl](2-methylpropyl)amino]-1-(phenylmethyl)propyl]-, 5-thiazolylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473738-94-2 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[(5-thiazolylcarbonyl)amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 8 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

RN 473738-96-4 CAPLUS
CN Carbamic acid, [(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[[2-[(1H-pyrrol-2-ylcarbonyl)amino]-6-benzothiazolyl]sulfonyl]amino]-1-(phenylmethyl)propyl]-, 5-thiazolylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 9 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:658092 CAPLUS
DN 137:185508
TI Preparation of 2-thioxo-1,2,3,4-tetrahydropyrimidines as neutral sphingomyelinase inhibitors
IN Delaet, Nancy; Williams, John; Wilson, Dean; Ohmawari, Nagashige; Nakai, Hisao
PA Ono Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 198 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002066443	A2	20020829	WO 2002-JP1471	20020220
<--					
	WO 2002066443	A3	20030306		
	W: JP				
PRAI	US 2001-269841P	P	20010221		

OS MARPAT 137:185508
GI



AB The title compds. [I; R1 = (un)substituted Ph, pyridyl, imidazolyl, alkyl, etc.; R2 = COR12, CO2R13, CONR14R15, H, etc. (R12 = alkyl; R13 = alkyl, alkenyl, alkoxyalkyl, etc.; R14 = H, alkyl; R15 = alkyl, phenylalkyl, naphthylalkyl); R3 = alkyl, alkoxyalkyl, CO2R28, etc. (R28 = alkyl); with provisos], useful as neutral sphingomyelinase inhibitors and therefore are useful for the treatment and/or prevention of arteriosclerosis, cerebral ischemia, cardiac ischemia, lung injury, renal injury, GVHD (graft vs. host diseases), transplant rejection, HIV, etc., were prepared and formulated. Thus, cyclization of 1,3-diphenyl-2-(thiophen-2-ylmethylene)propane-1,3-dione (preparation given) with S-(4-methoxybenzyl)thiourea.HCl in pyridine afforded I [R1 = 2-thienyl; R2 = COPh; R3 = Ph]. Biol. data for 27 compds. I was given.

IT **452065-37-1P 452065-38-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-thioxo-1,2,3,4-tetrahydropyrimidines as neutral sphingomyelinase inhibitors)

RN 452065-37-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 4-[4-(diethylamino)phenyl]-N-(6-ethoxy-2-benzothiazolyl)-1,2,3,4-tetrahydro-6-methyl-2-thioxo- (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 452065-38-2 CAPLUS
CN 5-Pyrimidinecarboxamide, N-2-benzothiazolyl-4-[4-(diethylamino)phenyl]-1,2,3,4-tetrahydro-6-methyl-2-thioxo- (9CI) (CA INDEX NAME)



L7 ANSWER 10 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:638332 CAPLUS
DN 137:169789
TI Preparation of novel succinate compounds as peptide deformylase inhibitors
IN Patel, Dinesh; Jacobs, Jeffrey W.; Jain, Rakesh; Ni, Zhi-jie; Yuan, Zhengyu
PA Vicuron Pharmaceuticals Inc., USA
SO U.S. Pat. Appl. Publ., 84 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002115863	A1	20020822	US 2000-738859	20001213
<--					
	US 6797820	B2	20040928		
PRAI	US 2000-738859		20001213		

OS MARPAT 137:169789
GI





AB Title hydroxamates I [R1,R3 = H, halo, OH, etc.; R2, R4 = H, alkyl, heteroalkyl, etc.; n = 1-5; zero or one of Y = O, NR11 (R11 = alkyl, heteroalkyl, alkenyl, etc.), S, and all remaining Y = CR6R7; R6, R7 = H, OH, NH2, etc.] which inhibit peptide deformylase (PDF), an enzyme present in prokaryotes, and useful as antimicrobials and antibiotics, were prepared and formulated. E.g., a multi-step synthesis of II was given. MIC for various compds. I against H. influenza and S. aureus was approx. 64 μg/mL or less. The compds. I display selective inhibition of peptidyl deformylase vs. other metalloproteinases such as matrix metalloproteinases (MMPs).

IT **345345-77-9P 345345-85-9P 345346-39-6P 345346-77-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel succinate compds. as peptide deformylase inhibitors)

L7 ANSWER 10 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 345345-77-9 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-[(2-benzothiazolylamino)carbonyl]-β-butyl-α-fluoro-N-hydroxy-γ-oxo-, (αR,βS,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 345345-85-9 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-[(2-benzothiazolylamino)carbonyl]-β-butyl-α-fluoro-N-hydroxy-γ-oxo-, (αS,βS,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 345346-39-6 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-[(2-benzothiazolylamino)carbonyl]-β-butyl-N,α-dihydroxy-γ-oxo-, (αS,βR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 10 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 345346-77-2 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-[(2-benzothiazolylamino)carbonyl]-β-butyl-N-hydroxy-γ-oxo-, (βR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 208 THERE ARE 208 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
inhibiting inflammatory cytokines, particularly IL-4, are prepd. Pharmaceutical compns. comprising title oxazole derivs. I and methods of prophylaxis and treatment of diseases mediated by cytokines, particularly allergic diseases are described. Thus, the title compd. II was prepd. from glycine Et ester hydrochloride, 4-tert-butylbenzoyl chloride, and 4-nitrobenzoyl chloride through hydrogenation, acylation, and amination, and was in vitro tested for inhibition of IL-4 prodn. and cellular viability.
IT 449160-17-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazole derivs. and their use as cytokine inhibitors)
RN 449160-17-2 CAPLUS
CN 4-Oxazolecarboxamide, 5-[4-(acetylamino)phenyl]-N-2-benzothiazolyl-2-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 11 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:637648 CAPLUS
DN 137:185516
TI Preparation of oxazole derivatives and their use as cytokine inhibitors
IN Naruto, Shunji; Sugano, Yuichi; Tatsuta, Tohru; Burdi, Douglas; Porte, Alexander; Grisostomi, Corinna
PA Sankyo Company, Limited, Japan
SO PCT Int. Appl., 444 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002064558	A2	20020822	WO 2002-US4326	20020213
<--					
	WO 2002064558	A3	20031120		
	W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, JP, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, VN, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
PRAI	US 2001-268771P	P	20010214		
OS	MARPAT 137:185516				

GI



I



II

AB Title oxazole derivs. [I; X = (un)substituted-aryl, (un)substituted-heteroaryl, (un)substituted-N-containing-heteroaryl; Y = (un)substituted-aryl, (un)substituted-heteroaryl; R2 = OH, alkoxy, NH2, alkylamino, arylamino, etc.] and pharmacol. acceptable salts thereof, which have activity in

L7 ANSWER 12 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:539663 CAPLUS
DN 137:109210
TI Preparation of substituted arylamine derivatives and methods of use as antitumor agents
IN Chen, Guoqing; Booker, Shon; Cai, Guolin; Croghan, Michael; Dipietro, Lucian; Dominguez, Celia; Elbaum, Daniel; Germain, Julie; Huang, Qi; Kim, Joseph L.; Kim, Tae-Seong; Patel, Vinod F.; Smith, Leon M.; Tasker, Andrew; Xi, Ning; Xu, Shimin; Yuan, Chester Chenguang
PA Amgen Inc., USA
SO PCT Int. Appl., 253 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002055501	A2	20020718	WO 2002-US742	20020111
<--					
	WO 2002055501	A3	20021219		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002147198	A1	20021010	US 2002-46526	20020110
<--					
	CA 2434274	AA	20020718	CA 2002-2434274	20020111
<--					
	EP 1358161	A2	20031105	EP 2002-717324	20020111
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004531473	T2	20041014	JP 2002-556173	20020111
PRAI	US 2001-261360P	P	20010112		
	US 2001-323686P	P	20010919		
	US 2002-46526	A	20020110		
	WO 2002-US742	W	20020111		
OS	MARPAT 137:109210				

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [B1 and B2 independently equal C or N, wherein B1B2 form part of 5-6 membered heteroaryl ring A; R1 = one or more substituents selected from H, halo, oxo, (un)substituted cycloalkyl, phenylalkyl, etc.; R2 = (un)substituted cycloalkyl, cycloalkenyl, 6-10 membered aryl or 5-6 membered heterocyclyl, etc.; R3 = (un)substituted aryl; R4 = H, alkyl, (un)substituted Ph or aralkyl; X1 = bond, alkylenyl, alkenylenyl and alkynylenyl, where one of the CH2 groups may be substituted with O or NH, wherein X1 is optionally substituted with OH; X2 = (un)substituted N containing linker, e.g., -NHCH2-], and there pharmaceutically acceptable derivs., are prepared and disclosed as agents effective for prophylaxis and

L7 ANSWER 12 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
treatment of diseases, such as angiogenesis mediated diseases. Thus, II was prepd. via arylation of 1-dimethylamino-2-propyne with 3-bromo-5-trifluoromethylaniline, hydrogenation, amidation with 2-chloropyridine-3-carbonyl chloride and chloro-substitution with 4-fluorobenzylamine. Selected compds. of the invention, e.g., II, inhibited VEGF-stimulated cell proliferation at a level below 50 nM. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable derivs. thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

IT **442846-39-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of substituted aminopyridines as antitumor agents)

RN 442846-39-1 CAPLUS

CN 3-Pyridinecarboxamide, N-2-benzothiazolyl-2-[[[3-(hydroxymethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



L7 ANSWER 13 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:539473 CAPLUS

DN 137:109293

TI Preparation of piperazinylchromans as 5-HT1B and 5-HT1D agonists/antagonists useful as antimigraine drugs.

IN Chapdelaine, Marc; Davenport, Timothy; Haeberlein, Markus; Horchler, Carey; McCauley, John; Pierson, Edward; Sohn, Daniel

PA Astrazeneca Ab, Swed.

SO PCT Int. Appl., 139 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002055014	A2	20020718	WO 2002-SE70	20020115
<--					
	WO 2002055014	A3	20021114		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2434015	AA	20020718	CA 2002-2434015	20020115
<--					
	EP 1353915	A2	20031022	EP 2002-715919	20020115
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002006514	A	20040106	BR 2002-6514	20020115
	JP 2004517130	T2	20040610	JP 2002-555751	20020115
	CN 1524077	A	20040825	CN 2002-806562	20020115
	NZ 526699	A	20050324	NZ 2002-526699	20020115
	ZA 2003005318	A	20041011	ZA 2003-5318	20030709
	NO 2003003205	A	20030902	NO 2003-3205	20030715
	US 2004110745	A1	20040610	US 2003-466565	20030716
PRAI	US 2001-262108P	P	20010116		
	SE 2001-3646	A	20011101		
	WO 2002-SE70	W	20020115		

OS MARPAT 137:109293

GI



I

AB Title compds. [I; R1 = H, thiomethoxy, NHA, NA2, NHCOA, halo, OH, OA,

L7 ANSWER 13 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
cyano, aryl, (substituted) alkyl, cycloalkyl, etc.; A = (substituted) alkyl, cycloalkyl, alkenyl, alkynyl; R2 = (substituted) piperazinyl, homopiperazinyl, aminoalkylamino, aminoheterocyclyl, heterocyclylamino; R6 = H, Me; Y = CONH, CONA, CSNH, CH2CO, CH2NA, piperazinylcarbonyl, 5-membered heterocyclylene, etc.; R7 = (substituted) mono- or bicyclic aryl, heterocyclyl], were prepd. Thus, 8-(4-methyl-1-piperazinyl)chroman-2-carboxylic acid hydrochloride (prepn. given) in DMF was treated sequentially with 1-hydroxybenzotriazole, O-(1H-benzotriazol-1-yl)-N,N,N',N'-pentamethyleneuronium tetrafluoroborate, Et3N, and 4-(4-morpholinyl)aniline (prepn. given) followed by stirring overnight to give 8-(4-methyl-1-piperazinyl)chroman-2-carboxylic acid (4-morpholin-4-ylphenyl)amide. Several I showed 5-HT1B antagonist activity in the range 0.006-5.5 mg/kg in a screen for reversal of hypothermia in guinea pigs.

IT **442548-50-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperazinylchromans as 5-HT1B and 5-HT1D agonists/antagonists useful as antimigraine drugs)

RN 442548-50-7 CAPLUS

CN 4H-1-Benzopyran-2-carboxamide, N-(5-ethoxy-2-benzothiazolyl)-8-(4-methyl-1-piperazinyl)-4-oxo- (9CI) (CA INDEX NAME)



L7 ANSWER 14 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:539472 CAPLUS

DN 137:93772

TI Preparation of piperazinylchromenones as 5-HT1B 5-HT1D agonists/antagonists useful as drugs.

IN Chapdelaine, Marc; Davenport, Timothy; Haeberlein, Markus; Horchler, Carey; McCauley, John; Pierson, Edward; Sohn, Daniel

PA Astrazeneca Ab, Swed.

SO PCT Int. Appl., 150 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002055013	A2	20020718	WO 2002-SE69	20020115
<--					
	WO 2002055013	A3	20021114		
	WO 2002055013	C1	20040513		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2433950	AA	20020718	CA 2002-2433950	20020115
<--					
	EP 1353914	A2	20031022	EP 2002-729623	20020115
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002006513	A	20040106	BR 2002-6513	20020115
	JP 2004517129	T2	20040610	JP 2002-555750	20020115
	ZA 2003005314	A	20041011	ZA 2003-5314	20030709
	NO 2003003204	A	20030902	NO 2003-3204	20030715
	US 2004087575	A1	20040506	US 2003-466449	20030716
PRAI	US 2001-262109P	P	20010116		
	SE 2001-3647	A	20011101		
	WO 2002-SE69	W	20020115		

OS MARPAT 137:93772

GI



I

AB Title compds. [I; R1 = H, thiomethoxy, NHA, NA2, NHCOA, halo, OH, OA, cyano, aryl, (substituted) alkyl, cycloalkyl, etc.; A = (substituted)

L7 ANSWER 14 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
alkyl, cycloalkyl, alkenyl, alkynyl; R2 = (substituted) piperazinyl, homopiperazinyl, aminoalkylamino, aminoheterocyclyl, heterocyclylamino;
R6
= H, Me; Y = CONH, CONA, CSNH, CH2CO, CH2NA, piperazinylcarbonyl, 5-membered heterocyclylene, etc.; R7 = (substituted) mono- or bicyclic aryl, heterocyclyl], were prepd. Thus, 8-(4-methyl-1-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid hydrochloride (prepn. given) in
DMF/Et3N
was treated sequentially with 1-hydroxybenzotriazole,
O-(1H-benzotriazol-1-
yl)-N,N,N',N'-pentamethyleneuronium tetrafluoroborate,
4-dimethylaminopyridine, and 4-(4-morpholinyl)aniline (prepn. given) to give 8-(4-methyl-1-piperazinyl)-N-[4-(4-morpholinyl)phenyl]-4-oxo-4H-chromene-2-carboxamide. Several I showed 5-HT1B antagonist activity in the range 0.006-5.5 mg/kg in a screen for reversal of hypothermia in guinea pigs.
IT 442548-50-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperazinylchromenones as 5-HT1B 5-HT1D
agonists/antagonists
useful as drugs)
RN 442548-50-7 CAPLUS
CN 4H-1-Benzopyran-2-carboxamide,
N-(5-ethoxy-2-benzothiazolyl)-8-(4-methyl-1-
piperazinyl)-4-oxo- (9CI) (CA INDEX NAME)



L7 ANSWER 15 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:539471 CAPLUS
DN 137:109205
TI Preparation of 4-oxo-4H-chromene-2-carboxamides and related compounds as antagonists or agonists of serotonin 5HT1B and 5HT1D receptors
IN Chapdelaine, Marc; Davenport, Timothy; Haeberlein, Markus; Horchler, Carey; McCauley, John; Pierson, Edward; Sohn, Daniel
PA Astrazeneca Ab, Swed.
SO PCT Int. Appl., 147 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002055012	A2	20020718	WO 2002-SE68	20020115
<--					
	WO 2002055012	A3	20021114		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2434152	AA	20020718	CA 2002-2434152	20020115
<--					
	EP 1353913	A2	20031022	EP 2002-729622	20020115
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002006512	A	20040106	BR 2002-6512	20020115
	JP 2004517128	T2	20040610	JP 2002-555749	20020115
	CN 1527827	A	20040908	CN 2002-806392	20020115
	NZ 526697	A	20050527	NZ 2002-526697	20020115
	US 2003013708	A1	20030116	US 2002-51776	20020116
	US 6812225	B2	20041102		
	ZA 2003005344	A	20041011	ZA 2003-5344	20030710
	NO 2003003203	A	20030902	NO 2003-3203	20030715
	US 2004082591	A1	20040429	US 2003-466540	20030716
	US 2005009818	A1	20050113	US 2004-889350	20040712
	US 2005182050	A1	20050818	US 2005-108587	20050418
PRAI	US 2001-262107P	P	20010116		
	SE 2001-3650	A	20011101		
	WO 2002-SE68	W	20020115		
	US 2002-51776	A1	20020116		
	US 2004-889350	A1	20040712		

OS MARPAT 137:109205
GI

L7 ANSWER 15 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I and their pharmaceutically acceptable salts [R1 = H, alkyl, cycloalkyl, thiomethoxy, etc.; R2 = NR3R3; R3 independently = H, (un)substituted alkylamine e.g., alkyl, alkenyl, alkynyl amino-heterocycle, etc; R3-R3 = (un)substituted cycloalkylamine or amino-heterocycle e.g., alkyl, alkenyl, alkynyl, etc; R5 = H, O, S, etc.; R6 = H, Me; R7 = (un)substituted mono-. or bicylo- aromatic,
(un)substituted
heterocycle; X = O, N, NH, S; Y = CONH, NHCO, CSNH, etc.] were prepd with the proviso that multiple bonds are separated from each other by at
least one
single bond. For example, condensation of 4-oxo-4H-chromene-2-carboxylic acid II e.g., prepared from diethylacetylenedicarboxylate and 2-bromo-4-fluorophenol in 5 steps, and 4-morpholin-4-yl-phenylamine provided preferred 4-oxo-4H-chromene-2-carboxamide III. The utility of the compds. of the present invention were tested using a guinea pig hypothermia test, ED50 values for compds. I range from 0.006-5.5 mg/kg. Compds. I are disclosed to be antagonists or agonists of serotonin 5HT1B and 5HT1D receptors (no data provided). Also I are claimed for use in
the
treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, etc..
IT 442548-50-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 4-oxo-4H-chromene-2-carboxamides and
related
compds. as antagonists or agonists of serotonin 5HT1B and 5HT1D receptors)
RN 442548-50-7 CAPLUS
CN 4H-1-Benzopyran-2-carboxamide,
N-(5-ethoxy-2-benzothiazolyl)-8-(4-methyl-1-

L7 ANSWER 15 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
piperazinyl)-4-oxo- (9CI) (CA INDEX NAME)



L7 ANSWER 16 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:504608 CAPLUS
DN 137:63252
TI Preparation of benzanilide and benzenesulfonanilide derivatives or salts thereof and cytokine production inhibitors containing the same
IN Kato, Fuminori; Kimura, Hirohiko; Yuki, Shunji; Yamamoto, Kazuhiro; Okada, Takashi
PA Ishihara Sangyo Kaisha, Ltd., Japan
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002051397	A1	20020704	WO 2001-JP11282	20011221
<--					
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2002249473	A2	20020906	JP 2001-384042	20011218
<--					
	CA 2432713	AA	20020704	CA 2001-2432713	20011221
<--					
	EP 1344525	A1	20030917	EP 2001-271863	20011221
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004048891	A1	20040311	US 2003-451101	20030619
PRAI	JP 2000-391175	A	20001222		
	WO 2001-JP11282	W	20011221		
OS	MARPAT 137:63252				

GI



I

AB Disclosed are cytokine production inhibitors containing as the active ingredient aniline derivs. represented by the general formula (I) or salts thereof [wherein A = CO, SO2; ring Cy = aryl, heterocyclic group; R1, R2 = halo, cyano, nitro, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted aryl, an optionally substituted heterocyclic group, optionally substituted

L7 ANSWER 16 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
amino, or B-Q (wherein B = O, CO, CO2, O2C, S, SO, SO2; Q = H, optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, or amino); R3 = M1-M2-R5 (wherein M1, M2 = O, S, NH, alkyl-N, single bond, C1-2 alkylene, CO, SO, SO2; or M1 and M2 are combined together to form N:N; R5 = optionally substituted cycloalkyl, aryl, or heterocyclyl); R4 = H, optionally substituted alkyl; m is an integer of 0 to 5; n is an integer of 0 to 4; and p is an integer of 0 to 1]. These compds. are inhibitors of prodn. of cytokines, in particular, Th1 and Th2 subtype cytokines, interferon γ, and interleukin 5 and are useful for the prevention or treatment of diseases assocd. with unusual increase in immune function such as urticaria, food allergy, anaphylaxis shock, eosinophilia syndromes, asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, systemic lupus erythematosus, chronic articular rheumatism, type I diabetes, Hashimoto thyroiditis, severe myasthenia, and multiple sclerosis. Thus, a soln. of 200 mg 2-chloro-5-nitrobenzoyl chloride in 5 mL THF was added dropwise to a soln. of 300 mg 4-(3-chloro-5-trifluoromethyl-2-pyridyloxy)-3-(1-pyrrolyl)aniline and 120 mg Et3N in 5 mL THF and stirred for .apprx.30 min to give 250 mg N-[4-(3-chloro-5-trifluoromethyl-2-pyridyloxy)-3-(1-pyrrolyl)phenyl]-2-chloro-5-nitrobenzamide (II),. II in vitro at 100 ppm inhibited the prodn. of IL-5 and interferon-γ in Balb/c mouse spleen cells by 100%.

IT 313233-81-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzanilide and benzenesulfonanilide derivs. or salts thereof as cytokine production inhibitors for prevention or treatment of diseases associated with unusual increase in immune function)
RN 313233-81-7 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2-chloro-5-nitro- (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 17 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:487562 CAPLUS
DN 137:47201
TI Preparation of azolyl dichloropyridinecarboxamides as microbicides and pesticides.
IN Gesing, Ernst-Rudolf; Haenssler, Gerd; Kuck, Karl-Heinz; Erdelen, Christoph; Mauler-Machnik, Astrid
PA Bayer Aktiengesellschaft, Germany
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002050072	A1	20020627	WO 2001-EP14446	20011210
<--					
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10063868	A1	20020627	DE 2000-10063868	20001221
<--					
	AU 2002024921	A5	20020701	AU 2002-24921	20011210
<--					
PRAI	DE 2000-10063868	A	20001221		
	WO 2001-EP14446	W	20011210		
OS	MARPAT 137:47201				

GI



I

AB Title compds. [I; R = alkylthio-substituted 1,2,4-thiadiazolyl, (substituted) 1,2,4-oxadiazolyl, 4,5-disubstituted 1,3-thiazol-2-yl, 1,3-thiazol-2-yl that is substituted in the 4 or 5 position with Ph or alkyl, (substituted) 1,3-thiazol-4-yl, benzothiazolyl, 2-thienyl, triazinyl], were prepared Thus, 2-(2-amino-4-tert-butyl-1,3-thiazol-5-yl)-1H-isoindol-1,3(2H)-dione in MeCN was treated with K2CO3 and then with 2,6-dichoropyridine-4-carbonyl chloride followed by reflux for 5 h to give 86% N-[4-tert-butyl-5-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-11,3-thiazol-2-yl]-2,6-dichlorisonicotinamide. I (R = 5-methylthio-1,2,4-thiadiazol-3-yl) at 0.1% on cabbage leaves gave 100% control of Spodoptera

L7 ANSWER 17 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
frugiperda.

IT 438568-38-8P 438568-44-6P 438568-45-7P
438568-46-8P 438568-47-9P 438568-48-0P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azolyl dichloropyridinecarboxamides as microbicides and pesticides)
RN 438568-38-8 CAPLUS
CN 4-Pyridinecarboxamide, N-2-benzothiazolyl-2,6-dichloro- (9CI) (CA INDEX NAME)



RN 438568-44-6 CAPLUS
CN 4-Pyridinecarboxamide, 2,6-dichloro-N-(4-methoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 438568-45-7 CAPLUS
CN 4-Pyridinecarboxamide, 2,6-dichloro-N-(4-methyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 438568-46-8 CAPLUS
CN 4-Pyridinecarboxamide, 2,6-dichloro-N-(6-methyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 17 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 438568-47-9 CAPLUS
CN 4-Pyridinecarboxamide, N-(4-bromo-6-chloro-2-benzothiazolyl)-2,6-dichloro- (9CI) (CA INDEX NAME)



RN 438568-48-0 CAPLUS
CN 4-Pyridinecarboxamide, 2,6-dichloro-N-[6-chloro-4-(trifluoromethyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 18 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:408678 CAPLUS
DN 136:401636
TI Preparation of 7-oxabicyclo[2.2.1]heptanes as pesticidal agents
IN Gesing, Ernst Rudolf F.; Erdelen, Christoph; Haenszler, Gerd; Kuck, Karl-Heinz; Loesel, Peter; Andersch, Wolfram; Xu, Yi-Mei; Chen, Liang; Tang, Qinghong; Cao, Jin
PA Bayer Aktiengesellschaft, Germany
SO PCT Int. Appl., 195 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002042310	A2	20020530	WO 2001-EP13212	20011115
<--					
	WO 2002042310	A3	20021114		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CN 1355168	A	20020626	CN 2000-128459	20001123
<--					
	AU 2002021853	A5	20020603	AU 2002-21853	20011115
<--					
	EP 1339720	A2	20030903	EP 2001-997494	20011115
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2005507852	T2	20050324	JP 2002-544443	20011115
	US 2004053996	A1	20040318	US 2003-432071	20030922
PRAI	CN 2000-128459	A	20001123		
	WO 2001-EP13212	W	20011115		

OS MARPAT 136:401636
GI



AB The title compds. [I; X = CH2CH2, CH:CH; R1, R2 = H, Me; R3 = OR5, SR6,

L7 ANSWER 18 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
NHR7 (wherein R5-R7 = H, alkyl, haloalkyl, etc.); R4 = OR8, SR9, NHR10 (R8-R10 = H, alkyl, haloalkyl, etc.); or R3 and R4 together represent a group NNHR11 (R11 = (un)substituted aryl), NR12 (R12 = (un)substituted aralkyl)] which are very suitable for controlling undesired microorganisms
and animal pests, were prepd. Thus, treating a soln. of 7-oxabicyclo[2.2.1]hept-2-ene-2,3-dicarboxylic acid anhydride in MeOH with
2 drops of conc. H2SO4 afforded 42% I [X = CH:CH; R1, R2 = H; R3, R4 = Me]
which killed 90% of greenhouse red spider mites (Tetranychus urticae) after 7 days at 1000 ppm.
IT 431035-59-5P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of 7-oxabicyclo[2.2.1]heptanes as pesticidal agents)
RN 431035-59-5 CAPLUS
CN 7-Oxabicyclo[2.2.1]hept-5-ene-2-carboxylic acid, 3-[[(6-chloro-2-benzothiazolyl)amino]carbonyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 19 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:332155 CAPLUS
DN 136:355070
TI Preparation of [(carboxybiphenyl)carboxamido]benzamidines and analogs as serine protease inhibitors
IN Babu, Yarlagadda S.; Rowland, Scott R.; Chand, Pooran; Kotian, Pravin L.; El-Kattan, Yahya; Niwas, Shri
PA Biocryst Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 341 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002034711	A1	20020502	WO 2001-US32582	20011022
<--					
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2426430	AA	20020502	CA 2001-2426430	20011022
<--					
	AU 2002013393	A5	20020506	AU 2002-13393	20011022
<--					
	EP 1383731	A1	20040128	EP 2001-981772	20011022
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004523481	T2	20040805	JP 2002-537705	20011022
	NZ 526003	A	20050930	NZ 2001-526003	20011022
	US 6699994	B1	20040302	US 2002-127460	20020423
	ZA 2003002645	A	20040716	ZA 2003-2645	20030404
	US 2004162281	A1	20040819	US 2003-738027	20031218
	US 6936719	B2	20050830		
PRAI	US 2000-241848P	P	20001020		
	US 2001-281735P	P	20010406		
	WO 2001-US32582	W	20011022		
	US 2002-127460	A3	20020423		

OS MARPAT 136:355070
GI

L7 ANSWER 19 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I

AB Title compds. (e.g., I; R = H alkoxycarbonyl; R1 = (ar)alkyl, etc.; R2 = alkenyl, (hetero)aryl, etc.], useful as inhibitors of trypsin-like serine protease enzymes such as thrombin, factor VIIa, factor Xa, TF/FVIIa, and trypsin, were prepared Title compds. could be useful to treat and/or prevent clotting disorders, and as anticoagulating agents. Data for biol.
activity of title compds. were given.

IT 420794-95-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [(carboxybiphenyl)carboxamido]benzamidines and analogs as
serine protease inhibitors)

RN 420794-95-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 2'-[[(6-methoxy-2-benzothiazolyl)amino]carbonyl]-4-[[(2-methylpropyl)amino]carbonyl]- (9CI) (CA INDEX NAME)



IT 420801-72-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of [(carboxybiphenyl)carboxamido]benzamidines and analogs as

L7 ANSWER 19 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
serine protease inhibitors)

RN 420801-72-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 2'-[[(6-methoxy-2-benzothiazolyl)amino]carbonyl]-4-[[(2-methylpropyl)amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 20 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:275753 CAPLUS

DN 136:309843

TI Preparation of thiophenes as phosphate transport inhibitors

IN Weinstock, Joseph; Franz, Robert G.

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002028353	A2	20020411	WO 2001-US31318	20011005
<--					
	WO 2002028353	A3	20020711		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002013048	A5	20020415	AU 2002-13048	20011005
<--					
PRAI	US 2000-238068P	P	20001005		
	WO 2001-US31318	W	20011005		

OS MARPAT 136:309843

GI



I



II



III

AB The title compds. [I-III; X = S, O; R1 = H, alkyl, aryl, etc.; R2, R3 = alkyl, haloalkyl, alky; interrupted by one or more O or S atoms, etc.; n =

L7 ANSWER 20 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
0-3], useful for treatment of chronic renal failure and uremic bone disease, were prepd. E.g., a 4-step synthesis of I [X = S; R1 = H; R2 = 4-FC6H4; R3 = Ph], starting with Me 3-aminothiophene-2-carboxylate, was presented. Biol. data were given.

IT 409363-34-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiophenes as phosphate transport inhibitors)

RN 409363-34-4 CAPLUS

CN 2-Thiophenecarboxamide, N-2-benzothiazolyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



L7 ANSWER 21 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:51452 CAPLUS
DN 136:118470
TI Preparation of substituted indoleoxoacetylpiperazines with antiviral activity against HIV-1
IN Wallace, Owen B.; Wang, Tao; Yeung, Kap-Sun; Pearce, Bradley C.; Meanwell, Nicholas A.; Qiu, Zhilei; Fang, Haiquan; Xue, Qiufen May; Yin, Zhiwei
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 277 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004440	A1	20020117	WO 2001-US20300	20010626
<--					
	WO 2002004440	C2	20051103		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2413044	AA	20020117	CA 2001-2413044	20010626
<--					
	EP 1299382	A1	20030409	EP 2001-946715	20010626
	EP 1299382	B1	20050921		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004502768	T2	20040129	JP 2002-509305	20010626
	AT 304853	E	20051015	AT 2001-946715	20010626
PRAI	US 2000-217444P	P	20000710		
	US 2001-265978P	P	20010202		
	WO 2001-US20300	W	20010626		

OS MARPAT 136:118470
GI



I

AB Indoleoxoacetylpiperazines I [A = (un)substituted alkoxy, aryl,

L7 ANSWER 21 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 21 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
heteroaryl; W = (un)substituted piperazino; R1 = H; R2-R5 = H, halogen, CN, NO2, (un)substituted NH2, OH, (un)substituted alkyl, cycloalkyl, alkoxy, CO2H, acyl, carbamoyl, amidino, aryl, heteroaryl, heterocyclic; R6 = H, alkyl] and their 2,3-dihydroindole analogs were prepd. for use as virucides in the treatment of HIV and AIDS. Thus, 2-bromo-5-fluoronitrobenzene was cyclized with CH2:CHMgBr to give 4-fluoro-7-bromoindole, which was treated with ClCOCO2Et, followed by ester hydrolysis to give 4-fluoro-7-bromo-3-indoleglyoxylic acid. This acid was amidated with N-benzoylpiperazine and treated with PhSnBu3 to give I [A = R5 = Ph, W = piperazino, R1, R3, R4, R6 = H, R2 = F]. This compd. gave >98% inhibition of HIV-1 infection in HeLa cells.
IT 389629-21-4P 389630-87-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted indoleoxoacetylpiperazines with antiviral activity against HIV-1)
RN 389629-21-4 CAPLUS
CN 1H-Indole-7-carboxamide, N-2-benzothiazolyl-3-[(4-benzoyl-1-piperazinyl)oxoacetyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 389630-87-9 CAPLUS
CN 1H-Indole-7-carboxamide, 3-[(4-benzoyl-1-piperazinyl)oxoacetyl]-4-fluoro-N-(6-methoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 22 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:10480 CAPLUS
DN 136:85818
TI Preparation of pyrrolo[2,3-d]pyrimidines as immunosuppressive agents
IN Blumenkopf, Todd Andrew; Flanagan, Mark Edward; Munchhof, Michael John
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002000661	A1	20020103	WO 2001-IB975	20010605
<--					
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2412560	AA	20020103	CA 2001-2412560	20010605
<--					
	EP 1294724	A1	20030326	EP 2001-934243	20010605
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001011561	A	20030909	BR 2001-11561	20010605
	JP 2004501922	T2	20040122	JP 2002-505785	20010605
	EE 200200711	A	20040615	EE 2002-711	20010605
	NZ 522364	A	20040924	NZ 2001-522364	20010605
	US 2002068746	A1	20020606	US 2001-891028	20010625
<--					
	US 6696567	B2	20040224		
	BG 107236	A	20030930	BG 2002-107236	20021031
	NO 2002006030	A	20021216	NO 2002-6030	20021216
<--					
	ZA 2002010275	A	20031219	ZA 2002-10275	20021219
	US 2003220353	A1	20031127	US 2003-463724	20030616
	US 6962993	B2	20051108		
	US 2005197349	A1	20050908	US 2005-112307	20050421
PRAI	US 2000-214287P	P	20000626		
	WO 2001-IB975	W	20010605		
	US 2001-891028	A1	20010625		
	US 2003-463724	A1	20030616		

OS MARPAT 136:85818
GI

L7 ANSWER 22 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB The title compds. [I; R1 = NR4(CH2)yR5 (wherein y = 0-2; R4 = H, alkyl, alkylsulfonyl, etc.; R5 = substituted heterocycloalkyl); R2, R3 = H, NH2, halo, etc.], useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3 (no data given), were prepared, e.g., a multi-step synthesis of II was given.

IT **384336-28-1P 384336-34-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolo[2,3-d]pyrimidines as immunosuppressive agents)

RN 384336-28-1 CAPLUS
CN 1-Piperidinecarboxamide, N-(5,6-dichloro-2-benzothiazolyl)-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



RN 384336-34-9 CAPLUS
CN 1-Piperidinecarboxamide, N-2-benzothiazolyl-4-methyl-3-(methyl-1H-pyrrolo[2,3-d]pyrimidin-4-ylamino)- (9CI) (CA INDEX NAME)



L7 ANSWER 22 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:935384 CAPLUS
DN 136:69803
TI Preparation of N-benzothiazol-2-yl amides having affinity toward the A2A adenosine receptor
IN Alanine, Alexander; Flohr, Alexander; Miller, Aubry Kern; Norcross, Roger David; Riemer, Claus
PA F. Hoffmann-La Roche A.-G., Switz.
SO PCT Int. Appl., 160 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001097786	A2	20011227	WO 2001-EP6506	20010608
<--					
	WO 2001097786	A3	20021212		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2413086	AA	20011227	CA 2001-2413086	20010608
<--					
	AU 2001081817	A5	20020102	AU 2001-81817	20010608
<--					
	EP 1303272	A2	20030423	EP 2001-960284	20010608
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001012395	A	20030708	BR 2001-12395	20010608
	JP 2003535887	T2	20031202	JP 2002-503263	20010608
	RU 2251419	C2	20050510	RU 2003-100518	20010608
	NZ 522928	A	20050527	NZ 2001-522928	20010608
	US 2002045615	A1	20020418	US 2001-881252	20010614
<--					
	US 6521754	B2	20030218		
	ZA 2002009730	A	20040301	ZA 2002-9730	20021129
	US 2003125318	A1	20030703	US 2002-310508	20021205
	US 6835732	B2	20041228		
	NO 2002005978	A	20021212	NO 2002-5978	20021212
<--					
	US 2003176695	A1	20030918	US 2002-322272	20021218
	US 6963000	B2	20051108		
	US 2005026906	A1	20050203	US 2004-930361	20040830
	US 2006003986	A1	20060105	US 2005-219577	20050902
PRAI	EP 2000-113219	A	20000621		
	WO 2001-EP6506	W	20010608		
	US 2001-881252	A3	20010614		
	US 2002-322272	A3	20021218		

OS MARPAT 136:69803
GI

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I

AB The title compds. [I; R1 = H, alkyl, alkoxy, etc.; R2, R3 = H, halo, alkyl, alkoxy; R4 = H, alkyl, alkenyl, etc.; R = (un)substituted Ph, (CH2)n(5-6 membered (non)aromatic heterocyclyl, (CH2)n+1Ph, etc.; n = 0-4; X = O, S, H2)], useful for the treatment of diseases related to the adenosine receptor, were prepared Thus, reacting 2-amino-4-methoxy-7-phenylbenzothiazole with benzoyl chloride in pyridine afforded 69% I [R1 = OMe; R2, R3 = H; R4 = Ph; R = Ph; X = O]. Biol. data for compds. I were given.

IT **383864-85-5P 383864-90-2P 383864-97-9P**
383865-17-6P, N-(7-Acetylamino-4-methoxybenzothiazol-2-yl)-4-fluorobenzamide **383865-35-8P 383865-40-5P**
383865-46-1P, 4-(4-Methoxy-2-[(5-methylthiophene-2-carbonyl)amino]benzothiazol-7-yl)piperazine-1-carboxylic acid benzyl ester
383865-61-0P 383865-69-8P, N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-6-(thiomorpholin-4-yl)nicotinamide hydrochloride salt **383865-73-4P**, 4-Bromomethyl-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide **383866-22-6P**, 4-Chloromethyl-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383866-74-8P**, Thiomorpholine-4-carboxylic acid (4-methoxy-7-phenylbenzothiazol-2-yl)amide **383867-09-2P**, 4-Fluoro-N-(4-methoxy-7-vinylbenzothiazol-2-yl)benzamide **383867-60-5P**, 4-Chloromethyl-N-(4-methoxy-7-(2-(morpholin-4-yl)thiazol-4-yl)benzothiazol-2-yl]benzamide **383867-70-7P**, N-[7-(2-Aminothiazol-4-yl)-4-methoxybenzothiazol-2-yl]-4-[(N-(2-methoxyethyl)-N-methylamino]methyl]benzamide **383867-79-6P**, N-[4-Methoxy-7-[2-(tritylamino)thiazol-4-yl]benzothiazol-2-yl]-4-(pyrrolidin-1-yl-methyl)benzamide **383868-28-8P**, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-((methylamino)methyl)benzamide **383868-56-2P 383868-58-4P**
383868-82-4P 383868-97-1P 383869-76-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of N-benzothiazolyl amides having affinity toward A2A adenosine receptor)

RN 383864-85-5 CAPLUS
CN 2-Thiophenecarboxamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-5-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383864-90-2 CAPLUS
CN 2-Thiophenecarboxamide, N-(4-methoxy-2-benzothiazolyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 383864-97-9 CAPLUS
CN Benzamide, 4-formyl-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 383865-17-6 CAPLUS
CN Benzamide, N-[7-(acetylamino)-4-methoxy-2-benzothiazolyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 383865-35-8 CAPLUS

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383865-69-8 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-6-(4-thiomorpholinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383865-73-4 CAPLUS
CN Benzamide, 4-(bromomethyl)-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 383866-22-6 CAPLUS
CN Benzamide, 4-(chloromethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383865-40-5 CAPLUS
CN 2-Thiophenecarboxamide, N-(7-bromo-4-methoxy-2-benzothiazolyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 383865-46-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-methoxy-2-[[(5-methyl-2-thienyl)carbonyl]amino]-7-benzothiazolyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 383865-61-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383866-74-8 CAPLUS
CN 4-Thiomorpholinecarboxamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 383867-09-2 CAPLUS
CN Benzamide, N-(7-ethenyl-4-methoxy-2-benzothiazolyl)-4-fluoro- (9CI) (CA INDEX NAME)



RN 383867-60-5 CAPLUS
CN Benzamide, 4-(chloromethyl)-N-[4-methoxy-7-[2-(4-morpholinyl)-4-thiazolyl]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383867-70-7 CAPLUS
CN Benzamide, N-[7-(2-amino-4-thiazolyl)-4-methoxy-2-benzothiazolyl]-4-[[(2-methoxyethyl)methylamino]methyl]- (9CI) (CA INDEX NAME)



RN 383867-79-6 CAPLUS
CN Benzamide, N-[4-methoxy-7-[2-[(triphenylmethyl)amino]-4-thiazolyl]-2-benzothiazolyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 383868-28-8 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
[(methylamino)methyl]- (9CI) (CA INDEX NAME)



RN 383868-56-2 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-thiomorpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-58-4 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-methoxy-7-(1-piperazinyl)-2-benzothiazolyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 383868-82-4 CAPLUS
CN Carbamic acid, [[1-[[[4-methoxy-7-(4-morpholinyl)-2-

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
benzothiazolyl]amino]carbonyl]-4-piperidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 383868-97-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-(hydroxymethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-76-9 CAPLUS
CN 4-Pyridinecarboxamide, 2-chloro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-6-methyl- (9CI) (CA INDEX NAME)



IT 5005-14-1P, N-Benzothiazol-2-ylbenzamide 35412-20-5P, N-(4-Methoxy-benzothiazol-2-yl)-benzamide 87074-18-8P 300567-89-9P 313375-58-5P, N-(4,6-Difluoro-benzothiazol-2-yl)-benzamide 383864-82-2P, N-(4-Methoxy-7-phenylbenzothiazol-2-yl)benzamide 383864-84-4P 383864-86-6P 383864-87-7P 383864-89-9P, 4-Cyano-N-(4-methoxy-7-phenyl-

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
benzothiazol-2-yl)-benzamide 383864-91-3P 383864-92-4P 383864-93-5P 383864-94-6P 383864-95-7P 383864-96-8P 383864-98-0P 383864-99-1P 383865-00-7P, N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-3-methylbenzamide 383865-01-8P, N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-4-methylbenzamide 383865-02-9P, 4-Fluoro-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide 383865-03-0P, 3-Methoxy-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide 383865-04-1P, 4-Methoxy-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide 383865-06-3P 383865-07-4P 383865-08-5P, 3-Cyano-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide 383865-09-6P, N-(4-Methoxy-7-phenoxybenzothiazol-2-yl)benzamide 383865-11-0P, 4-Dimethylamino-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide 383865-14-3P, 2-(4-Fluorobenzoylamino)-4-methoxybenzothiazole-7-carboxylic acid methyl ester 383865-16-5P, N-(7-tert-Butyl-4-methoxybenzothiazol-2-yl)-4-fluorobenzamide 383865-19-8P 383865-20-1P, 4-Fluoro-N-(4-methoxy-7-phenoxybenzothiazol-2-yl)benzamide 383865-21-2P 383865-22-3P, 4-Fluoro-N-(4-methoxy-7-((morpholin-4-yl)methyl)benzothiazol-2-yl)benzamide 383865-24-5P 383865-25-6P, 4-Fluoro-N-[4-methoxy-7-(1H-tetrazol-5-yl)benzothiazol-2-yl]benzamide 383865-27-8P, 2-Chloro-N-(4-methyl-2-benzothiazolyl)nicotinamide 383865-28-9P, 2-Chloro-N-(4-methoxy-2-benzothiazolyl)nicotinamide 383865-30-3P, 4-Fluoro-N-(7-hydroxymethyl-4-methoxybenzothiazol-2-yl)benzamide 383865-31-4P, 4-(N,N-Dipropylsulfamoyl)-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide 383865-32-5P, 4-Diethylsulfamoyl-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide 383865-33-6P, N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-4-(morpholine-4-sulfonyl)benzamide 383865-34-7P, 4-Ethylsulfamoyl-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide 383865-36-9P 383865-37-0P 383865-38-1P 383865-39-2P 383865-41-6P 383865-42-7P 383865-43-8P 383865-44-9P 383865-45-0P 383865-47-2P 383865-48-3P 383865-50-7P 383865-52-9P 383865-54-1P 383865-55-2P 383865-56-3P 383865-58-5P 383865-60-9P 383865-62-1P, N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-6-(pyrrolidin-1-yl)nicotinamide 383865-63-2P 383865-65-4P, N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-6-(morpholin-4-yl)nicotinamide 383865-67-6P, N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-6-(4-methyl-piperazin-1-yl)nicotinamide 383865-71-2P, N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-6-(1-oxo-thiomorpholin-4-yl)nicotinamide hydrochloride salt 383865-74-5P, N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-4-(pyrrolidin-1-ylmethyl)benzamide hydrochloride salt 383865-75-6P, N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-4-(piperidin-1-ylmethyl)benzamide hydrochloride salt 383865-76-7P, N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-4-(morpholin-4-ylmethyl)benzamide hydrochloride salt 383865-78-9P, 4-Diethylaminomethyl-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide hydrochloride 383865-80-3P, N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-4-[(N-methyl-N-(pyridin-3-ylmethyl)amino)methyl]benzamide dihydrochloride salt 383865-82-5P, N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-4-(4-methylpiperazin-1-ylmethyl)benzamide dihydrochloride salt 383865-83-6P, 4-Dimethylaminomethyl-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide hydrochloride salt 383865-84-7P, 4-Ethylaminomethyl-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide hydrochloride salt 383865-85-8P, 4-[(2-Methoxyethylamino)methyl]-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide hydrochloride salt 383865-86-9P, 4-[(2-Hydroxyethylamino)methyl]-N-(4-methoxy-7-

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
phenylbenzothiazol-2-yl)benzamide hydrochloride salt 383865-87-0P
, 4-(Benzylaminomethyl)-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide
hydrochloride salt 383865-88-1P, 4-[(N-Benzyl-N-
methylamino)methyl]-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide
hydrochloride salt 383865-89-2P, 4-[((3-(Imidazol-1-
yl)propyl)amino)methyl]-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide
dihydrochloride salt 383865-90-5P, N-(4-Methoxy-7-
phenylbenzothiazol-2-yl)-4-[[(pyridin-4-ylmethyl)amino]methyl]benzamide
dihydrochloride salt 383865-91-6P, 4-[[N-(2-Methoxyethyl)-N-
methylamino]methyl]-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide
hydrochloride salt 383865-92-7P 383865-94-9P,
N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-4-(thiomorpholin-4-
ylmethyl)benzamide hydrochloride salt 383865-95-0P,
4-(Imidazol-1-ylmethyl)-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide
hydrochloride salt 383865-96-1P, 4-(2-Hydroxymethylimidazol-1-
ylmethyl)-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide
383865-97-2P, N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-4-(2-
methylimidazol-1-ylmethyl)benzamide 383865-98-3P,
4-(4,5-Dimethylimidazol-1-ylmethyl)-N-(4-methoxy-7-phenyl-benzothiazol-2-
yl)benzamide 383865-99-4P, N-(4-Methoxy-7-phenylbenzothiazol-2-
yl)-4-(piperazin-1-ylmethyl)benzamide dihydrochloride salt
383866-00-0P, 4-Allylaminomethyl-N-(4-methoxy-7-phenylbenzothiazol-
2-yl)benzamide hydrochloride salt 383866-01-1P,
N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-4-propylaminomethylbenzamide
hydrochloride salt 383866-02-2P, N-(4-Methoxy-7-
phenylbenzothiazol-2-yl)-4-[[(pyridin-3-ylmethyl)amino]methyl]benzamide
dihydrochloride salt 383866-03-3P, 4-(4-Hydroxypiperidin-1-
ylmethyl)-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide hydrochloride
salt 383866-04-4P, (S)-4-(3-Hydroxypyrrolidin-1-ylmethyl)-N-(4-
methoxy-7-phenylbenzothiazol-2-yl)benzamide hydrochloride salt
383866-05-5P 383866-06-6P, (R)-4-(3-

(Dimethylamino)pyrrolidin-1-ylmethyl)-N-(4-methoxy-7-phenylbenzothiazol-2-
yl)benzamide dihydrochloride salt 383866-07-7P,
N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-4-[(2-morpholin-4-yl-
ethylamino)methyl]benzamide dihydrochloride salt 383866-08-8P,
N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-4-[(2-pyrrolidin-1-yl-
ethylamino)methyl]benzamide dihydrochloride salt 383866-09-9P,
N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-4-[(2-piperidin-1-yl-
ethylamino)methyl]benzamide dihydrochloride salt 383866-10-2P,
4-Cyclobutylaminomethyl-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide
hydrochloride salt 383866-11-3P, 4-Cyclopentylaminomethyl-N-(4-
methoxy-7-phenylbenzothiazol-2-yl)benzamide hydrochloride salt
383866-12-4P, 4-[[(Furan-2-ylmethyl)amino]methyl]-N-(4-methoxy-7-
phenylbenzothiazol-2-yl)benzamide hydrochloride salt 383866-13-5P
, N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-4-[[(thiophen-2-
ylmethyl)amino]methyl]benzamide hydrochloride salt 383866-14-6P,
4-(Dipropylaminomethyl)-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide
hydrochloride salt 383866-15-7P 383866-16-8P,
4-Aminomethyl-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide
hydrochloride salt 383866-17-9P, 4-[((Cyclopropylmethyl)amino)me
thyl]-N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide hydrochloride salt
383866-18-0P 383866-19-1P, N-(4-Methoxy-7-
phenylbenzothiazol-2-yl)-4-(thiazolidin-3-ylmethyl)benzamide
hydrochloride
salt 383866-20-4P, (S)-4-(3-Dimethylaminopyrrolidin-1-ylmethyl)-

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
N-(4-methoxy-7-phenylbenzothiazol-2-yl)benzamide dihydrochloride salt
383866-21-5P, 4-[(2-Dimethylaminoethylamino)methyl]-N-(4-methoxy-7-
phenylbenzothiazol-2-yl)benzamide dihydrochloride salt
383866-23-7P, 4-(4-Hydroxypiperidin-1-ylmethyl)-N-(4-methoxy-7-
(morpholin-4-yl)benzothiazol-2-yl)benzamide 383866-24-8P,
4-[[N-(2-Methoxyethyl)-N-methylamino]methyl]-N-(4-methoxy-7-(morpholin-4-
yl)benzothiazol-2-yl)benzamide 383866-25-9P,
4-[[N-(2-Hydroxyethyl)-N-methylamino]methyl]-N-(4-methoxy-7-(morpholin-4-
yl)benzothiazol-2-yl)benzamide 383866-28-2P,
N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-(piperazin-1-
ylmethyl)benzamide 383866-29-3P, N-(7-Benzyloxy-4-
methoxybenzothiazol-2-yl)-4-chloromethylbenzamide 383866-30-6P,

N-(7-Benzyloxy-4-methoxybenzothiazol-2-yl)-4-(3-dimethylaminopyrrolidin-1-
ylmethyl)benzamide hydrochloride 383866-31-7P,
Thiomorpholine-4-carboxylic acid
(4-methoxy-7-(morpholin-4-yl)benzothiazol-
2-yl)amide 383866-32-8P, Morpholine-4-carboxylic acid,
(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)amide 383866-54-4P
, 3,4-Dihydro-1H-isoquinoline-2-carboxylic acid (4-methoxy-7-
phenylbenzothiazol-2-yl)amide 383866-72-6P, Morpholine-4-
carboxylic acid (4-methoxy-7-phenylbenzothiazol-2-yl)amide
383866-76-0P, 1-Oxo-thiomorpholine-4-carboxylic acid
(4-methoxy-7-phenylbenzothiazol-2-yl)amide 383867-12-7P,
N-(7-Ethyl-4-methoxybenzothiazol-2-yl)-4-fluorobenzamide
383867-49-0P, 4-Fluoro-N-(4-methoxy-7-(2-(morpholin-4-yl)thiazol-4-
yl)benzothiazol-2-yl)benzamide 383867-50-3P,
N-(7-(2-Aminothiazol-4-yl)-4-methoxybenzothiazol-2-yl)-4-fluorobenzamide
383867-51-4P, 4-Fluoro-N-(4-methoxy-7-(2-(6-methyl-pyridin-3-
yl)thiazol-4-yl)benzothiazol-2-yl)benzamide 383867-52-5P,
N-(7-(2-(Dimethylamino)thiazol-4-yl)-4-methoxybenzothiazol-2-yl)-4-
fluorobenzamide 383867-53-6P, 4-Fluoro-N-(4-methoxy-7-(thiophen-
2-yl)benzothiazol-2-yl)benzamide 383867-54-7P,
4-Fluoro-N-(4-methoxy-7-(2-(4-methylpiperazin-1-yl)thiazol-4-
yl)benzothiazol-2-yl)benzamide 383867-55-8P,
4-Fluoro-N-(4-methoxy-7-(2-(pyridin-2-yl)thiazol-4-yl)benzothiazol-2-
yl)benzamide 383867-56-9P, 4-Fluoro-N-(4-methoxy-7-(2-
(pyrrolidin-1-yl)thiazol-4-yl)benzothiazol-2-yl)benzamide
383867-57-0P, 4-Fluoro-N-(4-methoxy-7-(2-methylthiazol-4-
yl)benzothiazol-2-yl)benzamide 383867-58-1P,
4-Fluoro-N-(4-methoxy-7-(5-methylthien-2-yl)benzothiazol-2-yl)benzamide
383867-59-2P, N-(7-(2,5-Dimethylthiazol-4-yl)-4-methoxy-
benzothiazol-2-yl)-4-fluorobenzamide 383867-61-6P,
4-Chloromethyl-N-(4-methoxy-7-(2-(6-methyl-pyridin-3-yl)thiazol-4-
yl)benzothiazol-2-yl)benzamide 383867-62-7P,

4-Chloromethyl-N-(4-methoxy-7-(2-(tritylamino)thiazol-4-yl)benzothiazol-2-
yl)benzamide 383867-63-8P, 4-Chloromethyl-N-(7-(2-
(dimethylamino)thiazol-4-yl)-4-methoxybenzothiazol-2-yl)benzamide
383867-64-9P, 4-Chloromethyl-N-(4-methoxy-7-(thien-2-
yl)benzothiazol-2-yl)benzamide 383867-65-0P,

4-Chloromethyl-N-(4-methoxy-7-(2-(pyridin-2-yl)thiazol-4-yl)benzothiazol-2-
yl)benzamide 383867-66-1P, 4-Chloromethyl-N-(4-methoxy-7-(2-
methylthiazol-4-yl)benzothiazol-2-yl)benzamide 383867-67-2P,
4-Chloromethyl-N-(4-methoxy-7-(5-methylthien-2-yl)benzothiazol-2-

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
yl)benzamide 383867-68-3P, 4-[(N-(2-Methoxyethyl)-N-
methylamino]methyl]-N-(4-methoxy-7-(2-(morpholin-4-yl)thiazol-4-
yl)benzothiazol-2-yl)benzamide 383867-69-4P,
4-[[N-(2-Methoxyethyl)-N-methylamino]methyl]-N-(4-methoxy-7-(2-
(tritylamino)thiazol-4-yl)benzothiazol-2-yl)benzamide 383867-71-8P
,
4-[[N-(2-Methoxyethyl)-N-methylamino]methyl]-N-(4-methoxy-7-(2-(6-methyl-
pyridin-3-yl)thiazol-4-yl)benzothiazol-2-yl)benzamide 383867-72-9P
, N-(7-(2-(Dimethylamino)thiazol-4-yl)-4-methoxybenzothiazol-2-yl)-4-[[N-
(2-methoxyethyl)-N-methylamino]methyl]benzamide 383867-73-0P,
4-[[N-(2-Methoxyethyl)-N-methylamino]methyl]-N-(4-methoxy-7-(thien-2-
yl)benzothiazol-2-yl)benzamide 383867-74-1P,

4-[[N-(2-Methoxyethyl)-N-methylamino]methyl]-N-[4-methoxy-7-(2-(pyridin-2-
yl)thiazol-4-yl)benzothiazol-2-yl]benzamide 383867-75-2P,
4-[[N-(2-Methoxyethyl)-N-methylamino]methyl]-N-(4-methoxy-7-(2-
methylthiazol-4-yl)benzothiazol-2-yl)benzamide 383867-76-3P,

4-[[N-(2-Methoxyethyl)-N-methylamino]methyl]-N-[4-methoxy-7-(5-methylthien-
2-yl)benzothiazol-2-yl]benzamide 383867-77-4P,
N-[4-Methoxy-7-(2-(morpholin-4-yl)thiazol-4-yl)benzothiazol-2-yl]-4-
(pyrrolidin-1-ylmethyl)benzamide 383867-78-5P,

N-[4-Methoxy-7-(2-(6-methyl-pyridin-3-yl)thiazol-4-yl]benzothiazol-2-yl]-4-
(pyrrolidin-1-yl-methyl)benzamide 383867-80-9P,
N-[7-(2-Aminothiazol-4-yl)-4-methoxybenzothiazol-2-yl]-4-(pyrrolidin-1-
ylmethyl)benzamide hydrochloride 383867-81-0P,
N-[7-(2-(Dimethylamino)thiazol-4-yl)-4-methoxybenzothiazol-2-yl]-4-
(pyrrolidin-1-ylmethyl)benzamide 383867-82-1P,
N-(4-Methoxy-7-(thien-2-yl)benzothiazol-2-yl)-4-(pyrrolidin-1-
ylmethyl)benzamide 383867-83-2P, N-[4-Methoxy-7-(2-(pyridin-2-
yl)thiazol-4-yl)benzothiazol-2-yl]-4-(pyrrolidin-1-ylmethyl)benzamide
383867-84-3P, N-(4-Methoxy-7-(5-methylthien-2-yl)benzothiazol-2-
yl)-4-(pyrrolidin-1-yl-methyl)benzamide 383867-85-4P,

N-[4-Methoxy-7-(2-methylthiazol-4-yl)benzothiazol-2-yl]-4-(pyrrolidin-1-yl-
methyl)benzamide 383867-86-5P, N-(4-Methoxy-7-(thien-2-
yl)benzothiazol-2-yl)-2-methylisonicotinamide 383867-87-6P,
N-[4-Methoxy-7-(2-(pyridin-2-yl)thiazol-4-yl)benzothiazol-2-yl]-2-
methylisonicotinamide 383867-88-7P, N-[4-Methoxy-7-(2-
(pyrrolidin-1-yl)thiazol-4-yl)benzothiazol-2-yl]-2-methylisonicotinamide
383867-89-8P, N-(4-Methoxy-7-[2-(4-methylpiperazin-1-yl)-thiazol-4-
yl]benzothiazol-2-yl]-2-methylisonicotinamide 383867-90-1P,
N-[4-Methoxy-7-(5-methylthien-2-yl)benzothiazol-2-yl]-2-
methylisonicotinamide 383867-91-2P, Morpholine-4-carboxylic acid

[4-methoxy-7-[2-(6-methylpyridin-3-yl)thiazol-4-yl]benzothiazol-2-yl]amide
383867-92-3P 383867-93-4P, Morpholine-4-carboxylic acid
[4-methoxy-7-(2-methylthiazol-4-yl)benzothiazol-2-yl]amide
383867-94-5P, Morpholine-4-carboxylic acid [4-methoxy-7-[2-(4-
methylpiperazin-1-yl)thiazol-4-yl]benzothiazol-2-yl]amide
383867-95-6P, Morpholine-4-carboxylic acid [4-methoxy-7-(2-
(piperidin-1-yl)thiazol-4-yl)benzothiazol-2-yl]amide 383867-96-7P
, Morpholine-4-carboxylic acid (4-methoxy-7-(thien-2-yl)benzothiazol-2-
yl)amide 383867-97-8P, Morpholine-4-carboxylic acid
[4-methoxy-7-(5-methylthien-2-yl)benzothiazol-2-yl]amide
383867-98-9P, 4-Hydroxypiperidine-1-carboxylic acid
[4-methoxy-7-(2-methylthiazol-4-yl)benzothiazol-2-yl]amide
383867-99-0P, 4-Hydroxypiperidine-1-carboxylic acid
(4-methoxy-7-(5-methylthien-2-yl)benzothiazol-2-yl]amide

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
383868-00-6P, 4-Methylpiperazine-1-carboxylic acid
[4-methoxy-7-(2-methylthiazol-4-yl)benzothiazol-2-yl]amide
383868-01-7P, N-[2-[4-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-
ylcarbamoyl)phenyl]ethyl]-N-methylcarbamic acid tert-butyl ester
383868-03-9P, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-
(1,1,2,2-tetrafluoroethoxy)benzamide 383868-05-1P,
4-[N-(2-Methoxyethyl)-N-methylsulfamoyl]-N-(4-methoxy-7-(morpholin-4-
yl)benzothiazol-2-yl)benzamide 383868-06-2P,
N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-
trifluoromethylbenzamide 383868-07-3P, N-(4-Methoxy-7-(morpholin-
4-yl)benzothiazol-2-yl)-3-trifluoromethoxybenzamide 383868-08-4P
, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-
trifluoromethoxybenzamide 383868-09-5P, 4-Ethyl-N-(4-methoxy-7-
(morpholin-4-yl)benzothiazol-2-yl)benzamide 383868-10-8P,
4-Fluoro-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide
383868-11-9P, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-2-
methylisonicotinamide 383868-12-0P, N-(4-Methoxy-7-(morpholin-4-
yl)benzothiazol-2-yl)benzamide 383868-13-1P,
4-Chloro-3-[[N-ethyl-N-(2-methoxyethyl)amino]methyl]-N-(4-methoxy-7-
(morpholin-4-yl)benzothiazol-2-yl)benzamide 383868-14-2P,
N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-3-((N-
methylamino)methyl)benzamide 383868-15-3P, 4-Chloro-N-(4-methoxy-
7-(morpholin-4-yl)benzothiazol-2-yl)-3-((N-methylamino)methyl)benzamide
383868-16-4P, 4-Chloro-3-[[N-(2-methoxyethyl)-N-
methylamino]methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-
yl)benzamide 383868-17-5P, 4-Chloro-3-[N-(2-
methoxyethylamino)methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-
yl)benzamide 383868-18-6P, 4-Chloro-N-(4-methoxy-7-(morpholin-4-
yl)benzothiazol-2-yl)-3-(pyrrolidin-1-ylmethyl)benzamide
383868-19-7P, 1-[4-(4-Benzyloxy-7-(morpholin-4-yl)benzothiazol-2-
ylcarbamoyl)benzyl]pyridinium chloride 383868-21-1P,

3-Fluoro-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-(pyrrolidin-1-
ylmethyl)benzamide 383868-22-2P, 3-[N-(2-Methoxy-
ethylamino)methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-
yl)benzamide 383868-23-3P, 3-[[N-(2-Methoxyethyl)-N-
methylamino]methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-
yl)benzamide 383868-24-4P, 1-[4-(4-Methoxy-7-(morpholin-4-
yl)benzothiazol-2-ylcarbamoyl)benzyl]pyridinium chloride
383868-25-5P, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-3-
(pyrrolidin-1-ylmethyl)benzamide 383868-26-6P,
4-[N-(2-Ethoxyethylamino)methyl]-N-(4-methoxy-7-(morpholin-4-
yl)benzothiazol-2-yl)-benzamide 383868-27-7P,
(R)-N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-((3-
methoxypyrrolidin-1-yl)methyl)benzamide 383868-29-9P,
(S)-N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-((3-
methoxypyrrolidin-1-yl)methyl)benzamide 383868-30-2P,
4-(Azetidin-1-ylmethyl)-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-
yl)benzamide 383868-31-3P, 4-[1-(2-Methoxyethylamino)ethyl]-N-(4-
methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide 383868-32-4P
,
4-[1-[N-(2-Methoxyethyl)-N-methylamino]ethyl]-N-(4-methoxy-7-(morpholin-
4-yl)benzothiazol-2-yl)benzamide 383868-33-5P,
N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-(1-(pyrrolidin-1-
yl)ethyl)benzamide 383868-34-6P, 4-(2-
(Dimethylamino)ethylsulfanylmethyl)-N-(4-methoxy-7-(morpholin-4-
yl)benzothiazol-2-yl)benzamide 383868-35-7P,
N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-[[N-methyl-N-(4,4,4-
trifluoro-3-hydroxybutyl)amino]methyl]benzamide 383868-37-9P,
4-[[N-Ethyl-N-(2-methoxy-ethyl)amino]methyl]-N-(4-methoxy-7-(morpholin-4-

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
yl)benzothiazol-2-yl)benzamide 383868-38-0P,
4-[[N-(2-Ethoxyethyl)-N-ethylamino]methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide 383868-40-4P,
3-Fluoro-4-[[N-(2-methoxyethyl)-N-methylamino]methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide 383868-41-5P,
4-[[N,N-Bis(2-ethoxyethyl)amino]methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide 383868-42-6P,
4-[[N-(2-Ethoxyethyl)-N-methylamino]methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide 383868-43-7P,

N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-((4-methoxypiperidin-1-yl)methyl)benzamide 383868-44-8P, 4-(Diethylamino)methyl-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide 383868-45-9P
,
4-[N-(2-Methoxyethylamino)methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide 383868-46-0P, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-((2-methylimidazol-1-yl)methyl)benzamide 383868-47-1P, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-((4-methylpiperazin-1-yl)methyl)benzamide 383868-48-2P,
N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-((pyrrolidin-1-yl)methyl)benzamide 383868-49-3P, N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-((morpholin-4-yl)methyl)benzamide 383868-50-6P, N-(4-Benzyloxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-[[N-(2-methoxyethyl)-N-methylamino]methyl]benzamide 383868-52-8P
,
N-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-[[N-methyl-N-(3,3,3-trifluoropropyl)amino]methyl]benzamide hydrochloride 383868-53-9P
,
4-((2-Methoxyethoxy)methyl)-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide 383868-54-0P, 4-Methoxymethyl-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide 383868-55-1P
383868-59-5P 383868-60-8P 383868-61-9P
383868-62-0P 383868-66-4P, N-(4-Hydroxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide 383868-69-7P 383868-70-0P
, 4-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-ylcarbamoyl)piperidine-1-carboxylic acid tert-butyl ester 383868-71-1P
383868-72-2P, Piperidine-4-carboxylic acid (4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)amide 383868-73-3P 383868-75-5P
383868-76-6P 383868-78-8P 383868-79-9P
383868-80-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-benzothiazolyl amides having affinity toward A2A adenosine receptor)
RN 5005-14-1 CAPLUS
CN Benzamide, N-2-benzothiazolyl- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 35412-20-5 CAPLUS
CN Benzamide, N-(4-methoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 87874-18-8 CAPLUS
CN 2-Furancarboxamide, N-2-benzothiazolyl- (9CI) (CA INDEX NAME)



RN 300567-89-9 CAPLUS
CN 2-Furancarboxamide, N-(4-methoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 313375-58-5 CAPLUS
CN Benzamide, N-(4,6-difluoro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383864-82-2 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 383864-84-4 CAPLUS
CN 2-Furancarboxamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 383864-86-6 CAPLUS
CN 2-Furancarboxamide, N-(4,6-difluoro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 383864-87-7 CAPLUS
CN 2-Thiophenecarboxamide, N-(4,6-difluoro-2-benzothiazolyl)-5-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383864-89-9 CAPLUS
CN Benzamide, 4-cyano-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 383864-91-3 CAPLUS
CN 2-Furancarboxamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 383864-92-4 CAPLUS
CN Benzo[b]thiophene-2-carboxamide, N-2-benzothiazolyl- (9CI) (CA INDEX NAME)



RN 383864-93-5 CAPLUS
CN 2-Thiophenecarboxamide, N-2-benzothiazolyl-3-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383864-94-6 CAPLUS
CN 2-Thiophenecarboxamide, N-2-benzothiazolyl-5-methyl- (9CI) (CA INDEX NAME)



RN 383864-95-7 CAPLUS
CN 3-Pyridinecarboxamide, N-2-benzothiazolyl-6-chloro- (9CI) (CA INDEX NAME)



RN 383864-96-8 CAPLUS
CN Benzamide, 4-(hydroxymethyl)-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 383864-98-0 CAPLUS
CN Benzamide, 2-methoxy-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383864-99-1 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 383865-00-7 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 383865-01-8 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 383865-02-9 CAPLUS
CN Benzamide, 4-fluoro-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 383865-03-0 CAPLUS
CN Benzamide, 3-methoxy-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 383865-04-1 CAPLUS
CN Benzamide, 4-methoxy-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 383865-06-3 CAPLUS
CN 2-Thiophenecarboxamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-3-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 383865-07-4 CAPLUS
CN 3-Furancarboxamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 383865-08-5 CAPLUS
CN Benzamide, 3-cyano-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 383865-09-6 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 383865-11-0 CAPLUS
CN Benzamide, 4-(dimethylamino)-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 383865-14-3 CAPLUS
CN 7-Benzothiazolecarboxylic acid, 2-[(4-fluorobenzoyl)amino]-4-methoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 383865-16-5 CAPLUS
CN Benzamide, N-[7-(1,1-dimethylethyl)-4-methoxy-2-benzothiazolyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 383865-19-8 CAPLUS
CN 4-Pyridinecarboxamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 383865-20-1 CAPLUS
CN Benzamide, 4-fluoro-N-(4-methoxy-7-phenoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383865-21-2 CAPLUS
CN 2-Thiophenecarboxamide, N-(4-methoxy-7-phenoxy-2-benzothiazolyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 383865-22-3 CAPLUS
CN Benzamide, 4-fluoro-N-[4-methoxy-7-(4-morpholinylmethyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383865-24-5 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-methoxy-7-(4-morpholinylmethyl)-2-benzothiazolyl]-5-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383865-25-6 CAPLUS
CN Benzamide, 4-fluoro-N-[4-methoxy-7-(1H-tetrazol-5-yl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383865-27-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-(4-methyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 383865-28-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-(4-methoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383865-30-3 CAPLUS
CN Benzamide, 4-fluoro-N-[7-(hydroxymethyl)-4-methoxy-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383865-31-4 CAPLUS
CN Benzamide, 4-[(dipropylamino)sulfonyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 383865-32-5 CAPLUS
CN Benzamide, 4-[(diethylamino)sulfonyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 383865-33-6 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-(4-morpholinylsulfonyl)- (9CI) (CA INDEX NAME)



RN 383865-34-7 CAPLUS
CN Benzamide, 4-[(ethylamino)sulfonyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 383865-36-9 CAPLUS
CN 2-Thiophenecarboxamide, N-[7-(2-chlorophenyl)-4-methoxy-2-benzothiazolyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 383865-37-0 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-methoxy-7-(3-nitrophenyl)-2-benzothiazolyl]-5-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383865-38-1 CAPLUS
CN 2-Thiophenecarboxamide, N-[7-[3-(dimethylamino)phenyl]-4-methoxy-2-benzothiazolyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 383865-39-2 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-methoxy-7-(4-pyridinyl)-2-benzothiazolyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 383865-41-6 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-methoxy-7-(3-pyridinyl)-2-benzothiazolyl]-5-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383865-42-7 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-methoxy-7-(2-pyridinyl)-2-benzothiazolyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 383865-43-8 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-methoxy-7-(2-methyl-4-pyridinyl)-2-benzothiazolyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 383865-44-9 CAPLUS
CN 2-Thiophenecarboxamide, N-[7-(3-aminophenyl)-4-methoxy-2-benzothiazolyl]-5-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383865-45-0 CAPLUS
CN 2-Thiophenecarboxamide, N-(4-hydroxy-7-phenyl-2-benzothiazolyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 383865-47-2 CAPLUS
CN 2-Thiophenecarboxamide, N-[7-[3-(dimethylamino)-1-pyrrolidinyl]-4-methoxy-2-benzothiazolyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 383865-48-3 CAPLUS
CN 2-Thiophenecarboxamide, N-(5-methoxy-7-phenyl-2-benzothiazolyl)-5-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 383865-50-7 CAPLUS
CN 2-Thiophenecarboxamide, N-(4,5-dimethoxy-2-benzothiazolyl)-5-methyl- (9CI)
(CA INDEX NAME)



RN 383865-52-9 CAPLUS
CN 2-Thiophenecarboxamide, N-(4-chloro-2-benzothiazolyl)-5-methyl- (9CI) (CA
INDEX NAME)



RN 383865-54-1 CAPLUS
CN 2-Thiophenecarboxamide, N-(4-fluoro-2-benzothiazolyl)-5-methyl- (9CI) (CA
INDEX NAME)



RN 383865-55-2 CAPLUS
CN 2-Thiophenecarboxamide,
5-methyl-N-[4-(trifluoromethoxy)-2-benzothiazolyl]-
(9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383865-56-3 CAPLUS
CN 2-Thiophenecarboxamide,
N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-5-
methyl- (9CI) (CA INDEX NAME)



RN 383865-58-5 CAPLUS
CN 2-Pyridinecarboxamide, 1,6-dihydro-N-(4-methoxy-2-benzothiazolyl)-6-oxo-
(9CI) (CA INDEX NAME)



RN 383865-60-9 CAPLUS
CN 2-Thiophenecarboxamide,
N-[4-methoxy-7-(phenylmethoxy)-2-benzothiazolyl]-5-
methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383865-62-1 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-6-(1-
pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 383865-63-2 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-6-(1-
piperidinyl)- (9CI) (CA INDEX NAME)



RN 383865-65-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-6-(4-
morpholinyl)- (9CI) (CA INDEX NAME)



RN 383865-67-6 CAPLUS
CN 3-Pyridinecarboxamide,
N-(4-methoxy-7-phenyl-2-benzothiazolyl)-6-(4-methyl-
1-piperazinyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383865-71-2 CAPLUS
CN 3-Pyridinecarboxamide,
N-(4-methoxy-7-phenyl-2-benzothiazolyl)-6-(1-oxido-
4-thiomorpholinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383865-74-5 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-(1-
pyrrolidinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383865-75-6 CAPLUS
CN Benzamide,
N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-(1-piperidinylmethyl)-
, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 383865-76-7 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-(4-morpholinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383865-78-9 CAPLUS
CN Benzamide, 4-[(diethylamino)methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383865-80-3 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-[[methyl(3-

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 383865-84-7 CAPLUS
CN Benzamide, 4-[(ethylamino)methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383865-85-8 CAPLUS
CN Benzamide, 4-[[(2-methoxyethyl)amino]methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383865-86-9 CAPLUS
CN Benzamide, 4-[[(2-hydroxyethyl)amino]methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383865-87-0 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
pyridinylmethyl)amino]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 383865-82-5 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-[(4-methyl-1-piperazinyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 383865-83-6 CAPLUS
CN Benzamide, 4-[(dimethylamino)methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
[[(phenylmethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383865-88-1 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-[[methyl(phenylmethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383865-89-2 CAPLUS
CN Benzamide, 4-[[[3-(1H-imidazol-1-yl)propyl]amino]methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 383865-90-5 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-[[(4-

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
pyridinylmethyl)amino]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 383865-91-6 CAPLUS
CN Benzamide,
4-[[(2-methoxyethyl)methylamino]methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383865-92-7 CAPLUS
CN Benzamide,
4-[(1,1-dioxido-4-thiomorpholinyl)methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 383865-94-9 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-(4-thiomorpholinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383865-95-0 CAPLUS
CN Benzamide, 4-(1H-imidazol-1-ylmethyl)-N-(4-methoxy-7-phenyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383865-96-1 CAPLUS
CN Benzamide, 4-[[2-(hydroxymethyl)-1H-imidazol-1-yl]methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383865-97-2 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-[(2-methyl-1H-imidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 383865-98-3 CAPLUS
CN Benzamide,
4-[(4,5-dimethyl-1H-imidazol-1-yl)methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 383865-99-4 CAPLUS
CN Benzamide,
N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-(1-piperazinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●2 HCl

RN 383866-00-0 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-[(2-propenylamino)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383866-01-1 CAPLUS
CN Benzamide,
N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-[(propylamino)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383866-02-2 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-[[(3-pyridinylmethyl)amino]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●2 HCl

RN 383866-03-3 CAPLUS
CN Benzamide, 4-[(4-hydroxy-1-piperidinyl)methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383866-04-4 CAPLUS
CN Benzamide,
4-[[(3S)-3-hydroxy-1-pyrrolidinyl]methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●2 HCl

RN 383866-08-8 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-[[[2-(1-pyrrolidinyl)ethyl]amino]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 383866-09-9 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-[[[2-(1-piperidinyl)ethyl]amino]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 383866-10-2 CAPLUS
CN Benzamide, 4-[(cyclobutylamino)methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 383866-05-5 CAPLUS
CN Benzamide, 4-[(hexahydro-1H-1,4-diazepin-1-yl)methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 383866-06-6 CAPLUS
CN Benzamide,
4-[[(3R)-3-(dimethylamino)-1-pyrrolidinyl]methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 383866-07-7 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-[[[2-(4-morpholinyl)ethyl]amino]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 383866-11-3 CAPLUS
CN Benzamide, 4-[(cyclopentylamino)methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383866-12-4 CAPLUS
CN Benzamide, 4-[[(2-furanylmethyl)amino]methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383866-13-5 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-[[[2-thienylmethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 383866-14-6 CAPLUS
CN Benzamide, 4-[(dipropylamino)methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383866-15-7 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 383866-16-8 CAPLUS
CN Benzamide, 4-(aminomethyl)-N-(4-methoxy-7-phenyl-2-benzothiazolyl)-,

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-(3-thiazolidinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383866-20-4 CAPLUS
CN Benzamide,
4-[[(3S)-3-(dimethylamino)-1-pyrrolidinyl]methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 383866-21-5 CAPLUS
CN Benzamide,
4-[[[2-(dimethylamino)ethyl]amino]methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383866-17-9 CAPLUS
CN Benzamide, 4-[[(cyclopropylmethyl)amino]methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383866-18-0 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-[[[2-(methylthio)ethyl]amino]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 383866-19-1 CAPLUS

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 383866-23-7 CAPLUS
CN Benzamide, 4-[(4-hydroxy-1-piperidinyl)methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383866-24-8 CAPLUS
CN Benzamide, 4-[[(2-methoxyethyl)methylamino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383866-25-9 CAPLUS
CN Benzamide, 4-[[(2-hydroxyethyl)methylamino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383866-28-2 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-(1-piperazinylmethyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383866-29-3 CAPLUS
CN Benzamide, 4-(chloromethyl)-N-[4-methoxy-7-(phenylmethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383866-30-6 CAPLUS
CN Benzamide, 4-[[3-(dimethylamino)-1-pyrrolidinyl]methyl]-N-[4-methoxy-7-(phenylmethoxy)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 383866-31-7 CAPLUS
CN 4-Thiomorpholinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383866-32-8 CAPLUS
CN 4-Morpholinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383866-54-4 CAPLUS
CN 2(1H)-Isoquinolinecarboxamide, 3,4-dihydro-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 383866-72-6 CAPLUS
CN 4-Morpholinecarboxamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383866-76-0 CAPLUS
CN 4-Thiomorpholinecarboxamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-, 1-oxide (9CI) (CA INDEX NAME)



RN 383867-12-7 CAPLUS
CN Benzamide, N-(7-ethyl-4-methoxy-2-benzothiazolyl)-4-fluoro- (9CI) (CA INDEX NAME)



RN 383867-49-0 CAPLUS
CN Benzamide, 4-fluoro-N-[4-methoxy-7-[2-(4-morpholinyl)-4-thiazolyl]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383867-50-3 CAPLUS
CN Benzamide, N-[7-(2-amino-4-thiazolyl)-4-methoxy-2-benzothiazolyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 383867-51-4 CAPLUS
CN Benzamide, 4-fluoro-N-[4-methoxy-7-[2-(6-methyl-3-pyridinyl)-4-thiazolyl]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 383867-52-5 CAPLUS
CN Benzamide, N-[7-[2-(dimethylamino)-4-thiazolyl]-4-methoxy-2-benzothiazolyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 383867-53-6 CAPLUS
CN Benzamide, 4-fluoro-N-[4-methoxy-7-(2-thienyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383867-54-7 CAPLUS
CN Benzamide, 4-fluoro-N-[4-methoxy-7-[2-(4-methyl-1-piperazinyl)-4-thiazolyl]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383867-55-8 CAPLUS
CN Benzamide, 4-fluoro-N-[4-methoxy-7-[2-(2-pyridinyl)-4-thiazolyl]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383867-56-9 CAPLUS
CN Benzamide, 4-fluoro-N-[4-methoxy-7-[2-(1-pyrrolidinyl)-4-thiazolyl]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383867-57-0 CAPLUS
CN Benzamide, 4-fluoro-N-[4-methoxy-7-(2-methyl-4-thiazolyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383867-58-1 CAPLUS
CN Benzamide, 4-fluoro-N-[4-methoxy-7-(5-methyl-2-thienyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383867-59-2 CAPLUS
CN Benzamide, N-[7-(2,5-dimethyl-4-thiazolyl)-4-methoxy-2-benzothiazolyl]-4-fluoro- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383867-61-6 CAPLUS
CN Benzamide, 4-(chloromethyl)-N-[4-methoxy-7-[2-(6-methyl-3-pyridinyl)-4-thiazolyl]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383867-62-7 CAPLUS
CN Benzamide, 4-(chloromethyl)-N-[4-methoxy-7-[2-[(triphenylmethyl)amino]-4-thiazolyl]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383867-63-8 CAPLUS
CN Benzamide, 4-(chloromethyl)-N-[7-[2-(dimethylamino)-4-thiazolyl]-4-methoxy-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383867-64-9 CAPLUS
CN Benzamide, 4-(chloromethyl)-N-[4-methoxy-7-(2-thienyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383867-65-0 CAPLUS
CN Benzamide, 4-(chloromethyl)-N-[4-methoxy-7-[2-(2-pyridinyl)-4-thiazolyl]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383867-66-1 CAPLUS
CN Benzamide, 4-(chloromethyl)-N-[4-methoxy-7-(2-methyl-4-thiazolyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383867-67-2 CAPLUS
CN Benzamide, 4-(chloromethyl)-N-[4-methoxy-7-(5-methyl-2-thienyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383867-68-3 CAPLUS
CN Benzamide, 4-[[(2-methoxyethyl)methylamino]methyl]-N-[4-methoxy-7-[2-(4-morpholinyl)-4-thiazolyl]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383867-69-4 CAPLUS
CN Benzamide, 4-[[(2-methoxyethyl)methylamino]methyl]-N-[4-methoxy-7-[2-

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
[(triphenylmethyl)amino]-4-thiazolyl]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383867-71-8 CAPLUS
CN Benzamide, 4-[[(2-methoxyethyl)methylamino]methyl]-N-[4-methoxy-7-[2-(6-methyl-3-pyridinyl)-4-thiazolyl]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383867-72-9 CAPLUS
CN Benzamide, N-[7-[2-(dimethylamino)-4-thiazolyl]-4-methoxy-2-benzothiazolyl]-4-[[(2-methoxyethyl)methylamino]methyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 383867-73-0 CAPLUS
CN Benzamide, 4-[[(2-methoxyethyl)methylamino]methyl]-N-[4-methoxy-7-(2-thienyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383867-74-1 CAPLUS
CN Benzamide, 4-[[(2-methoxyethyl)methylamino]methyl]-N-[4-methoxy-7-[2-(2-pyridinyl)-4-thiazolyl]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383867-75-2 CAPLUS
CN Benzamide, 4-[[(2-methoxyethyl)methylamino]methyl]-N-[4-methoxy-7-(2-methyl-4-thiazolyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383867-76-3 CAPLUS
CN Benzamide, 4-[[(2-methoxyethyl)methylamino]methyl]-N-[4-methoxy-7-(5-methyl-2-thienyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383867-77-4 CAPLUS
CN Benzamide, N-[4-methoxy-7-[2-(4-morpholinyl)-4-thiazolyl]-2-benzothiazolyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 383867-78-5 CAPLUS
CN Benzamide, N-[4-methoxy-7-[2-(6-methyl-3-pyridinyl)-4-thiazolyl]-2-benzothiazolyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383867-80-9 CAPLUS
CN Benzamide, N-[7-(2-amino-4-thiazolyl)-4-methoxy-2-benzothiazolyl]-4-(1-pyrrolidinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383867-81-0 CAPLUS
CN Benzamide, N-[7-[2-(dimethylamino)-4-thiazolyl]-4-methoxy-2-benzothiazolyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383867-82-1 CAPLUS
CN Benzamide, N-[4-methoxy-7-(2-thienyl)-2-benzothiazolyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 383867-83-2 CAPLUS
CN Benzamide, N-[4-methoxy-7-[2-(2-pyridinyl)-4-thiazolyl]-2-benzothiazolyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 383867-84-3 CAPLUS
CN Benzamide, N-[4-methoxy-7-(5-methyl-2-thienyl)-2-benzothiazolyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383867-85-4 CAPLUS
CN Benzamide, N-[4-methoxy-7-(2-methyl-4-thiazolyl)-2-benzothiazolyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 383867-86-5 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(2-thienyl)-2-benzothiazolyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 383867-87-6 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-[2-(2-pyridinyl)-4-thiazolyl]-2-benzothiazolyl]-2-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383867-88-7 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-[2-(1-pyrrolidinyl)-4-thiazolyl]-2-benzothiazolyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 383867-89-8 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-[2-(4-methyl-1-piperazinyl)-4-thiazolyl]-2-benzothiazolyl]-2-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383867-90-1 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(5-methyl-2-thienyl)-2-benzothiazolyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 383867-91-2 CAPLUS
CN 4-Morpholinecarboxamide, N-[4-methoxy-7-[2-(6-methyl-3-pyridinyl)-4-thiazolyl]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383867-92-3 CAPLUS
CN 4-Morpholinecarboxamide, N-[4-methoxy-7-[2-(2-pyridinyl)-4-thiazolyl]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383867-93-4 CAPLUS
CN 4-Morpholinecarboxamide, N-[4-methoxy-7-(2-methyl-4-thiazolyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383867-94-5 CAPLUS
CN 4-Morpholinecarboxamide, N-[4-methoxy-7-[2-(4-methyl-1-piperazinyl)-4-

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

thiazolyl]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383867-95-6 CAPLUS
CN 4-Morpholinecarboxamide, N-[4-methoxy-7-[2-(1-piperidinyl)-4-thiazolyl]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383867-96-7 CAPLUS
CN 4-Morpholinecarboxamide, N-[4-methoxy-7-(2-thienyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 383867-97-8 CAPLUS
CN 4-Morpholinecarboxamide, N-[4-methoxy-7-(5-methyl-2-thienyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383867-98-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[4-methoxy-7-(2-methyl-4-thiazolyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383867-99-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[4-methoxy-7-(5-methyl-2-thienyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-00-6 CAPLUS

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1-Piperazinecarboxamide, N-[4-methoxy-7-(2-methyl-4-thiazolyl)-2-benzothiazolyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 383868-01-7 CAPLUS
CN Carbamic acid, [2-[4-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]amino]carbonyl]phenyl]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 383868-03-9 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-(1,1,2,2-tetrafluoroethoxy)- (9CI) (CA INDEX NAME)



RN 383868-05-1 CAPLUS
CN Benzamide, 4-[[(2-methoxyethyl)methylamino]sulfonyl]-N-[4-methoxy-7-(4-

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-06-2 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 383868-07-3 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 383868-08-4 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383868-09-5 CAPLUS
CN Benzamide, 4-ethyl-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI)
(CA INDEX NAME)



RN 383868-10-8 CAPLUS
CN Benzamide, 4-fluoro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-11-9 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-2-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383868-12-0 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-13-1 CAPLUS
CN Benzamide,
4-chloro-3-[[ethyl(2-methoxyethyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-14-2 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-3-[(methylamino)methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383868-15-3 CAPLUS
CN Benzamide, 4-chloro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-3-[(methylamino)methyl]- (9CI) (CA INDEX NAME)



RN 383868-16-4 CAPLUS
CN Benzamide,
4-chloro-3-[[(2-methoxyethyl)methylamino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-17-5 CAPLUS
CN Benzamide, 4-chloro-3-[[(2-methoxyethyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383868-18-6 CAPLUS
CN Benzamide,
4-chloro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-3-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 383868-19-7 CAPLUS
CN Pyridinium, 1-[[4-[[[7-(4-morpholinyl)-4-(phenylmethoxy)-2-benzothiazolyl]amino]carbonyl]phenyl]methyl]-, chloride (9CI) (CA INDEX NAME)



● Cl⁻

RN 383868-21-1 CAPLUS
CN Benzamide,
3-fluoro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383868-22-2 CAPLUS
CN Benzamide, 3-[[(2-methoxyethyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-23-3 CAPLUS
CN Benzamide, 3-[[(2-methoxyethyl)methylamino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-24-4 CAPLUS
CN Pyridinium, 1-[[4-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]amino]carbonyl]phenyl]methyl]-, chloride (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Cl⁻

RN 383868-25-5 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-3-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 383868-26-6 CAPLUS
CN Benzamide, 4-[[(2-ethoxyethyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-27-7 CAPLUS

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[[(3R)-3-methoxy-1-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 383868-29-9 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[[(3S)-3-methoxy-1-pyrrolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 383868-30-2 CAPLUS
CN Benzamide, 4-(1-azetidinylmethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383868-31-3 CAPLUS
CN Benzamide, 4-[1-[(2-methoxyethyl)amino]ethyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-32-4 CAPLUS
CN Benzamide, 4-[1-[(2-methoxyethyl)methylamino]ethyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-33-5 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[1-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383868-34-6 CAPLUS
CN Benzamide, 4-[(dimethylamino)(ethylthio)methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-35-7 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[[methyl(4,4,4-trifluoro-3-hydroxybutyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 383868-37-9 CAPLUS
CN Benzamide, 4-[[ethyl(2-methoxyethyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383868-38-0 CAPLUS
CN Benzamide, 4-[[(2-ethoxyethyl)ethylamino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-40-4 CAPLUS
CN Benzamide, 3-fluoro-4-[[(2-methoxyethyl)methylamino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-41-5 CAPLUS
CN Benzamide, 4-[[bis(2-ethoxyethyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383868-45-9 CAPLUS
CN Benzamide, 4-[[(2-methoxyethyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-46-0 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[(2-methyl-1H-imidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 383868-47-1 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383868-42-6 CAPLUS
CN Benzamide, 4-[[(2-ethoxyethyl)methylamino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-43-7 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[(4-methoxy-1-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 383868-44-8 CAPLUS
CN Benzamide, 4-[(diethylamino)methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383868-48-2 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 383868-49-3 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 383868-50-6 CAPLUS
CN Benzamide, 4-[[(2-methoxyethyl)methylamino]methyl]-N-[7-(4-morpholinyl)-4-(phenylmethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383868-52-8 CAPLUS
CN Benzamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[[methyl(3,3,3-trifluoropropyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383868-53-9 CAPLUS
CN Benzamide, 4-[(2-methoxyethoxy)methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-54-0 CAPLUS

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzamide, 4-(methoxymethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-55-1 CAPLUS
CN Benzamide, N-[4-methoxy-7-(1-oxido-4-thiomorpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-59-5 CAPLUS
CN 2-Thiophenecarboxamide, N-[7-(4-acetyl-1-piperazinyl)-4-methoxy-2-benzothiazolyl]-5-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 383868-60-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-methoxy-2-[[(5-methyl-2-thienyl)carbonyl]amino]-7-benzothiazolyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 383868-61-9 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-methoxy-7-(4-methyl-1-piperazinyl)-2-benzothiazolyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 383868-62-0 CAPLUS
CN 2-Thiophenecarboxamide, N-[7-(2,3-dihydro-1H-indol-6-yl)-4-methoxy-2-benzothiazolyl]-5-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383868-66-4 CAPLUS
CN Benzamide, N-[4-hydroxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-69-7 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-70-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383868-71-1 CAPLUS
CN 4-Piperidinecarboxamide, 1-acetyl-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-72-2 CAPLUS
CN 4-Piperidinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-73-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-[[(4-fluorophenyl)amino]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383868-79-9 CAPLUS
CN 1-Piperidinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[(2-oxo-1-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 383868-80-2 CAPLUS
CN 1-Piperazinecarboxamide, 4-(2-methoxyethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



IT 383868-81-3P 383868-83-5P 383868-84-6P
383868-87-9P 383868-89-1P 383868-91-5P
383868-93-7P 383868-95-9P 383869-00-9P
383869-01-0P 383869-02-1P 383869-03-2P
383869-05-4P 383869-07-6P 383869-09-8P
383869-11-2P 383869-13-4P 383869-15-6P
383869-19-0P 383869-21-4P 383869-25-8P
383869-27-0P 383869-29-2P 383869-31-6P

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383868-75-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-(hydroxymethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 383868-76-6 CAPLUS
CN Carbamic acid, [[1-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]amino]carbonyl]-4-piperidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 383868-78-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-ethyl-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

383869-34-9P 383869-37-2P 383869-42-9P,
N-[4-(4-Methoxy-7-(morpholin-4-yl)benzothiazol-2-ylcarbamoyl)benzyl]-N-methylcarbamic acid methyl ester 383869-44-1P
383869-48-5P, N-(4-Ethoxy-7-(piperidin-1-yl)benzothiazol-2-yl)-4-fluorobenzamide 383869-54-3P, 4-Fluoro-N-(4-isopropoxy-7-(piperidin-1-yl)benzothiazol-2-yl)benzamide 383869-60-1P,
4-Fluoro-N-(4-methoxy-7-(pyrrolidin-1-yl)benzothiazol-2-yl)benzamide 383869-63-4P, 4-Fluoro-N-(4-methoxy-7-([1,4]oxazepan-4-yl)benzothiazol-2-yl)benzamide 383869-66-7P 383869-69-0P
, N-(7-(Azepan-1-yl)-4-methoxybenzothiazol-2-yl)-4-nitrobenzamide
383869-71-4P 383869-73-6P, 4-Fluoro-N-[4-methoxy-7-(2-methylimidazol-1-yl)-benzothiazol-2-yl]-benzamide 383869-82-7P,
2-Chloro-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)isonicotinamide
383869-84-9P, 2-Iodo-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-6-methylisonicotinamide 383871-39-4P 383871-47-4P,
4-[(2-Methoxyethylamino)methyl]-N-(4-methoxy-7-phenylbenzothiazol-2-yl)-benzamide 383871-49-6P, 4-[(2-Hydroxyethylamino)methyl]-N-(4-methoxy-7-phenylbenzothiazol-2-yl)-benzamide 383871-51-0P,
N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-4-[[(pyridin-4-ylmethyl)amino]methyl]benzamide 383871-53-2P,
N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-4-[[(pyridin-3-ylmethyl)amino]methyl]benzamide 383871-55-4P,
4-Aminomethyl-N-(4-methoxy-7-phenylbenzothiazol-2-yl)-benzamide
383871-57-6P, N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-4-[(2-methylsulfanylethylamino)methyl]benzamide 383871-76-9P,
4-[((2-(Dimethylamino)ethyl)sulfanyl)methyl]-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-benzamide 383871-83-8P,
4-(Imidazol-1-ylmethyl)-N-(4-methoxy-7-phenylbenzothiazol-2-yl)-benzamide
383871-85-0P, 4-(4-Hydroxypiperidin-1-ylmethyl)-N-(4-methoxy-7-phenylbenzothiazol-2-yl)-benzamide 383871-89-4P,
4-([1,4]Diazepan-1-ylmethyl)-N-(4-methoxy-7-phenylbenzothiazol-2-yl)-benzamide 383871-91-8P, (S)-4-(3-(Dimethylamino)pyrrolidin-1-ylmethyl)-N-(4-methoxy-7-phenylbenzothiazol-2-yl)-benzamide
383911-03-3P 383911-05-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-benzothiazolyl amides having affinity toward A2A adenosine
receptor)

RN 383868-81-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-(cyanomethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-83-5 CAPLUS

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1-Piperidinecarboxamide, 4-[2-(4-chlorophenyl)tetrahydro-2-furanyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-84-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2-hydroxyethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383868-87-9 CAPLUS
CN 1-Piperazinecarboxamide, 4-(methoxyacetyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 383868-89-1 CAPLUS
CN 1-Piperidinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 383868-91-5 CAPLUS
CN 1-Piperidinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 383868-93-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclopropyl-4-hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 383868-95-9 CAPLUS
CN 4-Thiomorpholinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 383869-00-9 CAPLUS
CN Spiro[1,3-benzodioxole-2,4'-piperidine]-1'-carboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-01-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 383869-02-1 CAPLUS
CN 1-Piperidinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-3-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383869-03-2 CAPLUS
CN 1-Piperidinecarboxamide, 3-(hydroxymethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-05-4 CAPLUS
CN Spiro[isobenzofuran-1(3H),4'-piperidine]-1'-carboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-07-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383869-09-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 383869-11-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 383869-13-4 CAPLUS
CN 1-Piperidinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383869-25-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-27-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-methoxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-29-2 CAPLUS
CN 4-Thiomorpholinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-, 1-oxide (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383869-15-6 CAPLUS
CN [1,4'-Bipiperidine]-1'-carboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-19-0 CAPLUS
CN 1,4-Dioxa-8-azaspiro[4.5]decane-8-carboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-21-4 CAPLUS
CN 2(1H)-Isoquinolinecarboxamide, 3,4-dihydro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383869-31-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-[[(methylsulfonyl)oxy]methyl]- (9CI) (CA INDEX NAME)



RN 383869-34-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-37-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-(aminomethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383869-42-9 CAPLUS
CN Carbamic acid, [[4-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]amino]carbonyl]phenyl]methyl]methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 383869-44-1 CAPLUS
CN 4-Thiomorpholinecarboxamide, N-[4-methoxy-7-(1-piperidinyl)-2-benzothiazolyl]-, 1-oxide, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383869-48-5 CAPLUS

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzamide, N-[4-ethoxy-7-(1-piperidinyl)-2-benzothiazolyl]-4-fluoro-(9CI)
(CA INDEX NAME)



RN 383869-54-3 CAPLUS
CN Benzamide, 4-fluoro-N-[4-(1-methylethoxy)-7-(1-piperidinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-60-1 CAPLUS
CN Benzamide, 4-fluoro-N-[4-methoxy-7-(1-pyrrolidinyl)-2-benzothiazolyl]-(9CI) (CA INDEX NAME)



RN 383869-63-4 CAPLUS
CN Benzamide, 4-fluoro-N-[4-methoxy-7-(tetrahydro-1,4-oxazepin-4(5H)-yl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383869-66-7 CAPLUS
CN 4-Morpholinecarboxamide, N-[4-methoxy-7-(4-methoxy-1-piperidinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-69-0 CAPLUS
CN Benzamide, N-[7-(hexahydro-1H-azepin-1-yl)-4-methoxy-2-benzothiazolyl]-4-nitro- (9CI) (CA INDEX NAME)



RN 383869-71-4 CAPLUS
CN 4-Morpholinecarboxamide, N-[4-methoxy-7-(3-thienyl)-2-benzothiazolyl]-(9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383869-73-6 CAPLUS
CN Benzamide, 4-fluoro-N-[4-methoxy-7-(2-methyl-1H-imidazol-1-yl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-82-7 CAPLUS
CN 4-Pyridinecarboxamide, 2-chloro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383869-84-9 CAPLUS
CN 4-Pyridinecarboxamide, 2-iodo-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-6-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383871-39-4 CAPLUS
CN 4-Thiomorpholinecarboxamide, N-[4-methoxy-7-(1-piperidinyl)-2-benzothiazolyl]-, 1-oxide (9CI) (CA INDEX NAME)



RN 383871-47-4 CAPLUS
CN Benzamide, 4-[[(2-methoxyethyl)amino]methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 383871-49-6 CAPLUS
CN Benzamide, 4-[[(2-hydroxyethyl)amino]methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 383871-57-6 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-[[[2-(methylthio)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 383871-76-9 CAPLUS
CN Benzamide, 4-[[[2-(dimethylamino)ethyl]thio]methyl]-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383871-83-8 CAPLUS
CN Benzamide, 4-(1H-imidazol-1-ylmethyl)-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 383871-85-0 CAPLUS
CN Benzamide, 4-[(4-hydroxy-1-piperidinyl)methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383871-51-0 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-[[(4-pyridinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 383871-53-2 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-[[(3-pyridinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 383871-55-4 CAPLUS
CN Benzamide, 4-(aminomethyl)-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383871-89-4 CAPLUS
CN Benzamide, 4-[(hexahydro-1H-1,4-diazepin-1-yl)methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 383871-91-8 CAPLUS
CN Benzamide, 4-[[(3S)-3-(dimethylamino)-1-pyrrolidinyl]methyl]-N-(4-methoxy-7-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 383911-03-3 CAPLUS
CN 2(1H)-Isoquinolinecarboxamide, hexahydro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

CM 1

CRN 383911-02-2
CMF C22 H30 N4 O3 S

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383911-05-5 CAPLUS
CN 1(2H)-Quinolinecarboxamide, hexahydro-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

CM 1

CRN 383911-04-4
CMF C22 H30 N4 O3 S



IT **383865-93-8**, N-(4-Methoxy-7-phenylbenzothiazol-2-yl)-4-(thiomorpholin-4-ylmethyl)benzamide **383866-26-0**, 3,4-Dimethoxybenzoic acid 2-[N-[4-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-ylcarbamoyl}benzyl]-N-methylamino]ethyl ester
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-benzothiazolyl amides having affinity toward A2A adenosine receptor)

RN 383865-93-8 CAPLUS
CN Benzamide, N-(4-methoxy-7-phenyl-2-benzothiazolyl)-4-(4-thiomorpholinylmethyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383866-26-0 CAPLUS
CN Benzoic acid, 3,4-dimethoxy-, 2-[[[4-[[[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]amino]carbonyl]phenyl]methyl]methylamino]ethyl ester (9CI) (CA INDEX NAME)



IT **383868-51-7P**, N-(4-Benzyloxy-7-(morpholin-4-yl)benzothiazol-2-yl)-4-chloromethylbenzamide **383870-98-2P**, 4-Chloromethyl-N-(4-hydroxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383871-01-0P**, 4-(1-Bromoethyl)-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383871-03-2P**, 3-Chloromethyl-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)benzamide **383871-04-3P**,
4-Chloromethyl-3-fluoro-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-benzamide **383871-06-5P**, 4-Chloro-3-chloromethyl-N-(4-methoxy-7-(morpholin-4-yl)benzothiazol-2-yl)-benzamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-benzothiazolyl amides having affinity toward A2A adenosine receptor)

RN 383868-51-7 CAPLUS
CN Benzamide, 4-(chloromethyl)-N-[7-(4-morpholinyl)-4-(phenylmethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383870-98-2 CAPLUS
CN Benzamide, 4-(chloromethyl)-N-[4-hydroxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383871-01-0 CAPLUS
CN Benzamide, 4-(1-bromoethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383871-03-2 CAPLUS
CN Benzamide, 3-(chloromethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 23 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 383871-04-3 CAPLUS
CN Benzamide, 4-(chloromethyl)-3-fluoro-N-(4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 383871-06-5 CAPLUS
CN Benzamide, 4-chloro-3-(chloromethyl)-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 24 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:816614 CAPLUS
DN 135:357944
TI Preparation of nitrophenylcarboxamide derivatives as peroxisome proliferator-activated receptor (PPAR) γ modulators
IN Amemiya, Yoshiya; Wakabayashi, Kenji; Takaishi, Sachiko; Fukuda, Chie
PA Sankyo Company, Ltd., Japan
SO PCT Int. Appl., 186 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001083427	A1	20011108	WO 2001-JP3655	20010426
<--					
	W: AU, BR, CA, CN, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, US, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	CA 2407587	AA	20011108	CA 2001-2407587	20010426
<--					
	AU 2001052612	A5	20011112	AU 2001-52612	20010426
<--					
	EP 1277729	A1	20030122	EP 2001-925984	20010426
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	BR 2001010428	A	20030617	BR 2001-10428	20010426
	JP 2002332266	A2	20021122	JP 2001-130983	20010427
<--					
	ZA 2002008465	A	20040212	ZA 2002-8465	20021018
	US 2003134859	A1	20030717	US 2002-278387	20021023
	NO 2002005142	A	20021227	NO 2002-5142	20021025
<--					
PRAI	JP 2000-129565	A	20000428		
	JP 2001-60366	A	20010305		
	WO 2001-JP3655	W	20010426		

OS MARPAT 135:357944
GI



AB The title compds. I [A represents Ph, etc.; B represents aryl, etc.; X represents oxygen, etc.; and n is 0 or 1] are prepared I are remedies for involutional osteoporosis which inhibit the accelerated differentiation of adipocytes and promote the formation and differentiation of osteoblasts from stem cells; I are also remedies for diabetes. In an in vitro test for PPAR γ modulating activity, N-[4-(4-methylpiperazin-1-ylcarbonyl)phenyl]-(2-chloro-5-nitrophenyl)carboxamide showed IC50 value of 0.6 nM.

IT 300712-72-5P 301236-55-5P 313233-81-7P 313373-89-6P 319429-47-5P 372094-31-0P 372094-33-2P 372094-61-6P 372095-20-0P 372096-21-4P 372096-22-5P 372096-41-8P 372096-42-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrophenylcarboxamide derivs. as PPAR γ modulators)

RN 300712-72-5 CAPLUS
CN Benzamide, 2-chloro-N-(6-methoxy-2-benzothiazolyl)-5-nitro- (9CI) (CA INDEX NAME)



RN 301236-55-5 CAPLUS
CN Benzamide, 2-chloro-N-(6-methyl-2-benzothiazolyl)-5-nitro- (9CI) (CA INDEX NAME)



RN 313233-81-7 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2-chloro-5-nitro- (9CI) (CA INDEX NAME)



L7 ANSWER 24 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 313373-89-6 CAPLUS
CN Benzamide, 2-chloro-N-(6-chloro-2-benzothiazolyl)-5-nitro- (9CI) (CA INDEX NAME)



RN 319429-47-5 CAPLUS
CN Benzamide, 2-chloro-5-nitro-N-(6-nitro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 372094-31-0 CAPLUS
CN Benzamide, 2-chloro-N-(4-chloro-2-benzothiazolyl)-5-nitro- (9CI) (CA INDEX NAME)



RN 372094-33-2 CAPLUS
CN Benzamide, 2-chloro-N-(6-fluoro-2-benzothiazolyl)-5-nitro- (9CI) (CA INDEX NAME)

L7 ANSWER 24 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 372094-61-6 CAPLUS
CN Benzamide, 2-chloro-N-[6-[(4-fluorophenyl)methyl]-2-benzothiazolyl]-5-nitro- (9CI) (CA INDEX NAME)



RN 372095-20-0 CAPLUS
CN Benzamide, 2-chloro-N-(2-[(4-methylbenzoyl)amino]-6-benzothiazolyl]-5-nitro- (9CI) (CA INDEX NAME)



RN 372096-21-4 CAPLUS
CN Carbamic acid, [2-[(2-chloro-5-nitrobenzoyl)amino]-6-benzothiazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 372096-22-5 CAPLUS
CN Benzamide, N-(6-amino-2-benzothiazolyl)-2-chloro-5-nitro- (9CI) (CA INDEX NAME)

L7 ANSWER 24 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 372096-41-8 CAPLUS
CN Benzamide, N-[6-(acetylamino)-2-benzothiazolyl]-2-chloro-5-nitro- (9CI) (CA INDEX NAME)



RN 372096-42-9 CAPLUS
CN Benzamide, N-[6-[(aminocarbonyl)amino]-2-benzothiazolyl]-2-chloro-5-nitro- (9CI) (CA INDEX NAME)



IT **325979-29-1P 372096-45-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of nitrophenylcarboxamide derivs. as PPAR γ modulators)
RN 325979-29-1 CAPLUS
CN Benzamide, 4-methyl-N-(6-nitro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 24 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 372096-45-2 CAPLUS
CN Benzamide, N-(6-amino-2-benzothiazolyl)-4-methyl- (9CI) (CA INDEX NAME)



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 25 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:730736 CAPLUS
DN 135:288785
TI Preparation of triazole derivatives as fungicides
IN Uchida, Takuya; Konosu, Toshiyuki
PA Sankyo Company, Ltd., Japan
SO PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001072743	A1	20011004	WO 2001-JP2443	20010327
<--					
	W: AU, BR, CA, CN, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, US, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	TW 591024	B	20040611	TW 2001-90106942	20010323
	JP 2001342187	A2	20011211	JP 2001-87407	20010326
<--					
	AU 2001042798	A5	20011008	AU 2001-42798	20010327
<--					
	CA 2404701	AA	20020926	CA 2001-2404701	20010327
<--					
	BR 2001009573	A	20030128	BR 2001-9573	20010327
	EP 1284267	A1	20030219	EP 2001-915807	20010327
	EP 1284267	B1	20041215		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	NZ 521603	A	20031031	NZ 2001-521603	20010327
	RU 2232761	C2	20040720	RU 2002-125872	20010327
	AT 284884	E	20050115	AT 2001-915807	20010327
	PT 1284267	T	20050228	PT 2001-915807	20010327
	ZA 2002007710	A	20040102	ZA 2002-7710	20020925
	NO 2002004615	A	20021122	NO 2002-4615	20020926
<--					
	US 2003176480	A1	20030918	US 2002-259944	20020927
	US 6653330	B2	20031125		
PRAI	JP 2000-86943	A	20000327		
	WO 2001-JP2443	W	20010327		
OS	MARPAT 135:288785				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; Ar1 = 4-C6H4, 3-C6H4, 2,6-naphthyl; X = S, CH2; R1 = 4-CNC6H4, 4-CNCH2C6H4, 4-ClC6H4, 4-FC6H4, 4-CF3C6H4, 4-CF3OC6H4, 4-CF3SC6H4, 4-CH3C6H4, 4-BrC6H4, 4-CN-3-ClC6H3, 4-pyridyl, 4-NO2C6H4, 4-CN-2,3,5,6-F4C6, 3,4-(CN)2C6H3, 4-CH3COC6H4, 4-OHC6H4, 4-CH3CO2C6H4, 4-CNC6H4CH2, 2-thiazolyl, 2-benzothiazolyl], stereoisomers, pharmacol. acceptable prodrugs, or salts thereof, exhibiting excellent antimycotic activity are prepared as fungicides. Thus, the title compound II was prepared
and biol. tested.
IT **215503-97-2**
RL: RCT (Reactant); RACT (Reactant or reagent)

L7 ANSWER 25 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(prepn. of triazole derivs. as fungicides)
RN 215503-97-2 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-formyl- (9CI) (CA INDEX NAME)



IT **364082-31-5P 364082-61-1P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazole derivs. as fungicides)
RN 364082-31-5 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[trans-5-[[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]thio]-1,3-dioxan-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 364082-61-1 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[cis-5-[[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]thio]-1,3-dioxan-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 25 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 26 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:693296 CAPLUS
DN 135:257247
TI Preparation of amido substituted diarylamines and benzoxazines as MEK inhibitors
IN Biwersi, Cathlin; Tecle, Haile; Warmus, Joseph Scott
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001068619	A1	20010920	WO 2001-US7816	20010312
<--					
	W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2403017	AA	20010920	CA 2001-2403017	20010312
<--					
	BR 2001009188	A	20030318	BR 2001-9188	20010312
	EP 1339702	A1	20030903	EP 2001-920301	20010312
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	JP 2003527379	T2	20030916	JP 2001-567711	20010312
	US 2003225076	A1	20031204	US 2002-221522	20020913
PRAI	US 2000-189714P	P	20000315		
	US 2000-210205P	P	20000708		
	WO 2001-US7816	W	20010312		

OS MARPAT 135:257247
GI



AB The title compds. [I or II; R1 = H, alkyl, alkoxy, etc.; R3, R4 = H, halo, haloalkyl, etc.; A = OH, alkoxy, NR6OR7; R6 = H, alkyl, Ph, etc.; R7 = H, alkyl, alkenyl, etc.; X = OR12, NR13R12, NR14; R12, R13 = H, alkyl,

L7 ANSWER 26 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
alkenyl, etc.; R14 taken with N = 5-7 membered heterocyclyl with 0-3 addnl. heteroatoms] which are inhibitors of MEK and are useful in the treatment of a variety of proliferative disease states, such as conditions related to the hyperactivity of MEK, as well as diseases modulated by the MEK cascade, were prepd. E.g., a multi-step synthesis of II [R1 = Me; R3, R4 = 7,8-F2; X = NHMe] which showed IC50 of 6.6 μM in MEK assay (in vitro), was given.

IT **361345-97-3P 361346-02-3P 361346-03-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amido substituted diarylamines and benzoxazines as MEK inhibitors)

RN 361345-97-3 CAPLUS
CN 2H-3,1-Benzoxazine-6-carboxamide, 7,8-difluoro-1,4-dihydro-1-(4-iodo-2-methylphenyl)-N-(4-methyl-2-benzothiazolyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 361346-02-3 CAPLUS
CN 2H-3,1-Benzoxazine-6-carboxamide, N-(6-ethoxy-2-benzothiazolyl)-7,8-difluoro-1,4-dihydro-1-(4-iodo-2-methylphenyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 361346-03-4 CAPLUS
CN 2H-3,1-Benzoxazine-6-carboxamide, N-2-benzothiazolyl-7,8-difluoro-1,4-dihydro-1-(4-iodo-2-methylphenyl)-4-oxo- (9CI) (CA INDEX NAME)

L7 ANSWER 26 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 27 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:581863 CAPLUS
DN 135:152801
TI Preparation of 2-benzothiazolyl ureas as protein kinase inhibitors
IN Cusack, Kevin P.; Scott, Barbara; Arnold, Lee D.; Ericsson, Anna
PA Basf Aktiengesellschaft, Germany
SO PCT Int. Appl., 189 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001057008	A1	20010809	WO 2001-US3803	20010206
<--					
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2398754	AA	20010809	CA 2001-2398754	20010206
<--					
	EP 1254123	A1	20021106	EP 2001-908878	20010206
<--					
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001008085	A	20030318	BR 2001-8085	20010206
	JP 2003521543	T2	20030715	JP 2001-556858	20010206
	US 2003153568	A1	20030814	US 2001-777554	20010206
	ZA 2002006235	A	20040213	ZA 2002-6235	20020805
	NO 2002003713	A	20021004	NO 2002-3713	20020806
<--					
	BG 107062	A	20030430	BG 2002-107062	20020904
PRAI	US 2000-180841P	P	20000207		
	WO 2001-US3803	W	20010206		

OS MARPAT 135:152801
GI



I II

AB The title compds. [I; Q = H or a bond which is taken together with X1 and two N atoms to which Q and X1 are attached and C:Y group to which the two N atoms are attached to form II; Q1 = alkyl; Y = O, S; W = H, Cl, Br, etc.; X1 = H, alkyl, hydroxyalkyl or a bond which is taken together with R3 to form pyrrolidino, piperazino or morpholino; R1, R2 = H, halo, OH, etc.; R3 = H, alkyl, aryl, etc.], useful as inhibitors of serine/threonine and tyrosine kinases such as FGFR, PDGFR, KDR, VEGFR-3, Tie-2, Tie-1; Lck, Fyn, Blk, Lyn, Src, cdc2 (cdk1) or Plk-1 (biol. data given), were prepd. and formulated. Thus, reacting 3,5-dimethoxyphenyl isocyanate with 2-amino-6-nitrobenzothiazole in the presence of Et3N in PhMe afforded I [W = NO2; Q, X1, R1, R2 = H; Y = O; R3 = 3,5-(MeO)2C6H3]. In particular, compds. I are useful as inhibitors of tyrosine kinases that are important in hyperproliferative diseases, esp. in cancer and in the process of angiogenesis.

IT **352526-49-9P 352527-02-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-benzothiazolyl ureas as protein kinase inhibitors)

RN 352526-49-9 CAPLUS
CN 1-Pyrrolidinecarboxamide, 3-amino-N-(6-nitro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 352527-02-7 CAPLUS
CN 1-Piperazinecarboxamide, 4-methyl-N-(6-nitro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 28 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:555215 CAPLUS
DN 135:137618
TI Preparation of benzylphosphonic acid diesters as hypolipemic agents and antidiabetic agents
IN Miyata, Kazuyoshi; Tsuda, Yoshihiko; Iwamoto, Takeshi; Shima, Atsushi
PA Ohtsuka Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001206891	A2	20010731	JP 2000-17327	20000126
<--					
PRAI	JP 2000-17327		20000126		

OS MARPAT 135:137618
GI



I

AB The title compds. I [R1 = lower alkyl; R2 = H, lower alkyl; R3 = alkyl, lower alkenyl, lower alkoxycarbonyl (lower alkyl), (un)substituted Ph (lower alkyl), etc.; R4 = H, lower alkoxy, lower haloalkoxy; X = CO, SO2; Y = NR6, S; R6 = lower alkyl, Ph (lower alkyl)] are prepared E.g., 4-[(diethoxyphosphoryl)methyl]benzoyl chloride (8.7 g) was reacted with 9.7 g 2-imino-4-methoxy-3-methyl-3H-benzothiazole hydrogeniodide in dichloroethane-pyridine at room temperature for 18 h to give 9.7 g diethoxy 4-[4-methoxy-3-methyl-2(3H)-benzothiazolylidenecarbamoyl]benzylphosphonate (I; R1 = R2 = Et, R3 = Me, R4 = MeO, R5 = H).

IT **154769-76-3**, Diethyl 4-[(4-methoxy-2-benzothiazolyl)carbamoyl]benzylphosphonate
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzylphosphonic acid diesters as hypolipemic agents and antidiabetic agents)

RN 154769-76-3 CAPLUS
CN Phosphonic acid, [[4-[[(4-methoxy-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 29 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:489367 CAPLUS
DN 135:76874
TI Preparation of heterocyclic compounds as remedies for hepatitis C
IN Hashimoto, Hiromasa; Mizutani, Kenji; Yoshida, Atsuhito
PA Japan Tobacco Inc., Japan
SO PCT Int. Appl., 438 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001047883	A1	20010705	WO 2000-JP9181	20001222
<--					
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2363274	AA	20010705	CA 2000-2363274	20001222
<--					
	EP 1162196	A1	20011212	EP 2000-987728	20001222
<--					
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000008525	A	20020102	BR 2000-8525	20001222
<--					
	TR 200103147	T1	20020621	TR 2001-200103147	20001222
<--					
	NZ 514403	A	20021025	NZ 2000-514403	20001222
<--					
	AU 763356	B2	20030717	AU 2001-24017	20001222
	RU 2223761	C2	20040220	RU 2001-126283	20001222
	NO 2001004134	A	20011022	NO 2001-4134	20010824
<--					
	US 2003050320	A1	20030313	US 2001-939374	20010824
	US 6770666	B2	20040803		
	ZA 2001007870	A	20020925	ZA 2001-7870	20010928
<--					
	US 2004097438	A1	20040520	US 2003-615329	20030708
PRAI	JP 1999-369008	A	19991227		
	WO 2000-JP9181	W	20001222		
	JP 2000-391904	A	20001225		
	JP 2001-193786	A	20010626		
	US 2001-939374	A3	20010824		

OS MARPAT 135:76874
GI



I



II

AB The title compds. I [the dotted line in rings B1 and B2 indicates a single or double bond; G1 = N, CR1; G2 = N, CR2, G3 = N, CR3; G4 = N, CR4; G5, G6, G8, G9 = C, N; G7 = O, etc.; R1 - R4 = H, nitro, etc.; ring Cy = (un)substituted cycloalkyl ring, etc.; ring A = C3-C8 cycloalkyl, etc. R5, R6 = H, halo, etc.; X = H, cyano, etc.] are prepared The benzimidazole derivative II in vitro showed IC50 of 0.011 μM against hepatitis C virus polymerase. A formulation is given.

IT **347169-99-7P 347170-23-4P 347170-74-5P 347170-88-1P 347171-92-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as remedies for hepatitis C)

RN 347169-99-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(2-benzothiazolylamino)carbonyl]phenyl]-1-cyclopentyl- (9CI) (CA INDEX NAME)

L7 ANSWER 29 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 347170-23-4 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[3-[(2-benzothiazolylamino)carbonyl]phenyl]-1-cyclopentyl- (9CI) (CA INDEX NAME)



RN 347170-74-5 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[(4-chloro-2-benzothiazolyl)amino]carbonyl]phenyl]-1-cyclopentyl- (9CI) (CA INDEX NAME)



RN 347170-88-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(2-benzothiazolylamino)carbonyl]phenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)

L7 ANSWER 29 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 347171-92-0 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[3-[(2-benzothiazolylamino)carbonyl]phenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 30 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:453007 CAPLUS
DN 135:61546
TI Preparation of novel succinate compounds as peptide deformylase inhibitors
IN Jain, Rakesh; Ni, Zhi-jie; Patel, Dinesh V.; Yuan, Zhengyu
PA Versicor, Inc., USA; Jacobs, Jeffrey, W.
SO PCT Int. Appl., 187 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001044179	A1	20010621	WO 2000-US34128	20001213
<--					
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2393825	AA	20010621	CA 2000-2393825	20001213
<--					
	EP 1237862	A1	20020911	EP 2000-986446	20001213
<--					
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003534239	T2	20031118	JP 2001-545267	20001213
PRAI	US 1999-466402	A1	19991217		
	WO 2000-US34128	W	20001213		

OS MARPAT 135:61546
GI



I



II

L7 ANSWER 30 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 345346-39-6 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-[(2-benzothiazolylamino)carbonyl]-β-butyl-N,α-dihydroxy-γ-oxo-, (αS,βR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 345346-77-2 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-[(2-benzothiazolylamino)carbonyl]-β-butyl-N-hydroxy-γ-oxo-, (βR,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 30 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB The title hydroxamates [I; R1 = H, halo, OH, etc.; R2 = H, alkyl, heteroalkyl, etc.; R3 = H, halo, OH, etc.; R4 = H, alkyl, heteroalkyl, etc.; n = 1-5; zero or one of Y = O, NR11 (wherein R11 = alkyl, heteroalkyl, alkenyl, etc.), S, and all remaining Y = CR6R7; R6, R7 = H, OH, NH2, etc.] which inhibit peptide deformylase (PDF), an enzyme present in prokaryotes, and useful as antimicrobials and antibiotics, were prepared and formulated. E.g., a multi-step synthesis of II was given. MIC for various compds. I against H. influenza and S. aureus was approx. 64 μg/mL or less. The compds. I display selective inhibition of peptidyl deformylase vs. other metalloproteinases such as matrix metalloproteinases (MMPs).
IT **345345-77-9P 345345-85-9P 345346-39-6P 345346-77-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel succinate compds. as peptide deformylase inhibitors)
RN 345345-77-9 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-[(2-benzothiazolylamino)carbonyl]-β-butyl-α-fluoro-N-hydroxy-γ-oxo-, (αR,βS,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 345345-85-9 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-[(2-benzothiazolylamino)carbonyl]-β-butyl-α-fluoro-N-hydroxy-γ-oxo-, (αS,βS,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 31 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:396661 CAPLUS
DN 135:19547
TI Preparation of sulfonamides and sulfinamides as NPY Y5 antagonists
IN Kawanishi, Yasuyuki; Takenaka, Hideyuki; Hanasaki, Kohji; Okada, Tetsuo
PA Shionogi & Co., Ltd., Japan
SO PCT Int. Appl., 273 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001037826	A1	20010531	WO 2000-JP8197	20001121
<--					
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2389681	AA	20010531	CA 2000-2389681	20001121
<--					
	AU 2001014186	A5	20010604	AU 2001-14186	20001121
<--					
	AU 780790	B2	20050414		
	BR 2000015843	A	20020827	BR 2000-15843	20001121
<--					
	EP 1249233	A1	20021016	EP 2000-976387	20001121
<--					
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NZ 519070	A	20050826	NZ 2000-519070	20001121
	RU 2264810	C2	20051127	RU 2002-117021	20001121
	ZA 2002003306	A	20030425	ZA 2002-3306	20020425
	US 6699891	B1	20040302	US 2002-111981	20020501
	NO 2002002481	A	20020726	NO 2002-2481	20020524
<--					
	US 2004176462	A1	20040909	US 2003-747034	20031230
	US 2004180964	A1	20040916	US 2003-747359	20031230
PRAI	JP 1999-336469	A	19991126		
	JP 1999-353786	A	19991214		
	WO 2000-JP8197	W	20001121		
	US 2002-111981	A3	20020501		

OS MARPAT 135:19547
GI



I

L7 ANSWER 31 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB The title compds. R1S(O)nN(R2)XYZ [R1 represents lower alkyl, cycloalkyl, etc.; R2 represents hydrogen, lower alkyl, etc.; n is 1 or 2; X represents lower alkylene, lower alkenylene, arylene, cycloalkylene, etc.; Y represents CONR7, CSNR7, NR7CO, NR7CS, etc. (wherein R7 represents hydrogen or lower alkyl); and Z represents lower alkyl, an optionally substituted hydrocarbon ring, an optionally substituted heterocycle, etc.] are prepared In an in vitro test for affinity for the neuropeptide Y5 receptors, the title compound I showed the IC50 value of 0.4 nM. Formulations are given.

IT **342577-87-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamides and sulfinamides as NPY Y5 antagonists)

RN 342577-87-1 CAPLUS

CN Cyclohexanecarboxamide, N-2-benzothiazolyl-4-[[(1,1-dimethylethyl)sulfonyl]amino]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 32 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.



RN 232951-47-2 CAPLUS

CN Benzamide, 4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluoro-N-(6-methoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 157 THERE ARE 157 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 32 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:392067 CAPLUS

DN 135:5606

TI Preparation of oxazolidinones as bactericides

IN Gordeev, Mikhail F.; Luehr, Gary W.; Patel, Dinesh V.; Ni, Zhi-jie; Gordon, Eric

PA Pharmacia & Upjohn Company, USA

SO U.S., 104 pp., Cont.-in-part of U.S. Ser. No. 12,535, abandoned.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6239152	B1	20010529	US 1999-235771	19990122
<--					
	US 6531470	B1	20030311	US 2000-652250	20000830
	US 2002183371	A1	20021205	US 2001-34754	20011228
<--					
	US 6562844	B2	20030513		
	US 2005004174	A1	20050106	US 2004-884717	20040702
PRAI	US 1998-12535	B2	19980123		
	US 1998-86702	B2	19980528		
	US 1999-235771	A3	19990122		
	US 2000-641396	A1	20000817		
	US 2000-652250	A3	20000830		

OS MARPAT 135:5606

GI



I

AB Title compds. [e.g., I; R = H; R1 = SR11, CONR7R8, etc.; R7,R8,R11 = H, alkyl, (hetero)aryl, etc.] were prepared Thus, 3,4-F(Me3CO2C)C6H3NHCO2CH2Ph (preparation given) was cyclocondensed with (R)-glycidyl butyrate and the product converted in several steps to I (R = resin, R1 = CO2C6F5) which was amidated by morpholine to give, after resin cleavage, I (R = H, R1 = CONHR8, R8 = morpholino). Data for biol. activity of I were given.

IT **232951-46-1P 232951-47-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolidinones as bactericides)

RN 232951-46-1 CAPLUS

CN Benzamide, 4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-N-2-benzothiazolyl-2-fluoro- (9CI) (CA INDEX NAME)

L7 ANSWER 33 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:372159 CAPLUS

DN 134:366868

TI Preparation of benzothiazolines as neuropeptide Y receptor antagonists

IN Sato, Yoshiya; Itani, Hiromichi; Tabuchi, Seiichiro; Sakata, Yoshihiko; Ohashi, Hiroko

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 88 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001139574	A2	20010522	JP 2000-296175	20000928
<--					
PRAI	AU 1999-3093	A	19990928		

OS MARPAT 134:366868

GI



I

AB The title compds. I [R1 = H, halo; W = S, O; A = (CH2)n, etc.; n = 1 - 6; Z = (un)substituted N-containing heterocyclic ring] are prepared 1-[(5-Chloro-2-oxobenzothiazolin-3-yl)acetyl]piperidine-4-carboxylic acid 4-benzoylanilide showed IC100 of 10-7 M in a neuropeptide Y5 receptor binding assay.

IT **340178-76-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzothiazolines as neuropeptide Y receptor antagonists)

RN 340178-76-9 CAPLUS

CN 4-Piperidinecarboxamide, 1-[(5-chloro-2-oxo-3(2H)-benzothiazolyl)acetyl]-N-(6-methyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 34 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:369709 CAPLUS
DN 134:366812
TI Preparation of indenopyridines or indenopyrimidines as cGMP-specific phosphodiesterase inhibitors
IN Ito, Kunihito; Umeda, Nobihiro; Uchida, Seiichi; Oshiki, Kousuke; Horikoshi, Hiromi; Mochizuki, Nobuo
PA Nippon Soda Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 40 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2001139556	A2	20010522	JP 2000-72712	20000315

<--
PRAI JP 1999-73646 A 19990318
JP 1999-247435 A 19990901
OS MARPAT 134:366812
GI



AB Indenopyridines or indenopyrimidines I [Z = NHCR2R3R4; R1 = NO2, halo, C1-6 (halo)alkyl, C1-6 (halo)alkoxy, C1-6 alkylthio, C1-6 alkoxycarbonyl, (alkyl)carbamoyl; X = CH2, CO; Y = N, CH; m = 0-4; R2, R3 = H, OH, halo, C1-6 (halo)alkyl, C1-6 alkoxy, (un)substituted Ph; R4 = H, C1-6 alkyl, C3-8 cycloalkyl, (un)substituted Ph, (un)substituted naphthyl, etc.; R5 = H, cyano, SPh, C1-6 haloalkyl, C1-6 alkylthio, C3-8 cycloalkyl, etc.] are prepared by reaction of I (Z = SMe, SO2Me, halo) with H2NCR2R3R4 (R2-R4 = same as above). I (Z = SO2Me, R1 = H, X = CO, Y = CH, R5 = 4-pyridyl) (0.2 g) was treated with benzylamine in DMF at 100° for 1 h to give 0.11 g I (Z = NHCH2Ph, R1 = H, X = CO, Y = CH, R5 = 4-pyridyl), which in vitro showed vasodilatory effect on rat thoracic aorta with EC50 of 160 nM, vs. 6.1 nM, for Sildenafil.
IT **340164-94-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indenopyridines or indenopyrimidines as cGMP-specific phosphodiesterase inhibitors)
RN 340164-94-5 CAPLUS
CN 5H-Indeno[1,2-d]pyrimidine-2-carboxamide, N-2-benzothiazolyl-4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-oxo- (9CI) (CA INDEX NAME)

L7 ANSWER 34 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 35 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:228694 CAPLUS
DN 134:261226
TI Carboxamide derivatives as selective inhibitors of pathogens
IN Ullrich, Axel; Marschall, Manfred; Stamminger, Thomas; Wallasch, Christian; Obert, Sabine
PA Axxima Pharmaceuticals Aktiengesellschaft, Germany
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001021160	A2	20010329	WO 2000-EP9306	20000922

<--
WO 2001021160 A3 20020131
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRAI EP 1999-118802 A 19990923
EP 2000-115240 A 20000713
OS MARPAT 134:261226
AB The invention relates to the use of carboxamide compds. as selective inhibitors of pathogens, particularly viruses and, more particularly, herpesviridae. Surprisingly, these compds. show reduced side effects in comparison with previous antiviral compds. Thus, a method for preventing or treating infections by pathogens, particularly herpesviridae is provided.
IT **331628-28-5P 331628-32-1P 331628-34-3P 331628-37-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(carboxamide derivs. as selective inhibitors of pathogens)
RN 331628-28-5 CAPLUS
CN 2-Thiophenecarboxamide, N-[2-[(2-benzothiazolylamino)carbonyl]-3,4-dichlorophenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 35 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331628-32-1 CAPLUS
CN 2-Thiophenecarboxamide, N-[2-[(2-benzothiazolylamino)carbonyl]-4-bromophenyl]- (9CI) (CA INDEX NAME)



RN 331628-34-3 CAPLUS
CN 2-Thiophenecarboxamide, N-[2-[(2-benzothiazolylamino)carbonyl]-4-chlorophenyl]- (9CI) (CA INDEX NAME)



RN 331628-37-6 CAPLUS
CN 2-Thiophenecarboxamide, N-[2-[(2-benzothiazolylamino)carbonyl]-3-chlorophenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 35 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 36 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:208252 CAPLUS

DN 134:252363

TI Preparation and effect of nitrogen-containing-six-membered aromatic compounds as PDE V activity inhibitors

IN Yamada, Koichiro; Matsuki, Kenji; Omori, Kenji; Kikkawa, Kohei

PA Tanabe Seiyaku Co., Ltd., Japan

SO PCT Int. Appl., 91 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019802	A1	20010322	WO 2000-JP6258	20000913
<--					
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2383466	AA	20010322	CA 2000-2383466	20000913
<--					
	AU 2000073118	A5	20010417	AU 2000-73118	20000913
<--					
	AU 767558	B2	20031113		
	BR 2000014526	A	20020618	BR 2000-14526	20000913
<--					
	TR 200200701	T2	20020621	TR 2002-200200701	20000913
<--					
	EP 1219609	A1	20020703	EP 2000-960979	20000913
<--					
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	RU 2233273	C2	20040727	RU 2002-109792	20000913
	US 2003032647	A1	20030213	US 2001-925892	20010810
	US 6656935	B2	20031202		
	ZA 2002001499	A	20020902	ZA 2002-1499	20020222
<--					
	NO 2002001308	A	20020424	NO 2002-1308	20020315
<--					
	BG 106566	A	20030228	BG 2002-106566	20020402
	US 2003229095	A1	20031211	US 2003-426884	20030501
	US 6797709	B2	20040928		
PRAI	JP 1999-261852	A	19990916		
	JP 2000-130371	A	20000428		
	WO 2000-JP6258	W	20000913		
	US 2001-925892	A3	20010810		

OS MARPAT 134:252363

GI

L7 ANSWER 36 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Title compds. [I; A is an optionally substituted nitrogenous heterocyclic group; R1 is optionally substituted lower alkyl, NHQR3 (wherein R3 is an optionally substituted nitrogenous heterocyclic group; and Q is lower alkylene or a single bond), or NHR4 (wherein R4 is optionally substituted cycloalkyl); R2 is optionally substituted aryl; and either of Y and Z is CH and the other is N], pharmacol. acceptable salts are prepared and are exhibiting an excellent selective inhibitory activity against PDE V and being useful as preventive or therapeutic drugs for erectile dysfunction (no data). Thus, the title compound II was prepared

IT **330785-26-7P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and effect of heteroarom. compds. as PDE V activity inhibitors)

RN 330785-26-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(6-methoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 36 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 37 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:78373 CAPLUS
DN 134:131524
TI Preparation of heterocycles in drug compositions exhibiting thrombopoietin agonism
IN Takemoto, Hiroshi; Takayama, Masami; Shiota, Takeshi
PA Shionogi & Co., Ltd., Japan
SO PCT Int. Appl., 168 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001007423	A1	20010201	WO 2000-JP4909	20000724
<--				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2380206	AA	20010201	CA 2000-2380206	20000724
<--				
EP 1207155	A1	20020522	EP 2000-946455	20000724
<--				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRAI JP 1999-211164	A	19990726		
WO 2000-JP4909	W	20000724		
OS MARPAT 134:131524				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [X1Y1Z1X2A1; wherein X1 is optionally substituted heteroaryl or the like; X2 = CH, CH2; Y1 is NRACO-(CH2)0-2- or the like (wherein RA is hydrogen or the like); Z1 is optionally substituted allylene or the like; and A1 is a ring represented by general formula Q1 or Q2], prodrugs of the same, pharmaceutically acceptable salts of both, and solvates of them are prepared as drug compns. containing as the active ingredient, and exhibiting thrombopoietin receptor agonism. Thus, the title compound I was prepared and tested.
IT 322415-62-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocycles in drug compns. exhibiting thrombopoietin

L7 ANSWER 37 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
agonism)
RN 322415-62-3 CAPLUS
CN Benzamide, 4-[(2,4-dioxo-5-thiazolidinylidene)methyl]-N-(5-methoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 38 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:31473 CAPLUS
DN 134:100864
TI Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
IN Kania, Robert Steven; Bender, Steven Lee; Borchardt, Allen J.; Braganza, John F.; Cripps, Stephan James; Hua, Ye; Johnson, Michael David; Johnson, Theodore Otto, Jr.; Luu, Hiep The; Palmer, Cynthia Louise; Reich, Siegfried Heinz; Tempczyk-russell, Anna Maria; Teng, Min; Thomas, Christine; Varney, Michael David; Wallace, Michael Brennan
PA Agouron Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 439 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001002369	A2	20010111	WO 2000-US18263	20000630
<--				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2383630	AA	20010111	CA 2000-2383630	20000630
<--				
BR 2000012352	A	20020514	BR 2000-12352	20000630
<--				
EP 1218348	A2	20020703	EP 2000-943375	20000630
<--				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003503481	T2	20030128	JP 2001-507809	20000630
NZ 516676	A	20030926	NZ 2000-516676	20000630
CN 1495171	A	20040512	CN 2003-154858	20000630
AU 777701	B2	20041028	AU 2000-57852	20000630
NO 2001005797	A	20020301	NO 2001-5797	20011128
<--				
ZA 2001010061	A	20030206	ZA 2001-10061	20011206
BG 106380	A	20020930	BG 2002-106380	20020201
<--				
HK 1048813	A1	20041210	HK 2003-101000	20030212
US 2004171634	A1	20040902	US 2003-326755	20030213
US 6884890	B2	20050426		
PRAI US 1999-142130P	P	19990702		
US 2000-609335	B3	20000630		
WO 2000-US18263	W	20000630		
US 2001-983786	A3	20011025		
OS MARPAT 134:100864				
GI				

L7 ANSWER 38 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Indazole compds. I [R1 = substituted or unsubstituted aryl or heteroaryl, R3CH:CH, R3N:CH; R2 = substituted or unsubstituted aryl, heteroaryl, Y-X; R3 = substituted or unsubstituted alkyl alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl; Y = O, S, C(:CH2), CO, SO, SO2, alkylidene, NH, N(C1-C8 alkyl); X = substituted or unsubstituted aryl, heteroaryl, NH(alkyl), NH(cycloalkyl), NH(heterocycloalkyl), NH(aryl), NH(heteroaryl), NH(alkoxy), NH(dialkylamide)] and their pharmaceutically acceptable prodrugs, active metabolites, and salts are disclosed. The compds. modulate and/or inhibit the activity of certain protein kinases. In particular, I and pharmaceutical compns. containing them are capable of mediating tyrosine kinase signal transduction, and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compns. containing such compds., and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amts. of such compds. E.g., I [R1 = (E)-3,4-(MeO)2C6H3CH:CH; R2 = 4-HO-3-MeOC6H3] (II) was prepared from 6-aminoindazole by diazotization and substitution with iodide, protection of the indazole nitrogen with 2,4,6-Me3C6H2SO2Cl, coupling of the regioisomeric mixture with 4-(methoxymethoxy)-3-methoxybenzeneboronic acid in the presence of dichlorobis(triphenylphosphine)palladium, and deprotection of the indazole moiety and iodination at the 3-position of the indazole. Treatment of the 3-indazolyl iodide with sec-butyllithium, phenyllithium, and DMF, regioselective protection of the indazole with 2,4,6-Me3C6H2SO2Cl, olefination with 3,4-dimethoxybenzyltriphenylphosphonium bromide, deprotection of the indazole, deprotection of the methoxymethyl group, and equilibration of the double bond with iodine gave II. Biol. data on protein kinase inhibition, cell proliferation inhibition, neovascularization inhibition, and i.p. and oral bioavailability, are given.
IT 319470-59-2P 319471-70-0P 319471-71-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of combinatorial libraries of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)
RN 319470-59-2 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-

L7 ANSWER 38 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
indazol-6-yl]thio]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 319471-70-0 CAPLUS
CN Benzamide, N-(4-methyl-2-benzothiazolyl)-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 319471-71-1 CAPLUS
CN Benzamide, N-(6-methyl-2-benzothiazolyl)-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L7 ANSWER 38 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L7 ANSWER 39 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:31459 CAPLUS
DN 134:86280
TI Preparation of N-heterocyclylphthalamide derivatives, intermediates in the production thereof, and agricultural/horticultural insecticides and method of using the same
IN Machiya, Kouzou; Endoh, Kazuyoshi; Furuya, Takashi; Nakao, Hayami; Gotoh, Makoto; Kohno, Eiji; Tohnishi, Masanori; Sakata, Kazuyuki; Morimoto, Masayuki; Seo, Akira
PA Nihon Nohyaku Co., Ltd., Japan
SO PCT Int. Appl., 165 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002354	A1	20010111	WO 2000-JP4444	20000704
<--					
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, IS, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1193254	A1	20020403	EP 2000-942473	20000704
<--					
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000012224	A	20020528	BR 2000-12224	20000704
<--					
	TR 200200210	T2	20020621	TR 2002-200200210	20000704
<--					
	EG 22172	A	20021031	EG 2000-874	20000704
<--					
	AU 773377	B2	20040520	AU 2000-57093	20000704
	JP 2001335563	A2	20011204	JP 2000-204178	20000705
<--					
	ZA 2001010136	A	20021210	ZA 2001-10136	20011210
<--					
	US 6875768	B1	20050405	US 2002-18464	20020424
PRAI	JP 1999-190746	A	19990705		
	JP 2000-80991	A	20000322		
	WO 2000-JP4444	W	20000704		

OS MARPAT 134:86280
GI

L7 ANSWER 39 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I

AB Heterocyclic amine derivs. represented by general formula [I; R1, R2, R3 = H, optionally halogenated C3-6 cycloalkyl, A1-(G)r (wherein A1 = C1-8 alkylene, C3-6 alkenylene, C3-6 alkynylene; G = H, halo, cyano, NO2, halo-C1-6 alkyl, C3-6 cycloalkyl etc.; r = 1-4); or R1 and R2 are linked to each other to form a 4- to 7-membered ring optionally interrupted by same or different 1-3 hetero atoms selected from O, S, and N; Q = an optionally substituted heterocycle containing O, S or N; X = halogeno, cyano, halo-C1-6 alkyl, etc.; n = 1 to 4; Z1, Z2 = O, S] and intermediates thereof represented by the following general formula Q'-NH2 (wherein Q' represents a definite heterocycle selected from among those represented by Q) are prepared The compds. I are useful as agricultural/horticultural insecticides having a remarkable effect of controlling pest insects of crops such as rice, fruit trees and vegetables, as well as various agricultural, forestry, horticultural and stored grain pest insects. Thus, isopropylamine was added to a solution of N-(4-methyl-3-trifluoromethylisoxazol-5-yl)-3-iodophthalimide (preparation given) in dioxane and stirred at room temperature for 3 h to give N1-(4-methyl-3-trifluoromethylisoxazol-5-yl)-N2-isopropyl-3-iodophthalamide, which at 1,000 ppm controlled the hatching of Plutella xylostella Plutella xylostella konaga eggs on cabbage by 90-99%.
IT 317813-22-2P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-heterocyclylphthalamide derivs. as agricultural and horticultural insecticides)
RN 317813-22-2 CAPLUS
CN 1,2-Benzenedicarboxamide, N~(6-chloro-2-benzothiazolyl)-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)



RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 39 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L7 ANSWER 40 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:824248 CAPLUS
DN 134:4933
TI Preparation of pyrazole carboxamides for the treatment of obesity and other disorders
IN Kordik, Cheryl P.; Lovenberg, Timothy W.; Reitz, Allen B.
PA Ortho-McNeil Pharmaceutical, Inc., USA
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000069849	A1	20001123	WO 2000-US11903	20000502
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2373510	AA	20001123	CA 2000-2373510	20000502
	US 6291476	B1	20010918	US 2000-563190	20000502
	EP 1177188	A1	20020206	EP 2000-928712	20000502
	EP 1177188	B1	20051012		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	AU 778393	B2	20041202	AU 2000-46906	20000502
	AT 306481	E	20051015	AT 2000-928712	20000502
	US 2002058816	A1	20020516	US 2001-898420	20010703
	US 6511998	B2	20030128		
PRAI	US 1999-133842P	P	19990512		
	US 2000-563190	A1	20000502		
	WO 2000-US11903	W	20000502		

OS MARPAT 134:4933
GI

L7 ANSWER 40 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I

AB The title compds. [I; R1 = alkyl, aryl, aralkyl, etc.; R2 = dialkylaminoalkyl, (un)substituted (heteroaryl)alkyl, (un)substituted (heterocycloalkyl)alkyl, etc.; R3 = H, halo, alkyl, etc.; R4 = halo, alkyl, aralkyl, etc.; R5 = H, alkyl] which are ligands for the neuropeptide Y, subtype 5 receptor, and therefore useful in the treatment of disorders and diseases associated with the NPY receptor subtype Y5, were prepared and formulated. E.g., a 3-step synthesis of the pyrazole I [R1 = 3-F3CC6H4; R2 = 5-isoquinolinyl; R3, R5 = H; R4 = Me] which showed IC50 of 80 nM against human NPY Y5 binding, was given.
IT **308337-70-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazole carboxamides for the treatment of obesity and other disorders)
RN 308337-70-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-(6-fluoro-2-benzothiazolyl)-5-methyl-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 41 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:814443 CAPLUS
DN 133:363109
TI Manufacture of carboxylated bisnaphthyl ether compounds useful for liquid-crystal polymers such as polyester and polyamide
IN Ueno, Ryuzo; Kitayama, Masaya; Minami, Kenji; Wakamori, Hiroyuki; Mori, Naoko
PA Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo, Japan
SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000068178	A1	20001116	WO 2000-JP2861	20000501
	W: CA, CN, JP, KR, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2336673	AA	20001116	CA 2000-2336673	20000501
	EP 1095930	A1	20010502	EP 2000-922923	20000501
	EP 1095930	B1	20030326		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	AT 235453	E	20030415	AT 2000-922923	20000501
	TW 575555	B	20040211	TW 2000-89108493	20000504
	US 6284924	B1	20010904	US 2001-743025	20010104
PRAI	JP 1999-127166	A	19990507		
	WO 2000-JP2861	W	20000501		

OS MARPAT 133:363109
AB The title compds. useful for improving weld strength and anisotropy of liquid crystal polymers (no data) are prepared, e.g., by reacting a 2-hydroxynaphthalene-3,6-dicarboxylic acid or its derivs. (including esters and amides) with a dibromo compound An example of the compds. is 1,2-bis(3',6'-dicarboxynaphth-2'-yloxy)ethane.
IT **306963-18-8P**
RL: IMF (Industrial manufacture); PREP (Preparation)
(manufacture of carboxylated bisnaphthyl ether compds. useful for liquid-crystal polymers such as polyester and polyamide)
RN 306963-18-8 CAPLUS
CN 2,7-Naphthalenedicarboxamide, 3,3'-[1,4-butanediylbis(oxy)]bis[N,N'-bis(2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 41 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



IT 205819-86-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(manufacture of carboxylated bisnaphthyl ether compds. useful for liquid-crystal polymers such as polyester and polyamide)
RN 205819-86-9 CAPLUS
CN 2,7-Naphthalenedicarboxamide, N,N'-bis(2-benzothiazolyl)-3-hydroxy- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 42 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:457058 CAPLUS
DN 133:73942
TI Preparation of heteroroaromatic amides as factor Xa inhibitors
IN Beight, Douglas Wade; Craft, Trelia Joyce; Franciskovich, Jeffry Bernard; Goodson, Theodore, Jr.; Hall, Steven Edward; Herron, David Kent; Joseph, Sajan Pariyadan; Klimkowski, Valentine Joseph; Masters, John Joseph; Mendel, David; Milot, Guy; Pineiro-Nunez, Marta Maria; Sawyer, Jason Scott; Shuman, Robert Theodore; Smith, Gerald Floyd; Tebbe, Anne Louise; Tinsley, Jennifer Marie; Weir, Leonard Crayton; Wikel, James Howard; Wiley, Michael Robert; Yee, Ying Kwong
PA Eli Lilly and Company, USA; Kyle, Jeffrey Alan
SO PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000039117	A1	20000706	WO 1999-US29887	19991215
<--					
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2358095	AA	20000706	CA 1999-2358095	19991215
<--					
	EP 1140905	A1	20011010	EP 1999-967352	19991215
<--					
	EP 1140905	B1	20030514		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	AT 240316	E	20030515	AT 1999-967352	19991215
	ES 2196917	T3	20031216	ES 1999-967352	19991215
	US 6689780	B1	20040210	US 2001-857749	20010608
PRAI	US 1998-113452P	P	19981223		
	EP 1999-967352	A	19991215		
	WO 1999-US29887	W	19991215		

OS MARPAT 133:73942
GI

L7 ANSWER 42 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



II

AB R2Z2ZCONHZ1R1 [I; R1 = Cl, F, Me; R2 = N-(un)substituted azacycloalkyl, 4-(un)substituted -1-piperazinyl, 4-aminocyclohexyl, 4-amino-1-piperidinyl, etc.; Z = (un)substituted-2,3- or -3,2-pyridinediyl, -5,4- or -4,5-pyrimidinediyl, -2,3-pyrazinediyl, etc.; Z1 = 2,5-pyridinediyl (R1 may addnl. = MeO or MeS), 2,5-pyrimidinediyl, 3,6-pyridazinediyl, 2,6-benzothiazolediyl; Z2 = NHCOX, NHCO2X, NHCONHX, NHCH2; X = bond or CH2] were prepared as factor Xa inhibitors (no data). Thus, 2-chloronicotinic acid was aminated by 1-(4-pyridinyl)piperidine-4-methylamine (preparation given) and the product amidated by 2-amino-5-chloropyridine to give title compound II.
IT 280115-51-7P 280115-56-2P 280115-57-3P 280115-58-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroroarom. amides as factor Xa inhibitors)
RN 280115-51-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-chloro-2-benzothiazolyl)-2-[[[1-(4-pyridinyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 280115-56-2 CAPLUS
CN 3-Pyridinecarboxamide, N-2-benzothiazolyl-2-[[[1-(4-pyridinyl)-4-

L7 ANSWER 42 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
piperidinyl]methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 280115-57-3 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-methyl-2-benzothiazolyl)-2-[[[1-(4-pyridinyl)-4-piperidinyl]methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 280115-58-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-bromo-2-benzothiazolyl)-2-[[[1-(4-pyridinyl)-4-

L7 ANSWER 42 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
piperidinyl]methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 43 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
without any damage to rice.
IT 272773-40-7
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses)
(preparation of isoxazolecarboxylic acid derivs. as agricultural pesticides)
RN 272773-40-7 CAPLUS
CN 5-Isoxazolecarboxamide, N-2-benzothiazolyl-3-chloro- (9CI) (CA INDEX NAME)



L7 ANSWER 43 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:388847 CAPLUS
DN 133:13715
TI Isoxazolecarboxylic acid derivatives and agricultural pesticides containing them
IN Hobara, Satoru; Onogami, Saneharu; Funamizu, Tatsuya; Ando, Masato; Ono, Hideki; Kutsuma, Seiichi; Maehara, Shinya; Watanabe, Yoshihisa
PA Hokko Chemical Industry Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 100 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000159610	A2	20000613	JP 1998-346682	19981120
<--					
PRAI	JP 1998-346682		19981120		

OS MARPAT 133:13715
GI



I

AB Agricultural pesticides contain the title derivs. I [R1 = halo, lower haloalkyl, lower haloalkoxy; R2 = H, halo, lower alkyl; X = O, S, NR4; R3, R4 = H, lower alkyl, lower alkenyl, lower alkynyl, C3-8 cycloalkyl which may be substituted with ≥1 lower alkyl, carboxy, or lower alkoxycarbonyl, lower haloalkyl, haloalkenyl, lower haloalkynyl, lower alkoxy-lower alkyl, lower haloalkoxycarbonyl, carboxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, lower alkylcarbonyl, lower haloalkylcarbonyl, lower alkylsulfonyl, lower haloalkylsulfonyl, benzoyl which may be substituted with 1-5 lower alkyl, lower alkoxy, lower haloalkyl, lower haloalkoxy, lower alkoxycarbonyl, lower alkylthio, lower alkylsulfonyl, halo, or cyano, phenylsulfonyl which have substituents like those given for benzoyl, Ph which may be substituted with 1-5 lower alkyl, lower alkoxy, lower haloalkyl, lower haloalkoxy, lower alkylthio, lower alkylsulfonyl, halo, O-, S-, and/or N-containing C3-10 (un)substituted heterocyclyl, CR5R6(CR6R7)mR9; R5-R8 = H, lower alkyl, lower alkoxy, lower alkoxy-lower alkyl, carboxy, lower alkoxycarbonyl, lower alkoxycarbonyl-lower alkyl; m = 0-8; R9 = Ph which may have any substituents like those given for benzoyl, O-, S-, and/or N-containing C3-10 (un)substituted heterocyclyl; if X = O or S, then R3 may be metal ion or protonated organic base]. A wettable powder of 3-Trifluoromethylisoxazole-5-carboxylic acid (prepared by oxidation of 3-Trifluoromethylisoxazole-5-methanol with KMnO4) showed ≥95% control rate against Pyricularia oryzae

L7 ANSWER 44 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:335409 CAPLUS
DN 132:334474
TI Preparation of spiroindolines as Y5 receptor antagonists
IN Gao, Ying-duo; Macneil, Douglas J.; Yang, Lihu; Morin, Nancy R.; Fukami, Takehiro; Kanatani, Akio; Fukuroda, Takahiro; Ishii, Yasuyuki; Morin, Masaki
PA Merck & Co., Inc., USA; Banyu Pharmaceutical Co., Ltd.; et al.
SO PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000027845	A1	20000518	WO 1999-US26447	19991108
<--					
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2350714	AA	20000518	CA 1999-2350714	19991108
<--					
	US 6191160	B1	20010220	US 1999-436120	19991108
<--					
	EP 1129089	A1	20010905	EP 1999-971808	19991108
<--					
	EP 1129089	B1	20051228		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
	AU 756797	B2	20030123	AU 2000-14732	19991108
	US 6313298	B1	20011106	US 2000-656698	20000907
<--					
	US 2002058813	A1	20020516	US 2001-896940	20010629
<--					
	US 6495559	B2	20021217		
	US 6638942	B1	20031028	US 2002-228250	20020826
	US 2004063942	A1	20040401	US 2003-624414	20030721
PRAI	US 1998-107835P	P	19981110		
	US 1999-436120	A3	19991108		
	WO 1999-US26447	W	19991108		
	US 2000-656698	A3	20000907		
	US 2001-896940	A3	20010629		
	US 2002-228250	A3	20020826		

OS MARPAT 132:334474
GI

L7 ANSWER 44 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I

AB The title compds. I [V, W, X, Z = CH, N; R1 = H, alkyl, etc.; R2 = CHO, etc.; R3 = H, alkyl; Ar = aryl, heteroaryl; R4, R5 = H, nitro, etc.] are prepared I are useful in the treatment of obesity and the complications associated therewith. 1-Methanesulfonyl-N-(5-phenyl-2-pyrazinyl)spiro[indoline-3,4'-piperidine]-1'-carboxamide at 3 mg/kg suppressed bovine pancreatic polypeptide-induced food intake in rats. Formulations are given.

IT **268537-20-8P 268537-28-6P 268537-47-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of spiroindolines as Y5 receptor antagonists)

RN 268537-20-8 CAPLUS

CN Spiro[3H-indole-3,4'-piperidine]-1'-carboxamide, N-(5-fluoro-2-benzothiazolyl)-1,2-dihydro-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 268537-28-6 CAPLUS

CN Spiro[3H-indole-3,4'-piperidine]-1'-carboxamide, 1,2-dihydro-N-(4-methyl-2-benzothiazolyl)-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 44 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 268537-47-9 CAPLUS

CN Spiro[3H-indole-3,4'-piperidine]-1'-carboxamide, N-2-benzothiazolyl-1,2-dihydro-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 45 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:335387 CAPLUS

DN 132:334364

TI Preparation of anthranilic acid amides as vascular endothelial growth factor receptor inhibitors.

IN Huth, Andreas; Seidelmann, Dieter; Thierauch, Karl-Heinz; Bold, Guido; Manley, Paul William; Furet, Pascal; Wood, Jeanette Marjorie; Mestan, Jurgen; Bruggen, Jose; Ferrari, Stefano; Kruger, Martin; Ottow, Eckhard; Menrad, Andreas; Schirner, Michael

PA Schering Aktiengesellschaft, Germany; Novartis Aktiengesellschaft

SO PCT Int. Appl., 96 pp.
CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000027819	A2	20000518	WO 1999-EP8478	19991109
<--					
	WO 2000027819	A3	20000817		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19910396	A1	20000907	DE 1999-19910396	19990303
<--					
	DE 19910396	C2	20011213		
	CA 2350208	AA	20000518	CA 1999-2350208	19991109
<--					
	BR 9915553	A	20010814	BR 1999-15553	19991109
<--					
	EP 1129074	A2	20010905	EP 1999-953967	19991109
<--					
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200101307	T2	20020521	TR 2001-200101307	19991109
<--					
	JP 2002529452	T2	20020910	JP 2000-580999	19991109
<--					
	EE 200100258	A	20021216	EE 2001-258	19991109
<--					
	NZ 511413	A	20040130	NZ 1999-511413	19991109
	AU 771180	B2	20040318	AU 2000-10454	19991109
	NO 2001002245	A	20010710	NO 2001-2245	20010507
<--					
	BG 105588	A	20020430	BG 2001-105588	20010611
<--					
	HK 1041882	A1	20050318	HK 2002-103628	20020514
PRAI	GB 1998-24579	A	19981110		
	DE 1999-19910396	A	19990303		
	WO 1999-EP8478	W	19991109		

OS MARPAT 132:334364

GI

L7 ANSWER 45 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I

AB Title compds. [I; A = NR2; W = O, S, H2, NR8; Z = NR10, N, NR10(CH2)q, alkyl, etc.; q = 1-6; AZR1 = tetrahydroisoquinolinyl, indazolyl, 5-chloroindolyl, etc.; R1 = (substituted) aryl, heteroaryl; R2 = H, alkyl; R3 = (substituted) mono- or bicyclic aryl, heteroaryl; R4-R7 = H, halo, (substituted) alkoxy, alkyl, carboxyalkyl; R5R6 = dioxetanyl; R8, R10 = H, alkyl]. Thus, Me N-(4-pyridylmethyl)anthranilate (preparation given) was stirred with Ph(CH2)3NH2 and Me3Al were stirred in PhMe to give N-(3-phenylprop-1-yl)-N2-(4-pyridylmethyl)anthranilamide. The latter inhibited VEGFR I with IC50 = 0.05 μM.

IT **267891-74-7P 267891-78-1P 267891-80-5P 267891-81-6P 267891-84-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of anthranilic acid amides as VEGF receptor inhibitors)

RN 267891-74-7 CAPLUS

CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[6-(trifluoromethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 267891-78-1 CAPLUS

CN Benzamide, N-(6-chloro-2-benzothiazolyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



L7 ANSWER 45 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 267891-80-5 CAPLUS
CN Benzamide, N-(6-fluoro-2-benzothiazolyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 267891-81-6 CAPLUS
CN Benzamide, N-2-benzothiazolyl-5-chloro-2-[(4-pyridinylmethyl)amino]- (9CI)
(CA INDEX NAME)



RN 267891-84-9 CAPLUS
CN Benzamide, N-2-benzothiazolyl-5-fluoro-2-[(4-pyridinylmethyl)amino]- (9CI)
(CA INDEX NAME)



IT **267892-14-8 267892-15-9**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(preparation of anthranilic acid amides as VEGF receptor inhibitors)
RN 267892-14-8 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-fluoro-2-[(4-pyridinylmethyl)amino]- (9CI)
(CA INDEX NAME)

L7 ANSWER 45 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 267892-15-9 CAPLUS
CN Benzamide, N-(4-chloro-2-benzothiazolyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



L7 ANSWER 46 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:335243 CAPLUS
DN 132:347565
TI Preparation of pyrazoles and indazoles as activators of soluble guanylate cyclase
IN Selwood, David; Glen, Robert; Liu, Qian; Kling, Marcel; Madge, David; Reynolds, Karen; Wishart, Grant; Powell, Ken
PA University College London, UK
SO PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000027394	A1	20000518	WO 1999-GB3663	19991105

<--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9964816	A1	20000529	AU 1999-64816	19991105

<--
PRAI GB 1998-24310 A 19981105
WO 1999-GB3663 W 19991105
OS MARPAT 132:347565
GI



AB The title compds. [I or II; Y = O, CH2, NH; R1 = H, aryl, heteroaryl, etc.; when Y = O then R2 = XNMe2, XNHMe (wherein X = alkylene), 2-hydroxymethylfuran-5-ylmethyl, WB (W = alkylene; B = N-containing heterocyclyl); when Y = CH2 then R2 = XNMe2, XNHMe (X is as defined above); when Y = NH then R2 = XNMe2, XNHMe (X = propylene); R3, R4 = CO2A (A = H, alkyl, aryl, etc.), CF3, halo, etc.; R3 and R4 together form the (un)substituted divalent group, (CH2)4], activators of soluble guanylate cyclase which are vasodilators and/or inhibit platelet aggregation and are
therefore useful in the treatment of peripheral vascular diseases such as hypertension, angina pectoris or atherosclerosis, or in the treatment of prevention of glaucoma, preeclampsia, Raynaud's syndrome, stroke or erectile disfunctions, were prepared E.g., a 2-step synthesis of II [Y = CH2; R1 = H; R2 = Ph; R3 = H; R4 = O(CH2)3NMe2] which showed IC50 of 35 μM against platelet aggregation, was given.
IT **268725-97-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrazoles and indazoles as activators of sol. guanylate cyclase)
RN 268725-97-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-(6-chloro-2-benzothiazolyl)-3-[3-(dimethylamino)propoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 47 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:241135 CAPLUS
DN 132:279106
TI Non-peptide GnRH agents, methods and intermediates for their preparation
IN Anderson, Mark Brian; Vazir, Haresh N.; Luthin, David Robert; Paderes, Genevieve Deguzman; Pathak, Ved P.; Christie, Lance Christopher; Hong, Yufeng; Tompkins, Eileen Valenzuela; Li, Haitao; Faust, James
PA Agouron Pharmaceuticals, Inc., USA; et al.
SO PCT Int. Appl., 444 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000020358	A2	20000413	WO 1999-US18790	19990820
	WO 2000020358	A3	20001116		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2341346	AA	20000413	CA 1999-2341346	19990820
	BR 9913374	A	20010515	BR 1999-13374	19990820
	EP 1105120	A2	20010613	EP 1999-968010	19990820
	EP 1105120	B1	20050323		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	EE 200100102	A	20020617	EE 2001-102	19990820
	SI 20746	C	20020630	SI 1999-20076	19990820
	TR 200100631	T2	20020821	TR 2001-200100631	19990820
	JP 2002535244	T2	20021022	JP 2000-574479	19990820
	AU 759310	B2	20030410	AU 2000-24709	19990820
	NZ 509252	A	20040528	NZ 1999-509252	19990820
	AT 291423	E	20050415	AT 1999-968010	19990820
	ES 2237966	T3	20050801	ES 1999-968010	19990820
	NO 2001000309	A	20010411	NO 2001-309	20010119
	ZA 2001000831	A	20020822	ZA 2001-831	20010130
	LV 12732	B	20020320	LV 2001-45	20010316
	BG 105362	A	20011231	BG 2001-105362	20010319
	LT 4904	B	20020425	LT 2001-24	20010319

L7 ANSWER 47 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

	US 2004010033	A1	20040115	US 2003-353160	20030708
PRAI	US 1998-97520P	P	19980820		
	WO 1999-US18790	W	19990820		
	US 2001-763216	B3	20010220		

OS MARPAT 132:279106
GI



I



II

AB Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. The compds. and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. The compds. include those of formula I [X = C:O, C:S, S:O, or SO2; Het = 5-membered NOS-heterocycle; R1, R2 = H, alkyl; R3-R7 = H, halo, (un)substituted alkyl, aryl, heteroaryl, CH2OR, OR, CO2R; R = alkyl, aryl, etc.; adjacent ring positions such as R6R7 may form (un)substituted 5- or 6-membered ring with up to 4 heteroatoms; R8 = lipophilic moiety such as alkyl, aryl, CH2OR, OR, etc.; R9 = H, (un)substituted alkyl]. Methods and intermediates for synthesizing the compds. are also described. For instance, 4,4,7-trimethylchroman (preparation given) was alkylated in the 6- and 8-positions using Et 5-(chloromethyl)-2-furoate (46% total yield), and the resulting esters were hydrolyzed to a mixture of acids. This unsepd. mixture was treated with SOCl2 and amidated with 2,4,6-trimethoxyphenylamine-HCl to give the invention compound II and its chroman-6-position isomer, which were separated by HPLC. Several compds. exhibited high affinity (<100 nM) at human GnRH receptors. The compds. antagonized GnRH-stimulated

L7 ANSWER 47 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
inositol phosphate accumulation in cells with recombinant human GnRH receptors, and an example compd. reduced plasma LH levels in castrated male rats. Various biol. data for several hundred compds. are given.

IT **263856-57-1P 263856-58-2P 263856-59-3P**
263856-60-6P 263856-65-1P 263856-66-2P
263856-75-3P 263856-77-5P 263856-81-1P
263856-87-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of non-peptide GnRH agents for regulating gonadotropin secretion)

RN 263856-57-1 CAPLUS
CN 2-Furancarboxamide, N-(4-methyl-2-benzothiazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 263856-58-2 CAPLUS
CN 2-Furancarboxamide, N-(4-chloro-2-benzothiazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 263856-59-3 CAPLUS
CN 2-Furancarboxamide, N-(6-methyl-2-benzothiazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 47 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 263856-60-6 CAPLUS
CN 2-Furancarboxamide, N-(6-ethoxy-2-benzothiazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 263856-65-1 CAPLUS
CN 2-Furancarboxamide, N-(6-fluoro-2-benzothiazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 263856-66-2 CAPLUS
CN 2-Furancarboxamide, N-(4-methoxy-2-benzothiazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 263856-75-3 CAPLUS
CN 2-Furancarboxamide, 5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]-N-[6-(trifluoromethyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 47 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 263856-77-5 CAPLUS
CN 2-Furancarboxamide, N-(6-methoxy-2-benzothiazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 263856-81-1 CAPLUS
CN 2-Furancarboxamide, N-2-benzothiazolyl-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 263856-87-7 CAPLUS
CN 2-Furancarboxamide, N-(5,6-dimethyl-2-benzothiazolyl)-5-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 48 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:210118 CAPLUS
DN 132:237107
TI Preparation of piperazino-substituted cyanophenyl derivatives as antiandrogen agents
IN Taniguchi, Nobuaki; Kinoyama, Isao; Kamikubo, Takashi; Toyoshima, Akira; Samizu, Kiyohiro; Kawaminami, Eiji; Imamura, Masakazu; Moritomo, Hiroyuki; Matsuhisa, Akira; Hirano, Masaaki; Miyazaki, Yoji; Nozawa, Eisuke; Okada, Minoru; Koutoku, Hiroshi; Ohta, Mitsuaki
PA Yamanouchi Pharmaceutical Co., Ltd., Japan; et al.
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000017163	A1	20000330	WO 1999-JP5149	19990921
<--					
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2345146	AA	20000330	CA 1999-2345146	19990921
<--					
	AU 9956544	A1	20000410	AU 1999-56544	19990921
<--					
	AU 754529	B2	20021121		
	BR 9914018	A	20010703	BR 1999-14018	19990921
<--					
	EP 1122242	A1	20010808	EP 1999-943446	19990921
<--					
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 3390744	B2	20030331	JP 2000-574073	19990921
	JP 2003137873	A2	20030514	JP 2002-328498	19990921
	CN 1129581	B	20031203	CN 1999-811198	19990921
	RU 2221785	C2	20040120	RU 2001-107612	19990921
	US 6673799	B1	20040106	US 2001-787672	20010321
	US 2004010037	A1	20040115	US 2003-608341	20030630
PRAI	JP 1998-267508	A	19980922		
	JP 1999-155398	A	19990602		
	JP 2000-574073	A3	19990921		
	WO 1999-JP5149	W	19990921		
	US 2001-787672	A3	20010321		

OS MARPAT 132:237107
GI

L7 ANSWER 48 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I

AB The title compds. I [T1 = (CH2)n; T2 = (CH2)k; T3 = (NR4Y)mR5; R = cyano, etc.; R1 = H, halo, etc.; R2 - R4 = H, alkyl, etc.; R5 = alkyl, etc.; k, n = 1 - 3; m = 0 or 1; X = CO, etc.; Z1, Z2 = CH, N; a proviso is given; Y = alkylene, etc.] are prepared These derivs. exhibit antiandrogen activities and are therefore useful in the prevention or treatment of prostatic cancer, prostatic hypertrophy and so forth. In an in vitro assay for inhibition of androgen binding to androgen receptors, (2R,5S)-N-(2-bromo-4-pyridyl)-4-(4-cyano-3-trifluoromethylphenyl)-2,5-dimethylpiperazine-1-carboxamide showed the Ki value of 7.5 nM.
IT 262294-71-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperazino-substituted cyanophenyl derivs. as antiandrogen agents)
RN 262294-71-3 CAPLUS
CN 1-Piperazinecarboxamide, N-2-benzothiazolyl-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-, (2R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 49 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:699078 CAPLUS
DN 131:317778
TI Phosphate derivatives for treatment of nephritis
IN Miyata, Kazuyoshi; Tsuda, Yoshihiko; Koji, Yasuo; Kuroki, Morihisa; Sakai, Yasuhiro; Mukai, Kiyoshi; Hashimoto, Kinji; Kori, Hideaki
PA Ohtsuka Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 19 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 11302177	A2	19991102	JP 1998-116645	19980427
<--					
PRAI	JP 1998-116645		19980427		

OS MARPAT 131:317778
AB Phosphate derivs. (Markush's structures given) are claimed for treatment of nephritis. The derivs. inhibited mesangium cell proliferation in vitro. Examples of tablets, capsules, and granules were formulated.
IT 154769-74-1 154769-75-2 154769-76-3
154769-83-2 154769-86-5 154770-04-4
154770-05-5 154770-07-7 154770-08-8
154770-10-2 154770-20-4 248594-66-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphate derivs. for treatment of nephritis)
RN 154769-74-1 CAPLUS
CN Phosphonic acid, [[4-[(2-benzothiazolylamino)carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154769-75-2 CAPLUS
CN Phosphonic acid, [[4-[[(4-methyl-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 49 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 154769-76-3 CAPLUS
CN Phosphonic acid,
[[4-[[(4-methoxy-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154769-83-2 CAPLUS
CN Phosphonic acid,
[[4-[[(6-chloro-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154769-86-5 CAPLUS
CN Phosphonic acid,
[[4-[[(4,6-dimethoxy-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 49 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 154770-04-4 CAPLUS
CN Phosphinic acid,
[[4-[[(4-methoxy-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 154770-05-5 CAPLUS
CN Phosphonic acid, [[4-[[[6-(trifluoromethyl)-2-benzothiazolyl]amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154770-07-7 CAPLUS
CN Phosphonic acid,
[[4-[[(4-acetyl-6-bromo-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 49 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 154770-08-8 CAPLUS
CN 6-Benzothiazolecarboxylic acid,
2-[[4-[(diethoxyphosphinyl)methyl]benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 154770-10-2 CAPLUS
CN Phosphonic acid,
[[4-[[(6-(phenylmethoxy)-2-benzothiazolyl]amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154770-20-4 CAPLUS
CN Phosphonic acid,
[2-[4-[[(4-methoxy-2-benzothiazolyl)amino]carbonyl]phenoxy]ethyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 248594-66-3 CAPLUS
CN Phosphonic acid,
[[4-[[(6-bromo-4-methoxy-2-benzothiazolyl)amino]carbonyl]

L7 ANSWER 49 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 50 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:610690 CAPLUS
DN 131:250395
TI Dispersion liquid for charge-generating layer and electrophotographic photoreceptor using same
IN Osamura, Hideki; Hirota, Nobuaki
PA Mitsubishi Paper Mills, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 34 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 11258841	A2	19990924	JP 1998-59816	19980311
<--				
PRAI JP 1998-59816		19980311		

OS MARPAT 131:250395
GI



I

AB The title dispersion liquid contains a bisazo pigment I [R = H, alkyl, (substituted) alkyl, aralkyl, aryl heterocyclic group; m = 0-2; n = 0, 1; Cp1, Cp2 = coupler residue] which is dispersed in a mixture of a resin and a solvent containing ≥1 selected from 4-methyl-2-pentanone, cyclohexanone, diethylene glycol di-Me ether, and 1,2-dimethoxyethane and ≥1 of C3-6 fatty acid esters. A photoreceptor using the dispersion liquid is also claimed. The dispersion liquid shows improved coatability and the photoreceptor provides high quality images without defect.
IT 244193-07-5
RL: DEV (Device component use); USES (Uses)
(electrophotog. photoreceptor using bisazo pigment dispersion liquid as charge-generating agent)
RN 244193-07-5 CAPLUS
CN 2-Naphthalenecarboxamide, N-2-benzothiazolyl-4-[[4-[2-[1-[4-[[3-[(2-benzothiazolylamino)carbonyl]-2-hydroxy-1-naphthalenyl]azo]phenyl]-3-(3,4-dimethylphenyl)-1H-pyrazol-4-yl]ethenyl]phenyl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 50 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 51 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:595169 CAPLUS
DN 131:228641
TI Preparation of benzofurylpyrone derivatives and effects on lipid metabolism
IN Naniwa, Yoshimitsu; Imai, Hiroshi; Ida, Tomohide; Muratani, Emiko; Kitai, Kazuo; Sugimoto, Yoshinori; Kosugi, Tomomi; Takeuchi, Akiko; Watanabe, Kunihito; Tomiyama, Takami; Takeuchi, Tomio; Hamada, Masa
PA Teijin Limited, Japan; Microbial Chemistry Research Foundation
SO PCT Int. Appl., 176 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9946262	A1	19990916	WO 1999-JP1225	19990312
<--				
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2323456	AA	19990916	CA 1999-2323456	19990312
<--				
AU 9932773	A1	19990927	AU 1999-32773	19990312
<--				
AU 756965	B2	20030130		
BR 9908706	A	20001121	BR 1999-8706	19990312
<--				
EP 1063235	A1	20001227	EP 1999-939191	19990312
<--				
EP 1063235	B1	20040512		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200002642	T2	20010122	TR 2000-200002642	19990312
<--				
EE 200000504	A	20020215	EE 2000-504	19990312
<--				
NZ 506802	A	20021126	NZ 1999-506802	19990312
<--				
RU 2199536	C2	20030227	RU 2000-125690	19990312
AT 266659	E	20040515	AT 1999-939191	19990312
NO 2000004517	A	20000911	NO 2000-4517	20000911
<--				
US 6589984	B1	20030708	US 2000-646005	20000911
HR 2000000600	A1	20010630	HR 2000-600	20000912
<--				
BG 104761	A	20010831	BG 2000-104761	20000912
<--				
US 2003186976	A1	20031002	US 2003-435746	20030512
PRAI JP 1998-61356	A	19980312		
WO 1999-JP1225	W	19990312		
US 2000-646005	A3	20000911		

OS MARPAT 131:228641
GI

L7 ANSWER 51 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Title compds. [I; wherein R1 represents hydrogen or C1-5 alkyl; R2 represents hydrogen, -CO-R5 or SO2R6; R3 represents hydrogen, C1-5 alkyl, etc.; and R4 is a substituent of a definite structure attached to the 4-, 5-, 6- or 7-position of the benzofuran ring] and salts thereof are prepared and tested as remedies for hyperglyceridemia, lipid metabolism improving agents, preventives/remedies for arteriosclerosis, etc. Thus, the title compound II was prepared
IT 244027-66-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzofurylpyrones and effects on lipid metabolism)
RN 244027-66-5 CAPLUS
CN 5-Benzofurancarboxamide, N-2-benzothiazolyl-2-(4-hydroxy-3,5-dimethyl-2-oxo-2H-pyran-6-yl)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 52 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:518672 CAPLUS
DN 131:189691
TI Pharmaceutical compositions containing thiazoles as protein kinase C inhibitors
IN Mori, Toyoki; Tominaga, Michiaki; Tabusa, Fujio; Ei, Kazuyoshi; Abe, Kaoru; Nakaya, Kenji; Takemura, Isao; Shinohara, Tomokazu; Tanada, Yoshihisa; Yamauchi, Takahito
PA Ohtsuka Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 345 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 11222431 <--	A2	19990817	JP 1998-43078	19980130
PRAI JP 1998-43078		19980130		

OS MARPAT 131:189691
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The compns. contain thiazoles I [R1, R2 = H, lower alkyl; R1R2 may form tetramethylene, pentamethylene, or (un)substituted benzene ring; R3 = Q1, Q2; p, s = 0, 1; R11b = H, lower alkyl; R11a = H, lower alkoxy, (un)substituted heterocyclyl; A = lower alkylene; Z = O, S; m = 1, 2; R5 = H, (hydroxy)alkyl, halo, etc.; R6 = COCH:CR11b(CO)pR11a, COC.tplbond.CCOR14; R14 = OH, lower alkoxy; when m = 1, AR5 may form (un)substituted benzopyranyl, benzofuranyl; R4 = H, lower alkanoyloxy-lower alkyl; T = lower alkylene; u = 0, 1] and/or their salts.
The compns. are useful for prevention and treatment of autoimmune disease, allergy, rejection in organ transplant, GVHD, ischemic disease, acute pancreatitis, sepsis, multiorgan failure, and ARDS. Thiazole derivative II inhibited protein kinase C with IC50 of 0.08 μM.

IT **202985-65-7P 202986-59-2P 202988-49-6P 202989-04-6P 202989-05-7P 240119-05-5P 240119-14-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazoles as protein kinase C inhibitors for treatment of diseases)

RN 202985-65-7 CAPLUS
CN 2-Benzofurancarboxamide, N-2-benzothiazolyl-2,3-dihydro-5-[4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-1,4-dioxo-2-butenyl]-, trihydrochloride

L7 ANSWER 52 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 202989-05-7 CAPLUS
CN 1-Piperidinecarboxamide, N-2-benzothiazolyl-4-[4-(4-methyl-1-piperazinyl)-1,4-dioxo-2-butenyl]- (9CI) (CA INDEX NAME)



RN 240119-05-5 CAPLUS
CN 2-Butenoic acid, 4-[2-[(2-benzothiazolylamino)carbonyl]-2,3-dihydro-5-benzofuranyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 240119-14-6 CAPLUS
CN 2-Butenoic acid, 4-[2-[(2-benzothiazolylamino)carbonyl]-2,3,4,5-tetrahydro-1-benzoxepin-7-yl]-4-oxo- (9CI) (CA INDEX NAME)



IT **202990-95-2P 202991-31-9P 202992-19-6P 202992-26-5P 240121-11-3P**
RL: PNU (Preparation, unclassified); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazoles as protein kinase C inhibitors for treatment of diseases)

L7 ANSWER 52 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(9CI) (CA INDEX NAME)



●3 HCl

RN 202986-59-2 CAPLUS
CN 1-Benzoxepin-2-carboxamide, N-2-benzothiazolyl-7-[4-[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1-piperidinyl]-1,4-dioxo-2-butenyl]-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 202988-49-6 CAPLUS
CN 2H-1-Benzopyran-2-carboxamide, N-2-benzothiazolyl-6-[3-(1-ethyl-1H-tetrazol-5-yl)-1-oxo-2-propenyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 202989-04-6 CAPLUS
CN 2-Butenoic acid, 4-[1-[(2-benzothiazolylamino)carbonyl]-4-piperidinyl]-4-oxo- (9CI) (CA INDEX NAME)

L7 ANSWER 52 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 202990-95-2 CAPLUS
CN 2H-1-Benzopyran-2-carboxamide, N-2-benzothiazolyl-6-(chloroacetyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 202991-31-9 CAPLUS
CN 2H-1-Benzopyran-2-carboxamide, N-2-benzothiazolyl-3,4-dihydro-6-[(triphenylphosphoranylidene)acetyl]- (9CI) (CA INDEX NAME)



RN 202992-19-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[(2-benzothiazolylamino)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 202992-26-5 CAPLUS
CN Phosphonic acid, [2-[1-[(2-benzothiazolylamino)carbonyl]-4-piperidinyl]-2-oxoethyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 240121-11-3 CAPLUS
CN 2H-1-Benzopyran-2-carboxamide, N-2-benzothiazolyl-6-formyl-3,4-dihydro- (9CI) (CA INDEX NAME)

L7 ANSWER 52 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 53 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:487281 CAPLUS
DN 131:116228
TI Preparation of oxazolidinones as bactericides
IN Gordeev, Mikhail F.; Luehr, Gary W.; Patel, Dinesh V.; Ni, Zhi-Jie; Gordon, Eric
PA Versicor, Inc., USA
SO PCT Int. Appl., 229 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9937630	A1	19990729	WO 1999-US1318	19990122
<--					
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2318969	AA	19990729	CA 1999-2318969	19990122
<--					
	AU 9924644	A1	19990809	AU 1999-24644	19990122
<--					
	AU 764184	B2	20030814		
	EP 1049682	A1	20001108	EP 1999-904193	19990122
<--					
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002501059	T2	20020115	JP 2000-528553	19990122
<--					
	BR 9907183	A	20030610	BR 1999-7183	19990122
	NZ 505902	A	20030829	NZ 1999-505902	19990122
PRAI	US 1998-12535	A	19980123		
	US 1998-86702	A	19980528		
	WO 1999-US1318	W	19990122		

OS MARPAT 131:116228
GI



AB Title compds. [e.g., I; R = H; R1 -SR11, CONR7R8, etc.; R7,R8. R11 = H, alkyl, (hetero)aryl, etc.] were prepared Thus, 3,4-F(Me3CO2C)C6H3NHCO2CH2Ph

L7 ANSWER 53 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(prepn. given) was cyclocondensed with (R)-glycidyl butyrate and the product converted in several steps to I (R = resin, R1 = CO2C6F5) which was amidated by morpholine to give, after resin cleavage, I (R = H, R1 = CONR8, R8 = morpholino). Data for biol. activity of I were given.
IT 232951-46-1P 232951-47-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolidinones as bactericides)
RN 232951-46-1 CAPLUS
CN Benzamide, 4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-N-2-benzothiazolyl-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232951-47-2 CAPLUS
CN Benzamide, 4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluoro-N-(6-methoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 54 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:460470 CAPLUS
DN 131:89074
TI Water-soluble azo compounds and process for their preparation
IN Ueno, Ryuzo; Kitayama, Masaya; Minami, Kenji; Kittaka, Masaharu
PA Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo, Japan
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9933925	A1	19990708	WO 1998-JP5755	19981221
<--					
	W: CA, CN, JP, KR, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	TW 527402	B	20030411	TW 1998-87121274	19981219
	CA 2282594	AA	19990708	CA 1998-2282594	19981221
<--					
	EP 984042	A1	20000308	EP 1998-961428	19981221
<--					
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1098319	B	20030108	CN 1998-803539	19981221
	US 6239263	B1	20010529	US 1999-380207	19990826
<--					
PRAI	JP 1997-359396	A	19971226		
	WO 1998-JP5755	W	19981221		

OS MARPAT 131:89074
GI



AB Azo compds. useful as raw materials for preparing dyes with good dyeing properties and fastness are prepared from a coupler consisting of 2-hydroxynaphthalene-3,6-dicarboxylic acid, its ester or amide and a diazonium compound bearing -B-(CH2)2-Q or -B'-(CH2)2-Q' group (wherein B and
B' are each an electron-attracting group; and Q and Q' are each a group capable of forming a vinyl group through the elimination with an alkali, provided the groups Q and Q' are each bonded at the β-position of the CH2CH2 group). Thus, coupling diazotized 4-(β-sulfatoethylsulfonyl)aniline with 2-hydroxynaphthalene-3,6-dicarboxylic acid in the presence of 10% NaHCO3 at pH 4-6 gave a red powdered crystal I.
IT 220799-84-8
RL: RCT (Reactant); RACT (Reactant or reagent)

L7 ANSWER 54 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(coupler; coupling with diazotized compd. in manuf. of water-sol. azo dye compds.)
RN 220799-84-8 CAPLUS
CN 2-Naphthalenecarboxylic acid, 7-[(2-benzothiazolylamino)carbonyl]-6-hydroxy- (9CI) (CA INDEX NAME)



IT 229612-19-5P
RL: IMF (Industrial manufacture); PRP (Properties); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(manufacture of water-soluble azo dye compds.)
RN 229612-19-5 CAPLUS
CN 2-Naphthalenecarboxylic acid, 7-[(2-benzothiazolylamino)carbonyl]-6-hydroxy-5-[[4-[[2-(sulfooxy)ethyl]sulfonyl]phenyl]azo]- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 55 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:460418 CAPLUS
DN 131:87915
TI Preparation of imidazole derivatives as therapeutic agents
IN Sueoka, Hiroyuki; Yasuoka, Jouji; Nishiyama, Akira; Kiuchi, Masatoshi; Yamamoto, Katsuya; Sugahara, Kunio
PA Yoshitomi Pharmaceutical Industries, Ltd., Japan
SO PCT Int. Appl., 183 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9933827	A1	19990708	WO 1998-JP5930	19981224
<--					
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	JP 2004067510	A2	20040304	JP 1997-359671	19971226
	AU 9916901	A1	19990719	AU 1999-16901	19981224
<--					
	US 6288061	B1	20010911	US 2000-598216	20000621
<--					
PRAI	JP 1997-359671	A	19971226		
	WO 1998-JP5930	W	19981224		
	JP 1999-174074	A	19990621		
	JP 2000-45165	A	20000217		

GI



I



II

L7 ANSWER 55 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB Title compds. [I; or pharmaceutically acceptable salts thereof: wherein R1 is hydrogen, optically substituted alkyl or the like; R2 is hydrogen, optically substituted alkyl or the like; R3 is optically substituted heteroaryl; and R4 is optically substituted cycloalkyl, optically substituted Ph or the like, provided that when R1 is hydrogen and R2 is Ph or Ph substituted with halogeno, lower alkyl or lower alkoxy, R3 is benzothiazolyl or phenyl-substituted benzothiazolyl; dotted bonds are singe or double] are prepared and exhibit an inhibitory activity against the production of IL-4 and IL-5 form Th2 cells, and are therefore useful as preventive and therapeutic agents for allergic diseases such as atopic dermatitis, bronchial asthma and allergic rhinitis. Title compound II was prepared
IT 229631-44-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazole derivs. as inhibitors)
RN 229631-44-1 CAPLUS
CN 1H-Imidazole-4-carboxamide, N-2-benzothiazolyl-5-(4-methylphenyl)-2-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 56 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:375544 CAPLUS
DN 131:19000
TI Preparation of phenyloxazolidinones as bactericides
IN Betts, Michael John; Swain, Michael Lingard
PA Zeneca Limited, UK
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9928317	A1	19990610	WO 1998-GB3496	19981124
<--					
	W: JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1034175	A1	20000913	EP 1998-955759	19981124
<--					
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001525320	T2	20011211	JP 2000-523209	19981124
<--					
	US 6495551	B1	20021217	US 2000-555203	20000525
<--					
PRAI	GB 1997-25244	A	19971129		
	WO 1998-GB3496	W	19981124		
OS	MARPAT 131:19000				

GI



I

AB Title compds. [I; R = Z1ZCH2R1; R1 = Cl, F, OH, alkoxy, NHCORa, etc.; Ra = H, CH2Cl, alkyl, alkoxy, etc.; R4 = YR2 or CH(OH)YR2; R2 = (un)substituted heterocyclyl or -heteroaryl; R5,R6 = H, halo, CF3, alkyl; Y = (CH2)m, CO(CH2)m, CONH(CH2)m, etc.; Z = 2-oxooxazolidine-3,5-diyl throughout; Z1 = (2-fluoro) 1,4-phenylene, 2,6-difluoro-1,4-phenylene; m = 0-3] were prepared
Thus, I (R = Z1R3, R4 = CH2R7, R5 = R6 = H, Z1 = 2-fluoro-1,4-phenylene)(II; R3 = NHCO2CH2Ph, R7 = Me3CMe2SiO)(preparation given) was cyclocondensed with (R)-glycidyl butyrate and the product converted in 4 steps to (R)-II (R3 = ZCH2NHAc)(III; R7 = OH) which was thioetherified by pyrimidine-2-thiol to give III (R7 = 2-pyrimidinylthio). Data for biol. activity of 1 prepared I were given.
IT 226384-98-1P 226385-31-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

L7 ANSWER 56 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenyloxazolidinones as bactericides)
RN 226384-98-1 CAPLUS
CN 1H-Imidazole-4-carboxamide, 1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-N-(6-methoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 226385-31-5 CAPLUS
CN 1H-Imidazole-4-carboxamide, 1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-N-2-benzothiazolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:325793 CAPLUS
DN 131:5252
TI Preparation of benzothiazolecarboxamides as protein tyrosine kinase inhibitors
IN Das, Jagabandhu; Barrish, Joel C.; Wityak, John
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 220 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9924035	A1	19990520	WO 1998-US23204	19981102
<--					
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2309319	AA	19990520	CA 1998-2309319	19981102
<--					
	AU 9913719	A1	19990531	AU 1999-13719	19981102
<--					
	AU 744281	B2	20020221		
	TR 200001312	T2	20000921	TR 2000-200001312	19981102
<--					
	EP 1037632	A1	20000927	EP 1998-957468	19981102
<--					
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	BR 9814956	A	20001003	BR 1998-14956	19981102
<--					
	JP 2001522800	T2	20011120	JP 2000-520127	19981102
<--					
	NZ 503491	A	20020828	NZ 1998-503491	19981102
<--					
	RU 2212407	C2	20030920	RU 2000-114635	19981102
	TW 510898	B	20021121	TW 1998-87118450	19981105
<--					
	ZA 9810219	A	20000622	ZA 1998-10219	19981109
<--					
	MX 200003266	A	20001110	MX 2000-3266	20000403
<--					
	NO 2000002121	A	20000509	NO 2000-2121	20000426
<--					
	US 2002123484	A1	20020905	US 2001-32609	20011026
<--					
	US 6825355	B2	20041130		
PRAI	US 1997-65042P	P	19971110		
	US 1998-173413	A1	19981015		
	WO 1998-US23204	W	19981102		

OS MARPAT 131:5252

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
AB R2R3NZZ1NR4R5 [R2,R3 = H, NH2, (ar)alkyl, aryl, etc.; R4,R5 = H, (ar)alkyl, aryl, etc.; NR4R5 = heterocyclyl; Z = (un)substituted benzothiazole-2,4-, -2,5-, -2,6-, or -2,7-diyl; Z1 = CH2CO, CS] were prepared as protein tyrosine kinase inhibitors (no data). Thus, 4-(H2N)C6H4CO2Et was cyclocondensed with NaSCN and the protected and saponified product amidated by 2,4,6-trimethylaniline to give, after deprotection, H2N2CONHR4 (R4 = 2,4,6-trimethylphenyl, Z = benzothiazole-2,6-diyl).
IT 225520-14-9P 225521-06-2P 225521-09-5P
225521-10-8P 225521-11-9P 225521-13-1P
225521-34-6P 225521-38-0P 225521-45-9P
225521-50-6P 225521-51-7P 225522-48-5P
225522-49-6P 225522-50-9P 225522-51-0P
225522-52-1P 225522-53-2P 225522-80-5P
225522-81-6P 225522-82-7P 225522-83-8P
225522-84-9P 225522-85-0P 225522-86-1P
225522-87-2P 225522-88-3P 225522-89-4P
225522-90-7P 225522-91-8P 225522-92-9P
225522-93-0P 225522-94-1P 225522-95-2P
225522-96-3P 225522-97-4P 225523-01-3P
225523-02-4P 225523-08-0P 225523-10-4P
225523-42-2P 225523-55-7P 225523-56-8P
225523-57-9P 225523-58-0P 225523-59-1P
225523-60-4P 225523-61-5P 225523-62-6P
225523-63-7P 225523-64-8P 225523-65-9P
225523-66-0P 225523-67-1P 225523-68-2P
225523-69-3P 225523-70-6P 225523-71-7P
225523-72-8P 225523-73-9P 225523-74-0P
225523-75-1P 225523-76-2P 225523-77-3P
225523-78-4P 225523-79-5P 225523-80-8P
225523-81-9P 225523-82-0P 225523-84-2P
225523-85-3P 225523-87-5P 225525-37-1P
225525-38-2P 225525-39-3P 225525-40-6P
225525-41-7P 225525-42-8P 225525-43-9P
225525-44-0P 225525-45-1P 225525-46-2P
225525-47-3P 225525-48-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzothiazolecarboxamides as protein tyrosine kinase inhibitors)
RN 225520-14-9 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-(benzoylamino)-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 225521-06-2 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[(4-methoxycyclohexyl)carbonyl]amino]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 225521-09-5 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[(cyclopropylcarbonyl)amino]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 225521-10-8 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[(cyclobutylcarbonyl)amino]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 225521-11-9 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[(cyclopentylcarbonyl)amino]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 225521-13-1 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[(1-cyclopenten-1-ylcarbonyl)amino]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 225521-34-6 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[(3-thienylcarbonyl)amino]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 225521-38-0 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[(3-cyclohexen-1-ylcarbonyl)amino]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 225521-45-9 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[(tetrahydro-2-furanyl)carbonyl]amino]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 225521-50-6 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[(tricyclo[3.3.1.13,7]dec-1-ylcarbonyl)amino]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 225521-51-7 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[(4-methylcyclohexyl)carbonyl]amino]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 225522-48-5 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(cyclopropylcarbonyl)amino]- (9CI) (CA INDEX NAME)



RN 225522-49-6 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[(2-methylcyclopropyl)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 225522-50-9 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[(2,2-dichloro-1-methylcyclopropyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 225522-51-0 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[(1-hydroxycyclopropyl)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 225522-52-1 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(cyclobutylcarbonyl)amino]- (9CI) (CA INDEX NAME)



RN 225522-53-2 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(cyclopentylcarbonyl)amino]- (9CI) (CA INDEX NAME)



RN 225522-80-5 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[(1-methylcyclopropyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 225522-81-6 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[(2-(trimethylsilyl)cyclopropyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 225522-82-7 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[[1-(4-methoxyphenyl)cyclopropyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 225522-83-8 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[[(1R,2R)-2-phenylcyclopropyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 225522-84-9 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[[1-(4-methylphenyl)cyclopropyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 225522-85-0 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[[1-(4-chlorophenyl)cyclopropyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 225522-86-1 CAPLUS
CN Carbamic acid, [1-[[[6-[[(2-chloro-6-methylphenyl)amino]carbonyl]-2-benzothiazolyl]amino]carbonyl]cyclopropyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)



RN 225522-87-2 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[[(1S,3S)-2,2-dimethyl-3-(2-methyl-1-propenyl)cyclopropyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 225522-91-8 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[[[6-[[(2-chloro-6-methylphenyl)amino]carbonyl]-2-benzothiazolyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 225522-92-9 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[[[6-[[(2-chloro-6-methylphenyl)amino]carbonyl]-2-benzothiazolyl]amino]carbonyl]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 225522-93-0 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[[2-(phenylmethyl)cyclopropyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 225522-94-1 CAPLUS
CN 2-Quinolinecarboxamide, N-[6-[[(2-chloro-6-methylphenyl)amino]carbonyl]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 225522-88-3 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[[(1S,3R)-2,2-dimethyl-3-(2-methyl-1-propenyl)cyclopropyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 225522-89-4 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[(1-phenylcyclopropyl)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 225522-90-7 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[(2-formylcyclopropyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 225522-95-2 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[(2-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)



RN 225522-96-3 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[(1-oxido-2-pyridinyl)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 225522-97-4 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[[(1R,2R)-2-[(dimethylamino)methyl]cyclopropyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 225523-01-3 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[[(1R,2R)-2-(1-

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
pyrrolidinylmethyl)cyclopropyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 225523-02-4 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[[(1R,2R)-2-(1-piperidinylmethyl)cyclopropyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 225523-08-0 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[(cyclobutylcarbonyl)amino]-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 225523-10-4 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[(cyclopentylcarbonyl)amino]-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 225523-42-2 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2,6-dimethylphenyl)-2-[[(1-methylcyclopropyl)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 225523-55-7 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2,6-dimethylphenyl)-2-[[[2-(phenylmethyl)cyclopropyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 225523-56-8 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2,6-dimethylphenyl)-2-[[[2-(trimethylsilyl)cyclopropyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 225523-57-9 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[(cyclopropylcarbonyl)amino]-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 225523-58-0 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2,6-dimethylphenyl)-2-[[(2-methylcyclopropyl)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 225523-59-1 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2,6-dimethylphenyl)-2-[[[(1R,2R)-2-phenylcyclopropyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 225523-60-4 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2,6-dimethylphenyl)-2-[[[1-(4-methylphenyl)cyclopropyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 225523-61-5 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[[1-(4-chlorophenyl)cyclopropyl]carbonyl]amino]-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 225523-62-6 CAPLUS
CN Carbamic acid, [1-[[[6-[[(2,6-dimethylphenyl)amino]carbonyl]-2-benzothiazolyl]amino]carbonyl]cyclopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 225523-63-7 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[[(1S,3R)-2,2-dimethyl-3-(2-methyl-1-propenyl)cyclopropyl]carbonyl]amino]-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 225523-64-8 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2,6-dimethylphenyl)-2-[[[1-(4-methoxyphenyl)cyclopropyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 225523-65-9 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2,6-dimethylphenyl)-2-[[(1-phenylcyclopropyl)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 225523-66-0 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2,6-dimethylphenyl)-2-[[(2-formylcyclopropyl)carbonyl]amino]- (9CI) (CA INDEX NAME)

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 225523-67-1 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[[[6-[[(2,6-dimethylphenyl)amino]carbonyl]-2-benzothiazolyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 225523-68-2 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[(2-cyanocyclopropyl)carbonyl]amino]-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 225523-69-3 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[[[6-[[(2,6-dimethylphenyl)amino]carbonyl]-2-benzothiazolyl]amino]carbonyl]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 225523-70-6 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[[(1S,3S)-2,2-dimethyl-3-(2-methyl-1-

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
propenyl)cyclopropyl]carbonyl]amino]-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 225523-71-7 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2,4,6-trimethylphenyl)-2-[[[2-(trimethylsilyl)cyclopropyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 225523-72-8 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[(2-methylcyclopropyl)carbonyl]amino]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 225523-73-9 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[[(1R,2R)-2-phenylcyclopropyl]carbonyl]amino]-N-(2,4,6-trimethylphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 225523-74-0 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[[[6-[[(2,4,6-trimethylphenyl)amino]carbonyl]-2-benzothiazolyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 225523-75-1 CAPLUS
CN Carbamic acid, [1-[[[6-[[(2,4,6-trimethylphenyl)amino]carbonyl]-2-benzothiazolyl]amino]carbonyl]cyclopropyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)



RN 225523-76-2 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[[(1S,3S)-2,2-dimethyl-3-(2-methyl-1-propenyl)cyclopropyl]carbonyl]amino]-N-(2,4,6-trimethylphenyl)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 225523-77-3 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[[[(1S,3R)-2,2-dimethyl-3-(2-methyl-1-propenyl)cyclopropyl]carbonyl]amino]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 225523-78-4 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[[(1-phenylcyclopropyl)carbonyl]amino]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 225523-79-5 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[(2-formylcyclopropyl)carbonyl]amino]-N-

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 225523-80-8 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[(2-cyanocyclopropyl)carbonyl]amino]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 225523-81-9 CAPLUS
CN Cyclopropanecarboxylic acid, 1-methyl-2-[[[6-[[(2,4,6-trimethylphenyl)amino]carbonyl]-2-benzothiazolyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 225523-82-0 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[[2-(phenylmethyl)cyclopropyl]carbonyl]amino]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 225523-84-2 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[[1-(4-methylphenyl)cyclopropyl]carbonyl]am

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ino]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 225523-85-3 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[[1-(4-chlorophenyl)cyclopropyl]carbonyl]amino]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 225523-87-5 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[[1-(4-methoxyphenyl)cyclopropyl]carbonyl]amino]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 225525-37-1 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[[(1R,2R)-2-[4-(1,1-dimethylethyl)phenyl]cyclopropyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 225525-38-2 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[[(1R,2R)-2-(4-ethoxyphenyl)cyclopropyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 225525-39-3 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[[(1R,2R)-2-(4-fluorophenyl)cyclopropyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 225525-40-6 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[[(1R,2R)-2-[4-(1-methylethyl)phenyl]cyclopropyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 225525-41-7 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[[(1R,2R)-2-[4-(trifluoromethyl)phenyl]cyclopropyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 225525-42-8 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[[(1R,2R)-2-(4-nitrophenyl)cyclopropyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 225525-45-1 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[[(1R,2R)-2-(1,3-benzodioxol-4-yl)cyclopropyl]carbonyl]amino]-N-(2-chloro-6-methylphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 225525-46-2 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[[(1R,2R)-2-(3-chlorophenyl)cyclopropyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 225525-43-9 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[[(1R,2R)-2-(4-cyanophenyl)cyclopropyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 225525-44-0 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[[(1R,2R)-2-[1,1'-biphenyl]-4-ylcyclopropyl]carbonyl]amino]-N-(2-chloro-6-methylphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 225525-47-3 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[[(1R,2R)-2-(3-cyanophenyl)cyclopropyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 225525-48-4 CAPLUS
CN 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[[(1R,2R)-2-(3-nitrophenyl)cyclopropyl]carbonyl]amino]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 57 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 58 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ole methanesulfonate (II; prepn. given) against rat brain protein kinase C
was 0.08 μM. II also suppressed increases in blood creatinine and urea-N in a rat renal ischemia-reperfusion injury model.
IT 224457-11-8P 224457-12-9P 224582-67-6P
224582-80-3P 224582-81-4P 224582-82-5P
224582-93-8P 224582-95-0P 224582-96-1P
224582-99-4P 224583-13-5P 224583-36-2P
224583-38-4P 224583-83-9P 224583-84-0P
224584-01-4P 224584-07-0P 224584-26-3P
224584-27-4P 224584-30-9P 224584-31-0P
224584-32-1P 224584-46-7P 224584-74-1P
224584-77-4P 224584-78-5P 224584-79-6P
224584-80-9P 224584-81-0P 224584-82-1P
224584-83-2P 224584-84-3P 224584-85-4P
224584-86-5P 224584-87-6P 224584-91-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzothiazole derivs. as protein kinase C inhibitors)
RN 224457-11-8 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[1-oxo-3-(2-pyridinyl)-2-propenyl]- (9CI) (CA INDEX NAME)



RN 224457-12-9 CAPLUS
CN 2-Butenoic acid, 4-[5-[(2-benzothiazolylamino)carbonyl]-2-furanyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 224582-67-6 CAPLUS
CN 2-Butenoic acid, 4-[2-[(2-benzothiazolylamino)carbonyl]-2,3-dihydro-1H-inden-5-yl]-4-oxo- (9CI) (CA INDEX NAME)



L7 ANSWER 58 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:312721 CAPLUS
DN 130:352268
TI Preparation of benzothiazole derivatives as protein kinase C inhibitors
IN Mori, Toyoki; Tominaga, Michiaki; Tabusa, Fujio; Ei, Kazuyoshi; Abe, Kaoru; Nakaya, Kenji; Takemura, Isao; Shinohara, Yuichi; Tanada, Yoshihisa; Yamauchi, Takahito
PA Ohtsuka Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 127 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 11130761	A2	19990518	JP 1997-292346	19971024
PRAI JP 1997-292346		19971024		

OS MARPAT 130:352268
GI



I



AB The derivs. I [R1 = H, lower alkanoyloxyl2-lower alkyl; R2 = Q [m = 0, 1; Z = AO (A = lower alkylene), A1NR5 (A1 = lower alkylene; R5 = H, lower alkyl); R3 = alkenylcarbonyl, COCR6R:CR7R8 (R6 = H, imidazolyl; R7, R8 = H, substituents); R4 = H, halo, lower alkyl, lower alkoxy, lower alkoxycarbonyl-lower alkyl, lower alkanoyloxy-lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower carboxyalkyl, A(CO)nNR21R22 [A = lower alkylene; n = 0, 1; R21, R22 = H, (un)substituted lower alkyl, or NR21R22 = (O-containing) 5-7-membered saturated heterocyclyl]], 2,3-dihydrobenzofuryl which may be substituted with lower alkenylcarbonyl, chromanyl which may be substituted with lower alkenylcarbonyl, anilino which may be ring-substituted with carboxy-lower alkenylcarboyl, condensed benzo(hetero)cyclyl, etc.] are prepared I inhibit protein kinase C and are useful for preventing or treating diseases caused by hyperfunctioning of protein kinase C-mediated biol. process, e.g. metabolic regulation, cell proliferation, cell differentiation, etc. IC50 of 2-[2-(4-morpholinobutyl)-4-(3-methylacryloyl)phenoxy]methylcarbonylaminobenzothiaz

L7 ANSWER 58 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 224582-80-3 CAPLUS
CN 2-Butenoic acid, 4-[2-[(2-benzothiazolylamino)carbonyl]-2,3-dihydro-1H-inden-5-yl]-4-oxo-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 224582-81-4 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-(1-oxo-3-butenyl)- (9CI) (CA INDEX NAME)



RN 224582-82-5 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-(1-oxo-2-butenyl)- (9CI) (CA INDEX NAME)



RN 224582-93-8 CAPLUS
CN 2-Benzofurancarboxamide, N-2-benzothiazolyl-2,3-dihydro-5-(4-methyl-1-oxo-2-pentenyl)- (9CI) (CA INDEX NAME)



RN 224582-95-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 3-[3-[4-[(2-benzothiazolylamino)carbonyl]phenyl]-3-oxo-1-propenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 58 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 224582-96-1 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[1-oxo-3-(3-piperidinyl)-2-propenyl]- (9CI) (CA INDEX NAME)



RN 224582-99-4 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[3-(1-methyl-3-piperidinyl)-1-oxo-2-propenyl]- (9CI) (CA INDEX NAME)



RN 224583-13-5 CAPLUS
CN 1H-Indene-2-carboxamide, N-2-benzothiazolyl-2,3-dihydro-5-[4-(4-methyl-1-piperazinyl)-1,4-dioxo-2-butenyl]- (9CI) (CA INDEX NAME)



RN 224583-36-2 CAPLUS
CN 2H-1-Benzopyran-2-carboxamide, N-2-benzothiazolyl-3,4-dihydro-6-(1-oxo-2-butenyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 58 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 224583-38-4 CAPLUS
CN 2H-1-Benzopyran-2-carboxamide, N-2-benzothiazolyl-3,4-dihydro-6-(2-methyl-1-oxo-2-propenyl)- (9CI) (CA INDEX NAME)



RN 224583-83-9 CAPLUS
CN 1H-Indene-2-carboxamide, N-2-benzothiazolyl-2,3-dihydro-5-[4-(4-hydroxy-1-piperazinyl)-1,4-dioxo-2-butenyl]- (9CI) (CA INDEX NAME)



RN 224583-84-0 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[4-(4-hydroxy-1-piperazinyl)-1,4-dioxo-2-butenyl]- (9CI) (CA INDEX NAME)



RN 224584-01-4 CAPLUS
CN 1H-Indene-2-carboxamide, N-2-benzothiazolyl-5-[3-[4-[[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1-piperidinyl]carbonyl]phenyl]-1-oxo-2-

L7 ANSWER 58 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
propenyl]-2,3-dihydro- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 224584-07-0 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3-[4-[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1-piperidinyl]-1,4-dioxo-2-butenyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 224584-26-3 CAPLUS
CN 2-Furancarboxamide, N-2-benzothiazolyl-5-[4-(4-methyl-1-piperazinyl)-1,4-dioxo-2-butenyl]- (9CI) (CA INDEX NAME)



RN 224584-27-4 CAPLUS
CN 2-Furancarboxamide, N-2-benzothiazolyl-5-[4-[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1-piperidinyl]-1,4-dioxo-2-butenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 58 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 224584-30-9 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3-methoxy-4-[4-(4-methyl-1-piperazinyl)-1,4-dioxo-2-butenyl]- (9CI) (CA INDEX NAME)



RN 224584-31-0 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[4-[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1-piperidinyl]-1,4-dioxo-2-butenyl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 224584-32-1 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[4-[4-(3,4-dimethyl-1-piperazinyl)-1-piperidinyl]-1,4-dioxo-2-butenyl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 224584-46-7 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[4-[2-[(4-methyl-1-piperazinyl)methyl]-4-

L7 ANSWER 58 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
morpholinyl]-1,4-dioxo-2-butenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 224584-74-1 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[3-[4-[[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1-piperidinyl]carbonyl]phenyl]-1-oxo-2-propenyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 224584-77-4 CAPLUS
CN 1H-Indene-2-carboxamide, N-2-benzothiazolyl-2,3-dihydro-5-[3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)-1-propenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 58 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 224584-81-0 CAPLUS
CN 1H-Tetrazolium, 1-[2-[2-[(2-benzothiazolylamino)carbonyl]-2,3-dihydro-1H-inden-5-yl]-1-(4-hydroxybenzoyl)ethenyl]-4-ethyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 224584-82-1 CAPLUS
CN 1H-Indene-2-carboxamide, N-2-benzothiazolyl-2,3-dihydro-5-[3-(4-hydroxyphenyl)-3-oxo-2-(1H-1,2,4-triazol-1-yl)-1-propenyl]- (9CI) (CA INDEX NAME)



RN 224584-83-2 CAPLUS
CN 1H-Tetrazolium, 1-[2-[2-[(2-benzothiazolylamino)carbonyl]-2,3-dihydro-1H-

L7 ANSWER 58 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 224584-78-5 CAPLUS
CN 1H-Indene-2-carboxamide, N-2-benzothiazolyl-2,3-dihydro-5-[2-(1H-imidazol-1-yl)-3-oxo-3-(1,2,3,4-tetrahydro-8-methyl-2-oxo-6-quinolinyl)-1-propenyl]- (9CI) (CA INDEX NAME)



RN 224584-79-6 CAPLUS
CN 1H-Indene-2-carboxamide, N-2-benzothiazolyl-2,3-dihydro-5-[3-oxo-3-(1,2,3,4-tetrahydro-8-methyl-2-oxo-6-quinolinyl)-2-(1H-1,2,4-triazol-1-yl)-1-propenyl]- (9CI) (CA INDEX NAME)



RN 224584-80-9 CAPLUS
CN Benzoic acid, 5-[3-[2-[(2-benzothiazolylamino)carbonyl]-2,3-dihydro-1H-inden-5-yl]-1-oxo-2-(1H-1,2,4-triazol-1-yl)-2-propenyl]-2-hydroxy-, methyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 58 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
inden-5-yl]-1-(4-hydroxy-3-methoxybenzoyl)ethenyl]-4-methyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 224584-84-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-(2-acetyl-3-oxo-1-butenyl)-N-2-benzothiazolyl- (9CI) (CA INDEX NAME)



RN 224584-85-4 CAPLUS
CN Propanedioic acid, [[5-[(2-benzothiazolylamino)carbonyl]-2-pyridinyl]methylene]-, diethyl ester (9CI) (CA INDEX NAME)



RN 224584-86-5 CAPLUS
CN 3-Pyridinecarboxamide, N-2-benzothiazolyl-6-[3-oxo-2-(1-oxobutyl)-1-hexenyl]- (9CI) (CA INDEX NAME)



RN 224584-87-6 CAPLUS
CN 2-Thiophenecarboxamide, N-2-benzothiazolyl-4-[4-(4-methyl-1-piperazinyl)-1,4-dioxo-2-butenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 58 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 224584-91-2 CAPLUS
CN 2-Butenoic acid, 4-[5-[(2-benzothiazolylamino)carbonyl]-3-thienyl]-4-oxo- (9CI) (CA INDEX NAME)



IT 224582-66-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzothiazole derivs. as protein kinase C inhibitors)
RN 224582-66-5 CAPLUS
CN 1H-Indene-2-carboxamide, N-2-benzothiazolyl-2,3-dihydro- (9CI) (CA INDEX NAME)



IT 215503-97-2P 215504-03-3P 224456-34-2P
224456-80-8P 224456-81-9P 224456-85-3P
224456-94-4P 224457-07-2P 224457-08-3P

L7 ANSWER 58 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 224456-81-9 CAPLUS
CN 1H-Indene-2-carboxamide, N-2-benzothiazolyl-5-formyl-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 224456-85-3 CAPLUS
CN Benzamide,
N-2-benzothiazolyl-2-[(2,2-dimethylhydrazino)methyl]-4-formyl-, compd. with 1H-indene (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 224456-84-2
CMF C18 H18 N4 O2 S



CM 2

CRN 95-13-6
CMF C9 H8

RN 224456-94-4 CAPLUS
CN 2-Thiophenecarboxamide,
N-2-benzothiazolyl-4-[(triphenylphosphoranylidene) acetyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 58 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of benzothiazole derivs. as protein kinase C inhibitors)
RN 215503-97-2 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-formyl- (9CI) (CA INDEX NAME)



RN 215504-03-3 CAPLUS
CN Benzamide,
N-2-benzothiazolyl-4-formyl-2-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 224456-34-2 CAPLUS
CN 2-Furancarboxamide,
N-2-benzothiazolyl-5-[(triphenylphosphoranylidene)acetyl]- (9CI) (CA INDEX NAME)



RN 224456-80-8 CAPLUS
CN Phosphonic acid, [2-[4-[(2-benzothiazolylamino)carbonyl]phenyl]-2-oxoethyl]-, dimethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 58 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 224457-07-2 CAPLUS
CN 3-Pyridinecarboxamide, N-2-benzothiazolyl-6-(1,2-dihydroxyethyl)- (9CI) (CA INDEX NAME)



RN 224457-08-3 CAPLUS
CN 3-Pyridinecarboxamide, N-2-benzothiazolyl-6-formyl- (9CI) (CA INDEX NAME)



L7 ANSWER 59 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:189145 CAPLUS
DN 130:197883
TI Water-soluble azo compounds and production process therefor
IN Ueno, Ryuzo; Kitayama, Masaya; Minami, Kenji; Kittaka, Masaharu
PA Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo, Japan
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9911717	A1	19990311	WO 1998-JP3750	19980825
<--					
	W: CA, CN, JP, KR, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2266258	AA	19990311	CA 1998-2266258	19980825
<--					
	EP 937753	A1	19990825	EP 1998-938963	19980825
<--					
	EP 937753	B1	20030806		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1098318	B	20030108	CN 1998-801222	19980825
	AT 246715	E	20030815	AT 1998-938963	19980825
	TW 222989	B1	20041101	TW 1998-87114143	19980827
	US 6020470	A	20000201	US 1999-254949	19990322
<--					
PRAI	JP 1997-232887	A	19970828		
	WO 1998-JP3750	W	19980825		

OS MARPAT 130:197883
AB New water-soluble azo compds. used as starting materials for dyes with excellent dyeing properties and fastness were produced from 2-hydroxynaphthalene-3,6-dicarboxylic acid or its derivs. and a diazonium salt having a sulfo group. Thus, an azo compound was prepared by reaction of sulfanilic acid with cyanuric chloride, followed by reaction of the product with m-phenylenediamine-4-sulfonic acid, then diazotization with 2-hydroxy-3-phenylaminocarbonyl-6-hydroxycarbonylnaphthalene to give NaCl-containing dark red crystal powder 90.3 g, showing good dyeing property with cotton fiber.
IT **220799-84-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(for preparation of water-soluble azo compds. and dyes)
RN 220799-84-8 CAPLUS
CN 2-Naphthalenecarboxylic acid, 7-[(2-benzothiazolylamino)carbonyl]-6-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 59 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT **220799-86-0P**
RL: PRP (Properties); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(preparation and properties of water-soluble azo compds. and dyes)
RN 220799-86-0 CAPLUS
CN 2-Naphthalenecarboxylic acid, 7-[(2-benzothiazolylamino)carbonyl]-5-[[3-[[4-chloro-6-[(4-sulfophenyl)amino]-1,3,5-triazin-2-yl]amino]-5-sulfophenyl]azo]-6-hydroxy- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:693417 CAPLUS
DN 129:343326
TI Preparation of benzenes as protein kinase C inhibitors
IN Mori, Toyoki; Tominaga, Michiaki; Tabusa, Fujio; Ei, Kazuyoshi; Nakaya, Kenji; Takemura, Isao; Shinohara, Tomokazu; Tanada, Yoshihisa; Yamauchi, Takahito; Kitano, Kazuyoshi
PA Otsuka Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 359 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10287634	A2	19981027	JP 1997-110527	19970411
<--					
PRAI	JP 1997-110527		19970411		

OS MARPAT 129:343326
GI



I

AB Benzenes I [R1 = 5- to 6-membered (un)substituted unsatd. heterocyclyl having 1-4 N, O, or S; cyano, carboxylalkyl, alkoxycarbonyl, H, Bz, (un)substituted amido, etc.; R2 = (un)substituted Bz, (un)substituted 1,2,3,4-tetrahydroquinolinylcarbonyl, pyridylcarbonyl, (un)substituted phenoxycarbonyl, etc.; R3 = H, lower alkyl, PhS, (un)substituted lower alkylthio, cycloalkylthio, cyano, etc.; R4 = H, (un)substituted lower alkyl, lower alkoxy, (un)substituted aminoalkylene, (un)substituted aminoalkylenyloxy; R5 = substituted alkenyl, phenylthioureidocarbonyl, pyrimidylaminocarbonylalkoxy, etc.; n = 1-3; the dot line may be double bond) or their salts are prepared I are useful for prevention and treatment of chronic rheumatoid arthritis, systemic lupus erythematosus, atopic dermatitis, heart failure, allergy, multiple sclerosis, tumor, Alzheimer-type dementia, etc. Condensation of 250 mg 2-(benzoylmethyl)pyridine with 300 mg 4-[(2-benzothiazolyl)aminocarbonyl]benzaldehyde in C6H6 for 10 h gave 0.3 g 2-[4-[2-benzoyl-2-(2-pyridyl)vinyl]benzoylamino]benzothiazole.
IT **215506-65-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzenes as protein kinase C inhibitors for treatment of diseases)
RN 215506-65-3 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[1-(ethylthio)-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT **215504-19-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzenes as protein kinase C inhibitors for treatment of diseases)
RN 215504-19-1 CAPLUS
CN Benzoic acid, 5-[3-[4-[(2-benzothiazolylamino)carbonyl]phenyl]-1-oxo-2-(1H-1,2,4-triazol-1-yl)-2-propenyl]-2-(methoxymethoxy)-, methyl ester (9CI) (CA INDEX NAME)



IT **215503-97-2P 215504-03-3P 215504-14-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzenes as protein kinase C inhibitors for treatment of diseases)
RN 215503-97-2 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-formyl- (9CI) (CA INDEX NAME)



RN 215504-03-3 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-formyl-2-[(4-methyl-1-piperazinyl)methyl]-

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(9CI) (CA INDEX NAME)



RN 215504-14-6 CAPLUS
CN Benzamide, N-[6-[2-(diethylamino)ethyl]-2-benzothiazolyl]-4-formyl- (9CI) (CA INDEX NAME)



IT 215504-17-9P 215504-20-4P 215504-28-2P
215504-89-5P 215505-39-8P 215505-71-8P
215505-73-0P 215505-77-4P 215505-78-5P
215505-81-0P 215505-82-1P 215505-83-2P
215505-84-3P 215505-88-7P 215505-93-4P
215505-94-5P 215506-00-6P 215506-01-7P
215506-15-3P 215506-19-7P 215506-20-0P
215506-21-1P 215506-23-3P 215506-24-4P
215506-35-7P 215506-36-8P 215506-37-9P
215506-40-4P 215506-42-6P 215506-44-8P
215506-46-0P 215506-51-7P 215506-52-8P
215506-53-9P 215506-55-1P 215506-56-2P
215506-67-5P 215506-68-6P 215506-69-7P
215506-71-1P 215506-72-2P 215506-73-3P
215506-74-4P 215506-75-5P 215506-76-6P
215506-77-7P 215506-78-8P 215506-79-9P
215506-82-4P 215506-83-5P 215506-84-6P
215506-85-7P 215506-86-8P 215506-89-1P
215506-91-5P 215506-92-6P 215506-93-7P
215506-95-9P 215506-97-1P 215506-98-2P
215507-00-9P 215507-01-0P 215507-02-1P
215507-03-2P 215507-05-4P 215507-09-8P
215507-10-1P 215507-11-2P 215507-12-3P
215507-14-5P 215507-16-7P 215507-17-8P
215507-18-9P 215507-19-0P 215507-23-6P
215507-26-9P 215507-33-8P 215507-51-0P
215507-56-5P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzenes as protein kinase C inhibitors for treatment of

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
diseases)

RN 215504-17-9 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[3-oxo-3-phenyl-2-(2-pyridinyl)-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215504-20-4 CAPLUS
CN Benzoic acid, 5-[3-[4-[(2-benzothiazolylamino)carbonyl]phenyl]-3-(ethylthio)-1-oxo-2-(1H-1,2,4-triazol-1-yl)propyl]-2-(methoxymethoxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 215504-28-2 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[(2-methyl-5-oxo-4(5H)-oxazolylidene)methyl]- (9CI) (CA INDEX NAME)



RN 215504-89-5 CAPLUS
CN Benzamide,
N-2-benzothiazolyl-4-[2-(1-methyl-1H-tetrazol-5-yl)-3-oxo-3-(4-pyridinyl)-1-propenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 215505-39-8 CAPLUS
CN Benzamide,
N-2-benzothiazolyl-4-[3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215505-71-8 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[2-(1H-imidazol-1-yl)-3-[4-(methoxymethoxy)-3-methylphenyl]-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215505-73-0 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[2-(1H-imidazol-1-yl)-3-[4-(methoxymethoxy)-3,5-dimethylphenyl]-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 215505-77-4 CAPLUS
CN Benzamide,
N-2-benzothiazolyl-4-[3-[4-[(dimethylamino)methyl]phenyl]-2-(1-methyl-1H-tetrazol-5-yl)-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215505-78-5 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[3-(4-hydroxy-3,5-dimethylphenyl)-2-(1H-imidazol-1-yl)-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215505-81-0 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[2-(1H-imidazol-1-yl)-3-[3-methoxy-4-(methoxymethoxy)phenyl]-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 215505-82-1 CAPLUS
CN Benzamide,
N-2-benzothiazolyl-4-[3-[4-(methoxymethoxy)phenyl]-2-(1-methyl-1H-tetrazol-5-yl)-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215505-83-2 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[3-(4-hydroxyphenyl)-2-(1-methyl-1H-tetrazol-5-yl)-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215505-84-3 CAPLUS
CN Benzamide,
N-2-benzothiazolyl-4-[3-[3-methoxy-4-(methoxymethoxy)phenyl]-2-(1-methyl-1H-tetrazol-5-yl)-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 215505-88-7 CAPLUS
CN Benzamide,
N-2-benzothiazolyl-4-[3-(4-hydroxy-3-methoxyphenyl)-2-(1-methyl-1H-tetrazol-5-yl)-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215505-93-4 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[3-(4-hydroxy-3-methoxyphenyl)-2-(1H-imidazol-1-yl)-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215505-94-5 CAPLUS
CN Benzoic acid,
5-[3-[4-[(2-benzothiazolylamino)carbonyl]phenyl]-1-oxo-2-(1H-1,2,4-triazol-1-yl)-2-propenyl]-2-hydroxy-, methyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 215506-00-6 CAPLUS
CN Benzamide,
N-2-benzothiazolyl-4-[3-[4-(methoxymethoxy)phenyl]-2-(1-methyl-1H-imidazol-2-yl)-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215506-01-7 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[3-(4-hydroxyphenyl)-2-(1-methyl-1H-imidazol-2-yl)-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215506-15-3 CAPLUS
CN Benzamide, N-(6-ethoxy-2-benzothiazolyl)-4-[3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)-1-propenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 215506-19-7 CAPLUS
CN Benzamide,
N-2-benzothiazolyl-4-(3-cyclohexyl-3-oxo-2-(1H-1,2,4-triazol-1-yl)-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215506-20-0 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[3-oxo-2-(1H-1,2,4-triazol-1-yl)-1-pentenyl]- (9CI) (CA INDEX NAME)



RN 215506-21-1 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[3-[4-[2-(dimethylamino)ethoxy]phenyl]-3-oxo-2-(1H-1,2,4-triazol-1-yl)-1-propenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 215506-23-3 CAPLUS
CN Benzamide,
N-2-benzothiazolyl-4-[2-(1-ethyl-1H-tetrazol-5-yl)-3-[3-methoxy-4-(methoxymethoxy)phenyl]-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215506-24-4 CAPLUS
CN Benzamide,
N-2-benzothiazolyl-4-[2-(1-ethyl-1H-tetrazol-5-yl)-3-(4-hydroxy-3-methoxyphenyl)-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215506-35-7 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[2-(1-methyl-1H-tetrazol-5-yl)-3-oxo-1-pentenyl]- (9CI) (CA INDEX NAME)



RN 215506-36-8 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[3-[3,5-dimethoxy-4-(methoxymethoxy)phenyl]-2-(1-methyl-1H-tetrazol-5-yl)-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 215506-44-8 CAPLUS
CN Benzamide,
N-2-benzothiazolyl-4-[3-(4-ethoxyphenyl)-2-(1-ethyl-1H-tetrazol-5-yl)-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215506-46-0 CAPLUS
CN Benzamide,
N-2-benzothiazolyl-4-[3-(4-butoxyphenyl)-2-(1-ethyl-1H-tetrazol-5-yl)-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215506-51-7 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[2-(1-ethyl-1H-tetrazol-5-yl)-3-[4-(methoxymethoxy)phenyl]-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 215506-37-9 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[3-(4-hydroxy-3,5-dimethoxyphenyl)-2-(1-methyl-1H-tetrazol-5-yl)-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215506-40-4 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[2-(1-ethyl-1H-tetrazol-5-yl)-3-(4-methoxyphenyl)-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215506-42-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid,
2-[3-[4-[(2-benzothiazolylamino)carbonyl]phenyl]-1-oxo-2-(1H-1,2,4-triazol-1-yl)-2-propenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 215506-52-8 CAPLUS
CN Carbamic acid,
[5-[4-[(2-benzothiazolylamino)carbonyl]phenyl]-3-oxo-4-(1H-1,2,4-triazol-1-yl)-4-pentenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 215506-53-9 CAPLUS
CN 1-Pyrrolidinecarboxylic acid,
2-[3-[4-[(2-benzothiazolylamino)carbonyl]phenyl]-1-oxo-2-(1H-1,2,4-triazol-1-yl)-2-propenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 215506-55-1 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[3-[3-ethoxy-4-(methoxymethoxy)phenyl]-2-(1-ethyl-1H-tetrazol-5-yl)-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 215506-56-2 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[3-(3-ethoxy-4-hydroxyphenyl)-2-(1-ethyl-1H-tetrazol-5-yl)-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215506-67-5 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[2-(1-ethyl-1H-tetrazol-5-yl)-1-(ethylthio)-3-[3-methoxy-4-(methoxymethoxy)phenyl]-3-oxopropyl]- (9CI) (CA INDEX NAME)



RN 215506-68-6 CAPLUS
CN 1H-Tetrazole-5-acetic acid, α-[[4-[(2-benzothiazolylamino)carbonyl]phenyl]methylene]-1-ethyl-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 215506-69-7 CAPLUS
CN 1H-Tetrazole-5-acetic acid, α-[[4-[(2-benzothiazolylamino)carbonyl]phenyl]methylene]-1-ethyl- (9CI) (CA INDEX NAME)



RN 215506-71-1 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[1-(methylthio)-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 215506-72-2 CAPLUS
CN Acetic acid, [[1-[4-[(2-benzothiazolylamino)carbonyl]phenyl]-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl]thio]- (9CI) (CA INDEX NAME)

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 215506-73-3 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[3-oxo-3-phenyl-1-(phenylthio)-2-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 215506-74-4 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[1-[(2-hydroxyethyl)thio]-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 215506-75-5 CAPLUS
CN Benzamide, 4-[2-(aminocarbonyl)-3-oxo-1-butenyl]-N-2-benzothiazolyl- (9CI)
(CA INDEX NAME)

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 215506-76-6 CAPLUS
CN 1H-Tetrazole-5-acetic acid, α-[[4-[(2-benzothiazolylamino)carbonyl]phenyl]methylene]-1-ethyl-, phenyl ester (9CI) (CA INDEX NAME)



RN 215506-77-7 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[1-(cyclohexylthio)-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 215506-78-8 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-(2-cyano-3-oxo-3-phenyl-1-propenyl)- (9CI)
(CA INDEX NAME)



L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 215506-79-9 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[3-(4-methoxyphenyl)-2-(1-methyl-1H-tetrazol-5-yl)-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215506-82-4 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-(3-oxo-2-(1H-1,2,4-triazol-1-yl)-1-butenyl]- (9CI) (CA INDEX NAME)



RN 215506-83-5 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[1-(ethylthio)-3-(4-methoxyphenyl)-2-(1-methyl-1H-tetrazol-5-yl)-3-oxopropyl]- (9CI) (CA INDEX NAME)



RN 215506-84-6 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[1-(ethylthio)-3-[4-(methoxymethoxy)phenyl]-2-(1-methyl-1H-tetrazol-5-yl)-3-oxopropyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 215506-85-7 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[1-(ethylthio)-3-(4-hydroxyphenyl)-2-(1-methyl-1H-tetrazol-5-yl)-3-oxopropyl]- (9CI) (CA INDEX NAME)



RN 215506-86-8 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[1-[(2-hydroxyethyl)thio]-3-[4-(methoxymethoxy)phenyl]-2-(1-methyl-1H-tetrazol-5-yl)-3-oxopropyl]- (9CI) (CA INDEX NAME)



RN 215506-89-1 CAPLUS
CN Ethanethioic acid, S-[1-[4-[(2-benzothiazolylamino)carbonyl]phenyl]-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl] ester (9CI) (CA INDEX NAME)

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 215506-91-5 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[1-(ethylthio)-3-oxo-2-(1H-1,2,4-triazol-1-yl)butyl]- (9CI) (CA INDEX NAME)



RN 215506-92-6 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[1-[(2-hydroxyethyl)thio]-3-oxo-2-(1H-1,2,4-triazol-1-yl)butyl]- (9CI) (CA INDEX NAME)



RN 215506-93-7 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[2-(1-ethyl-1H-tetrazol-5-yl)-3-oxo-3-phenyl-1-propenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 215506-95-9 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[2-(1-ethyl-1H-tetrazol-5-yl)-1-(ethylthio)-3-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)



RN 215506-97-1 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[2-(1-ethyl-1H-tetrazol-5-yl)-1-[(2-hydroxyethyl)thio]-3-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)



RN 215506-98-2 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[1-[(1,1-dimethylethyl)thio]-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 215507-00-9 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[1-[[2-(diethylamino)ethyl]thio]-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 215507-01-0 CAPLUS
CN Benzamide,
N-2-benzothiazolyl-4-[3-oxo-3-(3-pyridinyl)-2-(1H-1,2,4-triazol-1-yl)-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215507-02-1 CAPLUS
CN Benzamide,
N-2-benzothiazolyl-4-[1-(ethylthio)-3-oxo-3-(3-pyridinyl)-2-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 215507-03-2 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[1-[(2-hydroxyethyl)thio]-3-oxo-3-(3-pyridinyl)-2-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 215507-05-4 CAPLUS
CN Benzamide,
N-2-benzothiazolyl-4-[3-[4-(dimethylamino)phenyl]-2-(1-ethyl-1H-tetrazol-5-yl)-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215507-09-8 CAPLUS
CN Cysteine,
S-[1-[4-[(2-benzothiazolylamino)carbonyl]phenyl]-3-oxo-3-phenyl-2-(1H-1,2,4-triazol-1-yl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 215507-10-1 CAPLUS
CN 1H-Tetrazole-5-acetic acid, α-[[4-[(2-benzothiazolylamino)carbonyl]phenyl]methylene]-1-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 215507-11-2 CAPLUS
CN Benzamide,
N-2-benzothiazolyl-4-[3-[4-[2-(diethylamino)ethoxy]phenyl]-2-(1-methyl-1H-tetrazol-5-yl)-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215507-12-3 CAPLUS
CN Benzamide,
N-2-benzothiazolyl-4-[3-[4-[2-(diethylamino)ethoxy]phenyl]-2-(1-methyl-1H-tetrazol-5-yl)-3-oxo-1-propenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 215507-14-5 CAPLUS
CN 1H-Tetrazole-5-acetamide, α-[[4-[(2-benzothiazolylamino)carbonyl]phenyl]methylene]-1-ethyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 215507-16-7 CAPLUS
CN 1H-Tetrazole-5-acetic acid, α-[[4-[(2-benzothiazolylamino)carbonyl]phenyl]methylene]-1-ethyl-, 3-(diethylamino)propyl ester (9CI) (CA INDEX NAME)



RN 215507-17-8 CAPLUS
CN 1H-Tetrazole-5-acetic acid, α-[[4-[(2-benzothiazolylamino)carbonyl]phenyl]methylene]-1-[3-(diethylamino)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 215507-18-9 CAPLUS
CN Propanedioic acid,
[[4-[(2-benzothiazolylamino)carbonyl]phenyl]methylene]-, diethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 215507-19-0 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-(1-cyano-3-oxo-3-phenyl-1-propenyl)-(9CI)
(CA INDEX NAME)



RN 215507-23-6 CAPLUS
CN 1H-Tetrazole-5-acetamide, α-[[4-[(2-benzothiazolylamino)carbonyl]phenyl]methylene]-1-[3-(diethylamino)propyl]-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 215507-26-9 CAPLUS
CN Benzamide, 4-(2-acetyl-3-oxo-1-butenyl)-N-2-benzothiazolyl-2-[(diethylamino)methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



●6 HCl

PAGE 1-B

—CH_2—CH_2—NEt_2

L7 ANSWER 60 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 215507-33-8 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-[3-(1-ethyl-3-piperidinyl)-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



RN 215507-51-0 CAPLUS
CN Propanedioic acid, [[4-[(2-benzothiazolylamino)carbonyl]-3-[(4-methyl-1-piperazinyl)methyl]phenyl]methylene]-, diethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 215507-56-5 CAPLUS
CN Benzamide, 4-[3-[4-[2-(diethylamino)ethoxy]phenyl]-2-(1-ethyl-1H-tetrazol-5-yl)-3-oxo-1-propenyl]-N-[6-[2-(diethylamino)ethyl]-2-benzothiazolyl]-, hexahydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 61 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:685259 CAPLUS
DN 130:8866
TI Electrophotographic photoreceptor using bisazo pigment and phthalocyanines
IN Nagamura, Hideki; Horiuchi, Tamotsu
PA Mitsubishi Paper Mills, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 45 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10282700	A2	19981023	JP 1997-89561	19970408
<--					
PRAI	JP 1997-89561		19970408		

GI



AB The title photoreceptor comprises an elec. conductive support and a photoconductive layer containing ≥1 bisazo pigment I [R = H, (substituted) alkyl, aralkyl, aryl, heterocyclyl; m = 1, 2; n = 0, 1; Cp1, Cp2 = coupler residue] and ≥1 phthalocyanine compound. The photoreceptor shows high photosensitivity and durability in repeated use.
IT 215875-68-6
RL: DEV (Device component use); USES (Uses)
(electrophotog. photoreceptor using bisazo pigment and phthalocyanines)
RN 215875-68-6 CAPLUS
CN 2-Naphthalenecarboxamide, N-2-benzothiazolyl-4-[[4-[4-[2-[4-[[3-[(2-benzothiazolylamino)carbonyl]-2-hydroxy-1-naphthalenyl]azo]phenyl]ethenyl]-3-(2-furanyl)-1H-pyrazol-1-yl]phenyl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 61 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 62 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:268557 CAPLUS
DN 128:309460
TI Bisazo compounds and manufacture thereof, with good resistance to water, chemicals, solvents and heat, pigments, printing inks, coatings, coloring materials, organic photoconductors using the same
IN Ueno, Ryuzo; Kitayama, Masaya; Minami, Kenji; Wakamori, Hiroyuki
PA Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo, Japan
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9817728	A1	19980430	WO 1997-JP3760	19971017
<--	W: CA, CN, JP, KR, US RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2241099	AA	19980430	CA 1997-2241099	19971017
<--					
	CA 2241099	C	20051004		
	EP 882767	A1	19981209	EP 1997-944162	19971017
<--					
	EP 882767	B1	20030416		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1211270	A	19990317	CN 1997-192336	19971017
<--					
	CN 1098316	B	20030108		
	JP 3393870	B2	20030407	JP 1998-519210	19971017
	AT 237660	E	20030515	AT 1997-944162	19971017
	TW 385326	B	20000321	TW 1997-86115477	19971021
<--					
	US 5965715	A	19991012	US 1998-91558	19980622
<--					
PRAI	JP 1996-280643	A	19961023		
	WO 1997-JP3760	W	19971017		

OS MARPAT 128:309460
GI



AB The title compds. are prepared by coupling a 2-hydroxynaphthalene-3,6-

L7 ANSWER 62 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
dicarboxylic acid deriv. with a compd. having two diazo groups at a mole ratio of 2:1 and have the general formula AN:NEN:NA', wherein A, A' = I; Y = (CONH)nX, COR; Y' = (CONH)nX', COR'; X, X' = (un)substituted arom. group, conjugated double bond-contg. heterocyclic group; n = 1, 2; R, R' = OH, C1-6 alkoxy, benzyloxy, phenoxy, phenacyloxy; R2 = H, C1-6 alkyl, acyl, phenylalkyl; Q = C1-6 alkyl, alkoxy, halogen, nitro, NO; m = 0-3; when one of R and R' is OH, a salt may be formed; E = ring contg. conjugated double bond. 1,4-Phenylenediamine was tetrazotized and coupled with 2-hydroxy-3,6-diphenylaminocarbonylnaphthalene to obtain 1,4-bis(2-hydroxy-3,6-diphenylaminocarbonylnaphth-1-ylazo)benzene.
IT 206538-19-4P
RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(bisazo compds. and manufacture thereof, with good resistance to water, chems., solvents and heat, pigments, printing inks, coatings, coloring materials, organic photoconductors using the same)
RN 206538-19-4 CAPLUS
CN 2,7-Naphthalenedicarboxamide, 4,4'-[1,4-phenylenebis(azo)]bis[N,N'-bis(2-benzothiazolyl)-3-hydroxy- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 63 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:268348 CAPLUS
DN 128:321662
TI Compositions and methods for treating bone deficit conditions
IN Orme, Mark W.; Baindur, Nand; Robbins, Kirk G.; et al.
PA Zymogenetics, Inc., USA; Osteoscreen, Inc.
SO PCT Int. Appl., 215 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9817267	A1	19980430	WO 1997-US18864	19971023
<--	W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, US, US, US, US, US, US, US, US, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5990169	A	19991123	US 1997-806771	19970226
<--					
	US 6153631	A	20001128	US 1997-806768	19970226
<--					
	US 6251901	B1	20010626	US 1997-806769	19970226
<--					
	US 5919808	A	19990706	US 1997-808743	19970228
<--					
	US 5922753	A	19990713	US 1997-808742	19970228
<--					
	US 5948776	A	19990907	US 1997-808739	19970228
<--					
	US 5994358	A	19991130	US 1997-808744	19970228
<--					
	US 6342514	B1	20020129	US 1997-808741	19970228
<--					
	US 5965573	A	19991012	US 1997-812141	19970306
<--					
	AU 9749889	A1	19980515	AU 1997-49889	19971023
<--					
	EP 973513	A1	20000126	EP 1997-912787	19971023
<--	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001510450	T2	20010731	JP 1998-519529	19971023
<--					
	US 6649631	B1	20031118	US 1999-297188	19991119
PRAI	US 1996-735870	A2	19961023		
	US 1996-735873	A2	19961023		
	US 1996-735874	A2	19961023		
	US 1996-735876	A2	19961023		
	US 1996-735881	A2	19961023		
	US 1996-736220	A2	19961023		
	US 1996-736221	A2	19961023		
	US 1996-736222	A2	19961023		
	US 1996-736228	A2	19961023		
	US 1996-736318	A2	19961023		
	US 1996-736319	A2	19961023		
	WO 1997-US18864	W	19971023		

L7 ANSWER 63 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
OS MARPAT 128:321662
GI



AB Compds. containing 2 covalently linked aromatic systems, i.e. Ar1LAr2 [I; Ar1, Ar2 = (un)substituted Ph, naphthyl, or 5- or 6-membered aromatic heterocyclyl; L = linker (atoms or covalent bond per se) so as to space the aromatic systems at a distance of 1.5-15 Å] are effective in treating conditions associated with bone deficits. The compds. can be administered to vertebrate subjects alone or in combination with addnl. agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems. A variety of compds. were prepared and/or tested by high-throughput screening. For instance, title compound II was prepared by condensation of 2-chloro-5-(trifluoromethyl)pyridine with ethylenediamine in the presence of EtN(Pr-iso)2 at reflux. At 5-50 μg/kg/day in ovariectomized rats, II stimulated bone growth with volume increases of 21-71% observed In a calvarial bone growth assay, another compound I induced a 4-fold increase in width of new calvarial bone vs. controls.
IT 206983-85-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and/or use of linked aromatic and heteroarom. compds. for treating bone deficit conditions)
RN 206983-85-9 CAPLUS
CN 2-Quinolinecarboxamide, N-2-benzothiazolyl- (9CI) (CA INDEX NAME)



L7 ANSWER 63 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 206982-98-1 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2-chloro-4,5-dimethoxy- (9CI) (CA INDEX NAME)



RN 206982-99-2 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 206983-63-3 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2,3,4-trimethoxy- (9CI) (CA INDEX NAME)



RN 206983-64-4 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2,4,5-trimethoxy- (9CI) (CA INDEX NAME)



RN 206983-65-5 CAPLUS

L7 ANSWER 63 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IT 35353-19-6 206982-92-5 206982-96-9
206982-97-0 206982-98-1 206982-99-2
206983-63-3 206983-64-4 206983-65-5
206983-66-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation and/or use of linked aromatic and heteroarom. compds. for treating bone deficit conditions)
RN 35353-19-6 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-methoxy- (9CI) (CA INDEX NAME)



RN 206982-92-5 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2-hydroxy-4-(methylthio)- (9CI) (CA INDEX NAME)



RN 206982-96-9 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2-hydroxy-4-methoxy- (9CI) (CA INDEX NAME)



RN 206982-97-0 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2-chloro-3,4-dimethoxy- (9CI) (CA INDEX NAME)

L7 ANSWER 63 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzamide, N-2-benzothiazolyl-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



RN 206983-66-6 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-chloro-2-methoxy- (9CI) (CA INDEX NAME)



IT 139233-22-0 190437-16-2 190437-57-1
190437-79-7 190437-80-0 190437-88-8
190437-89-9 190437-92-4 190437-93-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of (hetero)aromatic compds. for treating bone deficit conditions)
RN 139233-22-0 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 190437-16-2 CAPLUS
CN Benzoic acid, 3-methyl-, 4-[(2-benzothiazolylamino)carbonyl]phenyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 63 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 190437-57-1 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2-methoxy-4-(methylthio)- (9CI) (CA INDEX NAME)



RN 190437-79-7 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2,4-dimethoxy- (9CI) (CA INDEX NAME)



RN 190437-80-0 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2-methoxy-4-nitro- (9CI) (CA INDEX NAME)



RN 190437-88-8 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2,4-dichloro- (9CI) (CA INDEX NAME)



RN 190437-89-9 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3,4-dichloro- (9CI) (CA INDEX NAME)

L7 ANSWER 63 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 190437-92-4 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2,4,6-trimethoxy- (9CI) (CA INDEX NAME)



RN 190437-93-5 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2-chloro-4-methoxy- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 64 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:251223 CAPLUS
DN 128:295823
TI Azo compounds, manufacture thereof, and pigments, printing inks, coatings,
and polymer colorants containing the same, with good water, chemical, and solvent resistance
IN Ueno, Ryuzo; Kitayama, Masaya; Minami, Kenji; Wakamori, Hiroyuki
PA Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo, Japan
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9816587	A1	19980423	WO 1997-JP3637	19971009
<--					
	W: CA, CN, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2239119	AA	19980423	CA 1997-2239119	19971009
<--					
	CA 2240073	AA	19980423	CA 1997-2240073	19971009
<--					
	EP 881267	A1	19981202	EP 1997-943169	19971009
<--					
	EP 881267	B1	20040428		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1205021	A	19990113	CN 1997-191420	19971009
<--					
	CN 1210520	A	19990310	CN 1997-191988	19971009
<--					
	CN 1105106	B	20030409		
	TW 403771	B	20000901	TW 1997-86114880	19971009
<--					
	TW 416975	B	20010101	TW 1997-86114879	19971009
<--					
	JP 3224397	B2	20011029	JP 1998-518183	19971009
<--					
	JP 3393869	B2	20030407	JP 1998-518181	19971009
	AT 265498	E	20040515	AT 1997-943169	19971009
	US 5973126	A	19991026	US 1998-68954	19980520
<--					
PRAI	JP 1996-269985	A	19961011		
	WO 1997-JP3637	W	19971009		

OS MARPAT 128:295823
GI

L7 ANSWER 64 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I

AB The title compds. having the general formula I, wherein Y = (CONH)nX, COR;
Y1 = (CONH)nX1, COR1; X, X1 = (un)substituted aromatic group, (un)substituted
conjugated double bond-containing heterocyclic group; R, R1 = OH, C1-6 alkoxy,
benzyloxy, phenoxy, phenacyloxy; n = 1, 2; R2 = H, C1-6 alkyl, acyl, phenylalkyl; Q = C1-6 (branched) alkyl, alkoxy, halogen, nitro, nitroso; m
= 0-3; Z = (un)substituted aromatic group. 2-Methyl-5-nitroaniline was diazotized and coupled with 2-hydroxy-3,6-bis(phenylaminocarbonyl)naphthal
ene to obtain 2-hydroxy-1-(2-methyl-5-nitrophenylazo)-3,6-bis(phenylaminocarbonyl)naphthalene.
IT 205819-86-9P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT
(Reactant or reagent)
(azo compds., manufacture thereof, and pigments, printing inks, coatings,
and polymer colorants containing the same, with good water, chemical, and
solvent resistance)
RN 205819-86-9 CAPLUS
CN 2,7-Naphthalenedicarboxamide, N,N'-bis(2-benzothiazolyl)-3-hydroxy- (9CI) (CA INDEX NAME)



IT 205819-88-1P
RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(azo compds., manufacture thereof, and pigments, printing inks, coatings,
and polymer colorants containing the same, with good water, chemical, and
solvent resistance)
RN 205819-88-1 CAPLUS
CN 2,7-Naphthalenedicarboxamide, N,N'-bis(2-benzothiazolyl)-3-hydroxy-4-[[2-

L7 ANSWER 64 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
methoxy-5-[(phenylamino)carbonyl]phenyl]azo]- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 65 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:251159 CAPLUS
DN 128:270604
TI Process for preparation of naphthol derivatives
IN Ueno, Ryuzo; Kitayama, Masaya; Minami, Kenji; Wakamori, Hiroyuki
PA Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo, Japan
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9816513	A1	19980423	WO 1997-JP3639	19971009
<--					
	W: CA, CN, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2240073	AA	19980423	CA 1997-2240073	19971009
<--					
	EP 872477	A1	19981021	EP 1997-943171	19971009
<--					
	EP 872477	B1	20041222		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1205021	A	19990113	CN 1997-191420	19971009
<--					
	CN 1210520	A	19990310	CN 1997-191988	19971009
<--					
	CN 1105106	B	20030409		
	TW 403771	B	20000901	TW 1997-86114880	19971009
<--					
	TW 416975	B	20010101	TW 1997-86114879	19971009
<--					
	AT 285401	E	20050115	AT 1997-943171	19971009
	US 6084101	A	20000704	US 1998-77921	19980605
<--					
PRAI	JP 1996-269985	A	19961011		
	WO 1997-JP3639	W	19971009		

OS CASREACT 128:270604; MARPAT 128:270604
GI



I

AB The title compds. [I; Y = (CONH)nX, COR; Y' = (CONH)nX', COR'; X, X' = pyridyl, thiazolyl, etc.; R, R' = OH, halo, branched C1-6 alkoxy, etc.; W = OR2; R2 = H, alkali metal, branched C1-6 alkyl, etc.; Z = H, halo, NO2,

L7 ANSWER 65 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
etc.; n = 1, 2] are prepd. by condensation of I (W = OR5; Y = COR4; Y' = COR4'; R4, R4' = OH, halo, branched C1-6 alkoxy, etc.; R5 = H, protecting group of OH; Z = same as above) with H2NR3X (R3 = single bond, CONH; X = same as above). I are useful as starting materials for dyes, pigments, and photosensitive materials. Thus, I (W = OH, Z = H, Y = Y' = CO2H) was reacted with 2-aminopyridine in the presence of N-methyl-2-pyrrolidone and
DCC at room temp. for 15 h to give I (W, Z = same as above; Y = Y' = COR4;
R4 = 2-pyridylamino).
IT 205443-68-1P 205443-71-6P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(process for preparation of naphthol derivs.)
RN 205443-68-1 CAPLUS
CN 2,6-Naphthalenedicarboxamide, N,N'-bis(2-benzothiazolyl)-3-hydroxy- (9CI) (CA INDEX NAME)



RN 205443-71-6 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[(2-benzothiazolylamino)carbonyl]-3-hydroxy-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 66 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:180848 CAPLUS
DN 128:243960
TI 8-Hydroxy-7-substituted quinolines as anti-viral agents
IN Vaillancourt, Valerie A.; Romines, Karen R.; Romero, Arthur G.; Tucker, John A.; Strohbach, Joseph W.; Bezencon, Olivier; Thaisrivongs, Suvit; et al.
PA Pharmacia & Upjohn Co., USA
SO PCT Int. Appl., 280 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9811073	A1	19980319	WO 1997-US15310	19970905
<--					
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2262786	AA	19980319	CA 1997-2262786	19970905
<--					
	AU 9741721	A1	19980402	AU 1997-41721	19970905
<--					
	EP 927164	A1	19990707	EP 1997-939690	19970905
<--					
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6310211	B1	20011030	US 1997-924683	19970905
<--					
	JP 2002505660	T2	20020219	JP 1998-513685	19970905
<--					
	US 6211376	B1	20010403	US 1999-425789	19991022
<--					
	US 6252080	B1	20010626	US 1999-425564	19991022
<--					
	US 6500842	B1	20021231	US 2001-14780	20011023
<--					
PRAI	US 1996-25870P	P	19960910		
	US 1997-50720P	P	19970625		
	US 1997-924683	A3	19970905		
	WO 1997-US15310	W	19970905		

OS MARPAT 128:243960
GI

L7 ANSWER 66 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I

AB The present invention provides for 8-hydroxy-7-substituted quinoline compds. I (R = alkyl, alkylamino, alkoxyalkyl, etc.; R1 = H, F, Cl, Br, Cf3, etc.; R2 = H, alkyl, OH, arylalkenyl, etc.; R3 = H, OH, CF3, C1-C3alkyl) are prepared as anti-viral agents. Specifically, these compds.
have anti-viral activity against the herpes virus, cytomegalovirus (CMV). Many of these compds. are also active against other herpes viruses, such as the varicella zoster virus, the Epstein-Barr virus, the herpes simplex virus and the human herpes virus type 8 (HHV-8).

IT 205037-76-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 8-hydroxy-7-substituted quinolines as anti-viral agents)

RN 205037-76-9 CAPLUS

CN 7-Quinolinecarboxamide, N-(6-chloro-2-benzothiazolyl)-8-hydroxy- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 67 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
antagonized CGRP receptors with IC50 = 0.001-100 μM.

IT 204261-39-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3,4-dinitrobenzamides as calcitonin gene related peptide
receptor ligands)

RN 204261-39-2 CAPLUS

CN Benzamide, N-(6-fluoro-2-benzothiazolyl)-3,4-dinitro- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 67 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:169454 CAPLUS

DN 128:217191

TI Preparation of 3,4-dinitrobenzamides as calcitonin gene related peptide receptor ligands.

IN Daines, Robert A.

PA Smithkline Beecham Corporation, USA; Daines, Robert A.

SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9809630	A1	19980312	WO 1997-US15931	19970909
<--					
	W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, GH, HU, ID, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9708046	A	19980401	ZA 1997-8046	19970908
<--					
	CA 2264942	AA	19980312	CA 1997-2264942	19970909
<--					
	AU 9742616	A1	19980326	AU 1997-42616	19970909
<--					
	EP 934068	A1	19990811	EP 1997-940951	19970909
<--					
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
	JP 2002511836	T2	20020416	JP 1998-512994	19970909
<--					
PRAI	US 1996-25690P	P	19960909		
	US 1997-48012P	P	19970529		
	WO 1997-US15931	W	19970909		

OS MARPAT 128:217191

GI



I

AB Title compds. [I; R1 = H, Me, alkyl, phenylalkyl, heterocyclylalkyl, aminoalkyl, carboxyalkyl, alkoxycarbonylalkyl, etc.; R2 = (substituted) aryl, heteroaryl, arylalkyl, heteroarylalkyl; R1R2N = (benzo-fused) 5-6 membered heterocyclyl], were prepared Thus, N-methylaniline in CH2Cl2 was
treated with Et3N and then with 3,4-dinitrobenzoyl chloride and the mixture
was shaken overnight to give N-methyl-N-phenyl-3,4-dinitrobenzamide. I

L7 ANSWER 68 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:105939 CAPLUS

DN 128:167413

TI Preparation of thiazole derivative as protein kinase c inhibitors

IN Mori, Toyoki; Tominaga, Michiaki; Tabusa, Fujio; Nagami, Kazuyoshi; Abe, Kaoru; Nakaya, Kenji; Takemura, Isao; Shinohara, Tomoichi; Tanada, Yoshihisa; Yamauchi, Takahito

PA Otsuka Pharmaceutical Company, Limited, Japan

SO PCT Int. Appl., 439 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9804536	A1	19980205	WO 1997-JP2609	19970729
<--					
	W: AU, BR, CA, CN, KR, MX, SG, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	TW 513418	B	20021211	TW 1997-86110703	19970728
<--					
	CA 2233611	AA	19980205	CA 1997-2233611	19970729
<--					
	AU 9736354	A1	19980220	AU 1997-36354	19970729
<--					
	AU 695817	B2	19980820		
	EP 858452	A1	19980819	EP 1997-933046	19970729
<--					
	EP 858452	B1	20020313		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1198160	A	19981104	CN 1997-190997	19970729
<--					
	CN 1070856	B	20010912		
	BR 9706792	A	20011127	BR 1997-6792	19970729
<--					
	AT 214381	E	20020315	AT 1997-933046	19970729
<--					
	PT 858452	T	20020731	PT 1997-933046	19970729
<--					
	ES 2179355	T3	20030116	ES 1997-933046	19970729
	JP 10095777	A2	19980414	JP 1997-230563	19970731
<--					
	US 6140330	A	20001031	US 1998-43642	19980324
<--					
	HK 1016586	A1	20020208	HK 1999-101470	19990412
<--					
PRAI	JP 1996-200898	A	19960731		
	WO 1997-JP2609	W	19970729		

OS MARPAT 128:167413

GI

L7 ANSWER 68 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I

Q =



Q =



AB Title compds. I [T = lower alkylene; R1, R2 is the same or different and is each H, or lower alkyl, etc.; R3 = H or lower alkanoyloxy-lower alkyl; R4 = H , or lower alkyl; R5 = OH, lower alkoxy, or a 5-10 membered heterocyclic,etc.; R6 = -COCH:CR4(CO)pR5 or -COCCCOR8; R7 = H, hydroxy-alkyl, alkyl, halogen, etc.; R8 = OH or lower alkoxy; A = lower alkylene; Z = O, S; p = 0 or 1] are prepared and shows inhibitory activity
or protein kinase C(PKC, Ca2+/phospholipid-depending serine/threonine protein phosphatase), and are useful as a protein kinase C inhibitor.

IT **202985-42-0P 202985-65-7P 202986-59-2P**
202988-49-6P 202989-04-6P 202989-05-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazole derivative as protein kinase c inhibitors)

RN 202985-42-0 CAPLUS
CN 2-Butenoic acid, 4-[2-[(2-benzothiazolylamino)carbonyl]-2,3,4,5-tetrahydro-1-benzoxepin-7-yl]-4-oxo-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L7 ANSWER 68 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 202985-65-7 CAPLUS
CN 2-Benzofurancarboxamide, N-2-benzothiazolyl-2,3-dihydro-5-[4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-1,4-dioxo-2-butenyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 202986-59-2 CAPLUS
CN 1-Benzoxepin-2-carboxamide, N-2-benzothiazolyl-7-[4-[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1-piperidinyl]-1,4-dioxo-2-butenyl]-2,3,4,5-tetrahydro- (9CI) (CA INDEX NAME)



RN 202988-49-6 CAPLUS
CN 2H-1-Benzopyran-2-carboxamide, N-2-benzothiazolyl-6-[3-(1-ethyl-1H-tetrazol-5-yl)-1-oxo-2-propenyl]-3,4-dihydro- (9CI) (CA INDEX NAME)

L7 ANSWER 68 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 202989-04-6 CAPLUS
CN 2-Butenoic acid, 4-[1-[(2-benzothiazolylamino)carbonyl]-4-piperidinyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 202989-05-7 CAPLUS
CN 1-Piperidinecarboxamide, N-2-benzothiazolyl-4-[4-(4-methyl-1-piperazinyl)-1,4-dioxo-2-butenyl]- (9CI) (CA INDEX NAME)



IT **202990-95-2P 202991-31-9P 202991-70-6P**
202992-19-6P 202992-26-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazole derivative as protein kinase c inhibitors)

RN 202990-95-2 CAPLUS
CN 2H-1-Benzopyran-2-carboxamide, N-2-benzothiazolyl-6-(chloroacetyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 202991-31-9 CAPLUS
CN 2H-1-Benzopyran-2-carboxamide, N-2-benzothiazolyl-3,4-dihydro-6-

L7 ANSWER 68 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
[(triphenylphosphoranylidene)acetyl]- (9CI) (CA INDEX NAME)



RN 202991-70-6 CAPLUS
CN 2-Benzofurancarboxamide, N-2-benzothiazolyl-5-formyl-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 202992-19-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[(2-benzothiazolylamino)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 202992-26-5 CAPLUS
CN Phosphonic acid, [2-[1-[(2-benzothiazolylamino)carbonyl]-4-piperidinyl]-2-oxoethyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 69 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:98336 CAPLUS
DN 128:167718
TI Preparation of tetrapeptide derivatives of dolastatin as antitumor agents
IN Barlozzari, Teresa; Haupt, Andreas; Janssen, Bernd; Griesinger, Christian;
Belik, Daniel; Boretzky, Michael
PA BASF Aktiengesellschaft, Germany
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9804278	A2	19980205	WO 1997-EP3898	19970721
<--					
	WO 9804278	A3	20030417		
	W: AL, AU, BG, BR, CA, CN, CZ, GE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5939527	A	19990817	US 1996-688335	19960730
<--					
	AU 9742965	A1	19980220	AU 1997-42965	19970721
<--					
	EP 920325	A2	19990609	EP 1997-918936	19970721
<--					
	EP 920325	A3	20030604		
	R: CH, DE, FR, GB, IT, LI, NL				
	JP 2002512590	T2	20020423	JP 1998-508457	19970721
<--					
	ZA 9706724	A	19990129	ZA 1997-6724	19970729
<--					
	ZA 9706723	A	19990212	ZA 1997-6723	19970729
<--					
	TW 491856	B	20020621	TW 1997-86110884	19970730
<--					
PRAI	US 1996-688335	A	19960730		
	WO 1997-EP3898	W	19970721		

OS MARPAT 128:167718
AB Peptides A-B-NR3-CHD-CH(OCH3)-CH2CO-E-K (A is an amino acid residue, including N-methyl-D-prolyl, N-methyl-D-homoprolyl, and N,N-dimethyl-2-ethylphenylglycyl; B = valyl, isoleucyl, leucyl, or 2-tert-butylglycyl; D = alkyl; E is an amino acid residue, including prolyl, homoprolyl, 5-methylprolyl, and phenylalanyl; K = alkoxy, benzyloxy, substituted amino; R3 = H, Me) or their pharmaceutically acceptable salts were prepared as antitumor agents. Thus, (3S,4S)-4-[N-(N,N-dimethyl-L-valyl-L-valyl)-N-methylamino]-3-methoxy-5-methylhexanoylproline 2-thiazolyl amide was prepared by a multistep procedure leading to coupling of the hexanoic acid derivative with the amide obtained from Boc-proline and 2-aminothiazole. The in vitro cytotoxicity of the product was determined (IC50 = 6x10-8 M).
IT 203006-84-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

L7 ANSWER 69 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tetrapeptide derivs. of dolastatin as antitumor agents)
RN 203006-84-2 CAPLUS
CN L-Prolinamide, N,N-dimethyl-L-valyl-L-valyl-(3R,4S)-3-methoxy-5-methyl-4-(methylamino)hexanoyl-N-2-benzothiazolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 70 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:31302 CAPLUS
DN 128:75390
TI Preparation of quinoline and benzothiazole derivatives having affinity to nuclear hormone receptors
IN Kerwin, Sean; Hurley, Laurence H.; DeLuca, Mark R.; Moore, Bob M., III
PA Board of Regents, the University of Texas System, USA; Kerwin, Sean; Hurley, Laurence H.; DeLuca, Mark R.; Moore, Bob M., III
SO PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9748694	A1	19971224	WO 1997-US10643	19970620
<--					
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2258822	AA	19971224	CA 1997-2258822	19970620
<--					
	AU 9737917	A1	19980107	AU 1997-37917	19970620
<--					
	AU 727708	B2	20001221		
	EP 912549	A1	19990506	EP 1997-934849	19970620
<--					
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1226245	A	19990818	CN 1997-196755	19970620
<--					
	JP 2000514048	T2	20001024	JP 1998-503338	19970620
<--					
	BR 9711805	A	20020115	BR 1997-11805	19970620
<--					
	NO 9805975	A	19990218	NO 1998-5975	19981218
<--					
	KR 2000022040	A	20000425	KR 1998-710438	19981219
<--					
	US 2003119791	A1	20030626	US 2002-108606	20020327
	US 6720344	B2	20040413		
PRAI	US 1996-16088P	P	19960620		
	WO 1997-US10643	W	19970620		
	US 1999-230208	B1	19990120		

OS MARPAT 128:75390
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to pharmacol. active compds. represented by,
e.g. quinoline derivs. (I) and benzothiazole derivs. (II) [wherein L = Q, N:N, SCH2, O2C, NR6CO, CH2CH(OR7), single bond ; Z = Q1, Q2, Q3; R1 = H, OH, C1-4 alkyl, alkoxy, or alkylthio, halo, C1-12 alkyl-carbonyloxy; R2, R3 = H, OH, halo, C1-6 alkyl, alkenyl, or alkoxy, C1-12 alkyl-carbonyloxy;
R4 = H, OH, halo, C1-6 alkyl or alkoxy, C1-12 alkyl-carbonyloxy; R5 = H, halo, C1-6 alkyl or alkoxy, OAc, phthalimide, C1-12 alkyl-carbonyloxy; R6 = H, OH, NH2, C1-4 alkyl or alkoxy; R7 = H, C1-4 alkyl, C1-4 alkyl-carbonyl, C7-10 arylalkyl; R8 = H, OH, halo, CF3, C1-4 haloalkyl, C1-4 alkyl or alkoxy, NHAc, di(C1-4 alkyl)amino; R9 = H, OH, halo, cyano, NO2, C1-4 haloalkyl, C1-8 alkyl, C1-8 alkoxy, NHAc, OAc; R10 = H, OH, halo, cyano, NO2, C1-4 haloalkyl, CO2H, C1-12 alkyl or alkoxy, Ph, C1-12 alkyl, etc.; R11 = H, OH, C1-4 haloalkyl, CF3, C1-4 alkyl, NH2, C1-4 alkoxy, NHAc, C1-4 alkenyl, etc.; R12, R13 = H, OH, halo, NH2, C1-4 alkyl or alkoxy, di(C1-4 alkyl)amino] which are capable of binding to nuclear hormone receptors and are useful for the stimulation of osteoblast proliferation and ultimately bone growth (no data). This invention also relates to the use of such compds. for the treatment or prevention of diseases and/or disorders assocd. with nuclear hormone receptor families. Thus, a soln. of 2-aminobenzothiazole and pyridine in CH2Cl2 was treated with 2,4-dimethoxybenzoyl chloride and stirred at 25° for 30 min to give 80% 2-(2,4-dimethoxybenzamido)benzothiazole.
IT 5005-14-1P, 2-(Benzoylamino)benzothiazole 35353-18-5P, 2-[(4-Chlorobenzoyl)amino]benzothiazole 35353-19-6P, 2-[(4-Methoxybenzoyl)amino]benzothiazole 77414-60-9P, 2-[(Cyclohexylcarbonyl)amino]benzothiazole 190437-79-7P, 2-[(2,4-Dimethoxybenzoyl)amino]benzothiazole 190437-89-9P, 2-[(3,4-Dichlorobenzoyl)amino]benzothiazole 200726-39-2P, 2-[(2-Methoxybenzoyl)amino]benzothiazole 200726-40-5P, 2-[(4-Phenylbenzoyl)amino]benzothiazole 200726-41-6P, 2-[[3,5-Bis(trifluoromethyl)benzoyl]amino]benzothiazole 200726-42-7P, 2-[(4-n-Butylbenzoyl)amino]benzothiazole 200726-43-8P, 2-[(4-tert-Butylbenzoyl)amino]benzothiazole 200726-44-9P, 2-[(4-Cyanobenzoyl)amino]benzothiazole 200726-45-0P, 2-[(2,3-Difluorobenzoyl)amino]benzothiazole 200726-46-1P, 2-[(3,5-Dimethoxybenzoyl)amino]benzothiazole 200726-47-2P, 2-[(4-Ethylbenzoyl)amino]benzothiazole 200726-48-3P, 2-[(3-Methylbenzoyl)amino]benzothiazole
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinoline and benzothiazole derivs. having affinity to nuclear hormone receptors for stimulation of osteoblast proliferation and bone growth)
RN 5005-14-1 CAPLUS
CN Benzamide, N-2-benzothiazolyl- (9CI) (CA INDEX NAME)



RN 35353-18-5 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-chloro- (9CI) (CA INDEX NAME)

L7 ANSWER 70 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 35353-19-6 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-methoxy- (9CI) (CA INDEX NAME)



RN 77414-60-9 CAPLUS
CN Cyclohexanecarboxamide, N-2-benzothiazolyl- (9CI) (CA INDEX NAME)



RN 190437-79-7 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2,4-dimethoxy- (9CI) (CA INDEX NAME)



RN 190437-89-9 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3,4-dichloro- (9CI) (CA INDEX NAME)



L7 ANSWER 70 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 200726-44-9 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-cyano- (9CI) (CA INDEX NAME)



RN 200726-45-0 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2,3-difluoro- (9CI) (CA INDEX NAME)



RN 200726-46-1 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3,5-dimethoxy- (9CI) (CA INDEX NAME)



RN 200726-47-2 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-ethyl- (9CI) (CA INDEX NAME)



RN 200726-48-3 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 70 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 200726-39-2 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2-methoxy- (9CI) (CA INDEX NAME)



RN 200726-40-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-2-benzothiazolyl- (9CI) (CA INDEX NAME)



RN 200726-41-6 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 200726-42-7 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-butyl- (9CI) (CA INDEX NAME)



RN 200726-43-8 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 70 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 71 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:765522 CAPLUS
DN 128:108383
TI Electrophotographic photoreceptor using novel azo compound
IN Osamura, Hideki; Kodera, Tatsuya
PA Mitsubishi Paper Mills, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 26 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 09311478	A2	19971202	JP 1996-129433	19960524
<--					
PRAI	JP 1996-129433		19960524		

OS MARPAT 128:108383
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title photoreceptor comprises a conductive support coated with a photosensitive layer containing ≥1 azo compound I-VI [R1-12 = H, halo, (substituted) alkyl, alkoxy, aryl, heterocycle; Cp = coupler residue]. The photoreceptor shows high photosensitivity and durability in repeated use.
IT 201166-74-7
RL: DEV (Device component use); USES (Uses)
(electrophotog. photoreceptor containing azo compound as charge-generating agent)
RN 201166-74-7 CAPLUS
CN 3-Dibenzofurancarboxamide, 1,1'-[(3,7-diphenyl-1,2-indolizinediyl)bis(3,1-phenyleneazo)]bis[N-2-benzothiazolyl-2-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A



L7 ANSWER 71 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



L7 ANSWER 72 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:735797 CAPLUS
DN 128:22928
TI Preparation of cyclic urea HIV protease inhibitors
IN Jadhav, Prabhakar Kondaji; Ko, Soo Sung
PA Dupont Merck Pharmaceutical Co., USA
SO U.S., 68 pp., Cont.-in-part of U.S. Ser. No. 406,240, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5683999	A	19971104	US 1996-613554	19960311
<--					
	CA 2215536	AA	19960926	CA 1996-2215536	19960313
<--					
	WO 9629329	A1	19960926	WO 1996-US3426	19960313
<--					
	W: AU, BR, CA, CN, CZ, EE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9653100	A1	19961008	AU 1996-53100	19960313
<--					
	EP 815108	A1	19980107	EP 1996-909680	19960313
<--					
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	ZA 9602133	A	19970915	ZA 1996-2133	19960315
<--					
PRAI	US 1995-406240	B2	19950317		
	US 1996-613554	A	19960311		
	WO 1996-US3426	W	19960313		

OS MARPAT 128:22928
GI



I

AB Cyclic ureas I [R1 = CH2XY2; X = alkyl, aryl, cycloalkyl, etc.; Y = (CH2)nO, (CH2)nS, (CH2)nC(:NH)NH, etc.; n = 0-2; Z = 2-, 3-, or 4-pyridyl, 2-pyrazinyl, etc.; R2 = R1, CH2XY1Z1, H, etc. Y1 = (CH2)nO(CH2)m, (CH2)nS(CH2)m, etc.; Z1 = H, alkyl, alkenyl, aryl, etc.; R3, R4 = benzyl, 2-pyrrolylmethyl, Et, iso-Bu, hexyl, etc.] useful as inhibitors of HIV protease (no data), were prepared The present invention also relates to pharmaceutical compns. comprising such compds. and to method of using these compds. for the treatment HIV infection. The present invention also relates to the use of such compds. in processes for the identification of HIV protease inhibitors and for the inhibition or detection of HIV in a bodily fluid sample (no data).

L7 ANSWER 72 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IT 183854-23-1P 183854-36-6P 183854-42-4P
183854-58-2P 183854-75-3P 183854-83-3P
199288-47-6P 199289-75-3P 199289-76-4P
199289-77-5P 199289-78-6P 199289-79-7P
199289-80-0P 199289-81-1P 199289-82-2P
199289-83-3P 199289-84-4P 199289-85-5P
199289-86-6P 199289-88-8P 199289-90-2P
199289-91-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic urea HIV protease inhibitors)
RN 183854-23-1 CAPLUS
CN Benzamide, 3,3'-[[tetrahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepine-1,3(2H)-diyl]bis(methylene)]bis[N-2-benzothiazolyl-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183854-36-6 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3-[[3-(cyclopropylmethyl)hexahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepin-1-yl]methyl]-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 72 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 183854-42-4 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3-[[3-butylhexahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepin-1-yl]methyl]-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183854-58-2 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3-[[hexahydro-5,6-dihydroxy-2-oxo-3,4,7-tris(phenylmethyl)-1H-1,3-diazepin-1-yl]methyl]-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 72 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 199289-75-3 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3-[[hexahydro-5,6-dihydroxy-3-(2-naphthalenylmethyl)-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepin-1-yl]methyl]-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 72 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 183854-75-3 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3-[[hexahydro-5,6-dihydroxy-2-oxo-3-pentyl-4,7-bis(phenylmethyl)-1H-1,3-diazepin-1-yl]methyl]-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183854-83-3 CAPLUS
CN Benzamide, 3,3'-[[tetrahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepine-1,3(2H)-diyl]bis(methylene)]bis[N-(4-methyl-2-benzothiazolyl)-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 199288-47-6 CAPLUS
CN Benzamide, 3,3'-[[tetrahydro-5,6-dihydroxy-4,7-bis[(4-methoxyphenyl)methyl]-2-oxo-1H-1,3-diazepine-1,3(2H)-diyl]bis(methylene)]bis[N-2-benzothiazolyl-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 72 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 199289-76-4 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3-[[3-[[3-(butylamino)phenyl]methyl]hexahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepin-1-yl]methyl]-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 199289-77-5 CAPLUS
CN Benzamide, 3-[[3-[(3-aminophenyl)methyl]hexahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepin-1-yl]methyl]-N-2-benzothiazolyl-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 199289-78-6 CAPLUS
CN Benzamide, 3-[[3-[(4-aminophenyl)methyl]hexahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepin-1-yl]methyl]-N-2-benzothiazolyl-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 72 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 199289-79-7 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3-[[hexahydro-5,6-dihydroxy-3-[[4-(methylamino)phenyl]methyl]-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepin-1-yl]methyl]-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 199289-80-0 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3-[[hexahydro-5,6-dihydroxy-3-[[3-(methylamino)phenyl]methyl]-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepin-1-yl]methyl]-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 72 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 199289-83-3 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3-[[hexahydro-5,6-dihydroxy-3-(1H-indazol-5-ylmethyl)-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepin-1-yl]methyl]-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 199289-84-4 CAPLUS
CN Benzamide, 3-[[3-[(3-amino-1H-indazol-5-yl)methyl]hexahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepin-1-yl]methyl]-N-2-benzothiazolyl-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 72 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 199289-81-1 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3-[[3-[[3-(ethylamino)phenyl]methyl]hexahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepin-1-yl]methyl]-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 199289-82-2 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3-[[3-[[3-(dimethylamino)phenyl]methyl]hexahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepin-1-yl]methyl]-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 72 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 199289-85-5 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3-[[hexahydro-5,6-dihydroxy-3-[(3-methyl-1H-indazol-5-yl)methyl]-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepin-1-yl]methyl]-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 199289-86-6 CAPLUS
CN Benzamide, 3-[[3-(1,3-benzodioxol-5-ylmethyl)hexahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepin-1-yl]methyl]-N-2-benzothiazolyl-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 72 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 199289-88-8 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3-[[hexahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-3-(3-pyridinylmethyl)-1H-1,3-diazepin-1-yl]methyl]-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 199289-90-2 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3-[[3-(3-furanylmethyl)hexahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepin-1-yl]methyl]-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 72 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 199289-91-3 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3-[[hexahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-3-(3-thienylmethyl)-1H-1,3-diazepin-1-yl]methyl]-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 73 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1997:716135 CAPLUS
DN 128:68488
TI Electrophotographic photoreceptor using novel azo compound
IN Nagamura, Hideki; Kodera, Tatsuya
PA Mitsubishi Paper Mills, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 24 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 09288365	A2	19971104	JP 1996-101129	19960423
<--				
PRAI JP 1996-101129		19960423		

GI



I



II

AB The title photoreceptor comprises a conductive support coated with a photosensitive layer containing ≥1 azo compound selected from I and II [R1-4 = H, halo, (substituted) alkyl, alkoxy, aryl, heterocycle; Cp = coupler residue}. The photoreceptor shows high photosensitivity and durability in repeated use.

IT 200202-69-3
RL: DEV (Device component use); USES (Uses)
(electrophotog. photoreceptor containing azo compound charge-generating agent)

RN 200202-69-3 CAPLUS
CN 3-Dibenzofurancarboxamide, N-2-benzothiazolyl-1-[[3-[6-[6-[[3-[(2-benzothiazolylamino)carbonyl]-2-hydroxy-1-dibenzofuranyl]azo][1,1'-biphenyl]-2-yl]-3,5,6,7-tetrahydro-1,3,5,7-tetraoxobenzo[1,2-c:4,5-c']dipyrrol-2(1H)-yl]phenyl]azo]-2-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 73 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 74 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:479386 CAPLUS
DN 127:121881
TI Preparation of [(carbamoylheterocyclyl)methyl]phosphonic acid diester derivatives as drugs
IN Miyata, Kazuyoshi; Sakai, Yasuhiro; Shoji, Yasuo; Tsuda, Yoshihiko; Inoue, Yasuhide; Sato, Keigo; Miki, Shinya
PA Otsuka Pharmaceutical Factory, Inc., Japan
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9724360	A1	19970710	WO 1996-JP3775	19961224
<--					
	W: AU, CA, CN, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2241679	AA	19970710	CA 1996-2241679	19961224
<--					
	CA 2241679	C	20020212		
	AU 9711734	A1	19970728	AU 1997-11734	19961224
<--					
	AU 702980	B2	19990311		
	EP 882730	A1	19981209	EP 1996-942639	19961224
<--					
	EP 882730	B1	20021002		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1206419	A	19990127	CN 1996-199436	19961224
<--					
	CN 1070863	B	20010912		
	AT 225357	E	20021015	AT 1996-942639	19961224
<--					
	ES 2181928	T3	20030301	ES 1996-942639	19961224
	JP 3500468	B2	20040223	JP 1997-524176	19961224
	TW 438806	B	20010607	TW 1996-85116065	19961226
<--					
	US 5985858	A	19991116	US 1998-91946	19980626
<--					
PRAI	JP 1995-340909	A	19951227		
	WO 1996-JP3775	W	19961224		

OS MARPAT 127:121881
GI



I

L7 ANSWER 74 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB Phosphonic acid diester derivs. represented by general formula R1R2NCO-A-CH2P(:O)(OR3)OR4 [R1 = cycloalkyl, (un)substituted Ph, lower haloalkyl, 1,3,4-thiadiazol-2-yl, thiazolyl, (halo)pyridyl, benzothiazol-2-yl having 1 or 2 lower alkyl group on the Ph ring, 4,5-dihydrothieno[3,2-e]benzothiazol-2-yl; R2 = H, phenyl-lower alkyl; R3, R4 = lower alkyl; A = a heterocycle selected from among pyrazine, thiophene and phenyl-substituted thiazole rings] which are useful as remedies for hyperlipidemia and diabetes, antitumor agents, and preventives or remedies for cataract, are prepared Thus, 5-bromomethyl-2-thiophenecarboxylic acid was heated with tri-Et phosphite at 160° under stirring for 1 h and the reaction mixture was dissolved in 200 mL EtOH, treated dropwise with 4 N aqueous NaOH under ice-cooling, and stirred at room temperature for 12 to give 5-[(diethoxyphosphoryl)methyl]-2-thiophenecarboxylic acid. The latter compound was stirred with SOCl2 at room temperature for 4 h to give 5-[(diethoxyphosphoryl)methyl]-2-thiophenecarbonyl chloride which was condensed with 4-methoxyaniline in the presence of pyridine in CH2Cl2 at room temperature for 12 h to give the title compound (I; X = MeO, X1 = H). I (X = Cl, X1 = COMe) at 100 mg/kg p.o. lowered the serum triglyceride level by 71% in rats administered i.v. with Triton WR1339.
IT **192723-68-5P 192723-69-6P 192723-70-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [(carbamoylheterocyclyl)methyl]phosphonic acid diester derivs. as drugs)
RN 192723-68-5 CAPLUS
CN Phosphonic acid, [[5-[[(4,6-dimethoxy-2-benzothiazolyl)amino]carbonyl]-2-thienyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 192723-69-6 CAPLUS
CN Phosphonic acid, [[5-[[(4-methoxy-2-benzothiazolyl)amino]carbonyl]-2-thienyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 192723-70-9 CAPLUS
CN Phosphonic acid, [[5-[(thieno[3,2-e]benzothiazol-2-ylamino)carbonyl]-2-thienyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 75 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:397336 CAPLUS
DN 127:17703
TI Preparation of (hetero)aromatic compounds for treating bone deficit conditions.
IN Petrie, Charles; Orme, Mark W.; Baindur, Nand; Robbins, Kirk G.; Harris, Scott M.; Kontoyianni, Maria; Hurley, Laurence H.; Kerwin, Sean M.; Mundy, Gregory R.
PA Zymogenetics, Inc., USA; Osteoscreen, Inc.; University of Texas At Austin
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9715308	A1	19970501	WO 1996-US17019	19961023
<--					
	W: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2235481	AA	19970501	CA 1996-2235481	19961023
<--					
	AU 9674710	A1	19970515	AU 1996-74710	19961023
<--					
	AU 706262	B2	19990610		
	EP 866710	A1	19980930	EP 1996-936906	19961023
<--					
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1201393	A	19981209	CN 1996-197827	19961023
<--					
	BR 9611210	A	19991228	BR 1996-11210	19961023
<--					
	JP 2000513324	T2	20001010	JP 1997-516761	19961023
<--					
	US 6008208	A	19991228	US 1997-878868	19970619
<--					
	NO 9801810	A	19980622	NO 1998-1810	19980422
<--					
	US 6413998	B1	20020702	US 1999-453828	19991202
<--					
PRAI	US 1995-5830P	P	19951023		
	US 1996-735875	B1	19961023		
	WO 1996-US17019	W	19961023		
	US 1997-878868	A3	19970619		

OS MARPAT 127:17703
GI

L7 ANSWER 75 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB A method for treating deficient bone growth and/or undesirable bone resorption comprises administration of compds. comprising 2 (substituted) aromatic systems spaced apart by a linker of 1.5-15 Å, is claimed. Thus, dithizone was refluxed in EtOH/HOAc for 18 h to give 25% title compound (I).
In a calvarial bone growth assay, I induced a 4-fold increase in width of new calvarial bone vs. controls.

IT 139233-22-0 190437-16-2 190437-57-1
190437-79-7 190437-80-0 190437-88-8
190437-89-9 190437-92-4 190437-93-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of (hetero)aromatic compds. for treating bone deficit conditions)

RN 139233-22-0 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 190437-16-2 CAPLUS
CN Benzoic acid, 3-methyl-, 4-[(2-benzothiazolylamino)carbonyl]phenyl ester (9CI) (CA INDEX NAME)



RN 190437-57-1 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2-methoxy-4-(methylthio)- (9CI) (CA INDEX NAME)

L7 ANSWER 75 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 190437-79-7 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2,4-dimethoxy- (9CI) (CA INDEX NAME)



RN 190437-80-0 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2-methoxy-4-nitro- (9CI) (CA INDEX NAME)



RN 190437-88-8 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2,4-dichloro- (9CI) (CA INDEX NAME)



RN 190437-89-9 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3,4-dichloro- (9CI) (CA INDEX NAME)

L7 ANSWER 75 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 190437-92-4 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2,4,6-trimethoxy- (9CI) (CA INDEX NAME)



RN 190437-93-5 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2-chloro-4-methoxy- (9CI) (CA INDEX NAME)



L7 ANSWER 76 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:113380 CAPLUS
DN 126:171587
TI Preparation of iminothio ether compounds as acaricides and agrochemical fungicides
IN Watanabe, Masanori; Tanaka, Toshifusa; Murakami, Tadashi; Umeyama, Hideaki
PA Ube Industries, Japan
SO Jpn. Kokai Tokkyo Koho, 19 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 09012551	A2	19970114	JP 1995-157906	19950623
<--					
	WO 9700862	A1	19970109	WO 1996-JP1718	19960621
<--					

W: US
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRAI JP 1995-157906 A 19950623
OS MARPAT 126:171587
GI



AB The title compds. (I; W = CH, N; R2 = OR5, NHR6; R1, R5, R6 = C1-4 alkyl; R3 = C3-8 cycloalkyl; R4 = 4-8 numbered heterocycle) are prepared by reacting bromomethylbenzene derivs. (II; R1, R5, W = same as above) with thioamide R3C(:S)NHR4 (R3, R4 = same as above). Agrochem. fungicides and acaricides containing I are also claimed. Thus, N-(2-methoxy-5-pyridyl)cyclopropanethiocarboxamide (preparation given) was reacted with II (R1 = R5 = Me, W = CH) in the presence of tert-BuOK to give I (W = CH, R1 = Me, R2 = OMe, R3 = cyclopropyl, R4 = 2-methoxy-5-pyridyl) (III). III at 200 ppm controlled 100% of Pseudoperonospora cubensis.

IT 32904-04-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of iminothio ether compds. as acaricides and agrochem. fungicides)

RN 32904-04-4 CAPLUS
CN Cyclopropanecarboxamide, N-2-benzothiazolyl- (8CI, 9CI) (CA INDEX NAME)

L7 ANSWER 76 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 77 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:751515 CAPLUS
DN 126:18896
TI preparation of cyclic urea derivatives as HIV protease inhibitors
IN Jadhav, Prabhakar Kondaji
PA E. I. Du Pont de Nemours & Co., USA
SO PCT Int. Appl., 195 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9629329	A1	19960926	WO 1996-US3426	19960313
<--					
	W: AU, BR, CA, CN, CZ, EE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5683999	A	19971104	US 1996-613554	19960311
<--					
	AU 9653100	A1	19961008	AU 1996-53100	19960313
<--					
	EP 815108	A1	19980107	EP 1996-909680	19960313
<--					
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
PRAI	US 1995-406240	A	19950317		
	US 1996-613554	A	19960311		
	WO 1996-US3426	W	19960313		

OS MARPAT 126:18896
GI



I

AB The title compds. [I; R1 = heterocyclylmethyl; R2 = H, R1], useful as HIV protease inhibitors and thus effective in treating HIV infections, are prepared and formulated. I are effective at 1.0-20 mg/kg-day p.o. Capsule, injectable, etc. formulations were given.

IT **183854-23-1P 183854-36-6P 183854-42-4P 183854-58-2P 183854-75-3P 183854-83-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic urea derivs. as HIV protease inhibitors)

L7 ANSWER 77 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 183854-23-1 CAPLUS
CN Benzamide, 3,3'-[[tetrahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepine-1,3(2H)-diyl]bis(methylene)]bis[N-2-benzothiazolyl-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183854-36-6 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3-[[3-(cyclopropylmethyl)hexahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepin-1-yl]methyl]-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183854-42-4 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3-[[3-butylhexahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepin-1-yl]methyl]-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 77 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 183854-58-2 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3-[[hexahydro-5,6-dihydroxy-2-oxo-3,4,7-tris(phenylmethyl)-1H-1,3-diazepin-1-yl]methyl]-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183854-75-3 CAPLUS
CN Benzamide, N-2-benzothiazolyl-3-[[hexahydro-5,6-dihydroxy-2-oxo-3-pentyl-4,7-bis(phenylmethyl)-1H-1,3-diazepin-1-yl]methyl]-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183854-83-3 CAPLUS
CN Benzamide, 3,3'-[[tetrahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepine-1,3(2H)-diyl]bis(methylene)]bis[N-(4-methyl-2-benzothiazolyl)-, [4R-(4α,5α,6β,7β)]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.



L7 ANSWER 78 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:485792 CAPLUS
DN 125:143335
TI Preparation of dolastatin 10 pentapeptide heterocyclic and halophenyl amide analogs as human cancer inhibitors
IN Pettit, George R.; Srirangam, Jayaram K.; Kantoci, Darko
PA Arizona Board of Regents, USA
SO PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9618408	A1	19960620	WO 1995-US16145	19951208
<--					
	W: AU, BR, CA, CN, FI, JP, KR, MX, NO, NZ				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5663149	A	19970902	US 1994-354551	19941213
<--					
	CA 2203689	AA	19960620	CA 1995-2203689	19951208
<--					
	CA 2203689	C	20010612		
	AU 9643781	A1	19960703	AU 1996-43781	19951208
<--					
	EP 797447	A1	19971001	EP 1995-942615	19951208
<--					
	EP 797447	B1	20040303		
	R: DE, FR, GB, IT, SE				
	JP 11503717	T2	19990330	JP 1995-519228	19951208
<--					
PRAI	US 1994-354551	A	19941213		
	WO 1995-US16145	W	19951208		

GI



I

AB The synthesis and elucidation of nineteen dolastatin 10 heterocyclic and halophenyl amide derivs. I (Ar = 4-FC6H4, 2-ClC6H4, 3-ClC6H4, 4-ClC6H4, 2,5-Cl2C6H3, CH2CH2C6H4Cl-4, 2-pyridyl, 3-quinolyl, 2-benzothiazolyl, 6-fluoro-2-benzothiazolyl, 6-chloro-2-benzothiazolyl; X = Met, Phe, Pro, Val, Ile, 4-chlorophenylalanine) are disclosed. These compds. and the methods of producing those compds. offer demonstrated significant in vitro activity against several human cancer cell lines. These compds. and the methods of producing those compds. offer a com. viable alternative to

L7 ANSWER 78 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
natural and synthetic dolastatin 10.
IT 179668-34-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antitumor activity of dolastatin 10 heterocyclic and halophenyl amide analogs)
RN 179668-34-9 CAPLUS
CN L-Valinamide, N,N-dimethyl-L-valyl-N-[4-[2-[3-[2-[(2-benzothiazolylamino)carbonyl]-1-pyrrolidinyl]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-, [2S-[1[1S*[1[1R*(R*),2S*],2R*],2S*],2R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A



PAGE 1-B

—Pr-i

IT 179667-96-0P 179668-15-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and antitumor activity of dolastatin 10 heterocyclic and halophenyl amide analogs)
RN 179667-96-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[(2-benzothiazolylamino)carbonyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L7 ANSWER 78 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 179668-15-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[(1R,2R)-3-[(2S)-2-[(2-benzothiazolylamino)carbonyl]-1-pyrrolidinyl]-1-methoxy-2-methyl-3-oxopropyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L7 ANSWER 79 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:290583 CAPLUS
DN 124:343279
TI Preparation of naphth[2,1-d]isoxazole-3-carboxamide derivatives as antiulcer drugs
IN Hasegawa, Yukio; Sato, Michitaka; Hasumi, Koichi; Yamamoto, Norio; Matsui, Teruaki; Shidara, Kazuhiro; Kenjo, Takashi; Myazawa, Katsuhiko; Ogawa, Chisato; Et, Al.
PA Teikoku Hormone Mfg Co Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08027131	A2	19960130	JP 1994-180457	19940711
<--					
	JP 3542826	B2	20040714		
PRAI	JP 1994-180457		19940711		

OS MARPAT 124:343279
GI



I



II

AB Naphthisoxazole derivs. [I; A = CH, CH2, S, O, SO2; R1 = H, alkyl; R2 = hydroxyalkyl, alkoxyalkyl, heterocyclyl containing 1-4 heteroatoms selected from N, S, and O; n = 2-5; R1R2N = heterocyclyl; R3, R4 = H, halo, alkyl, alkoxy, alkenyloxy, OH; when A is CH or CH2, R1 is H] and their salts are prepared for use as antiulcer drugs. Thus, 3-carboxynaphth[2,1-d]isoxazole was treated with PCl5 and then reacted with 5-amino-1H-tetrazole to give 3-(1H-tetrazol-5-ylcarbamoyl)naphth[2,1-d]ixoxazole (II), which inhibited stress-induced ulcer at 30 mg/kg oral in male rats.
IT **176432-03-4P**, 3-(2-(4-Chlorobenzothiazolyl)aminocarbonyl)-7-methoxy-4,5-dihydronaphth[2,1-d]isoxazole **176432-04-5P**, 3-(2-(4-Methylbenzothiazolyl)aminocarbonyl)-7-methoxy-4,5-dihydronaphth[2,1-d]isoxazole

L7 ANSWER 79 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of naphth[2,1-d]isoxazole-3-carboxamide derivs. as antiulcer drugs)
RN 176432-03-4 CAPLUS
CN Naphth[2,1-d]isoxazole-3-carboxamide, N-(4-chloro-2-benzothiazolyl)-4,5-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



RN 176432-04-5 CAPLUS
CN Naphth[2,1-d]isoxazole-3-carboxamide, 4,5-dihydro-7-methoxy-N-(4-methyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 80 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:281569 CAPLUS
DN 124:344112
TI Preparation of tetra- and pentapeptide dolastatin analogs as anticancer agents.
IN Pettit, George R.; Srirangam, Jayaram K.; Williams, Michael D.
PA Arizona Board of Regents, USA
SO Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 695757	A2	19960207	EP 1995-305128	19950721
<--					
	EP 695757	A3	19971126		
	EP 695757	B1	20020522		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	US 5530097	A	19960625	US 1994-283684	19940801
<--					
	CA 2154205	AA	19960202	CA 1995-2154205	19950719
<--					
	AT 217882	E	20020615	AT 1995-305128	19950721
<--					
	PT 695757	T	20020930	PT 1995-305128	19950721
<--					
	ES 2176284	T3	20021201	ES 1995-305128	19950721
<--					
	JP 08188594	A2	19960723	JP 1995-222447	19950728
<--					
	JP 3579752	B2	20041020		
	US 5665860	A	19970909	US 1996-671121	19960613
<--					
PRAI	US 1994-283684	A	19940801		

GI



I

AB Title compds. (I; R = Met-NHC6H4Cl-p, Met-NHC6H4Cl-o, Phe-NHC6H4Cl-m, etc.), were prepared Thus, I (R = Q1), prepared by solution phase methods, showed an ED50 of 0.0000312 μg/mL against PS-388 mouse leukemia.
IT **176307-22-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetra- and pentapeptide dolastatin analogs as anticancer agents)
RN 176307-22-5 CAPLUS
CN L-Prolinamide, N,N-dimethyl-L-valyl-L-leucyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(αR,βR,2S)-β-methoxy-α-methyl-2-pyrrolidinepropanoyl-N-2-benzothiazolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A



PAGE 1-B

IT **176307-40-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of tetra- and pentapeptide dolastatin analogs as anticancer agents)
RN 176307-40-7 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-2-benzothiazolyl-1-[3-methoxy-2-methyl-1-oxo-3-(2-pyrrolidinyl)propyl]-, [2S-[1[2S*,3S*(R*)],2R*]]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

L7 ANSWER 80 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CM 1

CRN 176307-39-4
CMF C21 H28 N4 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L7 ANSWER 81 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:902585 CAPLUS
DN 123:306551
TI 4-nitro-N-(4-ethoxyphenyl)anthranilic acid benzothiazolylamide showing antiviral activity
IN Gajdukevich, A. N.; Mikitenko, E. E.; Levitin, E. Ya.; Yavorovskaya, V. E.; Evstropov, A. N.
PA Kharkovskij Farmatsevticheskij Institut, Ukraine; Novosibirskij Gosudarstvennyj Meditsinskij Institut
SO U.S.S.R.
From: Izobreteniya 1993, (47-8), 174.
CODEN: URXXAF
DT Patent
LA Russian
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI SU 1340076	A1	19931230	SU 1985-4002310	19851230

<--
PRAI SU 1985-4002310 19851230
AB Title only translated.
IT 169941-76-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(virucidal activity of anthranilic acid benzothiazolylamide derivative)
RN 169941-76-8 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2-[(4-ethoxyphenyl)amino]-4-nitro- (9CI) (CA INDEX NAME)



L7 ANSWER 82 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:792601 CAPLUS
DN 123:198829
TI Preparation of piperazinedione-derivative superoxide radical inhibitors
IN Tone, Hitoshi; Morisue, Masatoshi; Tamura, Katsumi; Miyazaki, Toshiki; Nakano, Yoshimasa
PA Otsuka Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9502593	A1	19950126	WO 1994-JP1071	19940701

<--
W: AU, CA, CN, KR, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

JP 07025858	A2	19950127	JP 1993-172780	19930713

<--

CA 2143203	AA	19950126	CA 1994-2143203	19940701

<--

AU 9470832	A1	19950213	AU 1994-70832	19940701

<--

AU 676584	B2	19970313		
EP 659182	A1	19950628	EP 1994-919836	19940701

<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

CN 1112364	A	19951122	CN 1994-190493	19940701

<--

US 5607934	A	19970304	US 1995-397043	19950310

<--

PRAI JP 1993-172780	A	19930713
WO 1994-JP1071	W	19940701

OS MARPAT 123:198829
GI



I



II

AB The title compds. [I; R1 = lower alkyl; R2 = (un)substituted phenylalkyl,

L7 ANSWER 82 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(un)substituted imidazolylalkyl, (un)substituted aminocarbonyl; R3 = H, lower alkyl, phenylalkyl; R4 = OH, phenylalkoxy, tetrahydropyranyloxy], which have an inhibitory effect against superoxide radicals (O2-) and are useful in treating diseases mediated by such radicals [e.g., nephritis (no data), autoimmune diseases (no data)], are prepd. and I-contg. formulations presented. Thus, piperazinedione II [m.p. 222-225° (decompn.)] was prepd. and demonstrated a IC50 against superoxide radical release from guinea pig peritoneal macrophage cells of 0.025 x 10-5 g/mL.
IT 167849-22-1P 167849-23-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperazinedione-derivative superoxide radical inhibitors)
RN 167849-22-1 CAPLUS
CN 2-Piperazinecarboxamide, N-2-benzothiazolyl-5-(2-methylpropyl)-3,6-dioxo-4-(phenylmethoxy)-2-(phenylmethyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 167849-23-2 CAPLUS
CN 2-Piperazinecarboxamide, N-2-benzothiazolyl-4-hydroxy-5-(2-methylpropyl)-3,6-dioxo-2-(phenylmethyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 83 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:763486 CAPLUS
DN 123:169892
TI Preparation of indenothiazolyl phosphonates as hypolipidemic and hypoglycemic agents
IN Shoji, Yasuo; Tsuda, Yoshihiko; Tsutsumi, Kazuhiko; Inoue, Yasuhide
PA Otsuka Pharmaceutical Factory, Inc., Japan
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9418212	A1	19940818	WO 1994-JP209	19940210
<--					
	W: AU, CA, CN, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2118007	AA	19940818	CA 1994-2118007	19940210
<--					
	CA 2118007	C	20031202		
	AU 9460107	A1	19940829	AU 1994-60107	19940210
<--					
	AU 660125	B2	19950608		
	EP 638581	A1	19950215	EP 1994-906377	19940210
<--					
	EP 638581	B1	19981223		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1102528	A	19950510	CN 1994-190067	19940210
<--					
	CN 1046733	B	19991124		
	AT 174923	E	19990115	AT 1994-906377	19940210
<--					
	ES 2126097	T3	19990316	ES 1994-906377	19940210
<--					
	JP 2926273	B2	19990728	JP 1994-517889	19940210
<--					
	US 5480874	A	19960102	US 1995-318860	19950112
<--					
PRAI	JP 1993-25732	A	19930215		
	WO 1994-JP209	W	19940210		

OS MARPAT 123:169892
GI

L7 ANSWER 83 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB The title compds. I (R1, R2, R3, R4 = represent each independently H, lower alkyl, lower alkoxy, halogenated lower alkyl, nitro, halo, cyano, phenylthio, phenylsulfinyl, phenylsulfonyl, phenylated lower alkoxy, phenylated lower alkylthio, benzoyloxy substituted by di(lower alkoxy)phosphorylated lower alkyl, provided R3 and R4 may be combined together to form -CH:CHCH:CH-; R5 = H, lower alkyl, phenyl; R6 and R7 = each independently lower alkoxy, Ph or phenylated lower alkoxy; A = optionally phenylated lower alkylene; B = benzene or thiophene ring; D = -CO-, -CS- or -SO2-; E = -N:CMeS-, -SCMe:N-, -NR8CMe:N-, R8 = lower alkyl; Z = single bond, -O-; Y = optionally phenylated lower alkylene, vinylene; n = 0-1), useful in preventing hyperlipidemia and treating cataract and diabetes, is described. Thus, phosphonylation of indenothiazole II (R = H) with (EtO)2P(O)CH2C6H4COCl-4 in the presence of pyridine in CH2Cl2 gave title compound II (R = 4-COC6H4CH2P(O)(OEt)2). I lowered the total cholesterol by 29-78% and triglycerides by 59-96% at 100 mg/kg P.O. in rats with Triton-induced hyperlipemia. Tablet and granular formulations were also given.
IT **167148-66-5P 167148-92-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indenothiazolyl phosphonates as hypolipidemic and hypoglycemic agents)
RN 167148-66-5 CAPLUS
CN Phosphonic acid, [[4-[(naphtho[1,2-d]thiazol-2-ylamino)carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 83 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 167148-92-7 CAPLUS
CN Phosphonic acid, [3-[4-[(naphtho[1,2-d]thiazol-2-ylamino)carbonyl]phenoxy]propyl]-, diethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 84 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:761480 CAPLUS
DN 123:169619
TI Preparation of azabenzimidazoles for treatment of asthma, arthritis and related diseases
IN Marfat, Anthony; Eggler, James F.; Fray, Michael J.; Cooper, Kelvin
PA Pfizer Inc., USA
SO U.S., 34 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5322847	A	19940621	US 1992-941108	19921105
<--					
PRAI	US 1992-941108		19921105		

OS MARPAT 123:169619
GI



AB Title compds. I (Het = (substituted) heterocyclyl; A = CH2O, C.tplbond.C, CH:CH, CMeCH, CH2NH, (CH2)n, O, CONH, CONH, CH2S(O)m wherein n = 1,2; m = 0-2; W = (substituted) heterocyclyl, phenylene, tetralinyl; B = NHCH2, CH2O, etc.; R2 = H, F, Cl, Me, MeO, Ac, O2N, etc.) and a salt thereof, useful for treatment of asthma, arthritis or related diseases (no data), are prepared I are claimed as platelet activating factor inhibitors, leukotriene D4 receptor blockers, and treatment of psoriasis, gastrointestinal distress, myocardial infarction, stroke and shock. To a mixture of 3-(5-fluorbenzothiazol-2-ylmethoxy)aniline and NaBH3CN was added 1-(p-formylphenyl)-2-methyl-1H-imidazo[4,5-c]pyridine to give after workup I (Het = 5-fluorobenzothiazol-2-yl, A = CH2O, W = 1,3-C6H3, B = NHCH2, R2 = H).
IT **139401-87-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azabenzimidazoles for treatment of asthma, arthritis and related diseases)
RN 139401-87-9 CAPLUS
CN Benzamide, N-(5-fluoro-2-benzothiazolyl)-3-[[4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)phenoxy]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 84 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 85 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:563288 CAPLUS
DN 122:314542
TI Preparation of 2-(benzoylimino)benzothiazoline derivatives as antagonists of fibrinogen receptor and cell adhesion factor
IN Sato, Masakazu; Mannaka, Akira; Takahashi, Keiko; Kawashima, Yutaka; Hatayama, Katsuo
PA Taisho Pharma Co Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07010854	A2	19950113	JP 1993-150023	19930622
<--					
	JP 3132241	B2	20010205		
PRAI	JP 1993-150023		19930622		

OS MARPAT 122:314542
GI



AB The title compds. (I; R1 = cyano, thiocarbamoyl, lower alkylthioimidoyl, amidino; R2 = CO2H, lower alkoxycarbonyl), useful for the treatment and prevention of arteriosclerosis and ischemic diseases such as thrombus, brain infarction, and myocardial infarction and as cancer metastasis inhibitors, are prepared (no data). These compds. I inhibit the binding of adhesion proteins such as fibrinogen, fibronectin, and von Willebrand factor to a fibrinogen receptor on a blood platelet and has the inhibitory activity of blood platelet aggregation and adhesion. They inhibit the binding of the above adhesion proteins and adhesion proteins forming a cellular matrix such as fibronectin and collagen and effect the intercellular interaction and the interaction between cells and a cellular matrix. Thus, benzoyl chloride was added to NH4SCN in acetone and reacted at 80° for 15 min followed by adding dropwise 3-amino-4-methylbenzyl alc. over 20 min, stirring the resulting mixture for 45 min, and saponification with 10% aqueous NaOH at 100° to give N-(5-hydroxymethyl-2-methylphenyl)thiourea. The latter compound was brominated with Br in AcOH at 90° for 2 h to give 2-amino-7-bromomethyl-4-methylbenzothiazole

L7 ANSWER 85 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
which was condensed with Et thioglycolate in the presence of K2CO3 in DMF at room overnight to give 2-amino-7-ethoxycarbonylmethylthiomethyl-4-methylbenzothiazole. This was acylated by 4-cyanobenzoyl chloride in Et3N in CH2Cl2 to give 2-(4-cyanobenzoylamino)-7-ethoxycarbonylmethylthiomethyl-4-methylbenzothiazole which was treated with NaH in DMF at room temp. and then methylated by MeI to give a title compd. I (R1 = cyano, R2 = CO2Et).
IT 163217-89-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate for preparation of (benzoylimino)benzothiazoline derivs. as antagonists of fibrinogen receptor and cell adhesion factor)
RN 163217-89-8 CAPLUS
CN Acetic acid, [[[2-[(4-cyanobenzoyl)amino]-4-methyl-7-benzothiazolyl]methyl]thio]-, ethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 86 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:526601 CAPLUS
DN 122:265353
TI Tetrahydrothieno- or tetrahydrofuro[4,3,2-ef][3]benzazepine derivatives useful as α-adrenergic receptor antagonists
IN Bondinell, William Edward; Demarinis, Robert Michael; Ku, Thomas Wen-fu; Pfeiffer, Francis Richard; Shah, Dinubhai Himatlal; Venslavsky, Joseph Walter
PA Smithkline Beecham Corp., USA
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9419354	A1	19940901	WO 1994-US1739	19940216
<--					
	W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9401027	A	19941111	ZA 1994-1027	19940215
<--					
	CA 2156186	AA	19940901	CA 1994-2156186	19940216
<--					
	AU 9462433	A1	19940914	AU 1994-62433	19940216
<--					
	EP 684949	A1	19951206	EP 1994-909685	19940216
<--					
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08507069	T2	19960730	JP 1994-519148	19940216
<--					
	US 5599810	A	19970204	US 1995-505297	19951020
<--					
PRAI	US 1993-17713	A	19930216		
	WO 1994-US1739	W	19940216		

OS MARPAT 122:265353
GI



AB α-Adrenergic receptor antagonists I [X = H, halo, CF3, alkyl, COR1, CO2R2, CONR2R2, cyano, NO2, NR2R3, OR3, alkylthio, S(CH2)0-6Ph, SCF3, or combinations (≤3 groups); R = H, alkyl, alkenyl; R1 = alkyl, (CH2)0-6Ph; R2 = H, alkyl, (CH2)0-6Ph; R3 = groups given for R2, COR1, SO2R1; A = O, S; Y = bond, (CH2)1-4, CH:, CH:CHQ, (CH2)0-2E(CH2)0-2; Q = bond, SO2, CO; E = CH(OH), CO, O, S, CO2, NR2, CONR2; Het = stable, (un)saturated, (un)substituted, 5- to 7-membered mono- or 7- to 10-membered

L7 ANSWER 86 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
bicyclic heterocyclyl] and salts are prepd. The antagonists (no data) are
claimed useful for treatment of disorders such as benign prostatic hypertrophy, peripheral vascular disease, congestive heart failure, and hypertension. For example, cyclocondensation of 7-chloro-3,4,5,6-tetrahydro-4-methylthieno[4,3,2-ef][3]benzazepine-2-carboxaldehyde with tosylmethyl isocyanide in MeOH in the presence of K2CO3 gave I [X = 7-Cl, R = Me, A = S, Y = bond, Het = 5-oxazolyl], isolated as the HCl salt. Approx. 50 compds. (free bases and/or salts) were prepd. in 32 synthetic examples. Three std. formulations are given.
IT 162782-19-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of tetrahydrothieno- and tetrahydrofurobenzazepine derivs. as
α-adrenergic antagonists)
RN 162782-19-6 CAPLUS
CN Furo[4,3,2-ef][3]benzazepine-2-carboxamide, N-2-benzothiazolyl-7-chloro-3,4,5,6-tetrahydro-4-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 87 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:275356 CAPLUS
DN 122:147125
TI Silver halide photographic materials
IN Yabuki, Yoshiharu
PA Fuji Photo Film Co Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 19 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 06258769	A2	19940916	JP 1993-45175	19930305
<--					
PRAI	JP 1993-45175		19930305		

GI



AB The title materials contain solid fine particles of ≥1 indophenol compound I (Q1-4, R1-4 = H, halo, alkyl, alkenyl, alkynyl, aralkyl, aryl, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, acyl, carbamoyl, amino, acylamino, nitro, sulfonylamino, ureido, alkoxy, aryloxy, hydroxy, acyloxy, alkylthio, arylthio, sulfamoyl, alkylsulfonyl, arylsulfonyl; Q1 and Q3, Q2, and Q4, R1 and R3, or R2 and R4 may form a ring) dispersed in a hydrophilic colloid layer. The compound dyes the colloid layer without adverse effects on the photog. properties and the dyed layer is decolored readily during developing process. Thus, a photog. film was prepared by using gelatin-based undercoat layer containing II.
IT 161010-06-6
RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
(photog. materials containing indophenol derivative fine particles in hydrophilic colloid layer)
RN 161010-06-6 CAPLUS
CN 5-Benzothiazolecarboxylic acid, 2-[[[4-[(3,5-dichloro-4-hydroxyphenyl)imino]-1,4-dihydro-1-oxo-2-naphthalenyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

L7 ANSWER 87 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 88 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:231222 CAPLUS
DN 122:10056
TI Preparation of thiazolopyrimidinecarboxamides as angiogenesis inhibitors
IN Matsumoto, Hiroo; Tanaka, Noriko; Nakayama, Kiyoshi; Chatani, Haruko; Iwahana, Michio
PA Daiichi Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 72 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 618208	A1	19941005	EP 1994-105256	19940405
<--					
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
	NO 9401135	A	19941003	NO 1994-1135	19940328
<--					
	FI 9401487	A	19941002	FI 1994-1487	19940330
<--					
	CA 2120395	AA	19941002	CA 1994-2120395	19940331
<--					
	AU 9459252	A1	19941006	AU 1994-59252	19940331
<--					
	AU 672675	B2	19961010		
	JP 06336484	A2	19941206	JP 1994-65200	19940401
<--					
	JP 3670309	B2	20050713		
	CN 1100425	A	19950322	CN 1994-105279	19940401
<--					
	US 5599813	A	19970204	US 1994-221577	19940401
<--					
PRAI	JP 1993-110877	A	19930401		

OS MARPAT 122:10056
GI



AB Title compds. [I; R1,R2 = H, alkyl; R3 = OH, (un)substituted alkyl(oxy); R4,R5 = H, (un)substituted alkyl, alkenyl, aralkyl, etc.; n = 1-3] were prepared Thus, HO2CCH2CO2Et was amidated by 3,5-Cl2C6H3NH2 and the brominated product cyclocondensed with 3,4,5,6-tetrahydropyrimidine-2-thiol to give I (R1 = R2 = R4 = H, R3 = OH, R5 = 3,5-Cl2C6H3, n = 1) which
was etherified by HOCH2CO2Et to give, after saponification, title compound II. The
latter gave 94.3% inhibition of angiogenesis in egg chorioallantoic membrane (concentration not given).

L7 ANSWER 88 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IT 159502-74-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolopyrimidinecarboxamides as angiogenesis inhibitors)
RN 159502-74-6 CAPLUS
CN 5H-Thiazolo[3,2-a]pyrimidine-2-carboxamide, N-2-benzothiazolyl-6,7-dihydro-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L7 ANSWER 89 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1994:270815 CAPLUS
DN 120:270815
TI preparation of phosphonic acid diester derivatives
IN Miyata, Kazuyoshi; Shoji, Yasuo; Tsuda, Yoshihiko; Tsutsumi, Kazuhiko; Inoue, Yasuhide; Naba, Chieko; Kurogi, Yasuhisa
PA Otsuka Pharmaceutical Factory, Inc., Japan
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9323409	A1	19931125	WO 1993-JP660	19930520
<--					
	W: AU, CA, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2113561	AA	19931125	CA 1993-2113561	19930520
<--					
	CA 2113561	C	19990914		
	AU 9340887	A1	19931213	AU 1993-40887	19930520
<--					
	AU 653681	B2	19941006		
	EP 604657	A1	19940706	EP 1993-910361	19930520
<--					
	EP 604657	B1	20000112		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 2759228	B2	19980528	JP 1993-520067	19930520
<--					
	AT 188704	E	20000115	AT 1993-910361	19930520
<--					
	ES 2140456	T3	20000301	ES 1993-910361	19930520
<--					
	US 5376665	A	19941227	US 1994-182145	19940114
<--					
PRAI	JP 1992-128711	A	19920521		
	WO 1993-JP660	A	19930520		

OS MARPAT 120:270815
GI

L7 ANSWER 89 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Phosphonic diester deriva. [I; R1-R3 = H, alkyl, alkoxy, Ph, acyl, PhCO, etc.; R4 = H, alkyl, phenylalkyl; R5, R6 = alkoxy, Ph, PhO, OH, phenylalkoxy; A = CH, N; B = NH, alkylimino, O, S, etc.; X = O, bond; Y = CO, SO2; Z = bond, (substituted) alkylene; X = Z = bond], effective in reducing blood sugar and lipid levels, and thus useful for treating diabetes, hyperlipidemia, etc. A soln. of 5.8 g 4-ClCOC6H4CH2P(O)(OEt)2 in CH2Cl2 was added dropwise to a solution of 3.0 g 2-aminobenzothiazole in pyridine-CH2Cl2 with stirring, the mixture was treated with 10% NaHCO3 and extracted with CHCl3 to give 6.8 g diester II, which lowered the total cholesterol by 40% at 100 mg/kg i.v. in rats. Formulations were also given.
IT 154769-74-1P 154769-75-2P 154769-76-3P
154769-77-4P 154769-78-5P 154769-79-6P
154769-80-9P 154769-81-0P 154769-82-1P
154769-83-2P 154769-84-3P 154769-85-4P
154769-86-5P 154769-87-6P 154769-88-7P
154769-89-8P 154769-93-4P 154770-00-0P
154770-01-1P 154770-02-2P 154770-03-3P
154770-04-4P 154770-05-5P 154770-06-6P
154770-07-7P 154770-08-8P 154770-09-9P
154770-10-2P 154770-11-3P 154770-12-4P
154770-14-6P 154770-15-7P 154770-16-8P
154770-17-9P 154770-18-0P 154770-19-1P
154770-20-4P 154770-21-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as hypoglycemic and anticholesteremic agent)
RN 154769-74-1 CAPLUS
CN Phosphonic acid, [[4-[(2-benzothiazolylamino)carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 89 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 154769-75-2 CAPLUS
CN Phosphonic acid, [[4-[[(4-methyl-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154769-76-3 CAPLUS
CN Phosphonic acid, [[4-[[(4-methoxy-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154769-77-4 CAPLUS
CN Phosphonic acid, [[4-[[[4-(trifluoromethoxy)-2-benzothiazolyl]amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154769-78-5 CAPLUS

L7 ANSWER 89 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Phosphonic acid,
[[4-[[(4-chloro-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154769-79-6 CAPLUS
CN Phosphonic acid,
[[4-[[(6-methyl-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154769-80-9 CAPLUS
CN Phosphonic acid,
[[4-[[(6-methoxy-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154769-81-0 CAPLUS
CN Phosphonic acid,
[[4-[[(6-ethoxy-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 89 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Phosphonic acid,
[[4-[[(6-nitro-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154769-86-5 CAPLUS
CN Phosphonic acid,
[[4-[[(4,6-dimethoxy-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154769-87-6 CAPLUS
CN Phosphonic acid,
[[4-[[(5,6-dimethyl-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154769-88-7 CAPLUS
CN Phosphonic acid,
[[4-[[(5-chloro-6-methoxy-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 89 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 154769-82-1 CAPLUS
CN Phosphonic acid,
[[4-[[(6-fluoro-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154769-83-2 CAPLUS
CN Phosphonic acid,
[[4-[[(6-chloro-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154769-84-3 CAPLUS
CN Phosphonic acid,
[[4-[[(6-bromo-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154769-85-4 CAPLUS

L7 ANSWER 89 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 154769-89-8 CAPLUS
CN Phosphonic acid, [[4-[[(4-acetyl-6,7-dimethoxy-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154769-93-4 CAPLUS
CN Phosphonic acid,
[[4-[[(4-methoxy-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 154770-00-0 CAPLUS
CN Phosphonic acid, [[4-[(2-benzothiazolylamino)carbonyl]phenyl]methyl]-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)



RN 154770-01-1 CAPLUS
CN Phosphonic acid,
[[4-[[(4-methoxy-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, dibutyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 89 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 154770-02-2 CAPLUS
CN Phosphonic acid, [[4-[[(4-methoxy-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, ethyl methyl ester (9CI) (CA INDEX NAME)



RN 154770-03-3 CAPLUS
CN Phosphonic acid, [[4-[[(4-methoxy-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, ethyl 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 154770-04-4 CAPLUS
CN Phosphinic acid, [[4-[[(4-methoxy-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]phenyl-, ethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 89 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 154770-05-5 CAPLUS
CN Phosphonic acid, [[4-[[[6-(trifluoromethyl)-2-benzothiazolyl]amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154770-06-6 CAPLUS
CN Phosphonic acid, [[4-[[(4-benzoyl-6-chloro-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154770-07-7 CAPLUS
CN Phosphonic acid, [[4-[[(4-acetyl-6-bromo-2-benzothiazolyl)amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 89 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 154770-08-8 CAPLUS
CN 6-Benzothiazolecarboxylic acid, 2-[[4-[(diethoxyphosphinyl)methyl]benzoyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 154770-09-9 CAPLUS
CN Phosphonic acid, [[4-[[6-(methylthio)-2-benzothiazolyl]amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154770-10-2 CAPLUS
CN Phosphonic acid, [[4-[[[6-(phenylmethoxy)-2-benzothiazolyl]amino]carbonyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154770-11-3 CAPLUS
CN Phosphonic acid, [[4-[[[6-(aminocarbonyl)-2-benzothiazolyl]amino]carbonyl]

L7 ANSWER 89 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154770-12-4 CAPLUS
CN Phosphoric acid, 4-[[(4-methoxy-2-benzothiazolyl)amino]carbonyl]phenyl diphenyl ester (9CI) (CA INDEX NAME)



RN 154770-14-6 CAPLUS
CN Acetic acid, [[2-[[4-[(diethoxyphosphinyl)methyl]benzoyl]amino]-6-benzothiazolyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 154770-15-7 CAPLUS
CN Phosphonic acid, [1-[4-[[(4-methoxy-2-benzothiazolyl)amino]carbonyl]phenyl]-2-phenylethyl]-, diethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 89 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 154770-16-8 CAPLUS
CN Phosphonic acid,
[1-[4-[[(4-methoxy-2-benzothiazolyl)amino]carbonyl]phenyl
]ethyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154770-17-9 CAPLUS
CN Phosphonic acid,
[[4-[[(6-bromo-4-phenyl-2-benzothiazolyl)amino]carbonyl]p
henyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154770-18-0 CAPLUS
CN Phosphonic acid,
[[4-[[(4-methoxy-2-benzothiazolyl)amino]carbonyl]phenyl]m
ethyl]-, ethyl phenylmethyl ester (9CI) (CA INDEX NAME)



RN 154770-19-1 CAPLUS
CN Phosphonic acid,
[[4-[[(4-methoxy-2-benzothiazolyl)amino]carbonyl]phenyl]m
ethyl]-, monoethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 89 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 154770-20-4 CAPLUS
CN Phosphonic acid,
[2-[4-[[(4-methoxy-2-benzothiazolyl)amino]carbonyl]phenox
y]ethyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 154770-21-5 CAPLUS
CN Phosphonic acid,
[3-[4-[[(4-methoxy-2-benzothiazolyl)amino]carbonyl]phenox
y]propyl]-, diethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 90 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1994:270386 CAPLUS
DN 120:270386
TI 4,5,6,7-Tetrahydroimidazo[4,5-c]pyridine-6-carboxylic acid derivative antiemetics
IN Huang, Bao Shan; Feng, Danging D.; Gall, Martin; Evans, Suzanne M.; Paradkar, Vidyadhar M.; Nair, Raghunathan V.; Latham, Tamara B.
PA Anaquest, Inc., USA
SO U.S., 14 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5262537	A	19931116	US 1993-33522	19930319
<--				
PRAI US 1993-33522		19930319		

OS MARPAT 120:270386
GI



AB The title compds. [I; R1, R2 = H, lower alkyl; R3 = H, lower alkyl, NO2NH2CN, alkylmercapto; R4 R5 = H, (un)substituted lower alkyl, aryl; R6 = H, (un)substituted lower alkyl, CHO, arylcarbonyl, etc.; R7 = Ph, thienyl, indolyl, indazolyl, benzo[b]furanyl, benzo[b]thiophenyl, etc.; R4R5 may form a 5- or 6- member saturated hydrocarbon ring], which are selective antagonists of the serotonin 5-HT3 receptor with little of no D2
receptor antagonist activity, useful as antiemetics for treating nausea and vomiting, are prepared Thus, a title compound, II (having an S configuration at the 6th position) was prepared in 22% yield (m.p. 210°) and demonstrated 100% inhibition. of cisplatin-induced ferret vomiting at a 0.1 mg/kg, vs. 17% for metaclopramide. II also demonstrated
50% inhibitory concentration in rat brain-derived serotonin 5-HT3 receptors of
158.21 nM, vs. 514.00 nM for metaclopramide.
IT 154056-46-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(antiemetic activity)
RN 154056-46-9 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-6-carboxamide, N-2-benzothiazolyl-4,5,6,7-tetrahydro-5-methyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 90 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 154055-97-7P 154056-06-1P 154056-46-9P
154056-52-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antiemetic activity)
RN 154055-97-7 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-6-carboxamide, N-2-benzothiazolyl-4,5,6,7-tetrahydro-5-methyl-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 154056-06-1 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-6-carboxamide, N-2-benzothiazolyl-4,5,6,7-tetrahydro-5-methyl-, dihydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 154056-46-9 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-6-carboxamide, N-2-benzothiazolyl-4,5,6,7-tetrahydro-5-methyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 90 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 154056-52-7 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-6-carboxamide, N-2-benzothiazolyl-4,5,6,7-tetrahydro-5-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 91 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1994:90357 CAPLUS
DN 120:90357
TI Organic nonlinear optical material
IN Koike, Tsuneaki; Hama, Hideo; Yamanaka, Tooru
PA Mitsui Petrochemical Industries, Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 05107575	A2	19930430	JP 1991-47057	19910312
PRAI JP 1991-47057		19910312		

OS MARPAT 120:90357
AB A nonlinear optical material comprises (D)i@1(R1)kNR2C@@2(R2)l(A)j (A = acceptor substituent; D = donor substituent; @1,2 = aromatic, heterocyclic; R1-3 = H, alkyl, aryl, aralkyl, alkoxy; i-l = integers > 1).
The material exhibits large second-order susceptibilities.
IT 152586-99-7P 152587-00-3P
RL: PREP (Preparation)
(prepare and use of, as nonlinear optical materials)
RN 152586-99-7 CAPLUS
CN Benzamide, N-(4-methoxy-2-benzothiazolyl)-3,5-dinitro- (9CI) (CA INDEX NAME)



RN 152587-00-3 CAPLUS
CN Benzamide, N-(4-methoxy-2-benzothiazolyl)-4-nitro- (9CI) (CA INDEX NAME)



L7 ANSWER 92 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1993:659520 CAPLUS
DN 119:259520
TI Electrophotographic photoreceptors using specific azo compound
IN Harada, Hiroshi; Okada, Shinichi
PA Dainippon Ink & Chemicals, Japan
SO Jpn. Kokai Tokkyo Koho, 21 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 05150523	A2	19930618	JP 1991-317865	19911202
PRAI JP 1991-317865		19911202		

GI



I



II

AB The photoreceptors comprise a conductive substrate with a coating of a photosensitive layer containing an azo compound I (R1, R2 = coupler residue).
The photoreceptors show good photosensitivity and durability in repeated use and can be used in plain paper copiers. Thus, an Al vapor-deposited polyester film was coated with a composition containing II and a binder resin to
give a photoreceptor.
IT 151228-38-5
RL: USES (Uses)
(electrophotog. photoreceptor using)
RN 151228-38-5 CAPLUS
CN 2-Naphthalenecarboxamide, N-2-benzothiazolyl-4-[3-[4-[3-[(2-benzothiazolylamino)carbonyl]-2-hydroxy-1-naphthalenyl]phenyl]thiazolo[3,2-a]benzimidazol-7-yl]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 92 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 93 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1993:659507 CAPLUS
DN 119:259507
TI Electrophotographic photoreceptors containing benzothienoimidazole-containing bisazo dyes as charge-generating agents
IN Harada, Hiroshi; Okada, Shinichi
PA Dainippon Ink & Chemicals, Japan
SO Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 05188607	A2	19930730	JP 1992-1541	19920108
PRAI JP 1992-1541		19920108		

GI



I

AB Electrophotog. photoreceptors comprising an elec.-conductive support having thereon a photosensitive layer containing the title compds. I (A1-2 = coupler residue) are claimed. The electrophotog. photoreceptors are excellent in sensitivity and durability.
IT 151107-37-8
RL: TEM (Technical or engineered material use); USES (Uses)
(electrophotog. photoreceptor charge-generating agent)
RN 151107-37-8 CAPLUS
CN 2-Naphthalenecarboxamide, N-2-benzothiazolyl-4-[[4-[7-[[3-[(2-benzothiazolylamino)carbonyl]-2-hydroxy-1-naphthalenyl]azo]imidazo[2,1-b]benzothiazol-2-yl]phenyl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 93 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 94 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1993:495551 CAPLUS
DN 119:95551
TI Immunomodulators and thiazolopyrimidines
IN Suzuki, Fumio; Nakazato, Nobusuke; Oomori, Takemori; Tamura, Tadashi
PA Kyowa Hakko Kogyo Kk, Japan
SO Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 05039293	A2	19930219	JP 1992-9883	19920123
PRAI JP 1991-6590	A1	19910123		
OS MARPAT 119:95551				

GI



I

AB Immunomodulators contain thiazolopyrimidines I [X = ethylene, o-phenylene; Y = O, NH; Z = H, lower alkyl, (substituted) aralkyl, (substituted) aryl, (substituted) heterocycle, (CH2)nNR1R2; R1, R2 = H, lower alkyl; n = 1-4] or their salts as active ingredients. 2-Aminobenzothiazole and CH(CO2Et)3 in xylene were refluxed for 48 h to give 46% I (X = o-phenylene, Y = O, Z = Et), treatment of which with MeNH2 gave 84% I (X = o-phenylene, Y = NH, Z = Me) (II). II was orally applied to mice at 100 mg/kg to show 32.7% control of delayed-type hypersensitivity.
IT 149178-43-8P 149194-61-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as immunomodulator)
RN 149178-43-8 CAPLUS
CN 4H-Pyrimido[2,1-b]benzothiazole-3-carboxamide, N-2-benzothiazolyl-2-hydroxy-4-oxo-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 149194-61-6 CAPLUS
CN 4H-Pyrimido[2,1-b]benzothiazole-3-carboxamide, N-2-benzothiazolyl-2-hydroxy-4-oxo- (9CI) (CA INDEX NAME)

L7 ANSWER 94 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 95 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1993:219516 CAPLUS
DN 118:219516
TI Nonirritating antitartar and antiplaque oral compositions
IN Elliott, David L.; Patrick, Esther
PA Chesebrough-Pondo's USA Co., USA
SO U.S., 8 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5192533	A	19930309	US 1992-858374	19920325
<--					
	EP 562668	A1	19930929	EP 1993-200748	19930315
<--					
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
	CA 2092274	AA	19930926	CA 1993-2092274	19930323
<--					
	JP 06100425	A2	19940412	JP 1993-65330	19930324
<--					
PRAI	US 1992-858374	A	19920325		

OS MARPAT 118:219516
AB The title dentifrices comprise a hypophosphite-containing cotelomer in an amount effective for controlling tartar and an antibacterial agent selected from the group consisting of di-Ph ethers, bis-biguanides, halogenated carbanilides, and salicylamides. For example, a toothpaste contained Polyol II (manufactured by Roquette) 45.00, deionized water 17.89, acrylic acid-maleic acid cotelomer hypophosphite 10.92, Gasil-200 10.00, Sident 22S 8.00, polyethylene glycol 5.00, Na lauryl sulfate 1.50, CM cellulose 0.50, TiO2 0.50, triclosan 0.30, NaF 0.214, and Na saccharin 0.18%.
IT 78417-85-3
RL: BIOL (Biological study)
(dentifrices containing acrylate-maleate cotelomer hypophosphite and, antitartar and antiplaque)
RN 78417-85-3 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2-hydroxy-5-(1-oxodecyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 96 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1993:124562 CAPLUS
DN 118:124562
TI Preparation of pyrazine oxides as drugs
IN Tone, Hitoshi; Sato, Seiji; Sato, Hideaki; Tamura, Katsumi; Miyazaki, Toshiki; Nakano, Yoshimasa
PA Otsuka Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 65 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 511879	A1	19921104	EP 1992-303970	19920501
<--					
	EP 511879	B1	19950322		
	R: CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	CA 2067663	AA	19921102	CA 1992-2067663	19920430
<--					
	AU 9215908	A1	19921105	AU 1992-15908	19920430
<--					
	AU 652824	B2	19940908		
	CN 1067053	A	19921216	CN 1992-103130	19920430
<--					
	CN 1038586	B	19980603		
	JP 05170747	A2	19930709	JP 1992-110548	19920430
<--					
	ES 2073246	T3	19950801	ES 1992-303970	19920501
<--					
	KR 183043	B1	19990501	KR 1992-7486	19920501
<--					
	US 5459142	A	19951017	US 1993-110797	19930823
<--					
PRAI	JP 1991-100049	A	19910501		
	US 1992-876454	B1	19920430		

OS MARPAT 118:124562
GI



AB Title compds. [I; R = H, alkyl; R1 = alkoxy, alkyl, OH; R2 = (substituted) phenylalkyl, carbamoyl; R3 = alkyl, Ph, phenylalkyl, alkenyl, indolylalkyl] were prepared Thus, 3-isobutyl-5-methoxy-1,2-dihydropyrazin-2-one-6-carboxylic acid 4-oxide [preparation starting from H2NCH2(CO2Et)2 and

L7 ANSWER 96 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
α-hydroxyiminoisocapronic acid given] in dioxane was stirred with m-methoxybenzylamine, N-hydroxysuccinimide, and DCC to give title compd. II. II inhibited superoxide radicals from stimulated guinea pig macrophage cells with IC50 = 30 + 10-6 g/mL. A pharmaceutical compn. was prepd. contg. II.
IT **145943-99-3P 145944-00-9P 145944-28-1P 145944-33-8P 145944-70-3P 145944-71-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as drug)
RN 145943-99-3 CAPLUS
CN Pyrazinecarboxamide, N-2-benzothiazolyl-1,6-dihydro-3-methoxy-5-(2-methylpropyl)-6-oxo-, 4-oxide (9CI) (CA INDEX NAME)



RN 145944-00-9 CAPLUS
CN Pyrazinecarboxamide, 1,6-dihydro-3-methoxy-N-(6-methoxy-2-benzothiazolyl)-5-(2-methylpropyl)-6-oxo-, 4-oxide (9CI) (CA INDEX NAME)



RN 145944-28-1 CAPLUS
CN Pyrazinecarboxamide, N-2-benzothiazolyl-3-ethyl-1,6-dihydro-5-(2-methylpropyl)-6-oxo-, 4-oxide (9CI) (CA INDEX NAME)



RN 145944-33-8 CAPLUS
CN Pyrazinecarboxamide, N-2-benzothiazolyl-1,6-dihydro-3-methoxy-1-methyl-6-

L7 ANSWER 96 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
oxo-5-phenyl-, 4-oxide (9CI) (CA INDEX NAME)



RN 145944-70-3 CAPLUS
CN Pyrazinecarboxamide, N-2-benzothiazolyl-1,6-dihydro-3-methoxy-6-oxo-5-(phenylmethyl)-, 4-oxide (9CI) (CA INDEX NAME)



RN 145944-71-4 CAPLUS
CN Pyrazinecarboxamide, N-2-benzothiazolyl-5-(3-butenyl)-1,6-dihydro-3-methoxy-6-oxo-, 4-oxide (9CI) (CA INDEX NAME)



L7 ANSWER 97 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1993:38919 CAPLUS
DN 118:38919
TI Benzothiazole derivatives for suppression of leukotriene and thromboxane production and their preparation
IN Okamoto, Yasushi; Tagami, Katsuya; Hibi, Shigeki; Numata, Hirotoshi; Kobayashi, Naoki; Shinoda, Masanobu; Kawahara, Tetsuya; Murakami, Manabu; Oketani, Kiyoshi; et al.
PA Eisai Co., Ltd., Japan
SO Eur. Pat. Appl., 41 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 507318	A1	19921007	EP 1992-105777	19920403
<--					
	EP 507318	B1	19970910		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE				
	JP 05178855	A2	19930720	JP 1992-64545	19920323
<--					
	JP 2848998	B2	19990120		
	US 5300518	A	19940405	US 1992-861379	19920331
<--					
	CA 2064992	AA	19921005	CA 1992-2064992	19920402
<--					
	NO 9201282	A	19921005	NO 1992-1282	19920402
<--					
	NO 301274	B1	19971006		
	AU 9213990	A1	19921008	AU 1992-13990	19920402
<--					
	AU 658868	B2	19950504		
	HU 62890	A2	19930628	HU 1992-1141	19920403
<--					
	HU 219448	B	20010428		
	RU 2041216	C1	19950809	RU 1992-5011434	19920403
<--					
	AT 157976	E	19970915	AT 1992-105777	19920403
<--					
	ES 2104761	T3	19971016	ES 1992-105777	19920403
<--					
	CN 1065457	A	19921021	CN 1992-102349	19920404
<--					
	CN 1030451	B	19951206		
	KR 9700954	B1	19970121	KR 1992-5646	19920404
<--					
	US 5420144	A	19950530	US 1993-148914	19931105
<--					
	US 5635519	A	19970603	US 1995-388813	19950215
<--					
PRAI	JP 1991-71480	A	19910404		
	JP 1991-281366	A	19911028		
	US 1992-861379	A3	19920331		
	US 1993-148914	A3	19931105		

GI

L7 ANSWER 97 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I

AB Over 20 title compds. I [R1, R3 = H, alkyl, alkoxy, (CH2)pPy, CH(OCOR7)Py where Py = 2-, 3-, or 4-pyridyl; R2 = H, protecting group; R4 = H, alkyl, Ph, (CH2)qPy, CH(OCOR7)Py; or R3R4 forms benzene ring; R5, R6 = H, alkyl, (CH2)rPy, acyl; R7 = alkyl; p, q, r = 1-4] were prepared as inhibitors of 5-lipoxygenase and thromboxane synthetase, especially for treatment of inflammatory bowel diseases including ulcerative colitis. For example, 6-benzyloxy-2-bromo-5,7-dimethoxybenzothiazole was condensed with 3-(aminomethyl)pyridine at 120°, and the product was debenzylated by HCl in refluxing aqueous EtOH, to give I (R1 = R3 = OMe, R2 = R4 = R6 = H, R5 = 3-pyridylmethyl). In the rat TNB (trinitrobenzenesulfonic acid) colitis model, several I at 100 mg/kg orally gave up to 94% suppression of production and liberation of LTB4, and up to 85% suppression of TxB2. Addnl. test data show promotion of PGE2 production
IT 145096-38-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for lipoxygenase inhibitor)
RN 145096-38-4 CAPLUS
CN 3-Pyridinecarboxamide, N-(6-methoxy-4,5,7-trimethyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 98 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:592072 CAPLUS
DN 117:192072
TI Preparation of naphthol phosphates for detection of nucleic acids
IN Fujita, Satoshi; Kagiyama, Naoto; Momiyama, Masayoshi
PA Aisin Seiki K. K., Japan
SO Brit. UK Pat. Appl., 19 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2250991	A1	19920624	GB 1991-27232	19911223
<--					
	GB 2250991	B2	19940810		
	JP 04222600	A2	19920812	JP 1990-413201	19901221
<--					
	US 5484700	A	19960116	US 1991-806189	19911213
<--					
	DE 4142076	A1	19920709	DE 1991-4142076	19911219
<--					
	DE 4142076	C2	19960328		
PRAI	JP 1990-413201	A	19901221		
OS	MARPAT 117:192072				

GI



I



II

AB Title compds. [I; one of R1 - R3 = A, the others = H, halo, alkyl, alkoxy, PhO, aminoacetyl, cyano, alkoxycarbonyl; A = CONHR, NHCOR, CH:CHR, CO2R, C(OR4):NR; R = (substituted) alkyl, alkoxy, PhO, (hetero)aryl; R4 = alkoxy, PhO; with provisos], were prepared Thus, 2-acetoxy-3-formylnaphthalene (preparation given) in THF was added to a mixture of 3,4-dimethylbenzyl triphenylphosphonium chloride (preparation given) and NaOEt in THF to give 25% 2-acetoxy-3-(3,4-dimethylstyryl)naphthalene. The latter was stirred with CaCO3 in EtOH to give 90% 3-(3,4-dimethylstyryl)-2-naphthol. This was treated with POCl3 in pyridine followed by ice quenching to give title compound II. II successfully detected digoxigenin-labeled DNA at the 0.4 pg level.
IT 144077-65-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and phosphorylation of, in preparation of reagent for DNA detection)
RN 144077-65-6 CAPLUS
CN 2-Naphthalenecarboxamide, 3-hydroxy-N-(4-methyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 98 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 144077-57-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for DNA detection)
RN 144077-57-6 CAPLUS
CN 2-Naphthalenecarboxamide, N-(4-methyl-2-benzothiazolyl)-3-(phosphonooxy)- (9CI) (CA INDEX NAME)



L7 ANSWER 99 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:545313 CAPLUS
DN 117:145313
TI Preparation of 2-chloroisonicotinic acid derivatives as fungicides against
Phycomycetes.
IN Watanabe, Yutaka; Konishi, Kenji; Shimano, Shizuo; Yonekawa, Tsutomu
PA Nippon Kayaku Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 04124108	A2	19920424	JP 1990-242655	19900914
<--				
PRAI JP 1990-242655		19900914		

OS MARPAT 117:145313
GI



AB The title derivs. I [A = NHCXR, N:C(YR1)ZR2; X = O, S, :NCO2R3; R = lower alkoxy, allyloxy, OCH2C.tplbond.CH, lower alkylthio, NHPh, morpholino, 2,6-dimethylmorpholino, NHN:CMePh; when X = O, S; R = lower alkoxy, when X = :NCO2R3; R1, R2 = lower alkyl, allyl, CH2C.tplbond.C, CH2Ph, when Y, Z = O, S, NH; R1, R2 = lower alkylamino, 4,6-dimethyl-2-pyrimidinyl, when Y or Z = NH; Y = Z; R1R2 = (CH2)n or Q; T = H, Cl; l, m = 0, 1; l + m = 0, 1; n = 2, 3] are prepd, as fungicides. A wettable powder containing I (A = CONHCSNHPh) (II) (preparation given) 20, kaolin 75, Na higher alc. sulfate 3, and Na ligninsulfonate 2 parts was prepared II, at 200 ppm, completely inhibited spot formation on grape leaf inoculated with Plasmopara viticola.
IT 132222-03-8P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as fungicide)
RN 132222-03-8 CAPLUS
CN 4-Pyridinecarboxamide, N-2-benzothiazolyl-2-chloro- (9CI) (CA INDEX NAME)

L7 ANSWER 99 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 100 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:511465 CAPLUS
DN 117:111465
TI Preparation of pyrrolidinedionecarboxylates as aldose reductase inhibitors
IN Mylari, Banavara L.
PA Pfizer Inc., USA
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9206954	A2	19920430	WO 1991-US6483	19910913
<--				
WO 9206954	A3	19920806		
W: CA, FI, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CA 2091566	AA	19920416	CA 1991-2091566	19910913
<--				
EP 553130	A1	19930804	EP 1991-917487	19910913
<--				
EP 553130	B1	19960103		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05507284	T2	19931021	JP 1991-516047	19910913
<--				
JP 06092367	B4	19941116		
AT 132486	E	19960115	AT 1991-917487	19910913
<--				
ES 2082232	T3	19960316	ES 1991-917487	19910913
<--				
PRAI US 1990-597614	A2	19901015		
WO 1991-US6483	W	19910913		

OS MARPAT 117:111465
GI



AB Title compds. [I and II; R = (substituted) (hetero)aralkyl; R1 = OR2, NHR3; R2 = alkyl; R3 = furyl, thienyl, 2-(benzo)thiazolyl, etc.; R6 = H, R6R6 = benzopyranylidene and analogous groups Q; R4, R5 = H, Br, Cl, F, alkoxy; X = CH2, O, S] were prepared as aldose reductase inhibitors (no data). Thus, (2-thienylmethyl)amine was condensed with CH2:CHCO2Et and the product was cyclocondensed with (CO2Et)2 to give I (R = 2-thienylmethyl, R1 = Et, R6 = H).
IT 142774-24-1P 142774-34-3P 142774-36-5P
142774-37-6P 142774-39-8P 142774-40-1P
142774-41-2P 142774-47-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L7 ANSWER 100 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(prepn. of, as aldose reductase inhibitor)
RN 142774-24-1 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-2-benzothiazolyl-4,5-dioxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 142774-34-3 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-2-benzothiazolyl-1-[(3,4-dichlorophenyl)methyl]-2,4-dioxo- (9CI) (CA INDEX NAME)



RN 142774-36-5 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-(4-chloro-2-benzothiazolyl)-1-[(3,4-dichlorophenyl)methyl]-2,4-dioxo- (9CI) (CA INDEX NAME)



RN 142774-37-6 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-2-benzothiazolyl-1-[2-(3,4-dichlorophenyl)ethyl]-2,4-dioxo- (9CI) (CA INDEX NAME)



RN 142774-39-8 CAPLUS

L7 ANSWER 100 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 3-Pyrrolidinecarboxamide, N-2-benzothiazolyl-1-[(4-methoxyphenyl)methyl]-2,4-dioxo- (9CI) (CA INDEX NAME)



RN 142774-40-1 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-2-benzothiazolyl-2,4-dioxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 142774-41-2 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-2-benzothiazolyl-1-(1-naphthalenylmethyl)-2,4-dioxo- (9CI) (CA INDEX NAME)



RN 142774-47-8 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-2-benzothiazolyl-2,4-dioxo-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 100 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 101 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:490279 CAPLUS
DN 117:90279
TI Preparation of imidazo[4,5-c]pyridines as PAF and LTD4 receptor antagonists
IN Marfat, Anthony; Eggler, James Frederick; Cooper, Kevin; Fray, Michael Jonathan
PA Pfizer Inc., USA
SO PCT Int. Appl., 126 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9117163	A1	19911114	WO 1991-US2997	19910501
<--					
	W: AU, BG, BR, CA, FI, HU, JP, KR, LK, NO, PL, RO, SU, US				
	RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	CA 2080476	AA	19911110	CA 1991-2080476	19910501
<--					
	AU 9178671	A1	19911127	AU 1991-78671	19910501
<--					
	AU 642265	B2	19931014		
	EP 533695	A1	19930331	EP 1991-909431	19910501
<--					
	EP 533695	B1	19941005		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	BR 9106433	A	19930504	BR 1991-6433	19910501
<--					
	HU 62894	A2	19930628	HU 1992-3496	19910501
<--					
	JP 05505619	T2	19930819	JP 1991-509156	19910501
<--					
	JP 06078340	B4	19941005		
	ES 2061247	T3	19941201	ES 1991-909431	19910501
<--					
	RO 109450	B1	19950228	RO 1992-1395	19910501
<--					
	CN 1057839	A	19920115	CN 1991-103959	19910508
<--					
	ZA 9103497	A	19921230	ZA 1991-3497	19910508
<--					
	NO 9204290	A	19921106	NO 1992-4290	19921106
<--					
PRAI	US 1990-521199	A1	19900509		
	WO 1991-US2997	A	19910501		

OS MARPAT 117:90279
GI For diagram(s), see printed CA Issue.
AB Title compds. [I; R = R3AWB; A = CH2O, CH:CH, CH2NH, O, CONH, etc.; B = NHCH2, CH2O, CHMeO, CMe2O, O, CH2CH2, etc.; R2 = H, F, Cl, Me, MeO, MeCO, etc.; R3 = (un)substituted heteroaryl; W = (un)substituted arylenediyl] were prepared as PAF and LTD4 receptor antagonists (no data). Thus, 4-(HOCH2)C6H4NH2 was condensed with 4-chloro-3-nitropyridine and the reduced product refluxed with Ac2O to give I (R2 = H) (II; R = CH2OAc) which was converted in 2 steps to II (R = CHO). The latter was reductively condensed with 3-(R3CH2O)C6H4NH2 (R3 = 5-fluorobenzothiazol-2-yl) (preparation given) to give II (R = benzothiazolylmethoxyanilinomethyl

L7 ANSWER 101 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
group Q).
IT 139401-87-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as PAF and leukotriene receptor antagonist)
RN 139401-87-9 CAPLUS
CN Benzamide, N-(5-fluoro-2-benzothiazolyl)-3-[[4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)phenoxy]methyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 102 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:448551 CAPLUS
DN 117:48551
TI Preparation of imidazopyridines as platelet-activating factor (PAF) antagonists
IN Cooper, Kelvin; Fray, Michael Jonathan; Steele, John
PA Pfizer Ltd., UK; Pfizer Inc.
SO PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9117162	A1	19911114	WO 1991-EP737	19910417
<--					
	W: CA, FI, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	CA 2078007	AA	19911110	CA 1991-2078007	19910417
<--					
	EP 530207	A1	19930310	EP 1991-907827	19910417
<--					
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 05505199	T2	19930805	JP 1991-507697	19910417
<--					
PRAI	GB 1990-10404	A	19900509		
	WO 1991-EP737	W	19910417		

OS MARPAT 117:48551
GI



AB Imidazopyridines [I; R1-R3 = H, Me; A = C1-8 alkyl, perfluoroalkyl, cycloalkyl, (substituted) aryl, heterocyclyl; B = linear or branched alkylene, alkenylene, divalent radical containing ether, thioether linkage, etc.] are prepared A mixture of benzyl alc. II, Me salicylate, and Ph3P in

L7 ANSWER 102 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
THF was stirred at room temp. under N, di-Et azodicarboxylate was added dropwise and the resulting soln. was stirred at room temp. to give 92% ether III. Also prepd. were 161 addnl. I, which showed IC50 of 10-8 to 10-9M as PAF antagonists.
IT 138991-91-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as platelet-activating factor antagonist)
RN 138991-91-0 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)- (9CI) (CA INDEX NAME)



L7 ANSWER 103 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:255641 CAPLUS
DN 116:255641
TI Preparation of 1-fluoro-2-(4,6-dimethoxypyrimidinyl-2-oxy)-1-cyclopentanecarboxylates and analogs as herbicides
IN Goh, Atsushi; Kudo, Sachio; Kumamoto, Yorio; Watanabe, Michi; Takahashi, Takako; Aoki, Takako; Toshima, Norishige; Endo, Keiji; Mukaida, Hideshi; et al.
PA Mitsubishi Petrochemical Co., Ltd., Japan
SO Eur. Pat. Appl., 264 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 468766	A1	19920129	EP 1991-306743	19910724
<--					
	R: DE, ES, FR, GB, IT				
	CA 2047597	AA	19920125	CA 1991-2047597	19910723
<--					
	AU 9181247	A1	19920130	AU 1991-81247	19910723
<--					
	AU 642753	B2	19931028		
	US 5262385	A	19931116	US 1991-734698	19910723
<--					
	BR 9103173	A	19920519	BR 1991-3173	19910724
<--					
	JP 05208935	A2	19930820	JP 1991-206094	19910724
<--					
	JP 05262748	A2	19931012	JP 1992-127924	19920422
<--					
PRAI	JP 1990-193807	A	19900724		
	JP 1990-193808	A	19900724		
	JP 1991-50340	A	19910222		
	JP 1991-50523	A	19910222		
	JP 1991-118095	A	19910422		
	JP 1991-128188	A	19910502		
	JP 1991-128208	A	19910502		
	JP 1991-242352	A1	19910829		
	JP 1992-31254	A1	19920123		
	JP 1992-31260	A1	19920123		
	JP 1992-31295	A1	19920123		

OS MARPAT 116:255641
GI



L7 ANSWER 103 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
AB The title compds. [I; R1, R2 = H, halo (di)alkylamino, (halo)alkyl(thio), (halo)alkoxy; R3, R4 = H, halo, HO2C, alkoxycarbonyl, alkyl, alkenyl, alkynyl, aryl, aralkyl; R3R4 may form a 5- to 8-membered (un)substituted (un)saturated (hetero)ring with the C atoms to which they bind; R5 = H, alkyl; R3R5 may form a double bond; A = O, S, NB; B = HO, alkylcarbonyloxy, etc.; W = O, S, OCH2; X = halo; Y = H, HO, HS, alkoxy, aryloxy, azido, cyano, NO2, ON:CR6R7, NR8R9, azolyl, etc.; R6, R7 = H, alkyl, alkoxy, aryl, etc.; CR6R7 = cycloalkyl; R8, R9 = H, HO, (un)substituted alkyl, -alkoxy, etc.; Z1, Z2 = N, CH, with a proviso] were prepared Me 1-fluoro-2-oxocyclopentanecarboxylate was reduced by Me2S-BH3 complex in THF, the resulting (65%) 2-hydroxy analog (trans-form) was treated by NaH in DMF and etherified by 4,6-dimethoxy-2-methylsulfonylpyrimidine. The product (20.9%) was saponified and the acid (42.2%) reesterified by EtSH to give 52% title compound trans-II. The latter at 100 g/ha in a preemergence test gave complete kill of 8 weeds, e.g. barnyardgrass, giant foxtail, velvetleaf, etc., with no damage of soybean and cotton.
IT 141418-69-1P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as herbicide)
RN 141418-69-1 CAPLUS
CN Cyclohexanecarboxamide, N-2-benzothiazolyl-2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-1-fluoro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 104 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:235619 CAPLUS
DN 116:235619
TI Preparation of N-(7-chloro-2-benzothiazolyl)ureas and analogs as herbicides
IN Wagner, Klaus; Luerssen, Klaus; Santel, Hans Joachim; Schmidt, Robert R.
PA Bayer A.-G., Germany
SO Ger. Offen., 13 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4021658	A1	19920109	DE 1990-4021658	19900707
<--					
	AU 9179221	A1	19920109	AU 1991-79221	19910621
<--					
	EP 465901	A1	19920115	EP 1991-110326	19910622
<--					
	R: BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	JP 04230373	A2	19920819	JP 1991-186980	19910702
<--					
	CA 2046393	AA	19920108	CA 1991-2046393	19910705
<--					
	HU 58307	A2	19920228	HU 1991-2283	19910705
<--					
	ZA 9105213	A	19920429	ZA 1991-5213	19910705
<--					
PRAI	DE 1990-4021658	A	19900707		

OS MARPAT 116:235619
GI



I

AB Title compds. [I; R = NR2C(:X)R1; R1 = (halo)alkyl, alkoxyalkyl, (di)alkylamino, alkylthio, etc.; R2 = H, (cyclo)alkyl, R3 = H, halo, haloalkyl; X = O, S] were prepared as herbicides (no data). Thus, 7-chloro-2-(methoxycarbonyl)benzothiazole N-oxide was converted in 3 steps to I (R3 = H)(II; R = NHMe) which was condensed with MeNCO to give II (R = NMeCONHMe).
IT 139961-85-6P 139961-95-8P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as herbicide)
RN 139961-85-6 CAPLUS

L7 ANSWER 104 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Cyclopropanecarboxamide, N-(6,7-dichloro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 139961-95-8 CAPLUS
CN Cyclopropanecarboxamide, N-(7-chloro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 105 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:128908 CAPLUS
DN 116:128908
TI Isoxazole-4-carboxamides and (hydroxalkylidene)cyanoacetamides as neoplasm inhibitors and antirheumatics
IN Bartlett, Robert R.; Kaemmerer, Friedrich Johannes
PA Hoesch A.-G., Germany
SO PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9117748	A1	19911128	WO 1990-EP1800	19901024
<--					
	W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, RO				
	RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, BR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	CA 2083179	AA	19911119	CA 1990-2083179	19901024
<--					
	CA 2083179	C	20011023		
	AU 9065468	A1	19911210	AU 1990-65468	19901024
<--					
	AU 649421	B2	19940526		
	EP 527736	A1	19930224	EP 1990-915462	19901024
<--					
	EP 527736	B1	19970416		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	BR 9008022	A	19930406	BR 1990-8022	19901024
<--					
	JP 05506425	T2	19930922	JP 1990-514415	19901024
<--					
	JP 2995086	B2	19991227		
	HU 64314	A2	19931228	HU 1992-3619	19901024
<--					
	AT 151633	E	19970515	AT 1990-915462	19901024
<--					
	RU 2084223	C1	19970720	RU 1992-16445	19901024
<--					
	ES 2102367	T3	19970801	ES 1990-915462	19901024
<--					
	RU 2142937	C1	19991220	RU 1994-33835	19901024
<--					
	CN 1056684	A	19911204	CN 1991-103182	19910516
<--					
	CN 1051074	B	20000405		
	IL 98163	A1	19960131	IL 1991-98163	19910516
<--					
	SK 281316	B6	20010212	SK 1991-1450	19910516
<--					
	SK 281317	B6	20010212	SK 1998-1376	19910516
<--					
	SK 281318	B6	20010212	SK 1999-542	19910516
<--					
	CZ 290474	B6	20020717	CZ 1991-1450	19910516
<--					
	ZA 9103762	A	19920129	ZA 1991-3762	19910517
<--					

L7 ANSWER 105 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

	US 5494911	A	19960227	US 1992-938048	19921116
<--					
	NO 9204433	A	19921117	NO 1992-4433	19921117
<--					
	NO 180118	B	19961111		
	NO 180118	C	19970219		
	FI 105683	B1	20000929	FI 1992-5211	19921117
<--					
	LV 10575	B	19960420	LV 1993-310	19930507
<--					
	LT 3416	B	19950925	LT 1993-715	19930625
<--					
	AU 9457992	A1	19940707	AU 1994-57992	19940323
<--					
	AU 662465	B2	19950831		
	HR 940696	B1	20001031	HR 1994-940696	19941019
<--					
	FI 9501697	A	19950410	FI 1995-1697	19950410
<--					
	FI 105680	B1	20000929		
	US 5532259	A	19960702	US 1995-476278	19950607
<--					
	CZ 290717	B6	20021016	CZ 1995-2176	19950824
<--					
	CZ 290736	B6	20021016	CZ 1995-3091	19951123
<--					
	CZ 290737	B6	20021016	CZ 1995-3092	19951123
<--					
	JP 11322700	A2	19991124	JP 1999-52108	19990301
<--					
	JP 3233610	B2	20011126		
	JP 11343285	A2	19991214	JP 1999-52107	19990301
<--					
	JP 3201747	B2	20010827		
PRAI	DE 1990-4016178	A	19900518		
	DE 1990-4017020	A	19900526		
	DE 1990-4017043	A	19900526		
	JP 1990-514415	A3	19901024		
	WO 1990-EP1800	A	19901024		
	CZ 1991-1450	A3	19910516		
	YU 1991-884	A6	19910520		
	US 1992-938048	A3	19921116		
	FI 1992-5211	A	19921117		

OS MARPAT 116:128908
GI



I

AB Title compds. I [R1 = H, C1-6 alkyl, Ph, C1-4 haloalkyl; R2 = H, C1-4 alkyl, phenethyl, benzyl, C2-3 alkenyl; R3 = (substituted) mono-, di- or tricyclic unsatd. C3-13 heterocyclyl containing 1-4 heteroatoms of which 1 may

L7 ANSWER 105 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
be O or S and the rest are N, (substituted) Ph, (CH2)nCO2R10; NR2R3 = (substituted) 4-9 membered ring which may contain O, S; R10 = H, C1-4 alkyl; n = 1-12) and HOC(R7):C(CN)CONR3R8 [II; R7 = H, C1-17 alkyl, C1-3 haloalkyl, phenethyl, benzyl; R8 = H, Me, C2-3 alkenyl; R3 defined above] and their keto tautomers, some of which are novel, are useful as neoplasm inhibitors and antirheumatics. Thus, a soln. of 5-methylisoxazole-4-carbonyl chloride in MeCN was added dropwise to a soln. of 4-trifluoromethylaniline in MeCN and the mixt. was stirred for 20 min to give N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide. The latter was active in vitro against a no. of tumor cell lines and had an oral LD50 of 235 mg/kg in rats.
IT 67305-31-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(ring cleavage of, in preparation of neoplasm inhibitors and antirheumatics)
RN 67305-31-1 CAPLUS
CN 4-Isoxazolecarboxamide, N-(4-chloro-2-benzothiazolyl)-5-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 106 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:41442 CAPLUS
DN 116:41442
TI Preparation of 2-oxo-4-hydroxy-1,8-naphthyridine-3-carboxamides as antiinflammatories
IN Suzuki, Fumio; Kuroda, Takeshi; Ohmori, Kenji; Tamura, Tadafumi; Hosoe, Hisashi
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO Eur. Pat. Appl., 34 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 452873	A1	19911023	EP 1991-106040	19910416
<--				
EP 452873	B1	19960703		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 04217981	A2	19920807	JP 1991-79280	19910411
<--				
JP 2988739	B2	19991213		
US 5126341	A	19920630	US 1991-684214	19910412
<--				
CA 2040517	AA	19911017	CA 1991-2040517	19910415
<--				
CA 2040517	C	19970603		
AT 140003	E	19960715	AT 1991-106040	19910416
<--				
ES 2093041	T3	19961216	ES 1991-106040	19910416
<--				
PRAI JP 1990-100006	A	19900416		

OS MARPAT 116:41442
GI



AB Title compds. [I; X = H, alkyl, aralkyl, (substituted) (hetero)aryl, amino, Q; Y = bond, alkylene; W = N, CH; Z = bond, imino; m, n = 1-3] were prepared Thus, a mixture of Me 2-anilinonicotinate, tricholoromethyl chloroformate, ClCH2CH2Cl, and dioxane was refluxed 3 h to give 87% 1-phenyl-2H-pyrido[2,3-d][1,3]oxazine-2,4(1H)-dione. The latter was heated with di-Et malonate and NaH in dimethylacetamide to give 88% 3-ethoxycarbonyl-4-hydroxy-1-phenyl-1,8-naphthyridin-2(1H)-one. The latter was refluxed with BuNH2 in xylene to give 62% I (YX = Bu) (II).
II
gave 20.5% inhibition of zymosan-induced edema in rat paws. Tablets were

L7 ANSWER 106 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
prepd. contg. II.
IT 138304-99-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antiinflammatory)
RN 138304-99-1 CAPLUS
CN 1,8-Naphthyridine-3-carboxamide, N-2-benzothiazolyl-1,2-dihydro-4-hydroxy-2-oxo-1-phenyl- (9CI) (CA INDEX NAME)



L7 ANSWER 107 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1991:631860 CAPLUS
DN 115:231860
TI Preparation of polyhydric phenol derivatives as bone absorption inhibitors
IN Soda, Takashi; Tsuda, Masao; Oshio, Haruji
PA Takeda Chemical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 16 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 03130216	A2	19910604	JP 1990-167984	19900625
<--				
PRAI JP 1989-190158	A1	19890721		

GI



AB The title compds. [I; R1 = H, (un)substituted alkyl, alkenyl, or OH; R3,R3 = H, (un)substituted alkyl; or adjacent OR3R3O = O(CH2)nO where n = 1,2; A = H, Q; R4 = H, (un)substituted alkyl or OH, (esterified or amidated) CO2H; R5,R6 = H, (un)substituted OH: or adjacent R4R5 = R4R6 = O(CH2)mO where m = 1,2; X = CH2, CO], useful for treatment and prophylaxis of osteoporosis, are prepared Thus, a mixture of 1.38 g 3,4-methylenedioxyphenol, 1.98g 3,4,5-trimethoxybenzyl alc., 10 mL HCO2H, and 5 mL AcOH was refluxed for 2 h to give 8.8% 6-(3,4,5-trimethoxybenzyl)-1,3-benzodioxol-5-ol. 3,4,6,3',4',5'-Hexamethoxydiphenylmethane in vitro inhibited 85.6% the Ca absorption in rat's fetal forearm bones. A total of 62 I were prepared Tablets containing 6-ethoxy-3,4-methylenedioxy-4'-methoxydiphenylmethane were formulated.
IT 137015-46-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as absorption inhibitor for osteoporosis treatment)
RN 137015-46-4 CAPLUS
CN Benzamide, N-(5,6-dimethoxy-2-benzothiazolyl)-4-[(6-ethoxy-1,3-benzodioxol-5-yl)carbonyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 107 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L7 ANSWER 108 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1991:583282 CAPLUS
DN 115:183282
TI Preparation of [(hetero)arylacyl]tetralones, -chromenones, etc. as antiallergy and antiinflammatory agents
IN Kokura, Toshihide; Nako, Kazunari; Ito, Fumitaka; Nakane, Masami
PA Pfizer Inc., USA
SO Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 439265	A1	19910731	EP 1991-300224	19910111
<--					
	EP 439265	B1	19940323		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 03220165	A2	19910927	JP 1990-12342	19900122
<--					
	JP 07017589	B4	19950301		
	AT 103270	E	19940415	AT 1991-300224	19910111
<--					
	ES 2062678	T3	19941216	ES 1991-300224	19910111
<--					
	CA 2034546	AA	19910723	CA 1991-2034546	19910118
<--					
	CA 2034546	C	19970211		
	FI 9100300	A	19910723	FI 1991-300	19910121
<--					
	US 5166161	A	19921124	US 1991-644644	19910122
<--					
PRAI	JP 1990-12342	A	19900122		
	EP 1991-300224	A	19910111		

OS MARPAT 115:183282
GI



I

AB Title compds. I [R = substituted Ph, thienyl, phenylalkyl, phenylamino, pyridylamino, pyrazolylamino, benzothiazol-2-ylamino, thiazol-2-ylamino; X = CH2 Me2C, O, S, MeN; Y = H, Me, MeO, F, Cl, F3C, quinolin-2-ylmethyl; n = 1, 2] inhibitors of cyclooxygenase and lipoxygenase useful as antiallergy and antiinflammatory agents (no data), are prepared Et 3-hydroxy-2H-chromene-4-carboxylate and 2-amino-4-phenylthiazole in MePh were refluxed 3 h to give I (R = 4-phenyl-2-thiazolylamino, X = O, Y = H, n = 1).
IT 136526-75-5P

L7 ANSWER 108 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as antiallergy and antiinflammatory agent)
RN 136526-75-5 CAPLUS
CN 2H-1-Benzopyran-4-carboxamide, N-2-benzothiazolyl-3,4-dihydro-3-oxo- (9CI)
(CA INDEX NAME)



L7 ANSWER 109 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1991:438640 CAPLUS
DN 115:38640
TI Electrophotographic photoconductors
IN Kawahara, Tatsuro
PA Dainippon Ink and Chemicals, Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 16 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03010255	A2	19910117	JP 1989-144145	19890608
<--					
PRAI	JP 1989-144145		19890608		

GI For diagram(s), see printed CA Issue.
AB Compds. I are contained in the photoconductors (Cp = coupler groups). Typical coupler groups are II, III, IV, V (X = carbon or heterocyclic rings; Y = -CONR1R2, -CONHN:CR1R2; R1-3 = H, hydrocarbyl, heterocyclyl; R1-2 may jointly form a ring). High durability and sensitivity of the photoconductors are obtained. Thus, an Al-coated polyester film was coated with a composition containing phenoxy resin and compound I (Cp = VI), and then
with another composition containing p-diethylaminobenzaldehyde diphenylhydrazone
and polycarbonate to obtain a photoconductor that showed sensitivity (exposure required for half-decay of charged voltage) 2.4 lx-s.
IT 134718-81-3
RL: USES (Uses)
(as charge-generating agents, electrophotog. photoconductors containing)
RN 134718-81-3 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(9-oxo-9H-fluorene-2,7-diyl)bis(2,1-ethenediyl-4,1-phenyleneazo)]bis[N-2-benzothiazolyl-3-hydroxy- (9CI) (CA INDEX NAME)



L7 ANSWER 110 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1991:164215 CAPLUS
DN 114:164215
TI Preparation of (benzothiazolylmethoxy)chroman derivatives for the treatment of asthma, arthritis, and related diseases
IN Eggler, James F.; Masamune, Hiroko; Marfat, Anthony; Melvin, Lawrence S.
PA Pfizer Inc., USA
SO Eur. Pat. Appl., 17 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 404440	A2	19901227	EP 1990-306500	19900614
<--					
	EP 404440	A3	19920108		
	EP 404440	B1	19971105		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	WO 9015801	A1	19901227	WO 1989-US2748	19890622
<--					
	W: FI, HU, NO, RO, SU, US				
	AT 159941	E	19971115	AT 1990-306500	19900614
<--					
	ES 2109229	T3	19980116	ES 1990-306500	19900614
<--					
	CA 2019349	AA	19901222	CA 1990-2019349	19900620
<--					
	JP 03038569	A2	19910219	JP 1990-165484	19900622
<--					
	JP 07053722	B4	19950607		
	FI 96951	B	19960614	FI 1991-6065	19911220
<--					
	FI 96951	C	19960925		
	US 5384318	A	19950124	US 1992-835997	19920221
<--					
PRAI	WO 1989-US2748	A	19890622		

OS CASREACT 114:164215; MARPAT 114:164215
GI

L7 ANSWER 110 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB The title compds. [I; R1 = (substituted) quinolyl, benzothiazolyl, benzopyrimidinyl, etc.; R2, R3 = H, OH; X = CH2, O, S, NH, C1-4 alkylamino; Y = CH2O, C2H4, C2H2; Z = (substituted) carbanoyl, CONMe2; etc.; n = 0-3] are prepared NaH was added to a solution of 1.13 g MeSO2NH2 in THF with stirring at room temperature, 1.18 g ester cis-II (R = CO2C6H4NO2-4) was added, and the mixture was stirred at room temperature to give 670 mg amide cis-II (R = CONHSO2Me). Also prepared were 13 addnl. I, which at 2-20 mg/kg-day were effective in preventing or treating asthma, arthritis, and related discusses.
IT 133223-97-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiasthmatic, antiarthritic and antiallergic agent)
RN 133223-97-9 CAPLUS
CN Benzamide, 3-[[6-[(5-fluoro-2-benzothiazolyl)methoxy]-3,4-dihydro-4-hydroxy-2H-1-benzopyran-3-yl]methyl]-N-(4-methoxy-2-benzothiazolyl)-, cis-
(9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



L7 ANSWER 110 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B



L7 ANSWER 111 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1991:143415 CAPLUS
DN 114:143415
TI Preparation of tetrahydrobenzimidazoles as 5-HT3 receptor antagonists
IN Ohta, Mitsuaki; Koide, Tokuo; Suzuki, Takeshi; Matsuhisa, Akira; Miyata, Keiji; Ohmori, Junya; Yanagisawa, Isao
PA Yamanouchi Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 37 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 381422	A1	19900808	EP 1990-300918	19900130
<--					
	EP 381422	B1	19961023		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL				
	CA 2008815	AA	19900802	CA 1990-2008815	19900129
<--					
	CA 2008815	C	19980630		
	AU 9048890	A1	19900809	AU 1990-48890	19900130
<--					
	AU 626980	B2	19920813		
	ZA 9000673	A	19901031	ZA 1990-673	19900130
<--					
	AT 144511	E	19961115	AT 1990-300918	19900130
<--					
	ES 2095855	T3	19970301	ES 1990-300918	19900130
<--					
	FI 104720	B1	20000331	FI 1990-477	19900131
<--					
	NO 9000487	A	19900803	NO 1990-487	19900201
<--					
	NO 177007	B	19950327		
	NO 177007	C	19950705		
	HU 53099	A2	19900928	HU 1990-636	19900201
<--					
	HU 205350	B	19920428		
	DD 291761	A5	19910711	DD 1990-337484	19900201
<--					
	RU 2024516	C1	19941215	RU 1990-4743183	19900201
<--					
	CN 1045583	A	19900926	CN 1990-100544	19900202
<--					
	CN 1030252	B	19951115		
	JP 03223278	A2	19911002	JP 1990-24206	19900202
<--					
	JP 06025153	B4	19940406		
	RU 2059623	C1	19960510	RU 1991-5001605	19910930
<--					
	US 5223508	A	19930629	US 1992-843847	19920228
<--					
	US 5344927	A	19940906	US 1993-39633	19930330
<--					
	US 5496942	A	19960305	US 1994-195566	19940214
<--					
PRAI	JP 1989-25397	A	19890202		
	JP 1989-48897	A	19890228		
	JP 1989-273444	A	19891020		
	JP 1989-342939	A	19891228		

L7 ANSWER 111 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
JP 1989-309898 A 19891129
US 1989-455973 A3 19891222
US 1990-470950 B2 19900126
US 1990-567949 B1 19900815
US 1991-646699 B1 19910128
US 1991-713890 B1 19910612
US 1992-990540 B3 19921214
OS MARPAT 114:143415
GI



AB The title compds. [I; R = Het-X; Het = (un)substituted heterocyclyl including indolyl residue Q; X = bond, NH bonded to a C or N atom of a heterocyclic ring; R1 = H, C1-6 alkyl, alkenyl, or alkynyl, etc.; R2 = H, C1-6 alkyl or aralkyl; R3 = H, OH, halo, C1-6 alkoxy, NO2, (C1-6 alkoxy)carbonyl; when R = Q, X = bond] or their pharmaceutically acceptable salts, useful for the prevention or treatment of gastrointestinal disorders, migraine, anxiety, suppressing nausea and/or vomiting induced by chemotherapy or radiation, etc., were prepared A mixture of 0.27 g carboxamide I.HCl (R = Et2N) (preparation by amidation of the parent carboxylic acid given), 0.16 mL 1-methylindole, and 0.15 mL POCl3 was heated 2 h at 80° to give 20 mg base (I; R = Q, R1 = Me, R2 = R3 = H) (II) which was converted to its fumarate salt (10 mg). The latter in rats inhibited (2-methyl)serotonin-induced Bezold-Jarisch reflex with ED50 of 0.044 μg/kg i.v. Tablets, powder, capsules, syrup, and injections containing (R)-(-)-II.HCl were formulated.

IT 132907-65-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as 5-HT3 inhibitor)

RN 132907-65-4 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-2-benzothiazolyl-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



L7 ANSWER 112 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
give 2.6 g I [R1 = R2 = Ac, R3 = 2,4-(MeO)2C6H3NHCO]. Also prepd. were 137 addnl. I which showed 38.2-203.0% inhibition of bone absorption (measured by concn. of dissolved Ca) in culture.

IT 132794-37-7P 132794-38-8P 132794-45-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as medicine for osteoporosis)

RN 132794-37-7 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2-[bis[4-(acetyloxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 132794-38-8 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2-[bis(4-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 132794-45-7 CAPLUS
CN Benzamide, 2-[bis(4-hydroxyphenyl)methyl]-N-(6-ethoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 112 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1991:142887 CAPLUS
DN 114:142887
TI Triphenylmethane derivatives for treatment of osteoporosis
IN Kinoshita, Iwao; Machii, Daisuke; Onoda, Yasuo; Takai, Haruki; Kosaka, Nobuo; Shuto, Katsuichi; Gomi, Katsushige; Morimoto, Makoto; Ishii, Akio
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO Eur. Pat. Appl., 55 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 395093	A1	19901031	EP 1990-108091	19900427
<--					
	EP 395093	B1	19930901		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 2015473	AA	19901028	CA 1990-2015473	19900426
<--					
	CA 2015473	C	19980414		
	JP 03215461	A2	19910920	JP 1990-112819	19900427
<--					
	JP 2749951	B2	19980513		
	US 5112867	A	19920512	US 1990-515873	19900427
<--					
	AT 93838	E	19930915	AT 1990-108091	19900427
<--					
	US 5413997	A	19950509	US 1993-7104	19930121
<--					
PRAI	JP 1989-110995	A	19890428		
	EP 1990-108091	A	19900427		
	US 1990-515873	A1	19900427		
	US 1992-851967	B3	19920316		

OS MARPAT 114:142887
GI



AB The title compds. (I; R1, R2 = H, alkyl, aralkyl, acyl, alkoxymethyl; R3 = arylcarbamoyl, heterocyclylcarbamoyl, etc.) are prepared A solution of 3 g acid chloride II (preparation given) in CH2Cl2 was added to a solution of 1.08 g 2,4-(MeO)2C6H3NH2 and Et3N in CH2Cl2 under ice cooling and stirring to

L7 ANSWER 112 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 113 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1991:96806 CAPLUS
DN 114:96806
TI Preparation of N-(2-Chloroisonicotinoyl)imines as microbicides
IN Yoshida, Hiroshi; Konishi, Kenji; Shimano, Shizuo; Yamaguchi, Toru; Nakagawa, Taizo
PA Nippon Kayaku Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 02229164	A2	19900911	JP 1989-48608	19890302
<--				
PRAI JP 1989-48608		19890302		

OS MARPAT 114:96806
GI



AB Agrochem. microbicides contain the title compds. I [R1, R2 = lower (cyano)alkyl, allyl, propargyl, Ph, 2-pyridyl; R1R2 = (CH2)n, Q; X, Y = O, S, NH, NMe; X = Y = O; Z = H, Cl; n = 2, 3; l, m = 0, 1; l + m = 0, 1] as active ingredients. 2-Chloroisonicotinamide in DMF was treated with CS2, 1,2-dibromoethane, and NaH at 0° for 2 h to give 34.3% I (X = Y = S, R1R2 = CH2CH2) (II). A granule containing II was applied to soil at 20 mg II/pot to result in 89% control of Pyricularia oryzae with no damage to rice, vs. 65% control for IBP.

IT 132222-03-8
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses)
(agrochem. microbicides containing, preparation of)

RN 132222-03-8 CAPLUS
CN 4-Pyridinecarboxamide, N-2-benzothiazolyl-2-chloro- (9CI) (CA INDEX NAME)



L7 ANSWER 113 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L7 ANSWER 114 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1990:601274 CAPLUS
DN 113:201274
TI Silver halide photographic materials containing oxonol dyes for halation and irradiation prevention
IN Kawashima, Yasuhiko; Tanaka, Mari; Kojima, Tamotsu; Kagawa, Nobuaki
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 02093534	A2	19900404	JP 1988-244254	19880930
<--				
JP 2639830	B2	19970813		
US 4960686	A	19901002	US 1989-413305	19890927
<--				
EP 361949	A2	19900404	EP 1989-309955	19890929
<--				
EP 361949	A3	19901227		
R: DE, GB				
PRAI JP 1988-244254	A	19880930		

GI



AB The material contains a water-soluble oxonol dye I (R, R1 = H, alkyl, aryl, alkenyl; R2-5 = H, alkyl, aryl, alkenyl, heterocycle; ≥1 of R2-5 is heterocycle; R2 and R3, R4 and R5 may form heterocycle; R, R1-6 may be substituted, ≥1 of the R, R1-5 has water-soluble group; L, L1, L2 = (un)substituted methine; n = 0, 1, 2). The dye is easily washed out during processing and leaves little color stain on the processed material.
Thus, a multilayer chromogenic color paper prepared by incorporating compound I (R = R1 = Me; R2 = R4 = H; R3 = R5 = Q; L = L1 = L2 = CH; n = 2) into the red-sensitive layer and the adjacent interlayer, showed fogging and staining resistance at the unexposed parts.

IT 130161-81-8
RL: USES (Uses)
(photog. sensitizers)

RN 130161-81-8 CAPLUS
CN 5-Benzothiazolesulfonic acid, 2-[[[4-[5-[1,5-dihydro-1-methyl-5-oxo-3-[[(5-sulfo-2-benzothiazolyl)amino]carbonyl]-4H-pyrazol-4-ylidene]-1,3-pentadienyl]-4,5-dihydro-1-methyl-5-oxo-1H-pyrazol-3-yl]carbonyl]amino]-,

L7 ANSWER 114 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

dipotassium salt (9CI) (CA INDEX NAME)



L7 ANSWER 115 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1990:562461 CAPLUS
DN 113:162461
TI Electrophotographic photoreceptors containing biazo dyes
IN Hasegawa, Masaru; Suda, Osamu; Tanaka, Norio; Kono, Toshio; Umezaki, Tetsuhiro; Sekino, Toshifumi
PA Dainichiseika Color and Chemicals Mfg. Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 01076063	A2	19890322	JP 1987-232352	19870918

<--
PRAI JP 1987-232352 19870918
OS MARPAT 113:162461
GI

I

AB The title photoreceptor comprises an azo compound [prepared by reacting a A
(N2+X-)n (A = n valent organic residue; n = 2-4; X = Cl, Br, BF4, PF6, etc.)
with o-hydroxyaryl amide I (R = R1NH; R1 = cyclohydrocarbyl, heterocyclyl;
Z = to form aromatic or heteroarom. ring) and an o-hydroxyarylcarboxylate I
(R = R2O; R2 = Me, Et, Pr, hexyl, PhCH2, etc.), simultaneously or successively] on an elec. conductive support. The photoreceptor shows high sensitivity, good durability.
IT 127338-21-0DP, reaction product with hydroxynaphthalenecarboxylate esters or analogs and diazonium salts
RL: PREP (Preparation)
(preparation of, for electrophotog. photoreceptors)
RN 127338-21-0 CAPLUS
CN 2-Naphthalenecarboxamide, N-2-benzothiazolyl-7-bromo-3-hydroxy- (9CI) (CA
INDEX NAME)

L7 ANSWER 115 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 116 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1990:207910 CAPLUS
DN 112:207910
TI Laminated electrophotographic photoconductor using bisazo pigments and benzidines
IN Akasaki, Yutaka; Sato, Katsuhiro; Tanaka, Hiroyuki; Nukada, Katsumi; Taho, Fumiaki
PA Fuji Xerox Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 01257963	A2	19891016	JP 1988-85216	19880408

<--
PRAI JP 1988-85216 19880408
OS MARPAT 112:207910
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title laminated photoconductor, on an elec. conductive substrate, comprises a charge-generating layer containing a bisazo pigment I [A = aromatic
coupler residue Q1-2; X = (substituted) aralkyl, aryl, heterocycle] and a charge-transporting layer containing a benzidine II (R1 = alkyl, alkoxy; one
of R2-3 = C≥2 alkyl and the other R = H, alkyl, alkoxy, substituted amino). Thus, an Al sheet was coated with a charge-generating layer containing I [A = Q1 (X = 4-MeC6H4)] and a charge-transporting layer containing II
(R1 = Me, R2 = 4-Bu, R3 = H) to give the title photoconductor sheet showing elec. charging property, rapid elec. voltage decay under irradiation,
and no residual elec. voltage.
IT 99741-65-8
RL: USES (Uses)
(charge-generating agent, for electrophotog. photoconductor with charge-transporting agent from benzidines)
RN 99741-65-8 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis(3-hydroxy-N-(4-methyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 116 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L7 ANSWER 117 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1990:207909 CAPLUS
DN 112:207909
TI Laminated electrophotographic photoconductor using bisazo pigments and benzidines
IN Akasaki, Yutaka; Sato, Katsuhiro; Tanaka, Hiroyuki; Nukada, Katsumi; Taho, Fumiaki
PA Fuji Xerox Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 01257962 <--	A2	19891016	JP 1988-85215	19880408
JP 2762454	B2	19980604		
PRAI JP 1988-85215		19880408		

OS MARPAT 112:207909
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title laminated photoconductor, on an elec. conductive substrate, comprises a charge-generating layer containing a bisazo pigment I [A = aromatic coupler residue Q1-2; X = (substituted) aralkyl, aryl, heterocycle] and a charge-transporting layer containing a benzidine II (R1= H and R2-3 = H, alkyl, alkoxy, halo, alkoxycarbonyl, substituted amino; R1 = alkyl, alkoxy and R2-3 = H, Me, alkoxy, halo, alkoxycarbonyl, substituted amino). Thus, an Al sheet was coated with a charge-generating layer containing I (A = Q1, X = 2-MeC6H4) and a charge-transporting layer containing II (R1, R3 = H, R2 = 3-Me) to give the title photoconductor sheet showing elec. charging property, rapid elec. voltage decay under irradiation, and no residual elec. voltage.
IT 99741-65-8
RL: USES (Uses)
(charge-generating agent, for electrophotog. photoconductor with charge-transporting agent from benzidines)
RN 99741-65-8 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[3-hydroxy-N-(4-methyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 117 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1990:178956 CAPLUS
DN 112:178956
TI Preparation of aromatic and heterocyclic carboxamides as antineoplastic agents
IN Flirl, Anton Franz Josef; Schnur, Rodney Caughren
PA Pfizer Inc., USA
SO Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 343893 <--	A1	19891129	EP 1989-305141	19890522
EP 343893	B1	19920805		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4970318 <--	A	19901113	US 1989-336923	19890412
JP 02017181 <--	A2	19900122	JP 1989-128600	19890522
JP 06078331	B4	19941005		
AT 79114 <--	E	19920815	AT 1989-305141	19890522
ES 2043012 <--	T3	19931216	ES 1989-305141	19890522
FI 8902498 <--	A	19891125	FI 1989-2498	19890523
DK 8902493 <--	A	19891127	DK 1989-2493	19890523
NO 8902059 <--	A	19891127	NO 1989-2059	19890523
NO 172389	B	19930405		
NO 172389	C	19930714		
AU 8935098 <--	A1	19891130	AU 1989-35098	19890523
AU 601905	B2	19900920		
HU 51606 <--	A2	19900528	HU 1989-2578	19890523
HU 202507	B	19910328		
DD 283815 <--	A5	19901024	DD 1989-328832	19890523
ZA 8903862 <--	A	19910130	ZA 1989-3862	19890523
SU 1681728 <--	A3	19910930	SU 1989-4614242	19890523
CA 1328871 <--	A1	19940426	CA 1989-600370	19890523
CN 1037898 <--	A	19891213	CN 1989-103540	19890524
CN 1023700	B	19940209		
PL 154875 <--	B1	19910930	PL 1989-279613	19890524
PRAI US 1988-198034	A	19880524		
EP 1989-305141	A	19890522		

OS MARPAT 112:178956
GI

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB 2-Aminobenzothiazole derivs. I [R1 = H and A1 = Q or R1 = H or Me and A1 = Q1; X = C1-5 alkyl, H, C1-5 alkoxy, C1-5 alkylthio, F, Cl, Br, NO2, CF3, CONH2, Ph, FC6H4, MeOC6H4, cyano, cyclohexyl, etc.; Y = H, C1-5 alkyl, C1-5 alkoxy, F, Cl; W = H, C1-5 alkoxy, C1-5 alkyl, cyano, F, Cl, Br; XY = (tetrahydro) benzo ring; Z = H, F, Cl, Br, C1-3 alkyl; R = (CH2)n(NH)mC(:NR3)NR4R5, Z(CH2)pNR4R5; m = 0, 1; n = 0-2; R3-R5 = H, C1-3 alkyl; Z = CH2, O, S, (un)substituted imino; p = 0-3; NR4R5 = piperidino, pyrrolidino, (thio)morpholino, piperazido, 4-C1-5 alkylpiperidino; R2 = H, C1-4 alkyl, NO2, cyano, CF3, F, Cl, Br], and iminobenzothiazoles II (A2 = Q1) and III [A3 = COC6H4[NH(C:NH)NH2]-p; R6 = C1-3 alkyl, C1-3 alkoxycarbonylmethyl, PhCH2O2CCH2], useful as antitumor agents and also as protease inhibitors and thus as antiplasmin agents (no data), were prepared Thus, DCC was added to a stirred solution of 4-guanidinobenzoic acid-HCl and 1-hydroxybenzotriazole in DMF at -5°. After 2 h at 0° 6-nitro-2-amino benzothiazole was added and the reaction mixture was stirred 2 h at room temperature to give I (A = Q, R1 = W = Y = Z = R3 = R4 = R5 = H, X = 6 - NO2).
IT 126611-05-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(alkylation of, by benzyl bromoacetate)
RN 126611-05-0 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-(6-nitro-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

IT 126493-36-5P 126610-96-6P 126610-97-7P
126610-98-8P 126610-99-9P 126611-00-5P
126611-05-0P 126611-06-1P 126611-07-2P
126611-08-3P 126611-09-4P 126611-10-7P
126611-11-8P 126611-12-9P 126611-13-0P
126611-14-1P 126611-15-2P 126611-16-3P
126611-17-4P 126611-18-5P 126611-19-6P
126611-20-9P 126611-21-0P 126611-22-1P
126611-23-2P 126611-24-3P 126611-25-4P
126611-26-5P 126611-27-6P 126611-28-7P
126611-29-8P 126611-30-1P 126611-31-2P
126611-32-3P 126611-35-6P 126611-36-7P
126611-37-8P 126611-38-9P 126611-39-0P
126611-40-3P 126611-41-4P 126611-42-5P
126611-43-6P 126611-44-7P 126611-45-8P
126611-46-9P 126611-47-0P 126611-48-1P
126611-49-2P 126611-50-5P 126611-51-6P
126611-52-7P 126611-53-8P 126611-54-9P
126611-55-0P 126611-56-1P 126611-57-2P
126611-58-3P 126611-59-4P 126611-60-7P
126611-61-8P 126611-62-9P 126611-63-0P
126611-64-1P 126611-65-2P 126611-66-3P
126611-67-4P 126611-68-5P 126611-69-6P
126611-70-9P 126611-71-0P 126611-72-1P
126611-73-2P 126611-74-3P 126611-75-4P
126611-76-5P 126611-77-6P 126611-78-7P
126611-79-8P 126611-80-1P 126611-81-2P
126611-82-3P 126611-83-4P 126611-84-5P
126611-85-6P 126611-86-7P 126611-87-8P
126611-88-9P 126611-89-0P 126611-90-3P
126611-91-4P 126611-92-5P 126611-93-6P
126611-94-7P 126611-95-8P 126611-96-9P
126611-97-0P 126611-99-2P 126612-00-8P
126612-01-9P 126612-02-0P 126612-03-1P
126612-04-2P 126612-05-3P 126612-06-4P
126612-08-6P 126612-09-7P 126612-10-0P
126612-11-1P 126612-12-2P 126612-13-3P
126612-14-4P 126612-15-5P 126612-16-6P
126612-17-7P 126612-19-9P 126612-21-3P
126612-23-5P 126612-25-7P 126612-26-8P
126612-27-9P 126612-28-0P 126612-29-1P
126612-30-4P 126612-31-5P 126612-32-6P
126612-33-7P 126612-35-9P 126612-37-1P

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

126612-38-2P 126612-39-3P 126612-40-6P
126612-41-7P 126612-42-8P 126612-43-9P
126612-44-0P 126612-45-1P 126612-46-2P
126612-47-3P 126612-48-4P 126612-49-5P
126612-50-8P 126612-51-9P 126612-52-0P
126612-53-1P 126612-54-2P 126612-55-3P
126612-56-4P 126612-57-5P 126612-58-6P
126612-59-7P 126612-60-0P 126612-61-1P
126612-62-2P 126612-63-3P 126612-64-4P
126612-65-5P 126612-66-6P 126612-67-7P
126612-68-8P 126612-69-9P 126612-70-2P
126612-71-3P 126612-72-4P 126612-73-5P
126612-74-6P 126612-77-9P 126612-78-0P
126612-80-4P 126612-81-5P 126612-82-6P
126612-83-7P 126612-84-8P 126612-85-9P
126612-86-0P 126613-69-2P 126613-70-5P
126613-71-6P 126637-51-2P 126637-52-3P
126637-53-4P 126637-54-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as antitumor agent)

RN 126493-36-5 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5-fluoro-2-benzothiazolyl)-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 126610-96-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-5-methyl-N-(5-nitro-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126610-97-7 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-methyl-2-benzothiazolyl)-5-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126610-98-8 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-fluoro-2-benzothiazolyl)-5-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126610-99-9 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-[6-(1-methylethyl)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-00-5 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-cyano-4-ethyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-05-0 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-(6-nitro-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-06-1 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-(6-chloro-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-07-2 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-(6-methoxy-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-08-3 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-(6-ethoxy-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-09-4 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-(5,6-dimethyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-10-7 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-(6-methyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-11-8 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-2-benzothiazolyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-12-9 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-(4-methoxy-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-13-0 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-(6-bromo-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-14-1 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[4-[(aminoiminomethyl)amino]benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-15-2 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-[6-(trifluoromethyl)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-16-3 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-(4-methoxy-6-nitro-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-17-4 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-[6-(methylthio)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-18-5 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-[6-(aminosulfonyl)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-19-6 CAPLUS
CN Benzamide, N-(6-amino-2-benzothiazolyl)-4-[(aminoiminomethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-20-9 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-[6-(methylsulfonyl)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-21-0 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-(6-cyano-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-22-1 CAPLUS
CN 5-Benzothiazolecarboxamide, 2-[[4-[(aminoiminomethyl)amino]benzoyl]amino]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-23-2 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-(6-phenyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-24-3 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-(6-butyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-25-4 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-[6-(methylsulfinyl)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-26-5 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-[4-(trifluoromethyl)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-27-6 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-(4-methyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-28-7 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-[6-(2-hydroxyethyl)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-29-8 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-(7-chloro-4-methoxy-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-30-1 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-(4-nitro-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-31-2 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-(5-fluoro-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-32-3 CAPLUS
CN Benzamide, 4-[(aminoiminomethyl)amino]-N-(5,6-difluoro-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-35-6 CAPLUS
CN Benzamide, 4-[[(aminoiminomethyl)amino]methyl]-N-(6-nitro-2-benzothiazolyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 126611-34-5
CMF C16 H14 N6 O3 S

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 126611-36-7 CAPLUS
CN Benzamide, 4-[[(aminoiminomethyl)amino]methyl]-N-(6-nitro-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-37-8 CAPLUS
CN Benzamide, 4-[[(aminoiminomethyl)amino]methyl]-N-(4-methoxy-6-nitro-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-38-9 CAPLUS
CN Benzamide, 4-[[(aminoiminomethyl)amino]methyl]-N-[6-(trifluoromethyl)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-39-0 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[4-[[(aminoiminomethyl)amino]methyl]benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-40-3 CAPLUS
CN Benzamide, 3-[[(aminoiminomethyl)amino]methyl]-N-(6-phenyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-41-4 CAPLUS
CN Benzamide, 3-[[(aminoiminomethyl)amino]methyl]-N-(6-nitro-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-42-5 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5-chloro-6-methyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 126611-43-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5-fluoro-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 126611-44-7 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-[6-(trifluoromethyl)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-45-8 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-nitro-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-46-9 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(4-methoxy-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-47-0 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-chloro-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-48-1 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-2-benzothiazolyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-49-2 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-fluoro-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-50-5 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-methoxy-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-51-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-cyano-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-52-7 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(4-methyl-2-benzothiazolyl)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 126611-53-8 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-[4-(trifluoromethyl)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-54-9 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-ethyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-55-0 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-[5-(methylthio)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-56-1 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(4-methoxy-6-nitro-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-57-2 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5-methoxy-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-58-3 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-phenyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-59-4 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-butoxy-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-60-7 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(4,6-dimethyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-61-8 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5,6-dimethyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-62-9 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5-nitro-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-63-0 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-[4-(1-methylethyl)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-64-1 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-[4-(methylthio)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-65-2 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5-phenyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-66-3 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5-butoxy-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-67-4 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-[5-(1-methylethoxy)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-68-5 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(7-phenyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-69-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-[6-(pentylthio)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-70-9 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-[6-(2-hydroxyethyl)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-71-0 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5-methoxy-4-methyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-75-4 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(7-fluoro-4-methyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-76-5 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(7-nitro-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-77-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5-ethoxy-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-72-1 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5-chloro-4-methyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-73-2 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-naphtho[2,1-d]thiazol-2-yl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-74-3 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-[6-(4-fluorophenyl)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-78-7 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5-fluoro-4-methyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-79-8 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-[6-(1,1-dimethylethyl)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-80-1 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(4,6-difluoro-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-81-2 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-propyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-82-3 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-methoxy-4-methyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-83-4 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-5-methyl-N-(4-nitro-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-84-5 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-cyano-2-benzothiazolyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 126611-85-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-cyano-2-benzothiazolyl)-5-methyl-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 126611-84-5
CMF C14 H11 N7 O S2



CM 2

CRN 75-75-2
CMF C H4 O3 S

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 126611-86-7 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(4-methoxy-2-benzothiazolyl)-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-87-8 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5-methoxy-2-benzothiazolyl)-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-88-9 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-2-benzothiazolyl-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-89-0 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-5-methyl-N-(6-methyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-90-3 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-5-methyl-N-(6-phenyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-91-4 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-fluoro-2-benzothiazolyl)-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-92-5 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-5-methyl-N-(4-methyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-93-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(4,6-dimethyl-2-benzothiazolyl)-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-94-7 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-5-ethyl-N-[6-(2-hydroxyethyl)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 126611-99-2 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-5-ethyl-N-(5-methoxy-2-benzothiazolyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 126611-98-1
CMF C15 H16 N6 O2 S2



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 126612-00-8 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-5-ethyl-N-(4-methoxy-2-

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126611-95-8 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-cyano-2-benzothiazolyl)-5-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126611-96-9 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-5-ethyl-N-(5-fluoro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 126611-97-0 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-5-ethyl-N-(5-fluoro-2-benzothiazolyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 126611-96-9
CMF C14 H13 F N6 O S2

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126612-01-9 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-2-benzothiazolyl-5-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126612-02-0 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-5-ethyl-N-(5-nitro-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126612-03-1 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(4,6-dimethyl-2-benzothiazolyl)-5-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126612-04-2 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-5-ethyl-N-(6-methyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126612-05-3 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5,7-difluoro-2-benzothiazolyl)-5-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126612-06-4 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-5-ethyl-N-(4-fluoro-7-methyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126612-08-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-5-ethyl-N-(4-fluoro-2-benzothiazolyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 126612-07-5
CMF C14 H13 F N6 O S2



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 126612-09-7 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-[6-(aminosulfonyl)-2-benzothiazolyl]-5-propyl-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126612-10-0 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[[2-[(aminoiminomethyl)amino]-5-propyl-4-thiazolyl]carbonyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126612-11-1 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5-fluoro-2-benzothiazolyl)-5-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126612-12-2 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-[6-(2-hydroxyethyl)-2-benzothiazolyl]-5-propyl-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126612-13-3 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5,7-difluoro-2-benzothiazolyl)-5-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126612-14-4 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5-methoxy-2-benzothiazolyl)-5-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126612-15-5 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(7-chloro-4-methoxy-2-benzothiazolyl)-5-propyl-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126612-16-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(4-methoxy-2-benzothiazolyl)-5-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126612-17-7 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-2-benzothiazolyl-5-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126612-19-9 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-5-(1-methylethyl)-N-[6-(trifluoromethyl)-2-benzothiazolyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 126612-23-5 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-[6-(2-hydroxyethyl)-2-benzothiazolyl]-5-(1-methylethyl)-, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 126612-22-4
CMF C17 H20 N6 O2 S2



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 126612-25-7 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[[2-[(aminoiminomethyl)amino]-5-(1-methylethyl)-4-thiazolyl]carbonyl]amino]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 126612-24-6
CMF C16 H17 N7 O2 S2

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 1

CRN 126612-18-8
CMF C16 H15 F3 N6 O S2



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 126612-21-3 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-5-(1-methylethyl)-N-(6-nitro-2-benzothiazolyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 126612-20-2
CMF C15 H15 N7 O3 S2



CM 2

CRN 75-75-2
CMF C H4 O3 S

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 126612-26-8 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5-methoxy-2-benzothiazolyl)-5-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 126612-27-9 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5-methoxy-2-benzothiazolyl)-5-(1-methylethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 126612-26-8
CMF C16 H18 N6 O2 S2



L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 126612-28-0 CAPLUS
CN 4-Thiazolecarboxamide,
2-[(aminoiminomethyl)amino]-N-[5-(dimethylamino)-2-benzothiazolyl]-5-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 126612-29-1 CAPLUS
CN 4-Thiazolecarboxamide,
2-[(aminoiminomethyl)amino]-N-[5-(dimethylamino)-2-benzothiazolyl]-5-(1-methylethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 126612-28-0
CMF C17 H21 N7 O S2



CM 2

CRN 75-75-2
CMF C H4 O3 S

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 126612-30-4 CAPLUS
CN 4-Thiazolecarboxamide,
2-[(aminoiminomethyl)amino]-5-(1-methylethyl)-N-(6-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 126612-31-5 CAPLUS
CN 4-Thiazolecarboxamide,
2-[(aminoiminomethyl)amino]-5-(1-methylethyl)-N-(6-phenyl-2-benzothiazolyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 126612-30-4
CMF C21 H20 N6 O S2



CM 2

CRN 75-75-2
CMF C H4 O3 S

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 126612-32-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(4-methoxy-2-benzothiazolyl)-5-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 126612-33-7 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(4-methoxy-2-benzothiazolyl)-5-(1-methylethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 126612-32-6
CMF C16 H18 N6 O2 S2



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 126612-35-9 CAPLUS
CN 4-Thiazolecarboxamide,
2-[(aminoiminomethyl)amino]-N-(7-chloro-4-methoxy-2-benzothiazolyl)-5-(1-methylethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 126612-34-8
CMF C16 H17 Cl N6 O2 S2

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 126612-37-1 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5-fluoro-2-benzothiazolyl)-5-(1-methylethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 126612-36-0
CMF C15 H15 F N6 O S2



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 126612-38-2 CAPLUS
CN 4-Thiazolecarboxamide,
2-[(aminoiminomethyl)amino]-N-2-benzothiazolyl-5-(1-

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126612-39-3 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(4,6-dimethyl-2-benzothiazolyl)-5-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126612-40-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-fluoro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 126612-41-7 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-methoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 126612-46-2 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-(1-methylethyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 126612-47-3 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5,6-dimethoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 126612-48-4 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(4-nitro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 126612-49-5 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-[4-(methylthio)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 126612-42-8 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(4-chloro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 126612-43-9 CAPLUS
CN 6-Benzothiazolecarboxamide, 2-[[[2-[(aminoiminomethyl)amino]-4-thiazolyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 126612-44-0 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-ethoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 126612-45-1 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-methyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 126612-50-8 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5-chloro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 126612-51-9 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-[7-(trifluoromethyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 126612-52-0 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5-fluoro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 126612-53-1 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5-(trifluoromethyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 126612-54-2 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(7-chloro-4-methoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 126612-55-3 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-[5-(methylsulfonyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 126612-56-4 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(4-fluoro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 126612-57-5 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-[6-(pentylsulfonyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 126612-58-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(4-ethyl-7-fluoro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 126612-59-7 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(7-chloro-4-ethyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 126612-60-0 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(7-fluoro-4-methoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 126612-61-1 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-fluoro-4-methyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 126612-62-2 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(4,7-difluoro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 126612-63-3 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-[6-(trifluoromethyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 126612-64-4 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-[4-methyl-6-(trifluoromethyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 126612-65-5 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-[4-methoxy-7-(trifluoromethyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 126612-66-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-hexyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 126612-67-7 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-5-methyl-N-(6-nitro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 126612-68-8 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-5-methyl-N-[6-(trifluoromethyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 126612-69-9 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-[6-(2-hydroxyethyl)-2-benzothiazolyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 126612-70-2 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-5-ethyl-N-[6-(trifluoromethyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 126612-71-3 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-5-ethyl-N-(6-nitro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 126612-72-4 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-5-propyl-N-[6-(trifluoromethyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 126612-78-0 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(2-aminoethyl)thio]-N-(5-fluoro-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126612-80-4 CAPLUS
CN 4-Thiazolecarboxamide, N-(6-cyano-2-benzothiazolyl)-2-[[2-(dimethylamino)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 126612-81-5 CAPLUS
CN 4-Thiazolecarboxamide, 2-[[2-(dimethylamino)ethyl]amino]-N-(6-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 126612-82-6 CAPLUS
CN 4-Thiazolecarboxamide, N-(5,6-dichloro-2-benzothiazolyl)-2-[[2-(dimethylamino)ethyl]amino]-5-ethyl- (9CI) (CA INDEX NAME)



RN 126612-83-7 CAPLUS
CN 4-Thiazolecarboxamide, N-(5,6-dichloro-2-benzothiazolyl)-2-[[3-(dimethylamino)propyl]amino]-5-ethyl- (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 126612-73-5 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-nitro-2-benzothiazolyl)-5-propyl- (9CI) (CA INDEX NAME)



RN 126612-74-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-5-ethyl-N-(4-methoxy-6-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 126612-77-9 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(2-aminoethyl)thio]-N-(6-phenyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 126612-84-8 CAPLUS
CN 4-Thiazolecarboxamide, N-(6-cyano-2-benzothiazolyl)-2-[[3-(dimethylamino)propyl]amino]-5-ethyl- (9CI) (CA INDEX NAME)



RN 126612-85-9 CAPLUS
CN 4-Thiazolecarboxamide, N-(6-cyano-2-benzothiazolyl)-2-[[2-(1-piperidinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 126612-86-0 CAPLUS
CN 4-Thiazolecarboxamide, 2-(aminomethyl)-N-(6-butyl-2-benzothiazolyl)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 126613-69-2 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-5-ethyl-N-(6-fluoro-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126613-70-5 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-cyano-2-benzothiazolyl)-5-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126613-71-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(6-phenyl-2-benzothiazolyl)-5-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126637-51-2 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(7-fluoro-6-methyl-2-benzothiazolyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

RN 126637-52-3 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5-fluoro-2-benzothiazolyl)-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 126637-53-4 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-(5,7-difluoro-4-methoxy-2-benzothiazolyl)-5-ethyl- (9CI) (CA INDEX NAME)



RN 126637-54-5 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(aminoiminomethyl)amino]-N-[6-chloro-7-(trifluoromethyl)-2-benzothiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl

IT **126612-87-1P 126637-55-6P 126637-57-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for (acylamino)benzothiazole antitumor agent)

RN 126612-87-1 CAPLUS
CN Carbamic acid, [2-[[4-[[(5-fluoro-2-benzothiazolyl)amino]carbonyl]-2-thiazolyl]thio]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 126637-55-6 CAPLUS
CN Carbamic acid, [2-[[4-[[(6-phenyl-2-benzothiazolyl)amino]carbonyl]-2-thiazolyl]thio]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 126637-57-8 CAPLUS
CN Carbamic acid, [[4-[[(6-butyl-2-benzothiazolyl)amino]carbonyl]-2-thiazolyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 118 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L7 ANSWER 119 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1990:129162 CAPLUS
DN 112:129162
TI Azo dye-containing electrophotographic photoconductors
IN Takaoka, Kazucho; Okaji, Makoto; Enomoto, Kazuhiro
PA Mitsubishi Paper Mills, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 19 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 01252966	A2	19891009	JP 1988-80053	19880331
<--					
PRAI	JP 1988-80053		19880331		

GI For diagram(s), see printed CA Issue.
AB Photosensitive layer of the photoconductors contain azo dyes I (X = divalent organic group; Z = carbocyclic or heterocyclic aromatic group; Cp = coupler group). These dyes provide excellent photoconductor performance, in combination with many charge-transporting materials. Thus, a photoconductor having an Al-coated polyester substrate, charge carrier-generating layer containing II and polyarylate, and a charge carrier-transporting layer containing 4-N,N-diphenylaminobenzaldehyde 1,1-diphenylhydrazone showed sensitivity (irradiation dose required for half decay of voltage) 1.20 and 0.98 μJ/cm2, at 500 and 600 nm, resp. Residual voltage was low before and after 100 repetitive copying using this photoconductor.
IT **125832-46-4**
RL: USES (Uses)
(charge carrier-generating agent, electrophotog. photoconductors containing)
RN 125832-46-4 CAPLUS
CN 2-Naphthalenecarboxamide, N-2-benzothiazolyl-4-[[4-[5-[[3-[(2-benzothiazolylamino)carbonyl]-2-hydroxy-1-naphthalenyl]azo]-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl]phenyl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 119 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L7 ANSWER 120 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1990:118796 CAPLUS
DN 112:118796
TI Pyrroloquinoline- and pyrrolophenothiazine, and pyrrolophenoxazinecarboxamides as inflammation inhibitors
IN Mylari, Banavara Lakshmana; McManus, James Michael; Lombardino, Joseph George
PA Pfizer Inc., USA
SO Eur. Pat. Appl., 25 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 332364	A2	19890913	EP 1989-302197	19890306
<--					
	EP 332364	A3	19910403		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	WO 8908654	A1	19890921	WO 1988-US781	19880311
<--					
	W: FI, HU, NO, US				
	HU 51619	A2	19900528	HU 1988-5829	19880311
<--					
	HU 201757	B	19901228		
	IL 89480	A1	19940412	IL 1989-89480	19890303
<--					
	ZA 8901800	A	19901031	ZA 1989-1800	19890309
<--					
	CA 1335592	A1	19950516	CA 1989-593185	19890309
<--					
	DK 8901166	A	19890912	DK 1989-1166	19890310
<--					
	DK 169723	B1	19950123		
	AU 8931204	A1	19890914	AU 1989-31204	19890310
<--					
	AU 605410	B2	19910110		
	JP 01275580	A2	19891106	JP 1989-59481	19890310
<--					
	JP 06076408	B4	19940928		
	NO 8904350	A	19891101	NO 1989-4350	19891101
<--					
	NO 170418	B	19920706		
	NO 170418	C	19921014		
	FI 96315	B	19960229	FI 1989-5333	19891109
<--					
	FI 96315	C	19960610		
	US 5403839	A	19950404	US 1989-438469	19891113
<--					
	US 5624929	A	19970429	US 1995-445629	19950522
<--					
PRAI	WO 1988-US781	A	19880311		
	US 1989-438469	A3	19891113		
	US 1994-357615	B3	19941214		

OS CASREACT 112:118796; MARPAT 112:118796
GI For diagram(s), see printed CA Issue.
AB Title compds. I [X = O, S, CH2, (CH2)2; R1 = H, halo, alkoxy, alkanoyl, alkyl, CF3; R2 = (substituted) Ph, (substituted) heterocyclyl; R3, R4 = H, halo, alkyl, CF3; R3R4 = group to form (substituted) carbocyclic aromatic ring] are prepared I are useful for treating inflammation or other

L7 ANSWER 120 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
prostaglandin or leukotriene mediated diseases, e.g. arthritis, allergy, bronchitis, pulmonary hypertension, pulmonary hypoxia, peptic ulcers, inflammatory bowel disease, cardiovascular spasm, psoriasis, and asthma (no data). A pyrrolophenothiazinone II (R = H) in DMF was successively treated with NaH and 2,4-F2C6H3NCO to give II (R = 2,4-F2C6H3NHCO).
IT **125578-71-4P 125578-77-0P 125579-00-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for treating inflammation and prostaglandin or eukotriene mediated diseases)
RN 125578-71-4 CAPLUS
CN Indolo[1,7-ab][1]benzazepine-2-carboxamide, N-2-benzothiazolyl-1,2,6,7-tetrahydro-1-oxo- (9CI) (CA INDEX NAME)



RN 125578-77-0 CAPLUS
CN Pyrrolo[1,2,3-de]-1,4-benzoxazine-6-carboxamide, N-2-benzothiazolyl-2,3,5,6-tetrahydro-3,8-dimethyl-5-oxo- (9CI) (CA INDEX NAME)



RN 125579-00-2 CAPLUS
CN 4H-Pyrrolo[3,2,1-ij]quinoline-1-carboxamide, N-2-benzothiazolyl-1,2,5,6-tetrahydro-8-methyl-2-oxo- (9CI) (CA INDEX NAME)



L7 ANSWER 121 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1990:108504 CAPLUS
DN 112:108504
TI Electrophotographic photoconductor layer containing bisazo compound as charge-generating substance
IN Suzuki, Shinichi; Fukawa, Hiroko; Shibata, Toyoko; Takagi, Takahiro; Sasaki, Osamu
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 01179160	A2	19890717	JP 1988-2041	19880108
<--					
PRAI	JP 1988-2041		19880108		

GI



I

AB The photoconductor layer on an elec. conductive support contains a bisazo compound I (Cp = coupler residue; X1 = H, CN, halo; and X2 = NH, O, S) as a charge-generating substance.
IT 125502-11-6
RL: USES (Uses)
(charge-generating substance, electrophotog. photoconductor layer from)
RN 125502-11-6 CAPLUS
CN 2-Naphthalenecarboxamide, 3-hydroxy-4-[[4-[5-[4-[2-[4-[[2-hydroxy-3-[[(6-nitro-2-benzothiazolyl)amino]carbonyl]-1-naphthalenyl]azo]phenyl]ethenyl]phenyl]-1,3,4-oxadiazol-2-yl]phenyl]azo]-N-(6-nitro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 121 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



L7 ANSWER 121 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



PAGE 3-A

L7 ANSWER 122 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1990:79427 CAPLUS
DN 112:79427
TI Water-insoluble disazo dyes for polymers and coatings
IN Jung, Ruediger; Deubel, Reinhold
PA Hoechst A.-G., Fed. Rep. Ger.
SO Ger. Offen., 9 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3738542	A1	19890524	DE 1987-3738542	19871113
<--					
	EP 316649	A2	19890524	EP 1988-118181	19881102
<--					
	EP 316649	A3	19891102		
	EP 316649	B1	19920722		
	R: CH, DE, FR, GB, IT, LI				
	US 5026831	A	19910625	US 1988-269565	19881110
<--					
	DK 8806314	A	19890514	DK 1988-6314	19881111
<--					
	DK 167933	B1	19940103		
	JP 01165668	A2	19890629	JP 1988-284055	19881111
<--					
PRAI	DE 1987-3738542	A	19871113		

GI



I

AB The title dyes I [E1, E2 = (un)substituted aryl], useful for polymers, lacquers, and printing inks, are prepared by coupling diazotized arylamines with 1,5-diazabicyclo[3.3.0]octane-2,4,6,8-tetrone (II) (1:0.5 mol ratio, resp.) in the presence of an anionic or nonionic surfactant. 3-Amino-4-chlorobenzamide was diazotized and coupled with II in the presence of a 10% aqueous solution of polyethylene glycol oleyl ester, producing I (E1 = E2 = 2,5-Cl(H2NCO)C6H4) (no color data), which was used to color an alkyd-melamine resin lacquer.
IT 124282-55-9
RL: USES (Uses)
(coupling of diazotized, with diazabicyclooctanetetrone)
RN 124282-55-9 CAPLUS
CN Benzamide, 4-amino-N-(6-chloro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 122 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 124308-35-6P
RL: PREP (Preparation)
(manufacture of, as water-insol. dyes for polymers and coating materials)
RN 124308-35-6 CAPLUS
CN Benzamide, 4,4'-[(tetrahydro-1,3,5,7-tetraoxo-1H,5H-pyrazolo[1,2-a]pyrazole-2,6-diyl)bis(azo)]bis[N-(6-chloro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L7 ANSWER 123 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:553648 CAPLUS
DN 111:153648
TI Phenoxynicotinamide derivatives as herbicides
IN Tanyama, Eiji; Ogasawara, Yoko; Sugaya, Kyoshi
PA Mitsubishi Petrochemical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 01113369	A2	19890502	JP 1987-267383	19871023
<--				
PRAI JP 1987-267383		19871023		

OS MARPAT 111:153648
GI



I

AB The title derivs. I (R = H, halo, lower alkyl; R1 = H, lower alkyl; X = H, halo, lower alkyl, haloalkyl, NO2, cyano; Q = N-containing heterocyclic group) are prepared A suspension of KH in THF was stirred with 2-amino-5-trifluoromethylpyridine, then the suspension was treated with 2-(3'-trifluoromethylphenoxy)nicotinoyl chloride to give 21% 2-(3'-trifluoromethylphenoxy)-N-(5-trifluoromethyl-2-pyridyl)nicotinamide, which gave 100% control of Scirpus juncoides, Monochoria vaginalis, and Rotala indica at 1 kg/ha in pot expts. without any damage to rice.
IT 122928-16-9P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as herbicide)
RN 122928-16-9 CAPLUS
CN 3-Pyridinecarboxamide, N-2-benzothiazolyl-2-[3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)

L7 ANSWER 123 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 85678-85-9
RL: PROC (Process)
(substitution of, with trifluoromethylphenol)
RN 85678-85-9 CAPLUS
CN 3-Pyridinecarboxamide, N-2-benzothiazolyl-2-chloro- (9CI) (CA INDEX NAME)



L7 ANSWER 124 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:523804 CAPLUS
DN 111:123804
TI Electrophotographic photoreceptors containing vinylidenediamines as charge carrier-transporting agents.
IN Sano, Kenji; Hirao, Akiko
PA Toshiba Corp., Japan
SO Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 01088460	A2	19890403	JP 1987-245416	19870929
<--				
PRAI JP 1987-245416		19870929		

GI



I

AB Compds. R1R2C:C(NR3R4)2 (R1-2 = H, alkyl, allyl, aralkyl, aryl; R3-4 = alkyl, allyl, aralkyl, aryl) are contained in the electrophotog. photoconductors, as charge carrier-transporting agents. Bisazo compds. and phthalocyanines are the typical charge carrier-generating agents. Thus, a single-layer photoconductor with a layer containing 6 parts PhMeC:C(NMe2)2, bisazo dye I 4 parts, and polyester binder showed 90% retention of voltage 5 s after charging, and sensitivity (irradiation dose required for half-decay of voltage) 1.1 lx-s.
IT 101702-95-8 122655-21-4
RL: USES (Uses)
(as charge carrier-generating agent in electrophotog. photoconductors containing vinylidenediamines as charge transporting agents)
RN 101702-95-8 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-2-benzothiazolyl-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 124 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 122655-21-4 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-2-benzothiazolyl- (9CI) (CA INDEX NAME)

L7 ANSWER 124 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L7 ANSWER 125 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1989:515023 CAPLUS
DN 111:115023
TI Pyrrole derivatives as cardiotonics, process for their preparation and pharmaceutical compositions containing them
IN Dixon, John; Baxter, Andrew John Gilby; Manners, Carol Nancy; Teague, Simon
PA Fisons PLC, UK
SO Eur. Pat. Appl., 69 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 300688 <--	A1	19890125	EP 1988-306464	19880714
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DK 8804049 <--	A	19890122	DK 1988-4049	19880720
JP 01061455 <--	A2	19890308	JP 1988-179286	19880720
PRAI GB 1987-17193	A	19870721		
GB 1987-30116	A	19871224		

OS MARPAT 111:115023
GI For diagram(s), see printed CA Issue.
AB Title compds. I [R1 = R11, NHR11, NHCO2R11 wherein R11 = H, C1-6 alkyl; R2, R5 = OH, halo, NO2, etc.; G = (CH2)zWy in which W = CO, SOq, etc.; q = 0-2; z = 0-3; y = 0 or 1 (or 2 provided W = CO); up to 2 of the methylene segments in the chain (CH2)z are optionally replaced by NH and one segment is optionally replaced by O, etc.; the chain is optionally unsatd. and optionally substituted by C1-6 alkyl, alkoxy, etc.; A = (substituted) 5- or 6-membered ring or a bicyclic or tricyclic fused ring system; R3 = H, NO2, CN, halo, etc.; several provisos are given], useful as cardiotonics (no data), were prepared A mixture of 2-({4-nitrophenyl)thio)benzoyl chloride, Me 2,5-dimethyl-1H-pyrrole-3-carboxylate, and AlCl3 in CH2Cl2 was stirred at room temperature for 16 h to give Me 2,5-dimethyl-4-(2-({4-nitrophenyl)thio)benzoyl)-1H-pyrrole-3-carboxylate.
IT **120935-04-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as cardiotonic)
RN 120935-04-8 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 4-[(2-benzothiazolylamino)carbonyl]-2,5-dimethyl-, methyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 125 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 126 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:407392 CAPLUS
DN 111:7392
TI Preparation of N-(2-benzothiazolyl)- and N-(2-benzoxazolyl)benzamides as pesticides
IN Kume, Toyohiko; Tsuboi, Shinichi; Isono, Kunihiro; Sasaki, Shoko; Hattori, Yumi
PA Nihon Tokushu Noyaku Seizo K. K., Japan
SO Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 196547	A1	19861008	EP 1986-103686	19860318
<--	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
	JP 61225168	A2	19861006	JP 1985-65018	19850330
<--					
	US 4675331	A	19870623	US 1986-843888	19860325
<--					
	DK 8601431	A	19861001	DK 1986-1431	19860326
<--					
	BR 8601372	A	19861202	BR 1986-1372	19860326
<--					
	ES 553447	A1	19870601	ES 1986-553447	19860326
<--					
	AU 8655331	A1	19861002	AU 1986-55331	19860327
<--					
	ZA 8602323	A	19861126	ZA 1986-2323	19860327
<--					
	DD 244058	A5	19870325	DD 1986-288443	19860327
<--					
	CN 86102102	A	19870107	CN 1986-102102	19860328
<--					
	HU 41229	A2	19870428	HU 1986-1320	19860328
<--					
PRAI	JP 1985-65018	A	19850330		

OS CASREACT 111:7392
GI



I

AB The title compds. (I; R = haloalkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl; X = halo, alkyl, alkoxy, haloalkyl; Y = halo, alkyl; Z = O,

L7 ANSWER 126 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 110428-27-8 CAPLUS
CN Benzamide, 2-chloro-N-[6-(trifluoromethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 110428-29-0 CAPLUS
CN Benzamide, 2,6-difluoro-N-[6-(1,1,2,2-tetrafluoroethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 110428-30-3 CAPLUS
CN Benzamide, 2,6-difluoro-N-[6-(1,1,2,3,3,3-hexafluoropropoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 110428-31-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[6-[(trifluoromethyl)thio]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 121000-62-2 CAPLUS
CN Benzamide, 2-chloro-6-fluoro-N-[6-(trifluoromethyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 126 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
S; n = 0-2), useful as pesticides, esp. insecticides, were prepd. Thus, 2,6-F2C6H3COCl was added dropwise to a soln. of 2-amino-(6-trifluoromethyl)benzothiazole and Et3N in THF at 0-5°. The mixt. was stirred 5 h at 30-40° to give 2,6-difluoro-N-[6-(trifluoromethyl)-2-benzothiazolyl]benzamide. At 10 ppm the latter gave 100% kill of Plutella maculipennis larvae.
IT 110428-23-4P 110428-24-5P 110428-25-6P
110428-27-8P 110428-29-0P 110428-30-3P
110428-31-4P 121000-62-2P 121000-63-3P
121000-64-4P 121000-65-5P 121000-66-6P
121000-67-7P 121000-68-8P 121000-69-9P
121000-70-2P 121000-71-3P 121000-72-4P
121000-73-5P 121000-74-6P 121000-75-7P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as insecticide)
RN 110428-23-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[6-(trifluoromethyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 110428-24-5 CAPLUS
CN Benzamide, 2,6-difluoro-N-[6-(trifluoromethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 110428-25-6 CAPLUS
CN Benzamide, 2-chloro-N-[6-(trifluoromethyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 126 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 121000-63-3 CAPLUS
CN Benzamide, 2,6-difluoro-N-[4-(trifluoromethyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 121000-64-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[5-(trifluoromethyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 121000-65-5 CAPLUS
CN Benzamide, 2-chloro-N-[6-[(trifluoromethyl)thio]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 121000-66-6 CAPLUS
CN Benzamide, 2,6-difluoro-N-[6-[(trifluoromethyl)sulfinyl]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 126 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 121000-67-7 CAPLUS
CN Benzamide, 2,6-difluoro-N-[6-[(2,2,2-trifluoroethyl)thio]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 121000-68-8 CAPLUS
CN Benzamide, N-[6-(difluoromethoxy)-2-benzothiazolyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 121000-69-9 CAPLUS
CN Benzamide, 2-methyl-N-[6-(trifluoromethyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 121000-70-2 CAPLUS
CN Benzamide, 2-fluoro-N-[6-(trifluoromethyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 126 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 121000-75-7 CAPLUS
CN Benzamide, 2-chloro-N-[6-(1,1,2,3,3,3-hexafluoropropoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 126 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 121000-71-3 CAPLUS
CN Benzamide, 2,4-dichloro-N-[6-(trifluoromethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 121000-72-4 CAPLUS
CN Benzamide, 2-methoxy-N-[6-(trifluoromethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 121000-73-5 CAPLUS
CN Benzamide, 2-bromo-N-[6-(trifluoromethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 121000-74-6 CAPLUS
CN Benzamide, N-[6-(trifluoromethoxy)-2-benzothiazolyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 127 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:222587 CAPLUS
DN 110:222587
TI Positively charged laminated electrophotographic photoconductor with charge-generating layer containing disazo compound
IN Hirao, Akiko; Sano, Kenji
PA Toshiba Corp., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 63301047	A2	19881208	JP 1987-136306	19870530

<--
PRAI JP 1987-136306 19870530
OS MARPAT 110:222587
GI For diagram(s), see printed CA Issue.
AB The photoreceptor consists of an elec. conductive substrate coated successively with a charge-transporting layer and a charge-generating layer containing a charge-generating material of TN:NXN:NZ [I; X = divalent organic group forming conjugated system with azo-bonding two carbon atoms; T, Z = II, III, IV; A = group forming (un)substituted hydrocarbon or heterocyclic ring; E = (un)substituted hydrocarbon or heterocyclic ring; G = phenylenediamines residue; J = halo; m = 0-4] and a charge-transporting material R1CH:NNPhR2 (V; R1 = substituted aromatic ring; R2 = Ph, Me, Et). Al plate was coated with a charge-transporting layer containing 8-ethylcarbazole-3-carboxyaldehydephenylmethylhydrazone (VI) and a charge-generating layer containing VI and VII plate to give an electrophotog. plate showing excellent photosensitivity, charging properties, and no white point on a black image.
IT 120531-93-3 120531-97-7 120531-99-9
RL: USES (Uses)
(electrophotog. plate charge-generating layer using)
RN 120531-93-3 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4-[[4'-[[3-[(2-benzothiazolylamino)carbonyl]-2-hydroxy-1-naphthalenyl]azo]-3-methyl[1,1'-biphenyl]-4-yl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 127 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 120531-97-7 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(3-methyl[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-2-benzothiazolyl-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 127 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 120531-99-9 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4-[[4'-[[3-[(2-benzothiazolylamino)carbonyl]-2-hydroxy-1-naphthalenyl]azo]-3'-methyl[1,1'-biphenyl]-4-yl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 127 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L7 ANSWER 128 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:222586 CAPLUS
DN 110:222586
TI Positively charged electrophotographic photoreceptor with charge-generating material from disazo compound
IN Sano, Kenji; Hirao, Akiko
PA Toshiba Corp., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 63301046	A2	19881208	JP 1987-136304	19870530

<--
PRAI JP 1987-136304 19870530
OS MARPAT 110:222586
GI For diagram(s), see printed CA Issue.
AB The photoreceptor consists of an elec. conductive substrate coated with a photoreceptor layer containing an charge-generating material comprising TN:NXN:NZ [I; X = divalent organic group forming conjugated system with azo-bonding two carbon atoms; T, Z = II, III, IV; A = group forming (un)substituted hydrocarbon or heterocyclic ring; E = (un)substituted hydrocarbon or heterocyclic ring; G = phenylenediamines residue; J = halo; m = 0-4] and a charge-transporting material R1CH:NNPhR2(V; R1 = substituted aromatic ring; R2 = Ph, Me, Et). A photoreceptor using VI as a charge-generating material and VII as a charge-transporting material was applied on an Al plate to give an electrophotog. plate showing excellent photosensitivity and charging properties.
IT 120482-10-2 120482-13-5 120693-10-9 120693-11-0 120693-12-1
RL: USES (Uses)
(electrophotog. plate charge-generating layer using)
RN 120482-10-2 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4-[[2,2'-dichloro-4'-[[3-[[(6-ethoxy-2-benzothiazolyl)amino]carbonyl]-2-hydroxy-1-naphthalenyl]azo][1,1'-biphenyl]-4-yl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 128 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 120482-13-5 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(2,2'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-(6-ethoxy-2-benzothiazolyl)-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 128 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 120693-10-9 CAPLUS
CN 2-Naphthalenecarboxamide, 4-[[2,2'-dibromo-4'-[[3-[[(6-ethoxy-2-benzothiazolyl)amino]carbonyl]-2-hydroxy-1-naphthalenyl]azo][1,1'-biphenyl]-4-yl]azo]-3-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)

L7 ANSWER 128 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 120693-11-0 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4-[[2,2'-dibromo-4'-[[3-[[(6-ethoxy-2-benzothiazolyl)amino]carbonyl]-2-hydroxy-1-naphthalenyl]azo][1,1'-biphenyl]-4-yl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 128 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 120693-12-1 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(2,2'-dibromo[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-(6-ethoxy-2-benzothiazolyl)-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 128 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L7 ANSWER 129 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1989:222585 CAPLUS

DN 110:222585

TI Positively charged electrophotographic photoconductor with charge generating layer containing disazo compound

IN Hirao, Akiko; Sano, Kenji

PA Toshiba Corp., Japan

SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 63301045	A2	19881208	JP 1987-136303	19870530
<--					
PRAI	JP 1987-136303		19870530		

OS MARPAT 110:222585

GI For diagram(s), see printed CA Issue.

AB The photoreceptor consists of an elec. conductive substrate coated with a photoreceptor layer containing a charge-generating material comprising TN:NXN:NZ [I; X = divalent organic group forming conjugated system with azo-bonding two carbon atoms; T, Z = II, III, IV; A = group forming (un)substituted hydrocarbon or heterocyclic ring; E = (un)substituted hydrocarbon or heterocyclic ring; G = phenylenediamines residue; J = halo; m = 0-4]; and a charge-transporting material from V (R1 = H, alkyl, aryl, aralkyl, allyl, vinyl; R2 = alkyl, aralkyl; R3 = alkyl), VI, R4CH:CR5R6 (R4 = substituted aromatic ring; R5 = aromatic ring containing ≥1 alkylamino; R6 = H, benzene ring, substituted Ph, heterocyclic ring), or VII. A photoreceptor using VIII as a charge-generating material and PhCH:C(4-C6H4NMe2)2 as a charge-transporting material was applied on an Al plate to give an electrophotog. plate showing excellent photosensitivity and charging properties.

IT **120482-10-2 120482-13-5 120693-10-9 120693-11-0 120693-12-1**
RL: USES (Uses)
(electrophotog. plate charge-generating layer using)

RN 120482-10-2 CAPLUS

CN 2-Naphthalenecarboxylic acid, 4-[[2,2'-dichloro-4'-[[3-[[(6-ethoxy-2-benzothiazolyl)amino]carbonyl]-2-hydroxy-1-naphthalenyl]azo][1,1'-biphenyl]-4-yl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 129 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 120482-13-5 CAPLUS

CN 2-Naphthalenecarboxamide, 4,4'-[(2,2'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-(6-ethoxy-2-benzothiazolyl)-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 129 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 120693-10-9 CAPLUS

CN 2-Naphthalenecarboxamide, 4-[[2,2'-dibromo-4'-[[3-[[(6-ethoxy-2-benzothiazolyl)amino]carbonyl]-2-hydroxy-1-naphthalenyl]azo][1,1'-biphenyl]-4-yl]azo]-3-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)

L7 ANSWER 129 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 120693-11-0 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4-[[2,2'-dibromo-4'-[[3-[[(6-ethoxy-2-benzothiazolyl)amino]carbonyl]-2-hydroxy-1-naphthalenyl]azo][1,1'-biphenyl]-4-yl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 129 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 120693-12-1 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(2,2'-dibromo[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-(6-ethoxy-2-benzothiazolyl)-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 129 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L7 ANSWER 130 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:222534 CAPLUS
DN 110:222534
TI Electrophotographic photoreceptor containing azo pigment
IN Enomoto, Kazuhiro
PA Mitsubishi Paper Mills, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 63168655	A2	19880712	JP 1987-1404	19870106
<--					
PRAI	JP 1987-1404		19870106		

GI



I



II

AB A photosensitive layer of the title electrophotog. photoreceptor contains an azo pigment I or II (Coup = coupler moiety). Preferably, the photosensitive layer contains a charge carrier-generating substance represented by I or II and a charge carrier-transporting substance. The maximum light absorption is observed in 650-780 nm. This electrophotog. photoreceptor has high thermal and light stability and high charge-generating capability.

IT 120508-48-7 120531-46-6
RL: USES (Uses)
(electrophotog. charge-generating pigment)

RN 120508-48-7 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[[[4-[[3-[[(5-chloro-2-benzothiazolyl)amino]carbonyl]-2-hydroxy-1-naphthalenyl]azo]-1-naphthalenyl]imino]bis(methylene-4,1-phenyleneazo)]bis[N-(5-chloro-2-benzothiazolyl)-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 130 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

L7 ANSWER 130 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



L7 ANSWER 130 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 120531-46-6 CAPLUS
CN 11H-Benzo[a]carbazole-3-carboxamide, N-2-benzothiazolyl-1-[[4-[bis[[4-[[3-[(2-benzothiazolylamino)carbonyl]-2-hydroxy-1-naphthalenyl]azo]phenyl]methyl]amino]-1-naphthalenyl]azo]-2-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A



L7 ANSWER 131 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:202852 CAPLUS
DN 110:202852
TI Positively-charged laminated electrophotographic photoreceptor
IN Sano, Kenji; Hirao, Akiko
PA Toshiba Corp., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 63309962 <--	A2	19881219	JP 1987-144068	19870611
PRAI JP 1987-144068		19870611		

OS MARPAT 110:202852
GI For diagram(s), see printed CA Issue.
AB The photoreceptor consists of an elec. conductive substrate coated successively with a layer containing a binder resin and a charge-transporting material and a charge-generating layer containing a charge-generating material of TN:NXN:NZ [X = biphenyl derivative; T, Z = I, II, III; A = group forming (un)substituted hydrocarbon ring or heterocycle; E = substituted benzene ring with N at p position, (un)substituted heterocycle; G = phenylenediamines residue; J = halo; m = 0-4] and a charge-transporting material.
IT 120482-10-2 120482-13-5
RL: USES (Uses)
(electrophotog. plate charge-generating layer using)
RN 120482-10-2 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4-[[2,2'-dichloro-4'-[[3-[[(6-ethoxy-2-benzothiazolyl)amino]carbonyl]-2-hydroxy-1-naphthalenyl]azo][1,1'-biphenyl]-4-yl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 131 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 120482-13-5 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(2,2'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-(6-ethoxy-2-benzothiazolyl)-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 131 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L7 ANSWER 132 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1989:202849 CAPLUS
DN 110:202849
TI Positively charged laminated electrophotographic photoreceptor
IN Hirao, Akiko; Sano, Kenji
PA Toshiba Corp., Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 63301048	A2	19881208	JP 1987-136307	19870530

<--
PRAI JP 1987-136307 19870530
OS MARPAT 110:202849
GI For diagram(s), see printed CA Issue.
AB The photoreceptor consists of an elec. conductive substrate coated successively with a charge-transporting layer and a charge-generating layer containing a charge-generating material of TN:NXN:NZ [I; X = divalent organic group forming conjugated system with azo-bonding 2 C atoms; T, Z = II, III, IV; A = group forming (un)substituted hydrocarbon or heterocyclic ring; E = (un)substituted hydrocarbon or heterocyclic ring; G = phenylenediamines residue; J = halo; m = 0-4] and a charge-transporting material. Al plate was coated with a charge-transporting layer containing 9-ethylcarbazole-3-carboxyaldehydephenylmethylhydrazone and a charge-generating layer containing V and PhCH:C(4-C6H4NMe2)2 to give an electrophotog. plate showing excellent photosensitivity, charging properties, and no white dots on a black image.
IT 120482-10-2 120482-13-5 120531-93-3
120531-97-7 120531-99-9
RL: USES (Uses)
(electrophotog. plate charge-generating layer using)
RN 120482-10-2 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4-[[2,2'-dichloro-4'-[[3-[[(6-ethoxy-2-benzothiazolyl)amino]carbonyl]-2-hydroxy-1-naphthalenyl]azo][1,1'-biphenyl]-4-yl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 132 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 120482-13-5 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(2,2'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-(6-ethoxy-2-benzothiazolyl)-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 132 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 120531-93-3 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4-[[4'-[[3-[(2-benzothiazolylamino)carbonyl]-2-hydroxy-1-naphthalenyl]azo]-3-methyl[1,1'-biphenyl]-4-yl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 132 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 120531-97-7 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(3-methyl[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-2-benzothiazolyl-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 132 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 120531-99-9 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4-[[4'-[[3-[(2-benzothiazolylamino)carbonyl]-2-hydroxy-1-naphthalenyl]azo]-3'-methyl[1,1'-biphenyl]-4-yl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 132 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L7 ANSWER 133 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1989:192808 CAPLUS

DN 110:192808

TI Preparation of 2-amino-6-hydroxybenzothiazoles and analogs as antiasthmatic agents

IN Abe, Shinya; Miyamoto, Mitsuaki; Tanaka, Masayuki; Akasaka, Kozo; Hayashi, Kenji; Kawahara, Tetsuya; Katayama, Toshi; Sakuma, Yoshinori; Suzuki, Takeshi; Yamatsu, Isao

PA Eisai Co., Ltd., Japan

SO Eur. Pat. Appl., 66 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 295656	A1	19881221	EP 1988-109552	19880615
<--					
	EP 295656	B1	19921111		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	FI 8802692	A	19881218	FI 1988-2692	19880607
<--					
	FI 91859	B	19940513		
	FI 91859	C	19940825		
	NO 8802627	A	19881219	NO 1988-2627	19880615
<--					
	NO 170929	B	19920921		
	NO 170929	C	19930106		
	JP 01079162	A2	19890324	JP 1988-147141	19880615
<--					
	JP 2793195	B2	19980903		
	ZA 8804277	A	19890329	ZA 1988-4277	19880615
<--					
	AT 82276	E	19921115	AT 1988-109552	19880615
<--					
	CA 1322369	A1	19930921	CA 1988-569598	19880615
<--					
	ES 2045017	T3	19940116	ES 1988-109552	19880615
<--					
	DK 8803288	A	19881218	DK 1988-3288	19880616
<--					
	AU 8817699	A1	19881222	AU 1988-17699	19880616
<--					
	AU 610186	B2	19910516		
	HU 47554	A2	19890328	HU 1988-3098	19880616
<--					
	HU 205347	B	19920428		
	US 4929623	A	19900529	US 1988-207329	19880616
<--					
	DD 282686	A5	19900919	DD 1988-316839	19880616
<--					
	SU 1731051	A3	19920430	SU 1988-4356028	19880616
<--					
	CN 1030757	A	19890201	CN 1988-103660	19880617
<--					
PRAI	JP 1987-150987	A	19870617		

L7 ANSWER 133 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

EP 1988-109552 A 19880615

OS CASREACT 110:192808; MARPAT 110:192808

GI



I



II

AB The title compds. [I; R1, R3, R4 = H, alkyl, halo, etc.; or 2 of R1, R3, R4 = atoms to complete a fused aryl or heteroaryl group; R2 = H, acyl, (un)substituted CONH2; R5, R6 = H, alkyl, (un)substituted Ph, etc.] were prepared 2,3,5,4-Me3(MeO)C6HNH2 was stirred with KSCN and Br in HOAc to give benzothiazole II (R2 = Me, R5 = H) which was stirred 1 h with 4-(H2NO2S)C6H4COCl (preparation given) in (MeOCH2)2 containing pyridine to give II [R2 = Me, R5 = 4-(H2NO2S)C6H4CO]. The latter was refluxed 40 min with LiAlH4 in THF and the product refluxed 30 min with BBr3 in CH2Cl2 to give II [R2 = H, R5 = 4-(H2NO2S)C6H4CH2]. II (R2 = H, R5 = CH2CHMe2) gave 95% inhibition of leukotriene C4 synthesis in vitro at 3 μM.

IT **120165-54-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of antiasthmatic agents)

RN 120165-54-0 CAPLUS

CN Benzamide, 4-(aminosulfonyl)-N-(6-methoxy-4,5,7-trimethyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



IT **120164-63-8P 120164-64-9P 120164-66-1P 120164-67-2P 120164-68-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiasthmatic agent)

RN 120164-63-8 CAPLUS

CN 3-Pyridinecarboxamide, N-(6-hydroxy-4,5,7-trimethyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 133 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 120164-64-9 CAPLUS

CN Cyclohexanecarboxamide, N-(6-hydroxy-4,5,7-trimethyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 120164-66-1 CAPLUS

CN Benzamide, N-(6-hydroxy-4,5,7-trimethyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 120164-67-2 CAPLUS

CN Benzoic acid, 4-[[[(6-hydroxy-4,5,7-trimethyl-2-benzothiazolyl)amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 120164-68-3 CAPLUS

CN Benzamide, 4-(aminosulfonyl)-N-(6-hydroxy-4,5,7-trimethyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 133 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT **120165-63-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of antiasthmatic agents)

RN 120165-63-1 CAPLUS

CN Benzamide, 4-(aminosulfonyl)-N-(5,7-dichloro-6-methoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 134 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:135097 CAPLUS
DN 110:135097
TI Preparation of 1-aryl-3-quinolinecarboxamide as analgesics and antiinflammatory agents
IN Glamkowski, Edward J.; Hamer, R. Richard L.
PA Hoechst-Roussel Pharmaceuticals, Inc., USA
SO U.S., 14 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4786644	A	19881122	US 1987-125971	19871127
<--					
	US 4966906	A	19901030	US 1988-218783	19880714
<--					
	EP 317991	A2	19890531	EP 1988-119541	19881124
<--					
	EP 317991	A3	19901107		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	DK 8806586	A	19890528	DK 1988-6586	19881125
<--					
	JP 02138260	A2	19900528	JP 1988-296374	19881125
<--					
	US 4952588	A	19900828	US 1989-401386	19890831
<--					
PRAI	US 1987-125971	A3	19871127		
	US 1988-218783	B3	19880714		

OS CASREACT 110:135097; MARPAT 110:135097
GI



AB The title compds. [I; R1,R2 = halo, alkyl, alkoxy; R3 = (substituted) Ph, pyridyl, pyrimidyl, pyrazinyl, triazinyl, thiazolyl, thiadiazolyl, isoxazolyl oxadiazolyl, quinolyl, benzothiazolyl; m,n = 0, 1] oxo derivs. II, and isoquinoline analogs, useful as inflammation inhibitors and analgesics, were prepared 2,3-Dihydro-1-phenyl-4(1H)-quinolone was stirred 1 h with NaH in C6H6. (EtO)2CO was added and the mixture was refluxed 5 h. The product and 2-aminopyridine in PhMe were refluxed 16 h through a soxhlet extractor containing 4 Å mol. sieves to give 1,2-dihydro-4-hydroxy-

L7 ANSWER 134 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
1-phenyl-N-(2-pyridyl)-3-quinolinecarboxamide. I inhibited carrageenan-induced rat paw edema by 23-29% at 100 mg/kg orally.
IT 119686-88-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as analgesic and antiinflammatory)
RN 119686-88-3 CAPLUS
CN 3-Quinolinecarboxamide, N-2-benzothiazolyl-1,4-dihydro-4-oxo-1-phenyl- (9CI) (CA INDEX NAME)



L7 ANSWER 135 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:105093 CAPLUS
DN 110:105093
TI Erasable optical recording medium containing indoaniline dye
IN Inagaki, Yoshio; Adachi, Keiichi; Yabe, Masao
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 63179793	A2	19880723	JP 1987-12777	19870122
<--					
	JP 07080355	B4	19950830		
PRAI	JP 1987-12777		19870122		

OS MARPAT 110:105093
GI For diagram(s), see printed CA Issue.
AB The title recording medium contains an indoaniline dye I [R1 = (substituted) heterocyclyl; R2, R5, R6 = H, substituent; R3, R4 = H, halogen, (substituted) alkoxy, (substituted) alkyl; R7, R8 = atomic group necessary to form a 5- or 6-membered ring; R3 and R5, R4 and R6, R5 and R7, R6 and R8, and/or R7 and R8 may be connected to form a ring(s); Z = atom. group necessary to form a benzene, or 6- or 5-membered heterocyclic ring] and optionally a quencher. This optical recording medium shows high signal-to-noise ratio and improved storage stability.
IT 113419-62-8 119292-26-1
RL: TEM (Technical or engineered material use); USES (Uses)
(optical recording medium containing)
RN 113419-62-8 CAPLUS
CN 2-Naphthalenecarboxamide, N-2-benzothiazolyl-4-[[4-(diethylamino)-2,6-dimethylphenyl]imino]-1,4-dihydro-1-oxo- (9CI) (CA INDEX NAME)



RN 119292-26-1 CAPLUS
CN 2-Naphthalenecarboxamide, N-2-benzothiazolyl-5,6,7,8-tetrachloro-1,4-dihydro-1-oxo-4-[[4-(1-pyrrolidinyl)phenyl]imino]- (9CI) (CA INDEX NAME)

L7 ANSWER 135 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 113419-62-8P 119292-24-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and use of, as optical recording material)
RN 113419-62-8 CAPLUS
CN 2-Naphthalenecarboxamide, N-2-benzothiazolyl-4-[[4-(diethylamino)-2,6-dimethylphenyl]imino]-1,4-dihydro-1-oxo- (9CI) (CA INDEX NAME)



RN 119292-24-9 CAPLUS
CN 2-Naphthalenecarboxamide, N-2-benzothiazolyl-4-[[4-(diethylamino)-2-methylphenyl]imino]-1,4-dihydro-1-oxo- (9CI) (CA INDEX NAME)

L7 ANSWER 135 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 119292-29-4P
RL: PREP (Preparation)
(preparation of, as optical recording material)
RN 119292-29-4 CAPLUS
CN 2-Naphthalenecarboxamide, N-2-benzothiazolyl-4-[[4-[ethyl[2-[(methylsulfonyl)amino]ethyl]amino]-2-methylphenyl]imino]-1,4-dihydro-1-oxo- (9CI) (CA INDEX NAME)



IT 52923-65-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, indoaniline dye optical recording material from)
RN 52923-65-6 CAPLUS
CN 2-Naphthalenecarboxamide, N-2-benzothiazolyl-1-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 135 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 136 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1989:85387 CAPLUS
DN 110:85387
TI Electrophotographic photoreceptor with photosensitive layer containing azo compound
IN Kashizaki, Yoshiro; Umehara, Masashige
PA Canon K. K., Japan
SO Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 63159861	A2	19880702	JP 1986-306219	19861224
<--				
PRAI JP 1986-306219		19861224		

GI



I



II

AB In the electrophotog. photoreceptor, the photosensitive layer contains an azo compound containing the organic moiety I [Y = a group necessary to form a (substituted) aromatic hydrocarbon; X = O, S, (substituted) imino group] is bond to a (substituted) aromatic hydrocarbon or heterocyclic group directly or through a bonding group. The azo dye is represented by II [Z = an n valent (substituted) aromatic hydrocarbon or heterocyclic group bonding directly or through a bonding group]. A 9-fluorenone derivative may be used for the azo dye. The photosensitive layer containing this azo dye shows improved efficiency of carrier generating and/or carrier transporting.

L7 ANSWER 136 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IT 118688-15-6 118688-17-8 118688-21-4
RL: TEM (Technical or engineered material use); USES (Uses)
(charge-generating layer containing, for electrophotog. photoreceptor)
RN 118688-15-6 CAPLUS
CN 9H-Fluorene-2-carboxamide, 4,4'-[1,2-ethenediylbis(4,1-phenyleneazo)]bis[N-2-benzothiazolyl-3-hydroxy-9-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 118688-17-8 CAPLUS
CN 9H-Fluorene-2-carboxamide, 4,4'-[(9-oxo-9H-fluorene-2,7-diyl)bis(azo)]bis[N-(5-chloro-2-benzothiazolyl)-3-hydroxy-9-oxo- (9CI) (CA INDEX NAME)

L7 ANSWER 136 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 118688-21-4 CAPLUS
CN 9H-Fluorene-2-carboxamide, 4,4',4''-[nitrilotris(4,1-phenyleneazo)]tris[N-2-benzothiazolyl-3-hydroxy-9-oxo- (9CI) (CA INDEX NAME)

L7 ANSWER 136 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L7 ANSWER 137 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:640633 CAPLUS
DN 109:240633
TI Electrophotographic photoconductors containing disazo charge-generating compound
IN Enomoto, Kazuhiro; Haino, Kozo
PA Mitsubishi Paper Mills, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 63143557	A2	19880615	JP 1986-291304	19861205

<--
PRAI JP 1986-291304 19861205
GI



I

AB A disazo compound is used as a charge-generating photoconductor for an electrophotog. plate to improve resistance to heat and light and reduce the residual potential. The disazo compound has the formula I (A = alkyl, aryl, benzyl, heterocyclyl, alkenyl, alicyclyl; n = 0, 1; R = coupler residue having phenolic OH) (e.g., A = CH2Cl; n = 0; R = 2-hydroxy-3-naphthoic acid 3, 5-ditrifluoromethylanilide coupler residue).
IT 117850-53-0
RL: USES (Uses)
(electrophotog. charge-generating disazo photoconductor, for resistance to heat and light)
RN 117850-53-0 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[[9-[[[(4-chlorophenyl)acetyl]oxy]imino]-9H-fluorene-2,7-diyl]bis(azo)]bis[3-hydroxy-N-2-benzothiazolyl- (9CI) (CA INDEX NAME)

L7 ANSWER 137 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 138 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:640600 CAPLUS
DN 109:240600
TI Electrophotographic photoreceptor containing azo dye as charge-generating material
IN Enomoto, Kazuhiro
PA Mitsubishi Paper Mills, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 23 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 63089866	A2	19880420	JP 1986-235990	19861002
<--				
JP 05079983	B4	19931105		
PRAI JP 1986-235990		19861002		

GI



I



II

AB The title electrophotog. photoreceptor comprises a photosensitive layer containing an azo dye I [A = H, (substituted) alkyl, (substituted) Ph, (substituted) heterocyclyl; n = 0, 1; X = H, Me, CN, halogen; Cp = coupler moiety]. The azo dye is used as a carrier-generating material. The photoreceptor shows improved durability, and improved heat- and light-resistance. An electrophotog. photoreceptor using I [X = H; A = H; n = 0; Cp = II] showed Vo 980(-v), E1/2 2.8 lx*s, E50 15(-v) as a residual potential for a 1st use, and 980, 2.7, 20, resp. for a 500th use.

IT 117739-37-4
RL: USES (Uses)
(charge-generating material, electrophotog. photoreceptor containing)

RN 117739-37-4 CAPLUS
CN 2-Naphthalenecarboxamide, N-2-benzothiazolyl-4-[[3-[4-[2-[4-[[3-[(2-benzothiazolylamino)carbonyl]-2-hydroxy-1-naphthalenyl]azo]phenyl]ethenyl]-1H-pyrazol-1-yl]phenyl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 138 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L7 ANSWER 139 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:492995 CAPLUS
DN 109:92995
TI N-Benzothiazolyl amides, their preparation, and their use as insecticides
IN Kume, Toyohiko; Tsuboi, Shinichi; Sasaki, Shoko; Yanagi, Akihiko; Hattori, Yumi; Yagi, Shigeki; Sirrenberg, Wilhelm; Becker, Benedikt
PA Nihon Tokushu Noyaku Seizo K. K., Japan
SO Eur. Pat. Appl., 48 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 261459	A2	19880330	EP 1987-112784	19870902
<--				
EP 261459	A3	19880511		
R: BE, CH, DE, FR, GB, IT, LI, NL				
JP 63190880	A2	19880808	JP 1987-60129	19870317
<--				
PRAI JP 1986-210760	A	19860909		
JP 1987-60129	A	19870317		

OS MARPAT 109:92995

GI



I

AB Benzothiazolylamides I [X = O, S; T = bond, CONH (C connected to W); Y1-Y3 = H, halo, alkyl; Z = halo, (halo)alkoxy, aralkyloxy, alkylthio, -sulfinyl, -sulfonyl, aryl, heterocyclyloxy, etc.; W = substituted Ph, pyridyl; restrictions apply], useful as insecticides, were prepared A mixture of 2-amino-5,7-dichloro-6-(1,1,2,2-tetrafluoroethoxy)benzothiazole, PhCl, and 2,6-F2C6H3COCl was refluxed 3 h to give I (WT = 2,6-F2C6H3, X = O, Y1 = Y2 = Cl, Y3 = H, Z = OCF2CHF2). At 8 ppm, I (WT = 2,6-F2C6H3, X = O, Y1-Y3 = H, Z = Ph) killed 100% Plutella maculipennis on cabbage.

IT 115737-08-1P 115737-09-2P 115737-10-5P
115737-11-6P 115737-12-7P 115737-13-8P
115737-14-9P 115737-15-0P 115737-16-1P
115737-22-9P 115737-23-0P 115737-24-1P
115737-25-2P 115737-26-3P 115737-27-4P
115737-28-5P 115737-29-6P 115737-30-9P
115737-31-0P 115737-32-1P 115737-33-2P
115737-37-6P 115737-38-7P 115737-39-8P
115737-40-1P 115737-41-2P 115737-43-4P
115737-44-5P 115737-45-6P 115737-46-7P
115737-47-8P 115737-48-9P 115737-49-0P
115737-50-3P 115737-51-4P 115737-52-5P
115737-53-6P 115737-54-7P 115737-55-8P

L7 ANSWER 139 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
115737-56-9P 115737-57-0P 115762-98-6P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as insecticide)

RN 115737-08-1 CAPLUS
CN Benzamide, N-[5,7-dichloro-6-(1,1,2,2-tetrafluoroethoxy)-2-benzothiazolyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 115737-09-2 CAPLUS
CN Benzamide, N-[5,7-dichloro-6-(4-chlorophenoxy)-2-benzothiazolyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 115737-10-5 CAPLUS
CN Benzamide, N-[5,7-dichloro-6-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]oxy]-2-benzothiazolyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 115737-11-6 CAPLUS
CN Benzamide, N-[5,7-dichloro-6-[2-chloro-4-(trifluoromethyl)phenoxy]-2-benzothiazolyl]-2,6-difluoro- (9CI) (CA INDEX NAME)

L7 ANSWER 139 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 115737-12-7 CAPLUS
CN Benzamide, N-[5,7-dichloro-6-[4-(trifluoromethyl)phenoxy]-2-benzothiazolyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 115737-13-8 CAPLUS
CN Benzamide, N-[5,7-dichloro-6-[4-(trifluoromethoxy)phenoxy]-2-benzothiazolyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 115737-14-9 CAPLUS
CN Benzamide, 2-chloro-N-[5,7-dichloro-6-(1,1,2,2-tetrafluoroethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 115737-15-0 CAPLUS

L7 ANSWER 139 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzamide, 2-chloro-N-[5,7-dichloro-6-(2,4-dichlorophenoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 115737-16-1 CAPLUS
CN Benzamide, 2-chloro-N-[5,7-dichloro-6-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]oxy]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 115737-22-9 CAPLUS
CN Benzamide, N-(5,7-dichloro-6-ethoxy-2-benzothiazolyl)-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 115737-23-0 CAPLUS
CN Benzamide, N-(5,7-dichloro-6-fluoro-2-benzothiazolyl)-2,6-difluoro- (9CI) (CA INDEX NAME)



L7 ANSWER 139 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 115737-24-1 CAPLUS
CN Benzamide, 2,6-difluoro-N-(6-phenyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 115737-25-2 CAPLUS
CN Benzamide, N-[5,7-dichloro-6-(dimethylamino)-2-benzothiazolyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 115737-26-3 CAPLUS
CN Benzamide, N-[5,7-dichloro-6-[(2,2,2-trifluoroethyl)thio]-2-benzothiazolyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 115737-27-4 CAPLUS
CN Benzamide, N-[5,7-dichloro-6-[(4-chlorophenyl)thio]-2-benzothiazolyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



L7 ANSWER 139 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 115737-28-5 CAPLUS
CN Benzamide, N-(5,7-dichloro-6-phenoxy-2-benzothiazolyl)-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 115737-29-6 CAPLUS
CN Benzamide, N-[5,7-dichloro-6-[4-[(trifluoromethyl)thio]phenoxy]-2-benzothiazolyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 115737-30-9 CAPLUS
CN Benzamide, N-[5,7-dichloro-6-(2,4-dichlorophenoxy)-2-benzothiazolyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 115737-31-0 CAPLUS
CN Benzamide, N-[6-[2-chloro-4-(trifluoromethyl)phenoxy]-2-benzothiazolyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



L7 ANSWER 139 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 115737-32-1 CAPLUS
CN Benzamide,
2,6-difluoro-N-(7,7,8,8-tetrafluoro-7,8-dihydro[1,4]dioxino[2,3-g]benzothiazol-2-yl)- (9CI) (CA INDEX NAME)



RN 115737-33-2 CAPLUS
CN Benzamide,
2,6-difluoro-N-(6,6,7,7-tetrafluoro-6,7-dihydro[1,4]dioxino[2,3-f]benzothiazol-2-yl)- (9CI) (CA INDEX NAME)



RN 115737-37-6 CAPLUS
CN Benzamide, 2-chloro-N-(5,7-dichloro-6-phenoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 115737-38-7 CAPLUS
CN Benzamide,
2-chloro-N-[5,7-dichloro-6-(4-chlorophenoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 139 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 115737-39-8 CAPLUS
CN Benzamide, 2-chloro-N-[6-[2-chloro-4-(trifluoromethyl)phenoxy]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 115737-40-1 CAPLUS
CN Benzamide, 2-chloro-N-[5,7-dichloro-6-[4-(trifluoromethoxy)phenoxy]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 115737-41-2 CAPLUS
CN Benzamide,
2-chloro-N-[5,7-dichloro-6-[4-[(trifluoromethyl)thio]phenoxy]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 115737-43-4 CAPLUS
CN Benzamide, 2-chloro-N-[5,7-dichloro-6-(dimethylamino)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 139 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 115737-44-5 CAPLUS
CN Benzamide, 2-chloro-N-[5,7-dichloro-6-(2,6-dimethyl-4-morpholinyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 115737-45-6 CAPLUS
CN Benzamide, 2-chloro-N-(7,7,8,8-tetrafluoro-7,8-dihydro[1,4]dioxino[2,3-g]benzothiazol-2-yl)- (9CI) (CA INDEX NAME)



RN 115737-46-7 CAPLUS
CN Benzamide, 2-chloro-N-(6,6,7,7-tetrafluoro-6,7-dihydro[1,4]dioxino[2,3-f]benzothiazol-2-yl)- (9CI) (CA INDEX NAME)



RN 115737-47-8 CAPLUS
CN Benzamide,
N-[5,7-dichloro-6-(4-chlorophenoxy)-2-benzothiazolyl]-2-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 139 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 115737-48-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-[5,7-dichloro-6-(4-chlorophenoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 115737-49-0 CAPLUS
CN Benzamide,
2-chloro-N-(5,7-dichloro-6-(4-chlorophenoxy)-2-benzothiazolyl]-6-fluoro- (9CI) (CA INDEX NAME)



RN 115737-50-3 CAPLUS
CN Benzamide, 2,6-difluoro-N-[6-[4-(trifluoromethoxy)phenoxy]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 115737-51-4 CAPLUS
CN Benzamide, N-[6-[2-chloro-4-(trifluoromethoxy)phenoxy]-2-benzothiazolyl]-2,6-difluoro- (9CI) (CA INDEX NAME)

L7 ANSWER 139 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 115737-52-5 CAPLUS
CN Benzamide, N-[6-[2-chloro-4-(trifluoromethoxy)phenoxy]-5,7-dimethyl-2-benzothiazolyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 115737-53-6 CAPLUS
CN Benzamide, 2-chloro-N-[6-[2-chloro-4-(trifluoromethoxy)phenoxy]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 115737-54-7 CAPLUS
CN Benzamide, 2-chloro-N-[6-[2-chloro-4-(trifluoromethoxy)phenoxy]-5,7-dimethyl-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 115737-55-8 CAPLUS
CN Benzamide, 2-chloro-6-fluoro-N-[6-[4-(trifluoromethoxy)phenoxy]-2-

L7 ANSWER 139 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 139 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 115737-56-9 CAPLUS
CN Benzamide, 2-chloro-N-[6-[2-chloro-4-(trifluoromethoxy)phenoxy]-2-benzothiazolyl]-6-fluoro- (9CI) (CA INDEX NAME)



RN 115737-57-0 CAPLUS
CN Benzamide, 2-chloro-N-[6-[2-chloro-4-(trifluoromethoxy)phenoxy]-5,7-dimethyl-2-benzothiazolyl]-6-fluoro- (9CI) (CA INDEX NAME)



RN 115762-98-6 CAPLUS
CN Benzamide, N-[5,7-dichloro-6-(2-phenylethoxy)-2-benzothiazolyl]-2,6-difluoro- (9CI) (CA INDEX NAME)

L7 ANSWER 140 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:454670 CAPLUS
DN 109:54670
TI Preparation and formulation of carbamoyl[(imidazolylethoxy)methyl]dihydropyridinates as antiallergic and antiinflammatory agents
IN Cooper, Kelvin; Parry, Michael John; Cross, Peter Edward; Richardson, Kenneth
PA Pfizer Ltd., UK
SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 258033	A2	19880302	EP 1987-307494	19870825
<--					
	EP 258033	A3	19901107		
	EP 258033	B1	19930804		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 4788205	A	19881129	US 1987-75379	19870720
<--					
	AT 92486	E	19930815	AT 1987-307494	19870825
<--					
	FI 8703725	A	19880301	FI 1987-3725	19870827
<--					
	JP 63063661	A2	19880322	JP 1987-214129	19870827
<--					
	CN 87106032	A	19880323	CN 1987-106032	19870827
<--					
	DD 262023	A5	19881116	DD 1987-306414	19870827
<--					
	DK 8704506	A	19880301	DK 1987-4506	19870828
<--					
	NO 8703650	A	19880301	NO 1987-3650	19870828
<--					
	AU 8777678	A1	19880310	AU 1987-77678	19870828
<--					
	HU 45047	A2	19880530	HU 1987-3795	19870828
<--					
	ZA 8706437	A	19890329	ZA 1987-6437	19870828
<--					
PRAI	GB 1986-20880	A	19860829		
	EP 1987-307494	A	19870825		

OS MARPAT 109:54670
GI



I

AB Title compds. I [R = (un)substituted Ph; R1 = H, C1-4 (un)substituted alkyl, C3-7 cycloalkyl, aryl, indanyl, heteroaryl; R2 = H, C1-4 alkyl; R3

L7 ANSWER 140 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
= C1-6 alkyl; Y = C2-8 alkylene having at least 2 C in the chain linking X
to O; X = (un)substituted 1-imidazolyl] and their pharmaceutically acceptable salts, useful as antiallergic and antiinflammatory agents (no data) were prepd. MeC(NH2):CHCONHPh, 2-ClC6H4CHO and Me [2-(2,4,5-trimethylimidazol-1-yl)ethoxy]-3-ketobutanoate were refluxed for
8 h to give I (R = 2-ClC6H4, R1 = Ph, R2 = H, R3 = Me, Y = CH2CH2, X = 2,4,5-trimethylimidazol-1-yl).
IT **115064-00-1P 115064-05-6P 115064-30-7P**
115064-31-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as allergy and inflammation inhibitor)
RN 115064-00-1 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[(2-benzothiazolylamino)carbonyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-[[2-(2,4,5-trimethyl-1H-imidazol-1-yl)ethoxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 115064-05-6 CAPLUS
CN 3-Pyridinecarboxylic acid, 4-(2-chlorophenyl)-5-[[(6-ethoxy-2-benzothiazolyl)amino]carbonyl]-1,4-dihydro-6-methyl-2-[[2-(2,4,5-trimethyl-1H-imidazol-1-yl)ethoxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 115064-30-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[(2-benzothiazolylamino)carbonyl]-4-(3-chlorophenyl)-1,4-dihydro-6-methyl-2-[[2-(2,4,5-trimethyl-1H-imidazol-1-yl)ethoxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 140 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 115064-31-8 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[(2-benzothiazolylamino)carbonyl]-4-(2-fluorophenyl)-1,4-dihydro-6-methyl-2-[[2-(2,4,5-trimethyl-1H-imidazol-1-yl)ethoxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 141 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:414696 CAPLUS
DN 109:14696
TI Azoamine derivative charge-generating layer for electrophotographic photoreceptor
IN Kawahara, Tatsuro
PA Dainippon Ink and Chemicals, Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 19 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 62258461	A2	19871110	JP 1986-99399	19860501

<--
PRAI JP 1986-99399 19860501
GI For diagram(s), see printed CA Issue.
AB An electrophotog. photoreceptor suited for use in laser printers is claimed which is provided with a charge-generating layer containing an azoamine derivative I [X = II, III; Q = N, NHN=C; R, R1, R2 = H, (un)substituted hydrocarbyl, heterocyclic group; R1R2 may jointly form a ring; Z = (un)substituted hydrocarbon (heterocyclic) ring; Y = divalent organic group containing a benzene ring and a heterocyclic ring fused to the benzene ring].
IT **114936-60-6**
RL: TEM (Technical or engineered material use); USES (Uses)
(charge-generating layer containing, for electrophotog. photoreceptor)
RN 114936-60-6 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4',4''-[nitrilotris(4,1-phenyleneazo-4,1-phenyleneazo)]tris[N-2-benzothiazolyl-3-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A



L7 ANSWER 141 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



L7 ANSWER 142 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:195923 CAPLUS
DN 108:195923
TI Electrophotographic photoreceptor containing bisazo compound as charge-generating substance
IN Hirose, Hisahiro; Kinoshita, Akira; Sawada, Kiyoshi; Yamazaki, Hiroshi; Watanabe, Kazumasa
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 35 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 62269146	A2	19871121	JP 1986-113286	19860516

<--
PRAI JP 1986-113286 19860516
GI



I

AB In an electrophotog. photoreceptor containing a bisazo compound as a charge-generating substance, the bisazo compound is at least partially aggregated and the visible maximum absorption peak of the aggregate is ≥100 nm longer than that of the bisazo compound The preferable bisazo compound has the general formula I [A = Y or N:CHY; Y = (substituted) aromatic group; Q1 = :CQ2Q3; Q2, Q3 = H, CN, alkyl, (substituted) aromatic group, halogen, vinyl, acyl or ester, or Q2 and Q3 may form a ring with other group; P1, P2 = H, Me, methoxy]. The electrophotog. photoreceptor shows excellent chargeability and storage stability.
IT **114190-33-9 114190-36-2 114190-52-2 114190-65-7**
RL: USES (Uses)
(electrophotog. photoconductor containing, as charge-generating substance with improved chargeability and storage stability)
RN 114190-33-9 CAPLUS
CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[[9-(dicyanomethylene)-3,6-dimethyl-9H-fluorene-2,7-diyl]bis(azo)]bis[2-hydroxy-N-(6-methyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 142 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 114190-52-2 CAPLUS
CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[[9-(3-thienylmethylene)-9H-fluorene-2,7-diyl]bis(azo)]bis[N-2-benzothiazolyl-2-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 114190-65-7 CAPLUS
CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[[9-(3-methyl-2(3H)-benzothiazolylidene)-9H-fluorene-2,7-diyl]bis(azo)]bis[2-hydroxy-N-(6-methyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



L7 ANSWER 142 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 114190-36-2 CAPLUS
CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[[9-(phenylmethylene)-9H-fluorene-2,7-diyl]bis(azo)]bis[N-2-benzothiazolyl-2-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L7 ANSWER 142 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B



L7 ANSWER 143 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:177124 CAPLUS
DN 108:177124
TI Electrophotographic photoreceptors with trisazo compound carrier generators
IN Hasegawa, Masaru; Suda, Osamu; Kono, Toshio; Tanaka, Norio; Umezaki, Tetsuhiro
PA Daicel Chemical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 62192747	A2	19870824	JP 1986-32758	19860219
<--				
JP 04069949	B4	19921109		
PRAI JP 1986-32758		19860219		

GI For diagram(s), see printed CA Issue.
AB The photoreceptors comprise a photosensitive layer containing I [A = II, III, IV; X = (un)substituted aromatic hydrocarbon residue, (un)substituted aromatic heterocycle; Y = NR1R2, NHNR3R4, NHN:CR5R6; R1-R6 = H, (un)substituted alkyl, aryl, aralkyl, heterocyclyl; R1 and R2, R3 and R4, or R5 and R6 may form a ring with N or C]. The product is useful for high-speed printers. Thus, a carrier-generating layer containing Vylon 200 (polyester resin) and I (A = II; X = a fused benzene ring; Y = anilino) prepared from 4,4',4''-triamino-diphenylbenzylamine and Naphthol AS, and a carrier transport layer containing p-diethylaminobenzaldehyde N-phenyl-N-benzylhydrazone and Panlite L-1250 (polycarbonate resin) were formed on an Al support to give a photoreceptor.
IT 113963-12-5
RL: USES (Uses)
(charge-generating agents, in electrophotog. receptors)
RN 113963-12-5 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[[[[4-[[4-hydroxy-3-[[(6-methoxy-2-benzothiazolyl)amino]carbonyl]-1-naphthalenyl]azo]phenyl]methyl]imino]bis(4,1-phenyleneazo)]bis[1-hydroxy-N-(6-methoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 143 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

PAGE 2-A



L7 ANSWER 144 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:167472 CAPLUS
DN 108:167472
TI Preparation, testing, and formulation of benzimidazolylcarboxamides as cardiotonics
IN Sueda, Noriyoshi; Suzuki, Yoshikuni; Sugai, Toshiji; Yamada, Hiroaki; Yanai, Makoto
PA Nisshin Flour Milling Co., Ltd., Japan
SO Eur. Pat. Appl., 29 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 254322	A1	19880127	EP 1987-110741	19870724
<--				
EP 254322	B1	19920923		
R: BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
JP 63146871	A2	19880618	JP 1987-171139	19870710
<--				
JP 07084462	B4	19950913		
US 4886803	A	19891212	US 1987-73738	19870715
<--				
CA 1305481	A1	19920721	CA 1987-542315	19870716
<--				
FI 8703205	A	19880126	FI 1987-3205	19870721
<--				
FI 91152	B	19940215		
FI 91152	C	19940525		
AU 8775965	A1	19880128	AU 1987-75965	19870721
<--				
AU 597696	B2	19900607		
NO 8703091	A	19880126	NO 1987-3091	19870723
<--				
NO 168770	B	19911223		
NO 168770	C	19920401		
BR 8703857	A	19880329	BR 1987-3857	19870724
<--				
ES 2044878	T3	19940116	ES 1987-110741	19870724
<--				
PRAI JP 1986-173759	A	19860725		
JP 1987-171139	A	19870710		

OS CASREACT 108:167472; MARPAT 108:167472
GI



I

AB The title compds. [I; R1 = H, alkyl, alkoxy, dialkylamino, halo; R2 = H, alkyl, (substituted) aminoalkyl, acyl, aralkyl, carboxyalkyl, alkoxycarbonylalkyl, piperazinylalkyl; A = NH, alkylimino, alkylene, alkylidene; B = heterocyclyl; n = 1-4] were prepared for treatment of circulatory diseases. 2-Aminopyridine was stirred with NaH in DMSO for 1 h. Dibenzimidazo[1.2-a:1.2'-d]tetrahydropyrazine-6,12-dione was added with ice cooling and the mixture was stirred 2 h at room temperature to give

L7 ANSWER 144 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
N-(2-pyridyl)benzimidazole-2-carboxamide (II). II at 10-4 M changed cardiac contractility in isolated guinea pig atrium muscle by +600.9%.
IT 113826-91-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as cardiotonic)
RN 113826-91-8 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, N-(6-methoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 145 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:122066 CAPLUS
DN 108:122066
TI Near-IR absorbing composition for optical filter and recording media
IN Ono, Shigeru; Adachi, Keiichi; Ukai, Toshinao; Mihara, Yuji; Hayashi, Koichi
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 21 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 62181381	A2	19870808	JP 1986-28711	19860212
<--					
	JP 06047667	B4	19940622		
	US 4923638	A	19900508	US 1989-331075	19890328
<--					
PRAI	JP 1985-217315	A1	19850930		
	JP 1986-28711	A	19860212		
	US 1986-913278	B1	19860930		

OS CASREACT 108:122066
GI



I

AB A near-IR absorbing composition contains ≥1 compound I [R1 = alkyl, aryl, heterocyclyl; R2, R5 = H; R3, R4 = H, halo, alkoxy, alkyl; R6, R7 = alkyl, aryl, aryl, sulfonyl; R6, R7 may join to form 5- or 6-membered ring] which possesses absorption maximum at ≥720 nm. The composition is useful in near-IR optical filters and in optical recording media useful with near-IR.
IT 113419-62-8P
RL: PREP (Preparation)
(preparation of, near IR-absorber, optical filters and recording medium

L7 ANSWER 145 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
using)
RN 113419-62-8 CAPLUS
CN 2-Naphthalenecarboxamide, N-2-benzothiazolyl-4-[[4-(diethylamino)-2,6-dimethylphenyl]imino]-1,4-dihydro-1-oxo- (9CI) (CA INDEX NAME)



IT 52923-65-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with p-phenylenediamine derivs., near IR absorbers from)
RN 52923-65-6 CAPLUS
CN 2-Naphthalenecarboxamide, N-2-benzothiazolyl-1-hydroxy- (9CI) (CA INDEX NAME)



L7 ANSWER 146 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:118967 CAPLUS
DN 108:118967
TI Use of secondary amide compounds for the manufacture of medicaments for the treatment of dermatological inflammation
IN Ritchey, Thomas R.
PA Unilever PLC, UK; Unilever N. V.
SO Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 221211	A1	19870513	EP 1985-307531	19851018
<--					
	EP 221211	B1	19890111		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
	AT 39843	E	19890115	AT 1985-307531	19851018
<--					
PRAI	EP 1985-307531	A	19851018		

GI



I

AB Secondary salicylamides I [R1, R2 = H, (substituted) (cyclic) alkyl, aryl, heteroaryl; R3 = thiazol-2-yl, benzothiazol-2-yl, substituted Ph, CH2R1; Y = OH, ester], which are useful for treatment of dermatol. inflammation, are formulated into various pharmaceutical prepns. e.g. ointments, gels, eye drops, medicated bandages, suppositories, etc. I (R1 = 5-n-octanoyl; R2 = H; R3 = C6H4CF3-3; Y = OH) (II) reduced edema and erythema due to calcium ionophore on mouse ears by 80 and 76% resp., whereas the control 3,4'-5-tribromosalicylanilide reduced edema 12% and erythema 35%. II was formulated into a suppository containing II 1, cocoa butter 93, ZnO2 3, menthol 2, and balsam Peru 1%.
IT 78417-85-3
RL: BIOL (Biological study)
(medicaments containing, for treatment of dermatol. inflammation)
RN 78417-85-3 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2-hydroxy-5-(1-oxodecyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 146 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 147 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1988:112433 CAPLUS
DN 108:112433
TI Preparation of thiazole derivatives as leukotriene antagonists
IN Hayasi, Yosio; Oguri, Tomei; Shinoda, Masaki; Tsutsui, Mikio; Takahashi, Kazuo; Miida, Hitoshi
PA Mitsubishi Chemical Industries Co., Ltd., Japan
SO Eur. Pat. Appl., 96 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 219436	A2	19870422	EP 1986-402327	19861016
<--					
	EP 219436	A3	19891227		
	EP 219436	B1	19931222		
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
	JP 62142168	A2	19870625	JP 1985-228912	19851016
<--					
	JP 05007386	B4	19930128		
	DK 8604941	A	19870417	DK 1986-4941	19861015
<--					
	DK 169128	B1	19940822		
	AU 8663930	A1	19870430	AU 1986-63930	19861015
<--					
	AU 603343	B2	19901115		
	SU 1554763	A3	19900330	SU 1986-4028404	19861015
<--					
	CA 1326034	A1	19940111	CA 1986-520544	19861015
<--					
	HU 47090	A2	19890130	HU 1986-4318	19861016
<--					
	HU 203228	B	19910628		
	US 4902700	A	19900220	US 1988-279225	19881128
<--					
PRAI	JP 1985-228912	A	19851016		
	US 1986-919497	B1	19861016		

GI

L7 ANSWER 147 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

L7 ANSWER 147 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB The title thiazoles I [R = CO2H, alkoxy, OH, C2-6 alkoxycarbonyl, 5-tetrazolyl; R1, R2 = H, C1-8 alkyl, lower alkoxycarbonyl, (un)substituted Ph; R1R2 = (CH2)4, (un)substituted CH:CHCH:CH; R3-R6 = H, OH, lower alkoxy, halo, C1-3 alkyl; A = linking group having 2-4 chain members; B = linking group having 2-5 chain members] and II [R7, R8 = H, C1-8 alkyl; R7R8 = R1R2; R11 = HO2CCR9R10CH2; R9, R10 = H, C1-6 alkyl], useful as leukotriene antagonists and asthma inhibitors, were prepared A mixture of trans-2-(3-aminostyryl)benzothiazole and maleic anhydride in PhMe was heated at 80° for 1h to give 88% II (R7 = R8 = H, R11 = cis-HO2CCH:CH) (III). III inhibited slow reacting substance-induced contraction of isolated guinea pig ileum with an IC50 of 5 + 10-8 M. Tablets containing III.Na, lactose, crystalline cellulose, hydroxypropyl cellulose, and Mg stearate were prepared

IT **113174-70-2P 113191-23-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as leukotriene antagonist and asthma inhibitor)

RN 113174-70-2 CAPLUS
CN 2-Butenoic acid, 4-[[3-[(2-benzothiazolylamino)carbonyl]phenyl]amino]-4-oxo-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 113191-23-4 CAPLUS
CN 2-Butenoic acid, 4-[[3-[(2-benzothiazolylamino)carbonyl]phenyl]amino]-4-oxo-, monosodium salt, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L7 ANSWER 148 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1988:46833 CAPLUS
DN 108:46833
TI Electrophotographic photoreceptors containing tetrakisazo pigments
IN Enomoto, Kazuhiro
PA Mitsubishi Paper Mills, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 23 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 62174769	A2	19870731	JP 1986-17450	19860128
<--					
PRAI	JP 1986-17450		19860128		

GI



I

AB The claimed electrophotog. photoreceptors contain tetrakisazo pigment of the formula I (R, R1 = H, lower alkyl, lower alkoxy, halo, CF3, CN; Cp = coupler moiety; m, n = 1, 2). The tetrakisazo pigments are especially useful as charge carrier-generating compds. in composite electrophotog. photoconductors.

IT **112303-60-3**
RL: TEM (Technical or engineered material use); USES (Uses)
(electrophotog. charge carrier-generating pigment)

RN 112303-60-3 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[[[4-[[4-[[3-[(2-benzothiazolylamino)carbonyl]-2-hydroxy-1-naphthalenyl]azo]phenyl]azo]-2-chlorophenyl]imino]bis(methylene-4,1-phenyleneazo)]bis[N-2-benzothiazolyl-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 148 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A





L7 ANSWER 148 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-B



L7 ANSWER 149 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1988:39634 CAPLUS
DN 108:39634
TI Unsymmetrical 1:2 chrome complex azo dyes
IN Back, Gerhard; Beffa, Fabio; Schlesinger, Ulrich; Puentener, Alois
PA Ciba-Geigy A.-G., Switz.
SO Ger. Offen., 42 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3643619	A1	19870702	DE 1986-3643619	19861219
<--					
	CH 664764	A	19880331	CH 1985-5517	19851223
<--					
	CH 664972	A	19880415	CH 1985-5514	19851223
<--					
	GB 2185034	A1	19870708	GB 1986-30453	19861219
<--					
	GB 2185034	B2	19900110		
	US 4874849	A	19891017	US 1986-944621	19861219
<--					
	FR 2592054	A1	19870626	FR 1986-17977	19861222
<--					
	FR 2592054	B1	19881021		
PRAI	CH 1985-5514	A	19851223		
	CH 1985-5517	A	19851223		

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title complexes are useful for dyeing leather, pelts, and polyamide fibers. A 1:1 Cr complex monoazo dye (prepared from diazotized 1-amino-2-hydroxy-6-nitro-4-naphthalenesulfonic acid and 2-naphthol) was complexed with a monoazo dye (prepared from diazotized 2-amino-4-nitrophenol and CH3COCH2CONHC6H4-p-N:NC6H4SO3Na-p) to give I, which dyed leather brown with good fastness.
IT 111994-68-4
RL: USES (Uses)
(dye, for leather and nylon, manufacture of)
RN 111994-68-4 CAPLUS
CN Chromate(3-), [3-[[1-[(2-benzothiazolylamino)carbonyl]-2-oxopropyl]azo]-4-hydroxy-5-nitrobenzenesulfonato(3-)][2-hydroxy-3-[(2-hydroxy-1-naphthalenyl)azo]-5-nitrobenzenesulfonato(3-)]-, trisodium (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L7 ANSWER 150 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1987:554326 CAPLUS
DN 107:154326
TI Preparation of benzothiazolylbenzimidates as insecticides and acaricides
IN Kume, Toyohiko; Tsuboi, Shinichi; Sasaki, Shoko; Hattori, Yumi; Yagi, Shigeki
PA Nihon Tokushu Noyaku Seizo K. K., Japan
SO Eur. Pat. Appl., 34 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 223141	A1	19870527	EP 1986-115193	19861103
<--					
	R: BE, CH, DE, FR, GB, IT, LI, NL				
	JP 62114976	A2	19870526	JP 1985-252823	19851113
<--					
PRAI	JP 1985-252823	A	19851113		

OS CASREACT 107:154326
GI



I

AB The title compds. (I; R1 = halo, haloalkyl, haloalkoxy, haloalkylthio, haloalkylsufinyl, haloalkylsulfonyl; R2 = H, alkyl, haloalkyl, alkoxyalkyl, alkylthioalkyl, alkylthio, arylthio, aminoalkyl, aralkyl, alkylcarbonyl, alkoxycarbonyl, cyano, etc.; R3, R4 = halo, alkyl; Q = O, S, imino; Z = O, S; n = 0-2) were prepared as insecticides and acaricides. N-(6-Trifluoromethylbenzothiazol-2-yl)-2,6-difluorobenzamide (3.56 g) and PCl5 were stirred in PhMe at 95-100° for 5 min. followed by introduction of HgS and further stirring until HCl evolution ceased to give 1.3 g I (R1 = CF3, R2 = H, R3 = 2-F, R4 = 6-F) (II). At 8 ppm, II gave a complete kill of Spodoptera litura on cabbage leaves.
IT 60230-31-1 110427-74-2 110428-24-5
110428-25-6 110428-26-7 110428-27-8
110428-28-9 110428-29-0 110428-30-3
110428-31-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(chlorination of, benzimidoyl chloride derivative by)
RN 60230-31-1 CAPLUS
CN Benzamide, N-(6-chloro-2-benzothiazolyl)-2,6-difluoro- (9CI) (CA INDEX NAME)

L7 ANSWER 150 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 110427-74-2 CAPLUS
CN Benzamide, 3,5-dichloro-N-[6-(trifluoromethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 110428-24-5 CAPLUS
CN Benzamide, 2,6-difluoro-N-[6-(trifluoromethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 110428-25-6 CAPLUS
CN Benzamide, 2-chloro-N-[6-(trifluoromethyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 110428-26-7 CAPLUS
CN Benzamide, 2-methyl-N-[6-(trifluoromethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 150 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 110428-31-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[6-[(trifluoromethyl)thio]-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



IT **110427-74-2P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as insecticide and acaricide)
RN 110427-74-2 CAPLUS
CN Benzamide, 3,5-dichloro-N-[6-(trifluoromethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



IT **110428-23-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(sulfuration of)
RN 110428-23-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[6-(trifluoromethyl)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 150 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 110428-27-8 CAPLUS
CN Benzamide, 2-chloro-N-[6-(trifluoromethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 110428-28-9 CAPLUS
CN Benzamide, 2-chloro-6-fluoro-N-[6-(trifluoromethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 110428-29-0 CAPLUS
CN Benzamide, 2,6-difluoro-N-[6-(1,1,2,2-tetrafluoroethoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)



RN 110428-30-3 CAPLUS
CN Benzamide, 2,6-difluoro-N-[6-(1,1,2,3,3,3-hexafluoropropoxy)-2-benzothiazolyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 151 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1987:446095 CAPLUS
DN 107:46095
TI Oral compositions of salicylamides and zinc salts for the synergistic inhibition of dental plaque
IN Ritchey, Thomas W.; Sharpe, Erwin
PA Lever Brothers Co., USA
SO U.S., 8 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4647452	A	19870303	US 1985-796347	19851108
<--					
	CA 1272130	A1	19900731	CA 1986-522065	19861103
<--					
	EP 223515	A2	19870527	EP 1986-308659	19861106
<--					
	EP 223515	A3	19871216		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
	JP 62114908	A2	19870526	JP 1986-265421	19861107
<--					
	JP 05002646	B4	19930113		
PRAI	US 1985-796347	A	19851108		

GI



AB The title compns. comprise 0.001-10% I (R1 = n-decanoyl, R2 = p-NO2Ph; R1 = n-octanoyl, R2 = p-CF3Ph; R1 = n-octanoyl, R2 = m-CF3Ph; R1 = n-hexyl, R2 = p-NO2Ph; R1 = n-Bu, R2 = m-CF3Ph; R1 = n-nonanoyl, R2 = m-EtCOOPh; R1
= n-decanoyl, R2 = benzothiazol-2-yl; R1 = n-hexadecanoyl, R2 = p-NO2Ph, and OH may be replaced with CH2:CHCOO) and 0.001 - 10% Zn salts. A composition
containing 0.05% I(R1 = n-octanoyl, R2 = m-CF3Ph) and 0.2% ZnCl2, reduced 80.1% of plaque in an in-vitro test. A mouthwash was formulated containing I
(R1 = n-octanoyl, R2 = p-CF3Ph) 0.2, Zn glycinate 0.25, glycerol 35.00, EtOH 27.00, polyethylene glycol 10.00, a flavor and a color 0.90, polyoxyethylene sorbitan monolaurate 0.20, and water to 100% by weight
IT **78417-85-3**
RL: BIOL (Biological study)
(dentifrices containing zinc salt and, for retarding plaques)
RN 78417-85-3 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2-hydroxy-5-(1-oxodecyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 151 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 152 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1987:76074 CAPLUS
DN 106:76074
TI Electrophotographic photosensitive materials
IN Enomoto, Kazuhiro
PA Mitsubishi Paper Mills, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 61090164	A2	19860508	JP 1984-212827	19841009
<--					
	JP 04062578	B4	19921006		
PRAI	JP 1984-212827		19841009		

GI



I



II

AB Electrophotog. photosensitive materials contain an azo dye I [R = H, halo, CN; R1 = H, aryl, (substituted) alkyl, (substituted) benzyl; R2 = coupler residue]. The materials show high sensitivity and high durability during repeated use. Thus, an electrophotog. photosensitive material prepared using a charge-generating layer containing I (R = H; R1 = Et; R2 = II) showed high sensitivity and durability.

IT 106642-95-9
RL: TEM (Technical or engineered material use); USES (Uses)
(charge-generating layer containing, for electrophotog. photoreceptor)

RN 106642-95-9 CAPLUS
CN 11H-Benzo[a]carbazole-3-carboxamide, N-(6-chloro-2-benzothiazolyl)-1-[[4-[2-[6-[[3-[[(6-chloro-2-benzothiazolyl)amino]carbonyl]-2-hydroxy-11H-benzo[a]carbazol-1-yl]azo]-9-ethyl-9H-carbazol-3-yl]-1-cyanoethenyl]phenyl]azo]-2-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 152 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L7 ANSWER 153 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1987:18583 CAPLUS
DN 106:18583
TI 1,2-Benzothiazine-3-carboxamide derivatives
IN Kikawa, Kazuo; Hiiragi, Mineji; Irino, Osamu; Nakazato, Kikuo; Kanezuka, Satoyuki; Oba, Seiichi; Wakizaka, Kikuo; Murayama, Yu; Riyutsu, Masakatsu
PA Grelan Pharmaceutical Co., Ltd., Japan; Permachem Asia, Ltd.
SO Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 61161281	A2	19860721	JP 1985-1460	19850110
<--					
PRAI	JP 1985-1460		19850110		
OS	CASREACT 106:18583				

GI



I



AB The title compds. [I; R = alkyl; R1 = NHR2; R2 = Q (R3, R4, R5, R6 = H, Cl, Me, MeCH2CH2, OCH2Ph), Q1, Q2 (R7 = H, SH), pyrazol-3-yl, benzimidazol-2-yl, 4-methylbenzthiazole-2-yl], useful as antiinflammatory agents, were prepared Thus, a mixture of I (R = Me, R1 = OMe) and QNH2 (R3 = Me, R4 = R6 = H; R5 = Cl) in xylene was refluxed for 16 1/2 h to give 14.2% I (R = Me, R1 = QNH, R3 = Me, R4 = R6 = H; R5 = Cl). The title compds. at 4 mg/kg o.p. inhibited by 33.6% carrageenin-induced inflammation in rats.

IT 105924-98-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiinflammatory agent)

RN 105924-98-9 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(4-methyl-2-benzothiazolyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L7 ANSWER 153 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 154 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1987:18582 CAPLUS
DN 106:18582
TI 4-Hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides
IN Puigdellivol Llobet, Pere; Goday Baylina, Elisa
PA Laboratorio Fides S. A., Spain
SO Span., 13 pp.
CODEN: SPXXAD
DT Patent
LA Spanish
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ES 539524	A1	19851101	ES 1984-539524	19841228
<--					
PRAI	ES 1984-539524		19841228		

GI



AB Title compds. I [R = alkyl, (un)substituted Ph, heterocyclyl], which include members of the oxicam group of antiinflammatory agents (no data), are prepared by treating benzothiazinecarboxylic acid derivative II (R1 = CH2Ph, R2 = H) (III) with PhSO2Cl or p-MeC6H4SO2Cl at 0-40°, followed by RNH2 (4 examples). Thus, II (R1 = H, R2 = Et) was benzylated to give 87% II (R1 = CH2Ph, R2 = Et), which was hydrolyzed by NaOH to give 88% III. Treatment of III with PhSO2Cl in pyridine for 30 min at room temperature, followed by addition of 2-aminopyridine and stirring for 5 h, gave I (R = 2-pyridyl) via simultaneous amidation and deprotection.

IT 50664-38-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as analgesic and antiinflammatory agent)

RN 50664-38-5 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, N-2-benzothiazolyl-4-hydroxy-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)

L7 ANSWER 154 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 155 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1987:6410 CAPLUS
DN 106:6410
TI Trisazo compounds
IN Enomoto, Kazuhiro; Ito, Akira; Haino, Kozo
PA Mitsubishi Paper Mills, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 61163969	A2	19860724	JP 1985-5486	19850116
<--					
	JP 04058507	B4	19920917		
PRAI	JP 1985-5486		19850116		

GI For diagram(s), see printed CA Issue.

AB Hexazonium salts I (X = H, lower alkoxy, alkyl, halogen, CN, HO; n = 1, 2) were treated with HQ [R = (un)substituted hydrocarbon, cyclic hydrocarbon, aromatic hydrocarbon, heterocyclic group; Z = group of atoms required to form naphthalene, anthracene, carbazole, benzocarbazole, dibenzofuran ring with the benzene ring above it; Z1 = direct bond or N:CH] to obtain II useful in electrophotog. photoconductors. Thus, N,N-bis(4-aminobenzyl)-p-phenylenediamine was hexazotized and coupled with 2,3-HOC10H6CONHC6H4CN-3 to give the corresponding II.

IT 105781-80-4 105781-96-2 105812-33-7
RL: USES (Uses)
(photoconductors, for electrophotog.)

RN 105781-80-4 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[[[4-[[3-[(2-benzothiazolylamino)carbonyl]-2-hydroxy-1-naphthalenyl]azo]phenyl]imino]bis(methylene-4,1-phenyleneazo)]bis[N-2-benzothiazolyl-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 155 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 105781-96-2 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[[[4-[[3-[(2-benzothiazolylamino)carbonyl]-2-hydroxy-1-naphthalenyl]azo]-2-chlorophenyl]imino]bis(methylene-4,1-phenyleneazo)]bis[N-2-benzothiazolyl-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 155 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 105812-33-7 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[[[2-chloro-4-[[3-[[(6-chloro-2-benzothiazolyl)amino]carbonyl]-2-hydroxy-1-naphthalenyl]azo]phenyl]imino]bis(methylene-4,1-phenyleneazo)]bis[N-(6-chloro-2-benzothiazolyl)-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 155 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L7 ANSWER 156 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:562322 CAPLUS
DN 105:162322
TI Optical recording medium
IN Niwa, Toshio; Murata, Yukichi; Ozawa, Tetsuo; Maeda, Shuichi; Kurose, Yutaka
PA Mitsubishi Chemical Industries Co., Ltd., Japan
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8601460	A1	19860313	WO 1985-JP487	19850902
<--					
	W: US				
	RW: DE, FR, GB, NL				
	JP 61061893	A2	19860329	JP 1984-184317	19840903
<--					
	EP 192778	A1	19860903	EP 1985-904292	19850902
<--					
	EP 192778	B1	19910619		
	R: DE, FR, GB, NL				
	US 4737443	A	19880412	US 1986-865000	19860505
<--					
PRAI	JP 1984-184317	A	19840903		
	WO 1985-JP487	W	19850902		

AB A laser-sensitive optical recording medium is prepared by forming on a substrate an indophenol coloring substance recording layer. The above coloring substance may be coated on a PMMA substrate by vacuum deposition or by coating.
IT **104567-44-4 104567-45-5**
RL: USES (Uses)
(laser-sensitive optical recording medium with recording layer of)
RN 104567-44-4 CAPLUS
CN 2-Naphthalenecarboxamide, 4-[[4-(diethylamino)-2-methylphenyl]imino]-1,4-dihydro-N-(6-nitro-2-benzothiazolyl)-1-oxo- (9CI) (CA INDEX NAME)



RN 104567-45-5 CAPLUS
CN 2-Naphthalenecarboxamide, N-(6-bromo-2-benzothiazolyl)-4-[[4-(diethylamino)-2-methylphenyl]imino]-1,4-dihydro-1-oxo- (9CI) (CA INDEX NAME)

L7 ANSWER 156 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 157 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1986:505746 CAPLUS

DN 105:105746

TI Electrophotographic photoreceptors

IN Hasegawa, Masaru; Suda, Osamu; Tanaka, Norio; Kono, Toshio; Hoshino, Nobuo

PA Dainichiseika Color and Chemicals Mfg. Co., Ltd., Japan; Mitsubishi Paper Mills, Ltd.

SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 61006653 <--	A2	19860113	JP 1984-127755	19840621
JP 03010302	B4	19910213		
PRAI JP 1984-127755		19840621		

GI For diagram(s), see printed CA Issue.

AB The claimed electrophotog. photoreceptors contain a bisazo compound I {R, R1 = II, III, IV, V, VI, CH(COMe)CONR12R13, R2-R5 = H, halo, Me, Et, MeO, EtO, OH, NO2; R6, R7 = NR14R15, OR16, NHN:CHR17, NHNR18R19; R8, R9 = alkyl, aralkyl, aryl, heterocyclyl; R10 = alkyl, carboxyl, ester moiety; R11, R12, R17 = aryl, heterocyclyl; R13, R14, R15, R16, R18, R19 = H, ALKYL,ARALKYL, ARYL, HETEROCYCLYL). The bisazo compound is especially useful as the charge carrier-generator.

IT 103890-36-4
RL: TEM (Technical or engineered material use); USES (Uses)
(electrophotog. charge carrier-generating pigment)

RN 103890-36-4 CAPLUS

CN 2-Anthracenecarboxamide, 3-hydroxy-4-[[4'-[[4-hydroxy-3-[[(6-nitro-2-benzothiazolyl)amino]carbonyl]-1-naphthalenyl]azo]-3,3'-dinitro[1,1'-biphenyl]-4-yl]azo]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 157 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L7 ANSWER 158 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1986:466446 CAPLUS

DN 105:66446

TI Relieving pain and inflammatory conditions employing substituted salicylamides

IN Ritchey, Thomas W.

PA Lever Brothers Co., USA

SO U.S., 18 pp.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4560549 <--	A	19851224	US 1983-525916	19830824
US 4725590 <--	A	19880216	US 1985-774617	19850910
US 4742083 <--	A	19880503	US 1985-774613	19850910
JP 62099329 <--	A2	19870508	JP 1985-237164	19851023
PRAI US 1983-525916	A3	19830824		

GI



AB Medicated pads, plasters, bandages or dressings, and catamenial or noncatamenial tampons contain antiinflammatory salicylamides I [R1 and R2 which impart an octanol/water distribution function of 4.5-10 to the compound = H, normal or branched-chain or cyclic or fused-ring polycyclic or nonfused-ring polycyclic alkyl, alkenyl, alkynyl, (un)substituted aryl or heteroaryl; R3 = thiazol-2-yl, benzothiazol-2-yl, (un)substituted Ph; X1, X2 = CHOH, CH2, CO, OC(O), O, NH, S, SO, SO2, CONH, NHCH2, CONHCH2, bond]. Thus, a catamenial tampon is sprinkled with a 10% weight/weight Me2CO solution of S-4-F (II) to provide 0.01 g II/cm2 outer surface of tampon and dried in an aerated chamber at room temperature When the resulting tampon is intravaginally worn, relief of intravaginal pain and inflammation is noticed. Addnl., in view of the highly antimicrobial nature if I, including II, bacterial conditions such as monilia are effectively combated and prevented.

IT 78417-85-3 103426-23-9
RL: DEV (Device component use); USES (Uses)
(surgical dressings containing)

RN 78417-85-3 CAPLUS

CN Benzamide, N-2-benzothiazolyl-2-hydroxy-5-(1-oxodecyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 158 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 103426-23-9 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2-hydroxy-5-(1-oxohexadecyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 159 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:442772 CAPLUS
DN 105:42772
TI Furoindolone antiinflammatory agents
IN Lawrence, Melvin S., Jr.
PA Pfizer Inc., USA
SO Eur. Pat. Appl., 52 pp.
CODEN: EPXKDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 173520	A2	19860305	EP 1985-305830	19850816
<--					
	EP 173520	A3	19860514		
	EP 173520	B1	19900103		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	WO 8601510	A1	19860313	WO 1984-US1371	19840824
<--					
	W: FI, HU, US				
	HU 47580	A2	19890328	HU 1984-4219	19840824
<--					
	HU 203238	B	19910628		
	AT 49211	E	19900115	AT 1985-305830	19850816
<--					
	CA 1244427	A1	19881108	CA 1985-489226	19850822
<--					
	PL 147393	B1	19890531	PL 1985-255089	19850822
<--					
	PL 147395	B1	19890531	PL 1985-260270	19850822
<--					
	DK 8503826	A	19860225	DK 1985-3826	19850823
<--					
	DK 160098	B	19910128		
	DK 160098	C	19910624		
	JP 61057554	A2	19860324	JP 1985-185619	19850823
<--					
	JP 04050316	B4	19920813		
	ES 546377	A1	19870401	ES 1985-546377	19850823
<--					
	ZA 8506403	A	19870429	ZA 1985-6403	19850823
<--					
	IL 76175	A1	19890815	IL 1985-76175	19850823
<--					
	IL 87402	A1	19890815	IL 1985-87402	19850823
<--					
	IL 87403	A1	19890815	IL 1985-87403	19850823
<--					
	IL 87404	A1	19890815	IL 1985-87404	19850823
<--					
	AU 8546637	A1	19860227	AU 1985-46637	19850826
<--					
	AU 553859	B2	19860731		
	ES 552044	A1	19870601	ES 1986-552044	19860214
<--					
	US 4695571	A	19870922	US 1986-867185	19860402
<--					

L7 ANSWER 159 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

	FI 8601704	A	19860423	FI 1986-1704	19860423
<--					
	FI 79319	B	19890831		
	FI 79319	C	19891211		
PRAI	WO 1984-US1371	A	19840824		
	EP 1985-305830	A	19850816		
	IL 1985-76175	A	19850823		

OS CASREACT 105:42772
GI



AB Fused oxindoles I (Z = N, CH, CMe; Z1 = O, S; R = alkyl, Ph; R1 = Ph, halo- or methoxyphenyl, heteroaryl, etc.; R2 = H, Me), useful as antiinflammatory agent (no data), were prepared Furoindolone II (R3 = H) was treated with 4-ClC6H4NCO at 25° to give II (R3 = CONHC6H4Cl-4).
IT 103113-60-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as inflammation inhibitor)
RN 103113-60-6 CAPLUS
CN 5H-Furo[2,3-f]indole-7-carboxamide, N-2-benzothiazolyl-5-ethyl-6,7-dihydro-6-oxo- (9CI) (CA INDEX NAME)



L7 ANSWER 160 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:216455 CAPLUS
DN 104:216455
TI Electrophotographic photosensitive element
IN Ito, Akira; Enomoto, Kazuhiro
PA Mitsubishi Paper Mills, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 60243661	A2	19851203	JP 1984-101371	19840518
<--					
PRAI	JP 1984-101371		19840518		

GI For diagram(s), see printed CA Issue.
AB A photosensitive element for electrophotog. contains an azo compound of the formula I (A = thiazolyl, benzothiazolyl, naphthothiazolyl). It has a good carrier-generating property and is stable against heat and light. It has also high sensitivity and low residual voltage. Thus, a carrier-generating layer consisting of I (A = benzothiazolyl), a polyarylate (U-100), and 1,2-dichloroethane was coated on an Al plate and a charge-transport layer consisting of 4-(N,N-dibenzylamino)-2-methylbenzaldehyde diphenylhydrazone and U-100 was overcoated to make an electrophotog. photosensitive unit. It maintained high carrier-generating characteristics and low residual charge after 100 copies were made.
IT 102254-25-1 102254-26-2 102267-71-0
RL: USES (Uses)
(electrophotog. photoconductor containing, for improved stability against light and heat)
RN 102254-25-1 CAPLUS
CN 1lH-Benzo[a]carbazole-3-carboxamide, 1,1',1''-[nitrilotris(4,1-phenyleneazo)]tris[N-2-benzothiazolyl-2-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A



L7 ANSWER 160 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B



RN 102254-26-2 CAPLUS
CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1',1''-[nitrilotris(4,1-phenyleneazo)]tris[N-(6-ethoxy-2-benzothiazolyl)-2-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A



L7 ANSWER 160 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B



RN 102267-71-0 CAPLUS
CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1',1''-[nitrilotris(4,1-phenyleneazo)]tris[2-hydroxy-N-naphtho[2,1-d]thiazol-2-yl- (9CI) (CA INDEX NAME)

PAGE 1-A



L7 ANSWER 160 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



PAGE 2-B



L7 ANSWER 161 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:196943 CAPLUS
DN 104:196943
TI Electrophotographic photoreceptor
IN Enomoto, Kazuhiro; Ito, Akira
PA Mitsubishi Paper Mills, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 16 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 60220350	A2	19851105	JP 1984-78219	19840417
<--					
	JP 02060173	B4	19901214		
PRAI	JP 1984-78219		19840417		

GI For diagram(s), see printed CA Issue.
AB The photosensitive layer of the title photoreceptor contains an azo compound having the general formula I (Z = divalent group bonded to the azo groups; A, A1 = saturated, unsatd., aromatic or heterocyclic ring). The azo compds. may be included in the photosensitive layer as the charge generator, along with the charge transport agent. Z group in I may typically have the formula II, III, IV, V, VI, VII, VIII, IX, or X (m, n = 0, 1; R = H, OMe, OEt, halo, Me, Et, nitro; R1 = H, halo, CN; X = O, S, NH; R2 = H, alkyl, allyl, benzyl or Ph; R3 = H, alkyl, allyl, propagyl, (substituted) benzyl; X1 = O, S; R4 = alkyl, allyl, propagyl, methallyl, H; R5, R6 = H, halo, alkyl, OMe, nitro group). The azo compound as the charge generator is highly efficient, and is stable to heat, in combination with varieties of charge transport agents. Thus, an Al-laminated polyester film was undercoated with a maleic anhydride-vinyl acetate-vinyl chloride copolymer (MF-10) and a charge-generating layer 0.5 μm composed of 1:1 mixture of the azo compound XI and a polyarylate (U-100). A composition containing N,N-dibenzylaminobenzaldehyde 1,1-diphenylhydrazone 5 and the polyarylate 7 g was coated to form a 12-μm charge-transport layer. After 1 wk of ageing, the photoreceptor was charged to -870 V, the sensitivity was 2.8 lx-s and the residual potential was -5 V. These values were -840 V, 2.5 lx-s, and 0 V, resp., after 500 charge-discharge cycles.
IT 101951-66-0
RL: USES (Uses)
(electrophotog. photoconductor with charge generating layer containing, for stability against heat)
RN 101951-66-0 CAPLUS
CN 2-Anthracenecarboxamide, 4,4'-[1,3,4-oxadiazole-2,5-diylbis(4,1-phenyleneazo)]bis[N-2-benzothiazolyl-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 161 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



IT 101951-67-1 101951-68-2 101951-69-3
101951-70-6 101951-71-7 101951-72-8
101951-73-9 101996-37-6
RL: USES (Uses)
(electrophotog. photoreceptor with charge generating layer containing, with
improved stability against heat)
RN 101951-67-1 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[1,3,4-oxadiazole-2,5-diylbis(4,1-phenyleneazo)]bis[3-hydroxy-N-naphtho[2,1-d]thiazol-2-yl- (9CI) (CA INDEX NAME)

L7 ANSWER 161 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 101951-68-2 CAPLUS
CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[2-hydroxy-N-(6-methyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 161 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 101951-69-3 CAPLUS
CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[(3,3'-dibromo[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-(5,6-dimethyl-2-benzothiazolyl)-2-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 101951-70-6 CAPLUS
CN 11H-Benzo[a]carbazole-3-carboxamide, 1,1'-[(3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-2-benzothiazolyl-2-hydroxy- (9CI) (CA INDEX

L7 ANSWER 161 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
NAME)

PAGE 1-A



PAGE 1-B



RN 101951-71-7 CAPLUS
CN 9H-Carbazole-3-carboxamide, 1,1'-[(1-cyano-1,2-ethenediyl)bis(4,1-phenyleneazo)]bis[N-(6-ethoxy-2-benzothiazolyl)-2-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A



L7 ANSWER 161 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 101951-72-8 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(1-bromo-1,2-ethenediyl)bis(4,1-phenyleneazo)]bis[7-chloro-3-hydroxy-N-naphtho[1,2-d]thiazol-2-yl- (9CI) (CA INDEX NAME)



RN 101951-73-9 CAPLUS
CN 2-Anthracenecarboxamide, 4,4'-[[9-(dicyanomethylene)-9H-fluorene-3,6-diyl]bis(azo)]bis[N-(5-ethoxy-2-benzothiazolyl)-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 161 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B



L7 ANSWER 161 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 101996-37-6 CAPLUS
CN 9H-Carbazole-3-carboxamide, 1,1'-[(methylimino)bis(4,1-phenyleneazo)]bis[2-hydroxy-N-naphtho[2,1-d]thiazol-2-yl- (9CI) (CA INDEX NAME)

PAGE 1-A



L7 ANSWER 162 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:177660 CAPLUS
DN 104:177660
TI Electrophotographic photoreceptors
IN Enomoto, Kazuhiro; Chiga, Takao; Hasegawa, Masaru; Tanaka, Norio
PA Mitsubishi Paper Mills, Ltd., Japan; Dainichiseika Color and Chemicals Mfg. Co., Ltd.
SO Jpn. Kokai Tokkyo Koho, 21 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 60205454	A2	19851017	JP 1984-61792	19840329
<--					
	JP 02060172	B4	19901214		
PRAI	JP 1984-61792		19840329		

GI



I

AB The claimed electrophotog. photoreceptors contain azo pigments prepared by reaction of a bisdiazonium salt with I (R, R1 = H, halo, NO2, furyl, alkyl, Ph; and RR1 in combination may complete a ring) and 2-hydroxy-3-naphthoic acid. The azo pigments (a mixture of sym. and asym. bisazo pigments) are especially useful as charge carrier-generating pigments for composite electrophotog. photoconductors. Biphenylenebisdiazonium salts are especially useful as the reactants.
IT 25743-46-8 25829-71-4 26987-26-8 101750-45-2 101750-46-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(coupling reactions of, with biphenylene bisdiazonium salts and hydroxynaphthoic acid)
RN 25743-46-8 CAPLUS
CN 2-Naphthalenecarboxamide, 3-hydroxy-N-naphtho[2,1-d]thiazol-2-yl- (9CI) (CA INDEX NAME)



L7 ANSWER 162 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 25829-71-4 CAPLUS
CN 2-Naphthalenecarboxamide, N-2-benzothiazolyl-3-hydroxy- (8CI, 9CI) (CA INDEX NAME)



RN 26987-26-8 CAPLUS
CN 2-Naphthalenecarboxamide, 3-hydroxy-N-naphtho[1,2-d]thiazol-2-yl- (9CI) (CA INDEX NAME)



RN 101750-45-2 CAPLUS
CN 2-Naphthalenecarboxamide, N-(6-ethoxy-2-benzothiazolyl)-3-hydroxy- (9CI) (CA INDEX NAME)



RN 101750-46-3 CAPLUS
CN 2-Naphthalenecarboxamide, N-(5,6-dimethyl-2-benzothiazolyl)-3-hydroxy- (9CI) (CA INDEX NAME)



IT **99741-62-5P 101702-73-2P 101702-74-3P 101702-75-4P 101702-82-3P 101702-83-4P 101702-88-9P 101702-89-0P 101702-95-8P**

L7 ANSWER 162 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

101702-96-9P 101703-02-0P 101703-03-1P 101703-04-2P 101703-19-9P 101703-24-6P 101750-56-5P 101750-57-6P 101750-58-7P 101750-68-9P 101750-69-0P 101750-70-3P 101765-03-1P
RL: PREP (Preparation)
(prepn. of, as electrophotog. charge carrier generating pigment)
RN 99741-62-5 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-2-benzothiazolyl-3-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 101702-73-2 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4-[[3,3'-dichloro-4'-[[3-[[(5,6-dimethyl-2-benzothiazolyl)amino]carbonyl]-2-hydroxy-1-naphthalenyl]azo][1,1'-biphenyl]-4-yl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 162 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 101702-74-3 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4-[[3,3'-dichloro-4'-[[2-hydroxy-3-[(naphtho[1,2-d]thiazol-2-ylamino)carbonyl]-1-naphthalenyl]azo][1,1'-biphenyl]-4-yl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 162 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 101702-75-4 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4-[[3,3'-dichloro-4'-[[2-hydroxy-3-[(naphtho[2,1-d]thiazol-2-ylamino)carbonyl]-1-naphthalenyl]azo][1,1'-biphenyl]-4-yl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 162 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 101702-82-3 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-2-benzothiazolyl-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 162 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 101702-83-4 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-(6-ethoxy-2-benzothiazolyl)-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 162 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 101702-88-9 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4-[[4'-[[3-[(2-benzothiazolylamino)carbonyl]-2-hydroxy-1-naphthalenyl]azo]-3,3'-dimethoxy[1,1'-biphenyl]-4-yl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 162 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 101702-89-0 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4-[[4'-[[3-[[(6-ethoxy-2-benzothiazolyl)amino]carbonyl]-2-hydroxy-1-naphthalenyl]azo]-3,3'-dimethoxy[1,1'-biphenyl]-4-yl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 162 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 101702-95-8 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-2-benzothiazolyl-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 162 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 101702-96-9 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-(5,6-dimethyl-2-benzothiazolyl)-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 162 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 101703-02-0 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4-[[4'-[[3-[(2-benzothiazolylamino)carbonyl]-2-hydroxy-1-naphthalenyl]azo]-3,3'-dimethyl[1,1'-biphenyl]-4-yl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 162 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 101703-03-1 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4-[[4'-[[3-[[(6-ethoxy-2-benzothiazolyl)amino]carbonyl]-2-hydroxy-1-naphthalenyl]azo]-3,3'-dimethyl[1,1'-biphenyl]-4-yl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 162 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 101703-04-2 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4-[[4'-[[3-[[(5,6-dimethyl-2-benzothiazolyl)amino]carbonyl]-2-hydroxy-1-naphthalenyl]azo]-3,3'-dimethyl[1,1'-biphenyl]-4-yl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 162 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 101703-19-9 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(2,2'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-2-benzothiazolyl-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 162 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 101703-24-6 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4-[[4'-[[3-[(2-benzothiazolylamino)carbonyl]-2-hydroxy-1-naphthalenyl]azo]-2,2'-dichloro[1,1'-biphenyl]-4-yl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 162 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 101750-56-5 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-(6-ethoxy-2-benzothiazolyl)-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 162 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 101750-57-6 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-(5,6-dimethyl-2-benzothiazolyl)-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 162 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 101750-58-7 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[3-hydroxy-N-naphtho[2,1-d]thiazol-2-yl- (9CI) (CA INDEX NAME)

L7 ANSWER 162 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 101750-68-9 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4-[[4'-[[3-[(2-benzothiazolylamino)carbonyl]-2-hydroxy-1-naphthalenyl]azo]-3,3'-dichloro[1,1'-biphenyl]-4-yl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A



L7 ANSWER 162 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 101750-69-0 CAPLUS
CN 2-Naphthalenecarboxylic acid, 4-[[3,3'-dichloro-4'-[[3-[[(6-ethoxy-2-benzothiazolyl)amino]carbonyl]-2-hydroxy-1-naphthalenyl]azo][1,1'-biphenyl]-4-yl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 101750-70-3 CAPLUS

L7 ANSWER 162 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Naphthalenecarboxamide, 4,4'-[(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-(6-ethoxy-2-benzothiazolyl)-3-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 101765-03-1 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[3-hydroxy-N-naphtho[1,2-d]thiazol-2-yl- (9CI) (CA INDEX NAME)

L7 ANSWER 162 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 163 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:150126 CAPLUS
DN 104:150126
TI Heat-stable poly(arylene sulfide) compositions
IN Kitanaka, Minoru
PA Toray Industries, Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 60195158	A2	19851003	JP 1984-49283	19840316
<--				
PRAI JP 1984-49283		19840316		

GI



I

AB Title compns. useful for printed circuit boards contain poly(arylene sulfide) and 0.01-10 parts RCONHR1 (R = (substituted) Ph group; R1 = (substituted) heterocyclic group containing ≥1 N). Thus, a mixture of 32.6 kg Na2S and 36.1 g BzONa preheated to 205° was mixed with 37.5 kg 1,4-Cl2C6H4 and heated for 4 h at 265° to give 21.1 kg poly(phenylene sulfide) powder with melt viscosity 2900 P, which (1 kg) was mixed with 0.1 g I, pelletized, pressed into a 1-mm-thick sheet laminated with TAI (35-μ electrolytic Cu foil) at 300° for 3 min, then at 150° for 10 min under 120 kg/cm2 load to give 0.5-mm laminated board having peel strength 1.4 kg/cm initially and 1.6 after 20 days at 150°.
IT 101622-73-5
RL: MOA (Modifier or additive use); USES (Uses)
(heat stabilizer, for poly(arylene sulfide) in copper foil laminates for printed circuit boards)
RN 101622-73-5 CAPLUS
CN Benzamide, N-2-benzothiazolyl-2-hydroxy- (9CI) (CA INDEX NAME)



L7 ANSWER 164 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:59390 CAPLUS
DN 104:59390
TI Electrophotographic plates
IN Enomoto, Kazuhiro
PA Mitsubishi Paper Mills, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 60163048	A2	19850824	JP 1984-19134	19840204
<--				
JP 03035658	B4	19910529		
PRAI JP 1984-19134		19840204		

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title plates have a photosensitive layer containing an azo compound of the formula I [Z = divalent residue such as II (R1 = halo, OMe, NO2, alkyl; m = 0-2), III (x, y = 0, 1), p-C6H4NR3C6H4p (R3 = H, alkyl, aryl, ph), IV (X = O, S), V, VI (R4 = H, alkyl, aryl, HC.tplbond.CCH2, benzyl), VII (R5 = alkyl, aryl, H, HC.tplbond.CCH2), VIII (R6, R7 = H, halo, alkyl, OMe); R = halo, NO2, alkyl, alkoxy, alkylthio; n = 0-4]. The above plates may have a composite photosensitive layer containing a charge carrier-generating substance of the formula I and a charge carrier-transporting substance.
IT 25829-71-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(coupling reaction of, with dichlorodiaminodiphenyl)
RN 25829-71-4 CAPLUS
CN 2-Naphthalenecarboxamide, N-2-benzothiazolyl-3-hydroxy- (8CI, 9CI) (CA INDEX NAME)



IT 99741-63-6 99741-64-7 99741-65-8
99741-66-9 99741-67-0 99754-29-7
RL: USES (Uses)
(electrophotog. photosensitive layer containing charge carrier-generating substance from)
RN 99741-63-6 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[N-2-benzothiazolyl-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 164 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 99741-64-7 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[3-hydroxy-N-(6-methoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 164 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 99741-65-8 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[3-hydroxy-N-(4-methyl-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 164 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 99741-66-9 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(1-chloro-1,2-ethenediyl)bis(4,1-phenyleneazo)]bis[N-2-benzothiazolyl-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 164 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 99741-67-0 CAPLUS
CN 2-Naphthalenecarboxamide, N-(5-chloro-6-nitro-2-benzothiazolyl)-4-[[4-[6-[[3-[[(5-chloro-6-nitro-2-benzothiazolyl)amino]carbonyl]-2-hydroxy-1-naphthalenyl]azo]-2-benzoxazolyl]phenyl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 164 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 99754-29-7 CAPLUS
CN 2-Naphthalenecarboxamide, N-2-benzothiazolyl-4-[[4-[6-[[3-[(2-benzothiazolylamino)carbonyl]-2-hydroxy-1-naphthalenyl]azo]-2-benzothiazolyl]phenyl]azo]-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 164 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



IT 99741-62-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and use of, as electrophotog. charge carrier-generating compound)
RN 99741-62-5 CAPLUS
CN 2-Naphthalenecarboxamide, 4,4'-[(3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-2-benzothiazolyl-3-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 164 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L7 ANSWER 165 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1984:611164 CAPLUS
DN 101:211164
TI Carboxamido derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines
IN Doria, Gianfederico; Passarotti, Carlo; Buttinoni, Ada
PA Farmitalia Carlo Erba S.p.A., Italy
SO Ger. Offen., 59 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3346223	A1	19840628	DE 1983-3346223	19831221
<--					
	ZA 8309105	A	19840725	ZA 1983-9105	19831207
<--					
	US 4522944	A	19850611	US 1983-559322	19831208
<--					
	AT 8304383	A	19870715	AT 1983-4383	19831215
<--					
	AT 385036	B	19880210		
	GB 2132200	A1	19840704	GB 1983-33535	19831216
<--					
	GB 2132200	B2	19860604		
	NL 8304340	A	19840716	NL 1983-4340	19831216
<--					
	AU 8322525	A1	19840628	AU 1983-22525	19831219
<--					
	AU 558600	B2	19870205		
	FI 8304698	A	19840624	FI 1983-4698	19831220
<--					
	CH 657136	A	19860815	CH 1983-6783	19831220
<--					
	BE 898512	A1	19840621	BE 1983-212085	19831221
<--					
	DK 8305939	A	19840624	DK 1983-5939	19831222
<--					
	SE 8307133	A	19840624	SE 1983-7133	19831222
<--					
	SE 454698	B	19880524		
	SE 454698	C	19880901		
	JP 59139389	A2	19840810	JP 1983-241119	19831222
<--					
	IL 70522	A1	19860228	IL 1983-70522	19831222
<--					
	CA 1211440	A1	19860916	CA 1983-444151	19831222
<--					
	SU 1297731	A3	19870315	SU 1983-3682101	19831222
<--					
	FR 2538392	A1	19840629	FR 1983-20704	19831223
<--					
	FR 2538392	B1	19870116		
PRAI	GB 1982-36642	A	19821223		
	GB 1983-29746	A	19831108		

OS CASREACT 101:211164
GI

L7 ANSWER 165 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II



III

AB The title compds. [I; R = H, alkyl, alkoxyalkyl, halo, trihalomethyl, heterocyclyl, R3R4N(CH2)n, R5S(O)m; R1, R3, R4 = H, alkyl; R2 = (un)substituted Ph, unsatd. heterocyclyl; R5 = alkyl, PhCH2, (un)substituted Ph; n = 0-3; m = 0-2] were prepared Thus, 10 g 2-amino-5-(3-pyridyl)-1,3,4-thiadiazole was condensed with 18 g EtOCH:CH(CO2Et)2 to give 15.8 g II, which was cyclized by heating at 120° with polyphosphoric acid to give 6.6 g thiadiazolopyrimidinecarboxylate III. This was treated with 2-aminopyridine to give 5.3 g I (R = 3-pyridinyl, R1 = H, R2 = 2-pyridinyl) (IV). In the rat paw edema test IV had an antiinflammatory ED50 of 45.86 mg/kg.

IT **92930-34-2P 92930-42-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 92930-34-2 CAPLUS

CN 5H-1,3,4-Thiadiazolo[3,2-a]pyrimidine-6-carboxamide, N-2-benzothiazolyl-5-oxo- (9CI) (CA INDEX NAME)



RN 92930-42-2 CAPLUS

CN 5H-1,3,4-Thiadiazolo[3,2-a]pyrimidine-6-carboxamide, N-2-benzothiazolyl-2-(4-morpholinyl)-5-oxo- (9CI) (CA INDEX NAME)

L7 ANSWER 165 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 166 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1983:612536 CAPLUS

DN 99:212536

TI Substituted 1H-pyrazolo[1,5-a]pyrimidines

IN Doria, Gianfederico; Passarotti, Carlo; Buttinoni, Ada

PA Farmitalia Carlo Erba S.p.A., Italy

SO Ger. Offen., 98 pp.
CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3309432	A1	19830922	DE 1983-3309432	19830316
<--					
	AU 8312304	A1	19830922	AU 1983-12304	19830309
<--					
	AU 557300	B2	19861218		
	ZA 8301611	A	19831130	ZA 1983-1611	19830309
<--					
	US 4482555	A	19841113	US 1983-474205	19830310
<--					
	CH 654306	A	19860214	CH 1983-1325	19830311
<--					
	GB 2116971	A1	19831005	GB 1983-6905	19830314
<--					
	GB 2116971	B2	19850327		
	BE 896159	A1	19830915	BE 1983-210320	19830315
<--					
	DK 8301207	A	19830917	DK 1983-1207	19830315
<--					
	FI 8300864	A	19830917	FI 1983-864	19830315
<--					
	FI 74469	B	19871030		
	FI 74469	C	19880208		
	SE 8301412	A	19830917	SE 1983-1412	19830315
<--					
	SE 450573	B	19870706		
	SE 450573	C	19871015		
	FR 2523582	A1	19830923	FR 1983-4253	19830315
<--					
	FR 2523582	B1	19851206		
	JP 58167590	A2	19831003	JP 1983-41610	19830315
<--					
	NL 8300934	A	19831017	NL 1983-934	19830315
<--					
	CA 1192546	A1	19850827	CA 1983-423644	19830315
<--					
	IL 68133	A1	19851231	IL 1983-68133	19830315
<--					
	SU 1366060	A3	19880107	SU 1983-3565748	19830315
<--					
PRAI	GB 1982-7637	A	19820316		
	GB 1983-3089	A	19830204		

OS CASREACT 99:212536

GI

L7 ANSWER 166 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Antiinflammatory pyrazolopyrimidines I [R = alkyl, PhCH2, (un)substituted Ph, pyridyl; R1, R2 = H, alkyl, halo; R3 = H, alkyl, Ph; R4 = OH, alkoxy, amino, heterocyclyl] were prepared Thus, 1-phenyl-3-amino-1H-pyrazole was condensed with EtOCH:C(CO2Et)2 to give the pyrazolyl enamine II, which was cyclized by H3PO4-P2O5 to give I (R = Ph, R1-R3 = H, R4 = OEt). This was treated with 2-aminopyridine to give I (R = Ph, R1-R3 = H, R4 = 2-pyridylamino) (III). In the rat paw edema test III had an ED25 of 16 mg/kg orally.

IT **87948-79-6P 87949-03-9P 87949-22-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 87948-79-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-2-benzothiazolyl-1,7-dihydro-1-methyl-7-oxo- (9CI) (CA INDEX NAME)



RN 87949-03-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-2-benzothiazolyl-1,7-dihydro-7-oxo-1-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 87949-22-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-2-benzothiazolyl-1,7-dihydro-7-

L7 ANSWER 166 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
oxo-1-phenyl- (9CI) (CA INDEX NAME)



L7 ANSWER 167 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1983:198237 CAPLUS
DN 98:198237
TI Benzothiazole derivatives
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 57175189	A2	19821028	JP 1981-60368	19810421
<--					
	JP 63032073	B4	19880628		
PRAI	JP 1981-60368		19810421		

OS CASREACT 98:198237
GI



AB Thirty benzothiazole derivs. I [R = alkyl, alkoxy, halo, NO2; R1 = H, alkyl, alkanoyl, alkoxycarbonyl; R2 = H, alkyl, MeSCH2CH2, aralkyl; R1R2 = (CH2)p (p = 3, 4)); m = 0-4; n = 1, 2] were prepared by cyclization of II.
I had platelet aggregation inhibitory, hypotensive, herbicidal, and antibacterial activities (no data). Thus, stirring II (Rm = 6-EtO, R1 = Me, R2 = H, m = n = 1) in Ac2O 2 h at 70° gave 90.7% I (Rm = 6-EtO, R1 = Me, R2 = H, m = n = 1).
IT **84427-23-6P 84427-24-7P 84427-27-0P 84427-29-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 84427-23-6 CAPLUS
CN L-Proline, 1-[(2-benzothiazolylamino)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 84427-24-7 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[(2-benzothiazolylamino)carbonyl]- (9CI)

L7 ANSWER 167 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(CA INDEX NAME)



RN 84427-27-0 CAPLUS
CN L-Proline, 1-[[(6-methoxy-2-benzothiazolyl)amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 84427-29-2 CAPLUS
CN L-Proline, 1-[[(6-ethoxy-2-benzothiazolyl)amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 168 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1983:72084 CAPLUS
DN 98:72084
TI Benzothiazolyl amino acid derivatives
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 21 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 57149280	A2	19820914	JP 1981-34231	19810310
<--					
PRAI	JP 1981-34231		19810310		

GI



AB Forty-five title amino acids (I; R = H, alkyl, alkoxy, halo, O2N; R1 = HO, alkoxy, alkylamino; Z = amino acid residue; n = 1-4), effective herbicides, fungicides, anticholesteremics, and antiarrhythmics (no data), were prepared Thus, a mixture of 0.074 mol I (R = H, R1Z = PhO) and 0.147 mol glycine in pyridine was heated 48 h at 70° to give 83.9% I (R = H, R1 = HO, Z = HNCH2CO).
IT **84427-23-6P 84427-24-7P 84427-25-8P 84427-26-9P 84427-27-0P 84427-29-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 84427-23-6 CAPLUS
CN L-Proline, 1-[(2-benzothiazolylamino)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 84427-24-7 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[(2-benzothiazolylamino)carbonyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 168 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 84427-25-8 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[(2-benzothiazolylamino)carbonyl]- (9CI) (CA INDEX NAME)



RN 84427-26-9 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[(2-benzothiazolylamino)carbonyl]- (9CI) (CA INDEX NAME)



RN 84427-27-0 CAPLUS
CN L-Proline, 1-[[(6-methoxy-2-benzothiazolyl)amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 84427-29-2 CAPLUS
CN L-Proline, 1-[[(6-ethoxy-2-benzothiazolyl)amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 168 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 169 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1983:4563 CAPLUS
DN 98:4563
TI Quinoxaline derivatives
IN Issidorides, Costas H.; Haddadin, Makhluf J.
PA Research Corp. , USA
SO U.S., 24 pp. Cont.-in-part of U.S. Ser. No. 691,252, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4343942	A	19820810	US 1969-883577	19691209
<--					
	CA 923131	A1	19730320	CA 1967-4478	19671107
<--					
	GB 1308370	A	19730228	GB 1970-47202	19701005
<--					
	NL 157302	B	19780717	NL 1972-8887	19720628
<--					
	DK 7800142	A	19780112	DK 1978-142	19780112
<--					
	US 4866175	A	19890912	US 1979-29344	19790412
<--					
PRAI	US 1966-592729	A2	19661108		
	NL 1967-14882	A	19671102		
	US 1967-691252	A2	19671218		
	DK 1967-5535	A	19671107		
	US 1969-883577	A	19691209		
	CA 1970-923131	A5	19701118		
	US 1977-843510	A1	19771008		

OS CASREACT 98:4563
GI



AB Bactericidal quinoxaline dioxides I (R, R1 = H, alkyl; R2 = F3C, H2NSO2, MeNHSO2, Me2NSO2) and II [R3 = alkoxy, aryloxy, PhCH2O, NR4R5 (R4, R5 = H, alkyl, Ph); R2 = H, Cl, F, Me, MeO, F3C, H2NSO2, MeNHSO2] and III (R2 = as before) were prepared Thus, condensation of benzofuroxan with Me2CO in refluxing MeCN containing pyrrolidine gave 2-methylquinoxaline dioxide which possessed a min. inhibitory concentration of 50 μg/mL against Pasteurella

L7 ANSWER 169 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
multocida.
IT 31983-93-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 31983-93-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(6-ethoxy-2-benzothiazolyl)-3-methyl-, 1,4-dioxide (8CI, 9CI) (CA INDEX NAME)



L7 ANSWER 170 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1982:616159 CAPLUS
DN 97:216159
TI Benzothiazole derivs.
PA Yamanouchi Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 57120582	A2	19820727	JP 1981-6214	19810119
<--				
PRAI JP 1981-6214		19810119		

GI



AB Title compds. I (R = H, alkoxy; R1, R3 = H, alkyl; R2 = H, phenylalkyl; m,
n = 0, 1), useful as inflammation inhibitors (no data), were prepared Thus,
stirring 3 g 2-aminobenzothiazole with 2.4 g Me(CHO)NHCH2CO2H, 4 g DCC and
30 mg 4-MeC6H4SO3H in pyridine gave 1.5 I (R = R1 = R3 = H, R2 = Me, m = n
= 0).
IT 83758-53-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 83758-53-6 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-2-benzothiazolyl-1-formyl- (9CI) (CA INDEX NAME)



L7 ANSWER 171 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1982:85435 CAPLUS
DN 96:85435
TI 2-Substituted-4-hydroxy-3-quinolinecarboxylic acid derivatives, their use as medicaments, compositions containing them and intermediates
IN Allais, Andre; Clemence, Francois; Deraedt, Roger; Le Martret, Odile
PA Roussel-UCLAF , Fr.
SO Eur. Pat. Appl., 45 pp.
CODEN: EPXKDW
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 40573	A2	19811125	EP 1981-400783	19810519
<--				
EP 40573	A3	19820113		
EP 40573	B1	19840801		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
FR 2482596	A1	19811120	FR 1980-11100	19800519
<--				
FR 2482596	B1	19830429		
US 4397856	A	19830809	US 1981-262952	19810512
<--				
CA 1184558	A1	19850326	CA 1981-377751	19810515
<--				
DK 8102172	A	19811120	DK 1981-2172	19810518
<--				
DK 152212	B	19880208		
DK 152212	C	19880808		
FI 8101529	A	19811120	FI 1981-1529	19810518
<--				
FI 77030	B	19880930		
FI 77030	C	19890110		
AU 8170689	A1	19811126	AU 1981-70689	19810518
<--				
AU 543580	B2	19850426		
ES 502264	A1	19820401	ES 1981-502264	19810518
<--				
ZA 8103293	A	19820526	ZA 1981-3293	19810518
<--				
HU 26727	O	19830928	HU 1981-1403	19810518
<--				
HU 184853	B	19841029		
JP 57031665	A2	19820220	JP 1981-74341	19810519
<--				
JP 63040430	B4	19880811		
AT 8783	E	19840815	AT 1981-400783	19810519
<--				
EP 143123	A2	19850605	EP 1983-201252	19810519
<--				
EP 143123	A3	19860903		
EP 143123	B1	19900725		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 54913	E	19900815	AT 1983-201252	19810519
<--				
US 4518775	A	19850521	US 1983-495475	19830517
<--				

L7 ANSWER 171 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PRAI FR 1980-11100	A	19800519	
US 1981-262952	A3	19810512	
EP 1981-400783	A	19810519	
EP 1983-201252	A	19810519	

OS CASREACT 96:85435
GI



AB The title compds. I (R = H, halogen, alkyl, alkoxy, CF3, SCF3, OCF3; R1 = NH2; R2 = haloalkyl; R3 = H, alkyl, acyl) were prepared Thus I (R = 8-CF3,
R1 = OEt, R2 = Me, R3 = H) was chlorinated to give I (R = 8-CF3, R1 = OEt,
R2 = CHCl2, R3 = H) which was hydrolyzed to acid, converted to the acid chloride, and amidated to give I (R = 8-CF3, R1 = 2-thiazolylamino, R2 = CHCl2, R3 = H; II). II had a ED50 in the HOAc writing test of 0.6 mg/kg orally mice.
IT 80777-28-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 80777-28-2 CAPLUS
CN 3-Quinolinecarboxamide, N-2-benzothiazolyl-2-(dichloromethyl)-4-hydroxy-8-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 172 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1981:9969 CAPLUS
DN 94:9969
TI Forming an optical soundtrack
IN Kawai, Masayoshi; Sakai, Tadao
PA Fuji Photo Film Co., Ltd., Japan
SO U.S., 22 pp. Cont.-in-part of U.S. Ser. No. 642,629, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4208210	A	19800617	US 1977-780885	19770324
<--				
JP 51072302	A2	19760623	JP 1974-146088	19741219
<--				
JP 58004337	B4	19830126		
PRAI JP 1974-146088	A	19741219		
US 1975-642629	A2	19751219		

GI For diagram(s), see printed CA Issue.
AB An optical sound track is produced by UV exposure of an optical sound track-forming area of a multilayer color photog. film. The sound trace-forming area is a UV-sensitive Ag halide emulsion layer containing nondiffusible Ag bleach inhibitors and an IR dye-forming coupler having the general formula I, II, or III (R = H, halo, CNS, acyloxy, alkoxy, aryloxy, alkylthio, arylthio, cyclic imido; R1 = H, halo; R3, R4 = H, C1-20 alkyl; R5 = C≥12 alkyl, C≥12 alkenyl, IV; R6 = H, C1-4 alkyl, C1-4 alkoxycarbonyl; R2, R7 = ballast group having >6 C, each may be bonded to the Ph nuclei either directly or via an amino, ether, thioether, carbonamide, sulfonamide, urea, ester, imide, carbonyl or sulfonyl bond; Z = nonmetallic atoms necessary to complete a thiazole or benzothiazole nucleus) and forming a dye having an absorption maximum at wavelength longer than 125 nm. The color photog also contains ≥1 layer interposed between the UV-sensitive Ag halide emulsion and the support containing nondiffusible UV absorbers. The UV absorbers have the general formula IV (R8, R9, R10 = H, halo, NO2 alkyl, alkoxy, aryl, aryloxy). Thus, a color photog. film was prepared by coating a cellulose triacetate film with a blue-sensitive Ag halide emulsion layer, a gelatin intermediate layer, a red-sensitive Ag halide emulsion layer, a gelatin intermediate layer, a green-sensitive Ag halide emulsion layer containing the
UV absorbents V 0.25 and VI 0.25 g/m2, a gelatin intermediate layer, a UV-sensitive Ag halide emulsion layer containing the Ag bleach inhibitors VII
0.12 and VIII 0.24 and the IR coupler IX 0.6 g/m2, and a gelatin-paraffin protective layer, step-wise exposed (corresponding to sound image-forming exposure; 100,000 lx for 1/100 s) through a Ag wedge and a visible light-absorbing filter and processed to give an IR d. of 1.8.
IT 69656-12-8
RL: USES (Uses)
(IR dye-forming coupler, for optical sound track formation on color cine film)
RN 69656-12-8 CAPLUS
CN 2-Naphthalenecarboxamide, N-[5-[[2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-1-oxobutyl]amino]-2-benzothiazolyl]-1-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 172 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 173 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1980:471794 CAPLUS
DN 93:71794
TI 4-Hydroxy-2H[1]benzothieno[2,3-e]-1,2-thiazine-3-carboxamide 1,1-dioxides and their salts
IN Engel, Wolfhard; Trummlitz, Guenter; Seeger, Ernst; Haarmann, Walter; Engelhardt, Guenther; Zimmermann, Rainer
PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
SO Ger. Offen., 51 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2838377	A1	19800320	DE 1978-2838377	19780902
<--					
	EP 9142	A1	19800402	EP 1979-103150	19790827
<--					
	R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	ES 483711	A1	19800416	ES 1979-483711	19790829
<--					
	DK 7903658	A	19800303	DK 1979-3658	19790831
<--					
	FI 7902721	A	19800303	FI 1979-2721	19790831
<--					
	NO 7902828	A	19800304	NO 1979-2828	19790831
<--					
	JP 55035086	A2	19800311	JP 1979-110530	19790831
<--					
	AU 7950466	A1	19800313	AU 1979-50466	19790831
<--					
	ZA 7904618	A	19810527	ZA 1979-4618	19790831
<--					
	US 4259336	A	19810331	US 1979-86743	19791022
<--					
PRAI	DE 1978-2838377	A	19780902		
	US 1979-68673	A2	19790822		

GI



I

AB The title compds. I [R = NHR3 (R3 = optionally substituted C6-10 aromatic group or C2-9 heteroarom. group containing 1-2 N and/or O or S; R1 = H, halogen, alkyl; R2 = H, alkyl) were prepared for use as antiphlogistics and blood platelet aggregation inhibitors (test data tabulated). Thus, I (R =

L7 ANSWER 173 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
OMe, R1 = H, R2 = Me) was refluxed with 2-aminothiazole in xylene to give 66% I (R = 2-thiazolylamino, R1 = H, R2 = Me).
IT **74370-66-4P 74370-78-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 74370-66-4 CAPLUS
CN 2H-[1]Benzothieno[2,3-e]-1,2-thiazine-3-carboxamide, N-2-benzothiazolyl-4-hydroxy-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 74370-78-8 CAPLUS
CN 2H-[1]Benzothieno[2,3-e]-1,2-thiazine-3-carboxamide, N-(5,6-dimethyl-2-benzothiazolyl)-4-hydroxy-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



L7 ANSWER 174 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1980:6521 CAPLUS
DN 92:6521
TI N-Heterocyclic substituted adamantanecarboxylic acid amide
IN Paul, Heinz; Buchwald, Ute; Tonew, Marion
PA Ger. Dem. Rep.
SO Ger. (East), 9 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DD 133799	Z	19790124	DD 1977-202014	19771111
<--					
PRAI	DD 1977-202014	A	19771111		

AB RCONHR1 (I; R = 1-adamantyl; R1 = optionally substituted heterocycle, e.g., thiadiazolyl, benzothiazolyl, pyridyl) were prepared for use as virucides. Thus, 1-adamantanecarbonyl chloride reacted with 2-aminobenzothiazole to give N-(2-benzothiazolyl)-1-adamantanecarboxamide. Test data for I against mengo and coxsackie A9 viruses were tabulated.
IT **35871-25-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and virucidal activity of)
RN 35871-25-1 CAPLUS
CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, N-2-benzothiazolyl- (9CI) (CA INDEX NAME)



L7 ANSWER 175 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1979:178140 CAPLUS
DN 90:178140
TI Cinematographic films
IN Sakai, Masao; Hirose, Takeshi; Yokota, Yukio; Kawai, Masaetsu
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 25 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 53125836 <--	A2	19781102	JP 1977-41082	19770411
PRAI JP 1977-41082	A	19770411		

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB In preparing color cine films having a support, a color image-forming unit with blue-, red-, and green-sensitive emulsion layers, and an opticoacoustic sound track layer made from a UV-sensitive Ag halide emulsion layer containing an IR coupler (a coupler which forms an image with λmax ≥725 nm) and a nondiffusible Ag removal inhibitor, UV absorbers are added to ≥1 layer between the support and the opticoacoustic sound track layer. The color images are formed by exposing the imaging layer to visible light, whereas acoustic images are formed by UV irradiation of the sound track layer. The photog. films give high IR image d. even when the so called sound development step is not used. Thus, a cellulose acetate film support back-coated with a carbon black-containing antihalation layer was coated with a subbing layer, a blue-sensitive emulsion layer, an intermediate layer, a red-sensitive emulsion layer, an intermediate layer, a green-sensitive emulsion layer containing the UV absorbers I and II, a sound track layer containing the Ag removal inhibitors III and IV and the IR coupler V, and a protective layer to give a cine film. The cine film was sensitometrically exposed by using a visible light absorbing filter, color developed, fixed, bleached, fixed again, and stabilized to give an IR image d. of 1.9. The cine film also gave high quality color images.

IT **69656-12-8**
RL: USES (Uses)
(IR photog. coupler, for sound track production in cine films)

RN 69656-12-8 CAPLUS
CN 2-Naphthalenecarboxamide, N-{5-[[2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-1-oxobutyl]amino]-2-benzothiazolyl]-1-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 175 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 176 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1979:130629 CAPLUS
DN 90:130629
TI Color photographic photosensitive materials containing infrared couplers
IN Sakai, Masao; Hirose, Takeshi; Yokota, Yukio
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 53129036 <--	A2	19781110	JP 1977-44348	19770418
PRAI JP 1977-44348	A	19770418		

GI For diagram(s), see printed CA Issue.

AB Ag halide color photog. emulsion layers contain ≥1 IR coupler of the general formula I [R = H, group released during coupling; R1, R2 = H, C1-20 alkyl; R3 = C≥12 alkyl, C≥12 alkenyl, II, III (Z = a group of atoms required to form thiazole or benzothiazole rings; R4 = C≥6 ballast group bonded to the ring via amino, ether, carboamide, phosphamide, urea, ester, carbonyl, or sulfonyl bonding; R5 = H, C1-4 alkyl, C2-5 alkoxycarbonyl)]. Optionally the emulsion layers containing the coupler I may also contain a compound of the formula IV (R6, R7, R8, R9, R10 = H, halogen, NO2, OH, alkyl, alkenyl, alkoxy, acryloxy, aryl, aryloxy, alkylthio, arylthio, mono- or dialkylamino, O- or N-containing 5- or 6-membered heterocyclic moiety; R9R10 in combination may complete 5- or 6-membered C rings). The IR couplers of the general formula V (R, R4, R5, Z are same as in I, III) may also be used instead of I. The cinematog. films prepared from the above emulsion layers do not require the "sound development" step, i.e., the special development step for developing the sound track. Thus, a color cinematog. film having a blue-sensitive emulsion, intermediate, red-sensitive emulsion, second intermediate, green-sensitive emulsion, and protective layer was prepared with the IR coupler VI (0.6 g/m2) and a cyan coupler in the red-sensitive emulsion layer. The film was then sensitometrically exposed, color developed, fixed, bleached, and refixed to give an IR optical d. of 1.7 vs. 0.3 for a VI-free control.

IT **69656-12-8**
RL: USES (Uses)
(cinematog. IR couplers)

RN 69656-12-8 CAPLUS
CN 2-Naphthalenecarboxamide, N-[5-[[2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-1-oxobutyl]amino]-2-benzothiazolyl]-1-hydroxy- (9CI) (CA INDEX NAME)

L7 ANSWER 176 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 177 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1978:563592 CAPLUS
DN 89:163592
TI 2,5-Dihydro-1,2-thiazino[5,6-b]indole-3-carboxamide 1,1-dioxides
IN Trummlitz, Guenter; Engel, Wolfhard; Seeger, Ernst; Haarmann, Walter; Engelhardt, Guenther
PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
SO Ger. Offen., 74 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2704485	A1	19780810	DE 1977-2704485	19770203
<--					
	SE 7714833	A	19780804	SE 1977-14833	19771228
<--					
	SE 436749	B	19850121		
	SE 436749	C	19850502		
	AT 7800111	A	19790815	AT 1978-111	19780109
<--					
	AT 355585	B	19800310		
	US 4137313	A	19790130	US 1978-872889	19780127
<--					
	SU 654173	D	19790325	SU 1978-2571747	19780130
<--					
	CS 194195	P	19791130	CS 1978-650	19780131
<--					
	FI 7800324	A	19780804	FI 1978-324	19780201
<--					
	FI 62097	B	19820730		
	FI 62097	C	19821110		
	DD 134767	C	19790321	DD 1978-203510	19780201
<--					
	HU 175550	P	19800828	HU 1978-TO1069	19780201
<--					
	IL 53948	A1	19801026	IL 1978-53948	19780201
<--					
	BE 863588	A1	19780802	BE 1978-184854	19780202
<--					
	DK 7800484	A	19780804	DK 1978-484	19780202
<--					
	DK 150517	B	19870316		
	DK 150517	C	19871019		
	NO 7800370	A	19780804	NO 1978-370	19780202
<--					
	NO 148490	B	19830711		
	NO 148490	C	19831019		
	NL 7801183	A	19780807	NL 1978-1183	19780202
<--					
	JP 53098998	A2	19780829	JP 1978-11044	19780202
<--					
	JP 61011235	B4	19860401		
	ES 466555	A1	19781001	ES 1978-466555	19780202
<--					
	AU 7832931	A1	19790809	AU 1978-32931	19780202
<--					

L7 ANSWER 177 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

	AU 516178	B2	19810521		
	ZA 7800630	A	19791031	ZA 1978-630	19780202
<--					
	GB 1569238	A	19800611	GB 1978-4304	19780202
<--					
	PL 109705	B1	19800630	PL 1978-204401	19780202
<--					
	CA 1088064	A1	19801021	CA 1978-296063	19780202
<--					
	CH 639389	A	19831115	CH 1978-1147	19780202
<--					
	FR 2379542	A1	19780901	FR 1978-3158	19780203
<--					
	FR 2379542	B1	19821203		
	ES 469110	A1	19781116	ES 1978-469110	19780425
<--					
	ES 469111	A1	19781116	ES 1978-469111	19780425
<--					
	ES 469112	A1	19781116	ES 1978-469112	19780425
<--					
	ES 469113	A1	19781116	ES 1978-469113	19780425
<--					
	AT 7902695	A	19790815	AT 1979-2695	19790411
<--					
	AT 355590	B	19800310		
	AT 7902696	A	19790815	AT 1979-2696	19790411
<--					
	AT 355591	B	19800310		
PRAI	DE 1977-2704485	A	19770203		
	AT 1978-111	A	19780109		

GI


I


II

AB Thiazinoindoles I (R = optionally substituted or condensed 2-thiazolyl, 2-pyridyl, methyl-2-pyridyl, Ph, optionally substituted by F, Cl, Br, Me, Et, CF3, OMe; R1 = H, Me, Et; R2 = Me, Et; R3 = H, F, Cl, Br, OMe, Me, Et, CF3) were prepared Thus, the indole II (R4 = NH2, R5 = CO2Me) was treated with NaOMe to give II (R4R5 = NNaCO), which was treated with ClCH2CO2Me to give II [R4R5 = N(CH2CO2Me)CO]. Treatment of the latter compound with NaOMe gave II [R4R5 = NHC(CO2Me):COH], which was N-methylated and treated with 2-aminothiazole to give I (R = 2-thiazolyl, R1 = R2 = Me, R3 = OH; III). At 2 + 10-5 mol/L III gave 96% inhibition of blood platelet aggregation.
IT 67929-55-9P

L7 ANSWER 177 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 67929-55-9 CAPLUS
CN 1,2-Thiazino[5,6-b]indole-3-carboxamide, N-2-benzothiazolyl-2,5-dihydro-4-hydroxy-2,5-dimethyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



L7 ANSWER 178 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1978:509449 CAPLUS
DN 89:109449
TI 5-Methylisoxazole-4-carboxamide derivatives
IN Kaemmerer, Friedrich Johannes; Schleyerbach, Rudolf; Heubach, Guenther
PA Hoechst A.-G., Fed. Rep. Ger.
SO Ger. Offen., 13 pp. Addn. to Ger. Offen. 2,524,959.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2655009	A1	19780615	DE 1976-2655009	19761204
<--					
	DE 2655009	C2	19900329		
	CH 608498	A	19790115	CH 1977-13934	19771115
<--					
	NL 7713151	A	19780606	NL 1977-13151	19771129
<--					
	DK 7705386	A	19780605	DK 1977-5386	19771202
<--					
	AT 7708663	A	19801015	AT 1977-8663	19771202
<--					
	AT 362366	B	19810511		
	CA 1102341	A1	19810602	CA 1977-292302	19771202
<--					
	GB 1596383	A	19810826	GB 1977-50347	19771202
<--					
	JP 53071070	A2	19780624	JP 1977-145622	19771203
<--					
	BE 861503	A4	19780605	BE 1977-183170	19771205
<--					
	FR 2372830	A2	19780630	FR 1977-36547	19771205
<--					
	FR 2372830	B2	19800620		
PRAI	DE 1976-2655009	A	19761204		

GI


I II

AB The title compds. I (R = C3-13 optionally substituted heterocyclic group containing 1-4 N, S or O heteroatoms) were prepared by the reaction of II (R1 = Cl, 2,4-Cl2C6H3O, PhCH2O) with the appropriate amine. I are useful as analgesics, antipyretics, and antiinflammatory agents (no data).
IT 67305-31-1P 67305-37-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 67305-31-1 CAPLUS
CN 4-Isoxazolecarboxamide, N-(4-chloro-2-benzothiazolyl)-5-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 178 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 67305-37-7 CAPLUS
CN 4-Isoxazolecarboxamide, N-2-benzothiazolyl-5-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

L7 ANSWER 179 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
analgesics, antipyretics, and anesthetics (no data).
IT **61935-82-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)
RN 61935-82-8 CAPLUS
CN Carbamic acid, [2-[(2-benzothiazolylamino)carbonyl]cyclohexyl]-, phenylmethyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 179 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1977:502009 CAPLUS
DN 87:102009
TI 2-Aminocycloalkanecarboxylic acids and their derivatives
IN Bernath, Gabor; Gera, Lajos; Dondos, Gyorgy; Kovacs, Kalman; Janvari, Erzsebet; Sebestyen, Gyula; Ecsery, Zoltan; Hermann, Judit
PA Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Rt., Hung.
SO Ger. Offen., 34 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2624290	A1	19770414	DE 1976-2624290	19760531
<--					
	HU 19947	O	19810528	HU 1975-CI1580	19750602
<--					
	HU 177576	P	19811128		
	CS 217955	P	19830225	CS 1976-3591	19760528
<--					
	CS 217955	B	19830225		
	AT 350518	B	19790611	AT 1976-3954	19760531
<--					
	AT 7603954	A	19781115		
	FR 2313023	A1	19761231	FR 1976-16648	19760602
<--					
	FR 2313023	B1	19781215		
	AT 346826	B	19781127	AT 1977-6127	19770824
<--					
	AT 352099	B	19790827	AT 1977-6126	19770824
<--					
	AT 7706126	A	19790215		
	CS 217956	P	19830225	CS 1978-961	19780214
<--					
	CS 217957	P	19830225	CS 1978-962	19780214
<--					
PRAI	HU 1975-CI1580	A	19750602		
	CS 1976-3591	A	19760528		
	AT 1976-3954	A	19760531		

GI



AB The title compds., cis and trans-I (R = OH, OEt, NHPh, NHBu, etc; R1 = H, CO2CH2Ph, CHO, Ac, Me, etc; R2 = H, Me; n = 1, 2) were prepared Thus, Et 2-oxocyclohexanecarboxylate reacted with PhNH2, followed by hydrogenation,
to give II (R = Et), which was hydrolyzed to II (R = H). I are useful as

L7 ANSWER 180 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1977:405952 CAPLUS
DN 87:5952
TI N-(6-Ethyl-4-thiocyanato-2-benzothiazolyl)-5-nitrofuramide
IN Alaimo, Robert J.
PA Morton-Norwich Products, Inc., USA
SO U.S., 2 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4012409	A	19770315	US 1975-644620	19751229
<--					
PRAI	US 1975-644620	A	19751229		

GI



AB The title compound (I) was prepared by heating for 30 min equimolar amts. 2-amino-6-ethyl-4-thiocyanatobenzothiazole and 5-nitro-2-furoyl chloride in pyridine. I is effective against coccidiosis in the chicken.
IT **62821-33-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and anticoccidial activity of)
RN 62821-33-4 CAPLUS
CN Thiocyanic acid, 6-ethyl-2-[[(5-nitro-2-furanyl)carbonyl]amino]-4-benzothiazolyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 181 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1977:89641 CAPLUS
DN 86:89641
TI 4-Carbamoyl-1-benzazepines
IN Rodriguez, Herman R.
PA Ciba-Geigy Corp., USA
SO U.S., 7 pp. Continuation-in-part of U.S. 3,949,081.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3989689	A	19761102	US 1975-561821	19750325
<--					
	US 3949081	A	19760406	US 1974-458917	19740408
<--					
PRAI	US 1974-458917	A2	19740408		

GI



I

AB The benzazepines I (R = 2-thiazolylamino, 4-FC6H4NH, 4-F3CC6H4NH, 1,2,4-triazol-3-ylamino, etc., R1 = H, Me, Me2CH; R2, R3 = H, Cl, F) were prepared by amidation of I (R = MeO). Thus, 4,2-Cl(H2N)C6H3CO2H was successively treated with MeOH and MeO2CCH2CH2COCl to give 2,5-(MeO2C)(Cl)C6H3NHCOCH2CH2CO2Me which cyclized with Na to give I (R = OMe, R1 = R2 = H, R3 = Cl) which was methylated and then treated with 2-aminothiazole to give I (R = 2-thiazolyl, R1 = Me, R2 = H, R3 = Cl).
At
5-50 mg/kg/day I (R = substituted amino) were antiinflammatory.
IT 61809-34-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 61809-34-5 CAPLUS
CN 1H-1-Benzazepine-4-carboxamide, N-2-benzothiazolyl-8-chloro-2,3,4,5-tetrahydro-1-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)

L7 ANSWER 181 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 182 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1977:72677 CAPLUS
DN 86:72677
TI 4-Hydroxy-2H-naphtho[2,1-e]-1,2-thiazine-3-carboxamide 1,1-dioxides
PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
SO Neth. Appl., 62 pp.
CODEN: NAXXAN
DT Patent
LA Dutch
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	NL 7512271	A	19760511	NL 1975-12271	19751020
<--					
	DE 2452996	A1	19760520	DE 1974-2452996	19741108
<--					
	DE 2539112	A1	19770317	DE 1975-2539112	19750903
<--					
	DE 2539112	C2	19831215		
PRAI	DE 1974-2452996	A	19741108		
	DE 1975-2539112	A	19750903		

GI



I II III

AB Amides I (R = substituted phenyl, thiazolyl, pyridyl, etc.; R1 = Me, Et, H) (47 compds.) were prepared e.g. by aminating the corresponding esters. Thus the naphthisothiazolinone II (R2 = H) was treated with ClCH2CO2Me, the resulting II (R2 = CH2CO2Me) cyclized with NaOMe to give ester III (R3 = H), which was methylated, and III (R3 = Me) treated with 3-ClC6H4NH2 to give I (R = 3-ClC6H4, R1 = Me) which gave 96% platelet aggregation inhibition at 10-4 mole/l. in the Born test. Some I were also antiinflammatory.
IT 60206-92-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 60206-92-0 CAPLUS
CN 2H-Naphtho[2,1-e]-1,2-thiazine-3-carboxamide, N-2-benzothiazolyl-4-hydroxy-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)

L7 ANSWER 182 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 183 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1976:494380 CAPLUS
DN 85:94380
TI 4-Hydroxy-2H-naphtho[2,1-e]-1,2-thiazine-3-carboxamide 1,1-dioxides
IN Trummlitz, Guenter; Teufel, Helmut; Engel, Wolfhard; Seeger, Ernst; Haarmann, Walter; Engelhardt, Guenther
PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
SO Ger. Offen., 43 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2452996	A1	19760520	DE 1974-2452996	19741108
<--					
	AT 345847	B	19781010	AT 1975-7648	19751007
<--					
	AT 345844	B	19781010	AT 1977-4513	19751007
<--					
	AT 345845	B	19781010	AT 1977-4514	19751007
<--					
	NL 7512271	A	19760511	NL 1975-12271	19751020
<--					
	ES 442074	A1	19770316	ES 1975-442074	19751024
<--					
	US 3992535	A	19761116	US 1975-626623	19751029
<--					
	SU 575027	D	19770930	SU 1975-2183260	19751029
<--					
	GB 1485910	A	19770914	GB 1975-45407	19751031
<--					
	RO 68500	P	19810621	RO 1975-83800	19751103
<--					
	CS 185583	P	19781031	CS 1975-7427	19751104
<--					
	HU 174520	P	19800128	HU 1975-TO1014	19751105
<--					
	CH 618976	A	19800829	CH 1975-14330	19751105
<--					
	DD 122823	C	19761105	DD 1975-189304	19751106
<--					
	AU 7586359	A1	19770512	AU 1975-86359	19751106
<--					
	BE 835392	A1	19760507	BE 1975-161716	19751107
<--					
	DK 7505030	A	19760509	DK 1975-5030	19751107
<--					
	DK 140533	B	19790924		
	DK 140533	C	19800218		
	FI 7503124	A	19760509	FI 1975-3124	19751107
<--					
	FI 60011	B	19810731		
	FI 60011	C	19811110		
	SE 7512534	A	19760510	SE 1975-12534	19751107
<--					
	SE 420605	B	19811019		

L7 ANSWER 183 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

	SE 420605	C	19820128		
	NO 7503738	A	19760511	NO 1975-3738	19751107
<--					
	NO 143317	B	19801006		
	NO 143317	C	19810114		
	FR 2290211	A1	19760604	FR 1975-34140	19751107
<--					
	FR 2290211	B1	19800509		
	JP 51125292	A2	19761101	JP 1975-133182	19751107
<--					
	IL 48439	A1	19781217	IL 1975-48439	19751107
<--					
	CA 1048025	A1	19790206	CA 1975-239175	19751107
<--					
	PL 107647	P	19800229	PL 1975-184576	19751107
<--					
	ES 451865	A1	19771101	ES 1976-451865	19760925
<--					
	ES 451867	A1	19771101	ES 1976-451867	19760925
<--					
	ES 451868	A1	19771101	ES 1976-451868	19760925
<--					
	ES 451869	A1	19771101	ES 1976-451869	19760925
<--					
	AT 345843	B	19781010	AT 1977-4512	19770627
<--					
	CH 626080	A	19811030	CH 1980-1990	19800313
<--					
	CH 628040	A	19820215	CH 1980-1988	19800313
<--					
	CH 628041	A	19820215	CH 1980-1989	19800313
<--					
PRAI	DE 1974-2452996	A	19741108		
	DE 1975-2539112	A	19750903		
	AT 1975-7648	A	19751007		
	CH 1975-14330	A	19751105		

GI



I



II

AB Naphthothiazinecarboxamides I (R = 2-pyridyl, pyrazinyl, 2-thiazolyl, N-methyl-2-thiazolyl, 4,5-dimethyl-2-thiazolyl, 2-benzothiazolyl, 5-methyl-3-isoxazolyl, Ph, R1 = Me; R = 2-thiazolyl, Ph, R1 = H) were prepared e.g. by treating the naphthisothiazolone II (R2 = H) with ClCH2CO2Me, ring enlargement II (R2 = CH2CO2Me) with NaOMe, methylation and amination of naphthothiazinecarboxylic ester. I (R = 2-thiazolyl, R1

L7 ANSWER 183 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
= Me) had oral ED35 in the carrageenin edema of 11 mg/kg and 10-4 mole/l. 43% platelet aggregation inhibition in Morris test.
IT 60206-92-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 60206-92-0 CAPLUS
CN 2H-Naphtho[2,1-e]-1,2-thiazine-3-carboxamide, N-2-benzothiazolyl-4-hydroxy-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



L7 ANSWER 184 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1975:472175 CAPLUS
DN 83:72175
TI Benzothiazine dioxides as antithrombotic agents
IN Lombardino, Joseph G.; Wiseman, Edward A.
PA Pfizer, Inc.
SO U.S., 6 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3862319	A	19750121	US 1973-362518	19730521
<--					
PRAI	US 1969-829713	A1	19690602		
	US 1971-114037	A2	19710209		

GI For diagram(s), see printed CA Issue.
AB Compds. of the general structures I and II were effective antithrombotic agents. Physiol. testing data in animals and man was given.
IT 29139-87-5 29140-05-4 29140-06-5
29277-26-7
RL: BIOL (Biological study)
(antithrombotic)
RN 29139-87-5 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, N-2-benzothiazolyl-3,4-dihydro-2-methyl-4-oxo-, 1,1-dioxide (8CI, 9CI) (CA INDEX NAME)



RN 29140-05-4 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, N-(4-chloro-2-benzothiazolyl)-3,4-dihydro-2-methyl-4-oxo-, 1,1-dioxide (8CI, 9CI) (CA INDEX NAME)



RN 29140-06-5 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, 3,4-dihydro-2-methyl-N-(6-methyl-2-benzothiazolyl)-4-oxo-, 1,1-dioxide (8CI, 9CI) (CA INDEX NAME)

L7 ANSWER 184 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 29277-26-7 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, N-(6-bromo-2-benzothiazolyl)-3,4-dihydro-2-methyl-4-oxo-, 1,1-dioxide (8CI, 9CI) (CA INDEX NAME)



L7 ANSWER 185 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1975:444726 CAPLUS
DN 83:44726
TI Isoindolinone pigments
IN Ando, Hirohito; Takagi, Koichi; Takagi, Kunihiko
PA Dainippon Ink and Chemicals, Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 49128933 <--	A2	19741210	JP 1973-40333	19730411
JP 53035579	B4	19780928		
PRAI JP 1973-40333	A	19730411		

GI For diagram(s), see printed CA Issue.
AB Isoindolinone pigments (I; R = halogen; n = 0-4; Z is a direct link or a divalent aromatic radical) are prepared by intramol. cyclization of diamide II, by intramol. rearrangement of diimide III, or by reaction of a mixture of II and III with base, followed by water or acid treatment. For example, 300 g tetrachlorophthalic anhydride [117-08-8] was added at ≤30° to a solution of 54 g p-C6H4(NH2)2 [106-50-3] in DMF, stirred 1 hr, treated with 44 ml PCl3, after 2 hr treated with 80.5 ml 28% aqueous NH4OH, and after 4 hr recovered as a white material, which was dispersed in DMF and treated with POCl3 at 0° to give yellow II (R = Cl, n = 4, Z = p-C6H4)(IV) [55584-50-4]. Dispersion of 12.8 parts IV in 60 parts DMF at 60-70°, mixing for 1 hr with 16 parts 14% methanolic NaOMe at 10-15°, mixing for 1 hr at 15-20° with 5 parts 90% HOAc, and heating 2-3 hr at 120-30° gave 10.2 parts I (R = Cl, n = 4, Z = p-C6H4)(V) [5590-18-1], a nonbleeding reddish yellow pigment for melamine-alkyd resin coatings. Heating 12.8 parts IV in 100 parts refluxing xylene for 1 hr gave 12.7 parts III (R, n, z as above) [55647-99-9], which was converted to V by treatment with NaOEt in DMF at 5-10°. Among 8 other I prepared were yellow I (R = Br, n = 4, Z = benzothiazole-2,6-diyl) [55584-51-5] and bluish yellow I (n = 0, Z = pyridine-2,6-diyl) [55584-52-6].
IT 55584-44-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclization of)
RN 55584-44-6 CAPLUS
CN Benzamide, N,N'-2,6-benzothiazolediylbis[2,3,4,5-tetrabromo-6-cyano- (9CI)
(CA INDEX NAME)

L7 ANSWER 185 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 186 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1974:425454 CAPLUS
DN 81:25454
TI 1-Hydroxy-2-naphthamides
IN Sano, Kazuya
PA Fuji Photo Film Co., Ltd.
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 49020159 <--	A2	19740222	JP 1972-63054	19720623
PRAI JP 1972-63054	A	19720623		

GI For diagram(s), see printed CA Issue.
AB Hydroxynaphthoates (I; X = H, Cl, Br; R2 = Cl-substituted phenoxy) were treated with primary or secondary amines to give the hydroxynaphthamides (I, R2 = NRR1) (II). The Cl substituents, especially 0-Cl, enhanced the reactivity. Thus, 15 g I (X = H, R2 = OC6H4Cl-0), prepared by heating 1-hydroxynaphthoic acid and 0-chlorophenol with SOCl2 and a little DMF, was heated with 9.3 g dodecylamine at 140° for 1 hr to give 12 g II (R = dodecyl, R1 = X = H). Among 6 more II prepared were the following (R, R1, X given): C6H3(CO2C12H25)Cl-5,2, H, H; dodecyl, H, Br; 2-benzothiazolyl, H, H; hexadecyl, β-cyanoethyl, H.
IT 52923-65-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 52923-65-6 CAPLUS
CN 2-Naphthalenecarboxamide, N-2-benzothiazolyl-1-hydroxy- (9CI) (CA INDEX NAME)



L7 ANSWER 187 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1974:89535 CAPLUS
DN 80:89535
TI Oxonol dyes and photographic material comprising silver halide emulsions
IN Poppe, Ernse H.
PA VEB Filmfabrik Wolfen
SO Brit., 9 pp.
CODEN: BRXXAA
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 1338799	A	19731128	GB 1971-35007	19710726
<--				
PRAI GB 1971-35007	A	19710726		

GI For diagram(s), see printed CA Issue.
AB 3-Carbamoyl and N-substituted carbamoyl oxonol dyes, e.g. (I), which were easily decolorized in photog. processing baths and possessed absorption maximum in the main sensitization areas of color film, improved the definition or resolving power of photog. materials containing ≥1 Ag halide emulsion when incorporated in emulsion, backing or intermediate gelatin layers.
IT 51727-54-9 51727-61-8
RL: USES (Uses)
(for color photog.)
RN 51727-54-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-2-benzothiazolyl-4-[5-[3-[(2-benzothiazolylamino)carbonyl]-5-hydroxy-1-phenyl-1H-pyrazol-4-yl]-2,4-pentadienylidene]-4,5-dihydro-5-oxo-1-phenyl- (9CI) (CA INDEX NAME)



L7 ANSWER 187 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 51727-61-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-2-benzothiazolyl-4-[3-[3-[(2-benzothiazolylamino)carbonyl]-5-hydroxy-1-phenyl-1H-pyrazol-4-yl]-2-propenylidene]-4,5-dihydro-5-oxo-1-phenyl- (9CI) (CA INDEX NAME)



L7 ANSWER 188 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1974:14917 CAPLUS
DN 80:14917
TI 2-(o-Aminobenzamido)benzothiazoles
IN Murayama, Masao; Inoui, Sho; Ohata, Katsuya; Tsutsui, Satoshi; Sato, Shigeru; Sugahara, Yukio
PA Nippon Shinyaku Co., Ltd.; Mitsubishi Chemical Industries Co., Ltd.
SO Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 48067277	A2	19730913	JP 1971-102033	19711216
<--				
JP 55016146	B4	19800430		
PRAI JP 1971-102033	A	19711216		

GI For diagram(s), see printed CA Issue.
AB The antiinflammatory and analgesic title amides I (X = Cl, F) were prepared by heating 2-amino-6-halobenzothiazoles with isatoic anhydride in dioxane or THF.
IT 50993-66-3P 50993-67-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 50993-66-3 CAPLUS
CN Benzamide, 2-amino-N-(6-chloro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 50993-67-4 CAPLUS
CN Benzamide, 2-amino-N-(6-fluoro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 189 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1973:136065 CAPLUS
DN 78:136065
TI 2-Methylindole-3-carboxylic acid amide derivatives
IN Bourdais, Jacques
PA Agence Nationale de Valorisation de la Recherche (ANVAR)
SO Fr. Demande, 10 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 2121394	A5	19720825	FR 1971-498	19710108
<--				
FR 2121394	B1	19740322		
PRAI FR 1971-498	A	19710108		

AB About 10 indolecarboxamides (I, R = H, Me, R1 = Me, PhCH2, 2-pyridyl, Ph, 2-benzothiazolyl) were prepared by hydrogenation of o-O2NC6H4CH(COMe)CONRR1 to o-H2NC6H4CH(COMe)CONRR1 followed by ring closure to I.
IT 40729-37-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 40729-37-1 CAPLUS
CN 1H-Indole-3-carboxamide, N-2-benzothiazolyl-2-methyl-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 190 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1972:509576 CAPLUS
DN 77:109576
TI Benzothiazine dioxides as lipid-regulating agents
IN Lombardino, Joseph G.; Holland, Gerald F.
PA Pfizer Inc.
SO U.S., 5 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3674876	A	19720704	US 1969-831768	19690609

<--
PRAI US 1969-831768 A 19690609
AB A number of 2H-1,2-benzothiazine 1,1-dioxides including 1,2-dihydro-4-hydroxy-2-methyl-1,2-benzothiazine-3-(p-toluid) 1,1-dioxide (I) [35511-67-2] and 4'-bromo-3,4-dihydro-2-methyl-3-oxo-2H-1,2-benzothiazine-4-carboxanilide 1,1-dioxide (II) [29209-03-8] decreased the total plasma cholesterol [57-88-5] levels in rats and may be useful as lipid regulating agents in man.
IT **38402-30-1 38402-31-2**
RL: BIOL (Biological study)
(lipid metabolism response to)
RN 38402-30-1 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(6-methyl-2-benzothiazolyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 38402-31-2 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, N-(6-bromo-2-benzothiazolyl)-4-hydroxy-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)

L7 ANSWER 190 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 191 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1972:488541 CAPLUS
DN 77:88541
TI Quinoxaline di-N-oxides
IN Ley, Kurt; Eholzer, Ulrich; Nast, Roland; Seng, Florin
PA Farbenfabriken Bayer A.-G.
SO U.S., 25 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3660398	A	19720502	US 1970-24422	19700407

<--
PRAI US 1970-24422 A 19700407
AB Benzofurazan N-oxide, Me2CO, and BuNH2 gave 2-methylquinoxaline di-N-oxide (I, R = R1 = H, R2 = Me) after 5 hr at room temperature Similarly prepared were .apprx.118 quinoxaline di-N-oxide derivs. (e.g., I, R = R1 = H, R2 = Ph; R = H, R1R2 = (CH2)4; R = R2 = Me, R1 = H; II). The products were herbicides.
IT **23433-68-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 23433-68-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-2-benzothiazolyl-3-methyl-, 1,4-dioxide (8CI, 9CI) (CA INDEX NAME)



L7 ANSWER 192 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1972:99647 CAPLUS
DN 76:99647
TI 2-Benzamido- and 2-anilinobenzothiazoles
IN Donche, Alain; Pfister, Alain; Arretz, Emmanual
PA Societe Nationale des Petroles d'Aquitaine
SO Ger. Offen., 22 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2133649	A	19720113	DE 1971-2133649	19710706

<--
	FR 2097405	A5	19720303	FR 1970-24954	19700706

<--
	FR 2140862	A6	19730119	FR 1971-21070	19710610

<--
	NL 7109150	A	19720110	NL 1971-9150	19710702

<--
	BE 769490	A1	19711116	BE 1971-105464	19710705

<--
	GB 1345552	A	19740130	GB 1971-31664	19710706

<--
	IT 1005045	A	19760820	IT 1971-42944	19710706

<--
PRAI FR 1970-24954 A 19700706
FR 1971-21070 A 19710610
GI For diagram(s), see printed CA Issue.
AB Title compds. (I, R = Ph, substituted phenyl, Bz, substituted benzoyl, or 1-naphthyl; R1 = H, Cl, or OMe), useful as bactericides, fungicides, local anesthetics, additives in photog. emulsions, and stabilizers for fats, paraffins, and rubber, were prepared by reaction of o-aminobenzenethiols with RNCS. Thus, o-H2-NC6H4SH in xylene was refluxed 1 hr with p-MeSC6H4NCS with H2S evolution to give 90% I (R = p-MeSC6H4, R1 = H). Similarly prepared were 20 addnl. I, e.g. (R and R1 given): p-MeO-C6H4, H; p-ClC6H4CO, H; Bz, 6-Cl; 1-naphthyl, H. -Bis(2-benzothiazolylamino)benzene was also prepared
IT **5005-14-1P 16628-25-4P 35353-18-5P**
35353-19-6P 35353-20-9P 35353-21-0P
35353-24-3P 35353-26-5P 35412-17-0P
35412-19-2P 35412-20-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 5005-14-1 CAPLUS
CN Benzamide, N-2-benzothiazolyl- (9CI) (CA INDEX NAME)



RN 16628-25-4 CAPLUS
CN Benzamide, N-(6-chloro-2-benzothiazolyl)- (8CI, 9CI) (CA INDEX NAME)

L7 ANSWER 192 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 35353-18-5 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-chloro- (9CI) (CA INDEX NAME)



RN 35353-19-6 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-methoxy- (9CI) (CA INDEX NAME)



RN 35353-20-9 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-(methylthio)- (9CI) (CA INDEX NAME)



RN 35353-21-0 CAPLUS
CN Benzamide, N-2-benzothiazolyl-4-nitro- (9CI) (CA INDEX NAME)



L7 ANSWER 192 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 192 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 35353-24-3 CAPLUS
CN Benzamide, 4-chloro-N-(5-chloro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 35353-26-5 CAPLUS
CN Benzamide, N-(6-methoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 35412-17-0 CAPLUS
CN Benzamide, 4-(acetyloxy)-N-2-benzothiazolyl- (9CI) (CA INDEX NAME)



RN 35412-19-2 CAPLUS
CN Benzamide, N-(5-chloro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 35412-20-5 CAPLUS
CN Benzamide, N-(4-methoxy-2-benzothiazolyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 193 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1972:24217 CAPLUS
DN 76:24217
TI Fungicidal carboxamide derivatives
IN Ten Haken, Pieter; Armitage, Brian P.
PA Shell Internationale Research Maatschappij N. V.
SO Ger. Offen., 26 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2117807	A	19711028	DE 1971-2117807	19710413
<--					
	GB 1318291	A	19730523	GB 1970-17956	19700415
<--					
	NL 7104858	A	19711019	NL 1971-4858	19710413
<--					
	FR 2089546	A5	19720107	FR 1971-12905	19710413
<--					
	ZA 7102295	A	19720126	ZA 1971-2295	19710413
<--					
	ES 390121	A1	19740501	ES 1971-390121	19710413
<--					
	CA 946845	A1	19740507	CA 1971-110200	19710413
<--					
	CH 552339	A	19740815	CH 1971-5288	19710413
<--					
	JP 54007857	B4	19790410	JP 1971-22856	19710413
<--					
	US 3736330	A	19730529	US 1971-135389	19710419
<--					
PRAI	GB 1970-17956	A	19700415		
	GB 1970-30896	A	19700625		

AB The title compds. XMeC:CYCONHR [I, X = alkyl and Y = H, or (XY =) e.g. OCH:CH, CH:CHCH:CH, and OCH2CH2S; R = methylenedioxyphenyl or an N-heterocyclic group) were prepared e.g. from XMeC:CYCOCl and RNH2 in the presence of an acid acceptor. I were active against e.g. Plasmospora viticola, Phytophthora infestans, Puccinia recondita, Erysiphe cichoracearum, and Uromyces fabae. Thus, o-MeC6H4COCl was added portionwise at 0-5° to 2-aminopyridine in pyridine and the mixture stirred 1 hr at 0-5° and kept 16 hr at 25° to give 2-methyl-N-(2-pyridyl)benzamide. Similarly prepared were 46 other I including benzamides, o-toluamides, 3-furancarboxamides, and 1,4-oxathiin-3-carboxamides, substituted with thiazolyl, pyridyl, and pyrimidinyl groups. The activity of I in leaf-spray and root treatment tests was reported.

IT 35498-42-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 35498-42-1 CAPLUS
CN 3-Furancarboxamide, N-2-benzothiazolyl-2-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 193 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 194 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1972:14533 CAPLUS
DN 76:14533
TI 2-Carbamoyl-1,2-benzisothiazolin-3-one 1,1-dioxides
IN Mine, Seizo; Shioyama, Itaru
PA Japan Agricultural Chemicals and Insecticides Co., Ltd.
SO Jpn. Tokkyo Koho, 6 pp.
CODEN: JAXXAD
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 46036613	B4	19711027	JP	19691203

<--
GI For diagram(s), see printed CA Issue.
AB I, useful as a fungicide for phytopathogenic fungi, was prepared Thus, 2-chlorocarbonylsaccharine was gradually added to a solution of PhCH2NH2 in
dioxane and the mixture stirred 2 hr to give 71% I (R1 = PhCH2, R2 = H). Similarly prepared were 65 more I.
IT 35137-19-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 35137-19-0 CAPLUS
CN 1,2-Benzisothiazole-2(3H)-carboxamide, N-2-benzothiazolyl-3-oxo-, 1,1-dioxide (9CI) (CA INDEX NAME)



L7 ANSWER 195 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1971:449068 CAPLUS
DN 75:49068
TI Herbicidal cyclopropanecarboxylic acid benzothiazolylamides
IN Schaefer, Werner; Sasse, Klaus; Eue, Ludwig; Hack, Helmut
PA Farbenfabriken Bayer A.-G.
SO Ger. Offen., 17 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1953357	A	19710506	DE 1969-1953357	19691023

<--

	NL 7014930	A	19710427	NL 1970-14930	19701012

<--

	US 3761490	A	19730925	US 1970-81117	19701015

<--

	ES 384795	A1	19730301	ES 1970-384795	19701022

<--

	FR 2066494	A5	19710806	FR 1970-38437	19701023

<--

	GB 1282686	A	19720719	GB 1970-1282686	19701023

<--
PRAI DE 1969-1953357 A 19691023
GI For diagram(s), see printed CA Issue.
AB Cyclopropanecarboxylic acid benzothiazolylamides (I) are prepared by reacting cyclopropanecarboxylic acid chloride with a 2-aminobenzothiazole.
Thus 600 g 2-aminobenzothiazole was solved in 3 l PhMe, 556 ml Et3N added,
418 g cyclopropanecarboxylic acid chloride added in 1 hr at 0-5°, and the mixture heated 1 hr at 100° to give I (R = H, R1 = H) m. 220-2° (PhMe). Other I prepared were (R, R1, and m.p. given): Me, H, 120-3°; Et, H, 90-3°; Pr, H, 97-9°; iso-Bu, H, -; H, 5-Me, 133-5°; H, 4-Et, 140-2°; H, 6-iso-Pr, 159-62°; H, 5-Cl, -; H, 4,6-Cl2, 246-8°; H, 4-Me-6-Br, 176-8°; H, 6-MeO, 206-7°. I are herbicides which can be used against mono- and dicotyledonous weeds. They are valuable as selective herbicides and are applied at 0.5-15 kg/ha.
IT 32904-04-4
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses)
(herbicides)
RN 32904-04-4 CAPLUS
CN Cyclopropanecarboxamide, N-2-benzothiazolyl- (8CI, 9CI) (CA INDEX NAME)



IT 32895-07-1P 32895-08-2P 32895-09-3P
32895-10-6P 32895-11-7P 32904-08-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

L7 ANSWER 195 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 32895-07-1 CAPLUS
CN Cyclopropanecarboxamide, N-(4-ethyl-2-benzothiazolyl)- (8CI) (CA INDEX NAME)



RN 32895-08-2 CAPLUS
CN Cyclopropanecarboxamide, N-(6-isopropyl-2-benzothiazolyl)- (8CI) (CA INDEX NAME)



RN 32895-09-3 CAPLUS
CN Cyclopropanecarboxamide, N-(4,6-dichloro-2-benzothiazolyl)- (8CI) (CA INDEX NAME)



RN 32895-10-6 CAPLUS
CN Cyclopropanecarboxamide, N-(6-bromo-4-methyl-2-benzothiazolyl)- (8CI) (CA
INDEX NAME)



RN 32895-11-7 CAPLUS
CN Cyclopropanecarboxamide, N-(6-methoxy-2-benzothiazolyl)- (8CI, 9CI) (CA INDEX NAME)

L7 ANSWER 195 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 32904-08-8 CAPLUS
CN Cyclopropanecarboxamide, N-(5-methyl-2-benzothiazolyl)- (8CI) (CA INDEX NAME)



L7 ANSWER 196 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1971:407424 CAPLUS
DN 75:7424
TI Pigment for acrylic resin-based paints
PA Badische Anilin- & Soda-Fabrik AG
SO Fr. Demande, 4 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2018135	A5	19700529	FR 1969-31317	19690915
<--					
	FR 2018135	B1	19760220		
	DE 1794150	A	19711007	DE 1967-1794150	19680914
<--					
	US 3682923	A	19720808	US 1969-856805	19690910
<--					
	GB 1275668	A	19720524	GB 1969-1275668	19690912
<--					
PRAI	DE 1967-1794150	A	19680914		

GI For diagram(s), see printed CA Issue.
AB 1-[N-(6-Ethoxy-2-benzothiazolyl)carbamoyl]-1,2-propanedione dioxime 1:1 nickel complex (I), an orange pigment for acrylate varnishes, was prepared by the nitrosation of 2-acetoacetylamino-6-ethoxybenzothiazole, oximation of the product, and metallization with NiSO4. A varnish composition having a metallic luster was prepared comprising acrylate resin, BuOH, xylene, melamine-formaldehyde resin, I, and Al bronze powder.
IT 31406-68-5P
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of)
RN 31406-68-5 CAPLUS
CN Nickel, bis[N-(6-ethoxy-2-benzothiazolyl)-2,3-dioxobutyramide 2,3-dioximato]- (8CI) (CA INDEX NAME)



L7 ANSWER 197 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1971:141873 CAPLUS
DN 74:141873
TI Antibacterial quinoxaline-di-N-oxides and benzimidazole mono- and di-N-oxides
IN Issidorides, Costas H.; Haddadin, Makhluf J.
PA Research Corp.
SO Brit., 16 pp.
CODEN: BRXXAA
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 1215815		19701216	GB	19671220
<--					

AB Benzofurazan 1-oxide (I) was refluxed with MeCOEt in MeCN in the presence of morpholine to give 2,3-dimethylquinoxaline 1,4-dioxide. Over 40 quinoxaline 1,4-dioxides were prepared similarly. I reacted with EtNO2 and Et2NH in THF to give 1-hydroxy-2-methylbenzimidazole 3-oxide. Five addnl. 1-hydroxybenz-imidazole 3-oxides were similarly prepared I reacted with iso-PrNO2 and Et2NH in THF to give 2,2-dimethyl-2H-benzimidazole 1,3-dioxide (II). The 2-ethyl-2-methyl and 2,2-pentamethylene analogs of II were similarly prepared Some phenazine 5,10-dioxides were also prepared The quinoxaline 1,4-dioxides were virucides and bactericides.
IT 31983-93-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 31983-93-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(6-ethoxy-2-benzothiazolyl)-3-methyl-, 1,4-dioxide (8CI, 9CI) (CA INDEX NAME)



L7 ANSWER 198 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1970:520647 CAPLUS
DN 73:120647
TI Isomeric 3,4-dihydro-2H-1,2-benzothiazine 1,1-dioxides valuable for their chemotherapeutic qualities
IN Lombardino, Joseph G.
PA Pfizer, Chas., and Co., Inc.
SO Ger. Offen., 67 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1943265	A	19700813	DE 1969-1943265	19690826
<--					
	DE 1943265	B2	19810514		
	DE 1943265	C3	19820204		
	US 3591584	A	19710706	US 1968-767594	19680827
<--					
	GB 1257180	A	19711215	GB 1968-1257180	19681231
<--					
	NO 129746	B	19740520	NO 1969-3274	19690812
<--					
	BR 6911817	A0	19730213	BR 1969-211817	19690825
<--					
	FI 51189	B	19760802	FI 1969-2460	19690825
<--					
	BE 737962	A	19700226	BE 1969-737962	19690826
<--					
	NL 6912981	A	19700303	NL 1969-12981	19690826
<--					
	NL 157013	B	19780615		
	ES 370861	A1	19710701	ES 1969-370861	19690826
<--					
	AT 294113	B	19711110	AT 1969-8146	19690826
<--					
	CH 520705	A	19720331	CH 1969-520705	19690826
<--					
	AT 298503	B	19720510	AT 1970-9366	19690826
<--					
	CH 527840	A	19720915	CH 1969-527840	19690826
<--					
	DE 1967325	B2	19810813	DE 1969-1967325	19690826
<--					
	DE 1967325	C2	19820318		
	DK 145297	B	19821025	DK 1969-4570	19690826
<--					
	DK 145297	C	19830314		
	FR 2016455	A5	19700508	FR 1969-29284	19690827
<--					
	FR 2016455	B1	19740201		
	JP 50000677	B4	19750110	JP 1969-67265	19690827
<--					
	SE 373854	B	19750217	SE 1969-11871	19690827
<--					
	SE 402459	C	19781012	SE 1973-511	19730115
<--					
	JP 51042114	B4	19761113	JP 1973-82782	19730724
<--					
PRAI	US 1968-767594	A	19680827		

L7 ANSWER 198 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
GI For diagram(s), see printed CA Issue.
AB I or II (.apprx.160) (Z = S or O) nonsteroidal antiinflammatory agents, were prepared by treating III where X = H,H and Q = O or vice versa with R2NCZ in the presence of base or by treating III where X = O and Q = carbalkoxy or vice versa with amines. Thus, III (X = H,H; Q = O; R1 = Me, R3 = H) (IV) was prepared by cyclodehydration of o-HO2CCH2C6H4SO2NHMe (prepared by carboxylation of 2-MeC6H4SO2NHMe in the presence of BuLi). Treating IV with o-ClC6H4NCO in Me2SO in the presence of Et3N 20 hr at 25° gave 46% II (Z = O, R1 = Me, R2 = o-ClC6H4NH, R3 = H). III (X = O; Q = H, CO2Me; R1 = R3 = H), prepared by rearrangement of V in the presence of NaOMe in dry DMF, was treated with MeI to give the 2-Me derivative, which was treated with PhNH2 in dry AcNMe2 in the presence of p-MeC6H4SO3H to give 35% I (Z = O; R1 = Me; R2 = NHPh, R3 = H).
IT **29139-87-5P 29140-05-4P 29140-06-5P**
29277-26-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 29139-87-5 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, N-2-benzothiazolyl-3,4-dihydro-2-methyl-4-oxo-, 1,1-dioxide (8CI, 9CI) (CA INDEX NAME)



RN 29140-05-4 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, N-(4-chloro-2-benzothiazolyl)-3,4-dihydro-2-methyl-4-oxo-, 1,1-dioxide (8CI, 9CI) (CA INDEX NAME)



RN 29140-06-5 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, 3,4-dihydro-2-methyl-N-(6-methyl-2-benzothiazolyl)-4-oxo-, 1,1-dioxide (8CI, 9CI) (CA INDEX NAME)

L7 ANSWER 198 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 29277-26-7 CAPLUS
CN 2H-1,2-Benzothiazine-3-carboxamide, N-(6-bromo-2-benzothiazolyl)-3,4-dihydro-2-methyl-4-oxo-, 1,1-dioxide (8CI, 9CI) (CA INDEX NAME)



L7 ANSWER 199 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1970:100969 CAPLUS
DN 72:100969
TI Amebicidal and antibacterial N-heterocyclic aconamides
IN Bruderlein, Francois T.; Campbell, David J.
PA American Home Products Corp.
SO U.S., 2 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3496187	A	19700217	US 1967-624208	19670320
PRAI	US 1967-624208	A	19670320		

GI For diagram(s), see printed CA Issue.
AB The title amebicidal and antibacterial compds. (I) were prepared by reacting aconyl chloride with a suitable heterocyclic amine. Thus, I (X = CH, R1 = NO2), m. 208-10° (MeOH), was obtained by refluxing aconyl chloride with 5-nitro-2-aminothiazole 0.5 hr. Similarly, the following N-aconamides were prepared: 4-methylthiazol-2-yl, m. 171-2° (EtOH); benzothiazol-2-yl, m. 219-23° (acetone); 4-chlorobenzothiazol-2-yl), m. 231-3° (acetone-EtOH); (5-methyl-1,3,4-thiadiazol-2-yl), m. 226-7° (HCONMe2).
IT **26420-76-8P 26420-77-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 26420-76-8 CAPLUS
CN 3-Furamide, N-2-benzothiazolyl-2,5-dihydro-5-oxo- (8CI) (CA INDEX NAME)



RN 26420-77-9 CAPLUS
CN 3-Furamide, N-(4-chloro-2-benzothiazolyl)-2,5-dihydro-5-oxo- (8CI) (CA INDEX NAME)



L7 ANSWER 200 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1969:470643 CAPLUS
DN 71:70643
TI Quinoxaline di-N-oxides
PA Farbenfabriken Bayer A.-G.
SO Fr., 21 pp.
CODEN: FRXXAK
DT **Patent**
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 1521907		19680419	FR	
	DE 1670693			DE	
	DE 1670730			DE	
	GB 1187991			GB	
PRAI	DE		19660504		
	DE		19660810		

GI For diagram(s), see printed CA Issue.
AB The title compds. useful as intermediates in the preparation of pharmaceuticals and plant protection agents are prepared by reacting benzofuroxans with a ketone and an amine, or with a Schiff base. Addg. 73 g. BuNH2 dropwise to a solution of the benzofuroxan (I) in 450 ml. Me2CO at 20-30°, stirring 5 hrs. at room-temperature and cooling to 0° gave 77 g. II (R2 = X = H, R1 = Me), m. 171° (EtOH). Similar treatment of 136 g. I and 86.5 g. MeCOEt (III) in 500 ml. MeOH with 119 g. cyclohexylamine at 30° gave 140 g. II (X = H, R1 = R2 = Me) (IV), m. 188-9° decomposition (EtOH). IV was also obtained (260 g.) by passing NH3 into a mixture of 204 g. I, 118 g. III, and 700 ml. MeOH at 50° for 8 hrs. By similar methods were prepared the following II (X, R1, R2, m.p., and % yield given): H, Me, Et, 141-2°, prepared both from Et2CO and MeCOPr in 84 and 88.5% yield resp.; H, Me, C10H21, 111-13°, 80; H, Me, C16H33, 111-13°, 77-80; H, Ph, H, 209-10°, 56.7; Cl, Me, H, 190-1°, -; Cl, Me, Me, 175-6°, 71.5-91; Cl, Me, Et, 142-4°, 73; Cl, Me, C10H21, 79-80°, 71.5; Cl, Me, C16H33, 92-3°, 68-85; Me, Me, H, 183-4° (decomposition), 49; Me, Me, Me, 155-6°, 77.5; Me, ME, Et, 150-2°, 55; MeO, Me, Me, 196-8°, 88.5; MeO, Me, C16H33, 77-8°, 81.5; EtO, Me, H, 202° (decomposition), 24; EtO, Me, Me, 160-2°, 84; EtO, Me, Et, 167-8°, 56.5; EtO, Et, Me, 174-5°, 50.5; EtO, Me, C16H33, 97-8°, 84.5; MeO2C, C26H33, Me, 90-1°, 61.5. To a solution of 27.2 g. I in 100 ml. MeOH was added 35.6 g. cyclohexylidene(cyclohexyl)amine dropwise at 35°. After stirring for a further hr., cooling gave 22 g. V, m. 182-3°. By treatment of a mixture of 68 g. I, 91 g. cyclododecanone, and 400 ml. EtOH at 50° with 40 g. BuNH2 and heating at 60° 2 hrs. 90 g. VI (X = H) (VII), m. 132-3°, was obtained. VII was also prepared in 60% yield from I and cyclodecylenyl(cyclohexyl)amine at 50° and in 83.5% yield using NH3 in place of BuNH2. Similarly were prepared VI (X = Cl), m. 122-4° (54-77.5% yield), VI (X = Me), m. 144-6° (60%), and VI (X = EtO), m. 202-4° (43-61 %). To a solution of 13.6 g. I and 13 g. AcOEt in 50 ml. MeOH at 40° was added 8 g. BuNH2 dropwise and the mixture heated at 50° 4 hrs. to give 10 g. II (X = H, R1 = Me, R2 = EtO2C), m. 134-6° (MeOH). Other quinoxaline dioxides VIII similarly prepared were (R1, R2, R3, R4, R5, m.p. and % yield given): Me, Me, H, H, 4-ClC6H4NHCO, 248°, 74.5; Me, Me, Me, H, Me, 164-6°, 41; Me,

L7 ANSWER 200 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Me, H, 2-pyridylsulfonamido, H, 234° (decompn.), 62.6; Me, Me, Br, H, H, 189-90°, 62.5; Me, Me, MeO2C, H, H, 185-6°, 68.6; Me, C10H21, H, H, MeO, 97-9°, 89; Me, C10H21, H, H, EtO, 84-6°, 39; Me, C16H33, Me, H, Me, 75-6°, 27; Me, C16H33, H, H, Me, 91-3°, 60; Me, CH2CONH2, H, H, MeO, 238°, 51; Me, CH2CONHPh, H, H, H, 220-1° (decompn.), 82.5; Me, 3,4- C13C6H3NHCOCH2, H, H, H, 220°, 84; Me, CO2Et, H, H, Cl, 178-9°, 37.5; Me, 3,4-C12C6H3NHCOCH2, H, H, Cl, 183-4°, 77.5; Me, 4,2,5-Cl(MeO)2C6H2NHCO, H, H, H, 227-8° (decompn.), 50; Me, 2-MeOC6H4NHCO, H, H, H, 190-1°, 53; Me, 2,4- Me(Cl)C6H3NHCO, H, H, H, 207°, 46; Me, 2-ClC6H4-NHCO, H, H, H, 208-9°, 30; Me, PhNHCO, H, H, Cl, 206-7°, 55; Me, 2-ClC6H4NHCO, H, H, Cl, 185-6°, 46; Me, 4,2,5-Cl-(MeO)2ClC6H2NHCO, H, H, Cl, 224-5° (decompn.), 44; Me, 2-MeC6H4NHCO, H, H, Cl, 197-8°, 32; Me, 2,4-Me2C6H3NHCO, H, H, Cl, 180-1°, 45; Me, 2-MeOC6H4NHCO, H, H, Cl, 150-2°, 30.5; Me, 2,4-Me-4-(Cl)C6H3NHCO, H, H, Cl, 209°, 32; Me, 4-H2NSO2C6H4NHCO, H, H, H, 254° (decompn.), 62; Me, pyrrolidinocarbonyl, H, H, EtO, 132-3°; 67.5; Me, piperidinocarbonyl, H, H, Me, 135° (decompn.), 69; Me, C12H25NHCO, H, H, H, 151-2°, 71; Me, C12H25NHCO, H, H, Me 150-1°; 52; Me, C12H25NHCO, H, H, EtO, 152-4°, 58; Me, C12H25NHCO, H, H, Cl, 155-6°, 34; Me, N-morpholinoaminocarbonyl, H, H, H, 204-5° (decompn.), 20; Me, H2NCO, H, H, H, 245° (decompn.), 33; Me, 4-methyl-2-pyrimidinylaminocarbonyl, H, H, Cl, 220° (decompn.), 20; Me, 2-benzothiazolylaminocarbonyl, H, H, H, 222° (decompn.), 45. Addg. 8 g. BuNH2 dropwise at 40° to a soln. of 16.6 g. 5-methoxybenzofuroxan and 28.1 g. acetylacetoazobenzamide, stirring at 40° 4 hrs. and cooling gave 28 g. 3-carboxyazobenzamide of 2-methyl-7- methoxyquinoxaline 1,4-di-N-oxide, m. 231-2° decompn. (Me2NCHO- EtOH). IX (R = H) methanolate, m. 235° (decompn.) (Me2NCHO-MeOH) was similarly prepd. in 5.9 g. yield from 2.72 g. I, 5.8 g.

dihydrotestosterone, and 2.2 g. BuNH2 in 45 ml. MeOH at 60°. Also, prepd. were IX (R = Cl) methanolate, m. 253° (decompn.), 42.5% yield; IX (R = MeO).2H2O, m. 23o° (decompn.), 53%; X, m. 224-5° (decompn.), in 17.5% yield from N-(2-phenylbenzo-1,2,3-triazole-5- yl)acetylacetamide; II (R1 = Me, X = H, R2 = 2-pyridylaminocarbonyl), m. 218° (decompn.), 34%; II (R1 = Me, X = H, R2 = 2,6-Me2C6H3NHCO), m. 234° (decompn.), 72.5%; II (R1 = Me, X = H, R2 = 2-thiazolylamino-carbonyl, m. 212-13° (decompn.), 33%; XI (R = Cl), m. 256° (decompn.), 65.5% (from N,N'-diacetoacetylpiperazine); XI (R = EtO), m. 267° (decompn.), 84%; XI (R = Me), m. 250° (decompn.), 85%; II (R1 = Me, X = H, R2 = cyclohexylamino-carbonyl, m. 205° 68%; II [R1 = Me, X = Cl, R2 = CMe-(:NOH)], m. 222-3° (Me2NCHO-MeCN), 73.5% yield (from 2-oximino-3-pentanone); II [R1 = Me, X = H, R2 = CMe(:NOH)], m. 219° (decompn.), 58.5%; II (R1 = Me, R2 = Ph, X = H), m. 194- 6°, 72%; II (R1 = Me, R2 = Ph, X = Cl,) m. 162-3°, 77%; II (R1 = Me, R2 = Ac, X = Cl), m. 170-1°, 57.5%; II (R1 = Me, R2 = Ac, X = EtO), m. 178-80°, 43%; II (R1 = Me, R2 = N-morpholinomethyl, X = H), m. 138-9°, 69% (from 1-morpholino-3-butanone); XII (R = H). Me2NCHO, m. 202-4°, 42% [from cis-2-decalone, 5-chlorobenzofuroxan (XIII), and BuNH2]. Into a soln. of 50 g. 2-oximino-cyclododecan-1-one (m. 73-5°) and 40 g. XIII in 200 ml. MeOH at 50° was passed NH3 gas 5 hrs. to give 47 g. Na salt of XIV, crystd. from MeOH-Me2-CO. Acidification with AcOH gave XIV, m. 197-9° (MeOH). The following

L7 ANSWER 200 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
II were also prepd. (R1, R2, X, m.p., and % yield given): Me, PhCH(CN)CH2, EtO, 172-3°, 37.4; Me, EtNH-CO, H, 208-9°, 70; H2NCO, H2NCO, H, 217° (decompn.), 81; H2NCO, H2NCO, MeO, 222° (decompn.), 73; H2NCO, H2NCO, EtO, 218° (decompn.), 54; H2NCO, H2NCO, Cl, 300° (decompn.), 69; Me, HON:CHCH2, Me, 234° (decompn.), 51; Me, HON:CHCH2, MeO, 220° (decompn.), 55; Me, H2NCO, Me, 223° (decompn.), 56; Me, H, MeO, 245° (decompn.), 56; Me, H, Et, 227° (decompn.), 31; Me, N- piperidylcarbonyl, H, 178°, 60; Me, N-pyrrolidinocarbonyl, H, 185°, 63; Me, iso-Pr, H, 184°, 73; Me, iso-Pr, Cl, 158°, 75; Me, iso- Pr, Me, 148°, 69; Me, iso-Pr, MeO, 212°, 60; Me, iso-Pr, EtO, 174°, 65; Me, HON:cHCH2, Et2O, 222° (decompn.), 52; Me, HON:CHCH2, H2NCO, 231° (decompn.), 55; Me, H2NCO, Cl, 232° (decompn.), 40. XII (R = H), m. 196°, was prepd. in 47% yield.

IT **23433-68-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 23433-68-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-2-benzothiazolyl-3-methyl-, 1,4-dioxide (8CI, 9CI) (CA INDEX NAME)



L7 ANSWER 201 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1967:491689 CAPLUS
DN 67:91689
TI Couplers for color photography
PA Ferrania Societa per Azioni
SO Brit., 9 pp.
CODEN: BRXXAA
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 1071180		19670607	GB	
<--				
PRAI IT		19621224		

GI For diagram(s), see printed CA Issue.
AB Derivs. of 4-HO3SC6H4COCH2CN are useful color couplers for subtractive process color photography; they yield magenta color couplers. Thus, 1272 g. 4-H2NC6H4Ac was diazotized at 5°, poured into 3840 g. SO2 in 1.4 l. AcOH containing 84 g. Cu2Cl2 at 5-10° (gas evolved and product separated), poured into 70 l. H2O, and centrifuged to give 1850 g. (77%) 4-AcC6H4SO2Cl (I), m. 85-7°. To 20 g. I suspended in 100 ml. EtOH was added 100 ml. NH3 solution The mixture was treated with 200 ml. H2O and

acidified with concentrated from HCl to yield 15 g. 4-AcC6H4SO2NRR' (II, R = R'

= H) (III), m. 179-81° (EtOH). Similarly, other II were prepared (R, R', and m.p. given): H, C8H17, 95°; H, 4-C6H4SO2NHC8H17, 140-1°; Ph, Ph, 125-7°; H, 2-benzothiazolyl (Q), 233-5°; H, 4-C6H4Ac, 171-4° (IV); H, 3-C6H4Ac, 143-5° (V); H, 4-C6H4SO2NHZ (Z = 2-thiazolyl), 207-9°; H, COC17H35, 104-6°. Bromination of III in AcOH gave 4-BrCH2COC6H4SO2NRR' (VI, R = R' = H) (VII), m. 153-5° (EtOH). Similarly, other VI were prepared (R, R', and m.p. given): H, C8H17, 83-5° (EtOH); H, 4-C6H4SO2NHC8H17, 137-9°; Ph, Ph, 146-8°; H, Q, 222-4°. VII (27.8 g.) was suspended in 300 ml. EtOH, treated with 13 g. KCN in 80 ml. H2O at 50°, allowed to stand for 30 min. at 50°, poured into water, and acidified with HCl to give VIII (R1 = R2 = H), m. 166-8°, which in a photographic developer composition with 4-Et2NC6H4NH2 (IX) gave a magenta image, λmaximum 514 mμ. Similarly, other VIII were prepared (R1, R2, m.p., and λmaximum in mμ with IX given): H, n-C8H17, 121-3° (EtOH), 512; H, 4-C6H4SO2NHC14H29, -, -; 4-C6H4SO2NHC8H17, 160-72°, 510-12; Bu, Bu, 79-91°, -; Ph, Ph, 216° (decomposition), 512; H, Q, -, -; H, 3,5-C6H3(CO2H)NHCOC17H35), -, 516; H, COC17H35, -, -; H, 4-C6H4COCH2CN, -,

-; H, 3-C6H4COCH2CN, -, -; H, 4-C6H4SO2NHZ, 194-6°, 512. IV (124 g.) in 200 ml. H2O and 40 g. NaOH was treated with 1 mole n-C6H13Br, refluxed for 24 hrs., treated with 1 mole n-C6H13Br and 40 g. NaOH, and heated for 24 hrs. to give II (R = n-C6H13, R' = 4-C6H4Ac), m. 94-6° (C8H18) which was brominated and cyanidated to give VIII (R = n-C6H13, R' = 4-C6H4COCH2CN), m. 147-9°, λmaximum with IX 508-10 mμ. Similarly, V gave II (R = n-C6H13, R' = 3-C6H4Ac), m. 84-6°, which was brominated to VI (R = n-C6H13, R' = 3-C6H4COCH2Br, m. 90-2°, and converted to VIII (R = n-C6H13, R' = 3-C6H4COCH2CN), m. 159-61°, λmaximum with IX 508 mμ. A solution of 20 g. PhOH and 16 g. NaOH in 350 ml. H2O at 50° was treated with 44 g. I to give 40 g. 4-AcC6H4SO3R (X, R = Ph) (XI), m. 85-7° (EtOH). Similarly, other X were prepared (R and m.p. given): 1-C10H7, 120-1°; 2-C6H4Cl, 77-8.5°; 1,2-C10H6CONHC18H37, 108-10°; 2,3-C10H6CONH2, 174-5°; 2-C6H4CONHQ, 224-6°. Bromination of

L7 ANSWER 201 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
XI in AcOH gave 4-BrCH2COC6H4SO3R (XII, R = Ph) (XIII), m. 100-5° (EtOH). Similarly, other XII were prepd. (R and m.p. given): 1-C10H7, 101-3°; 2,3-C10H6CONH2, 179-81.5°. Treatment of XIII with KCN gave XIV (R = Ph), m. 106°, λmax. with IX 512 mμ. Similarly, other XIV were prepd. (R, m.p. and λmax. with IX in mμ given): 1-C10H7, 158-60°, 512-14; 2-C10H7, 115-17°, 514; 2-C6H4CONHPh, 12 6-8°, 520; 2-C6H4CONHC6H4SO2NHC14H29-4 (XV), 130-2°, 518; 2-C6H4Cl, 92-4°, 512-14; 1,2-C10H6CONHC18H37, 100-3°, 512-18; 1,2-C10H6CONHC6H4SO2NHC14H29-4, 173-5° (EtOH), 516; 2,3-C10H6CONH2, 235-6°, 518-20; 2-C6H4CONHC6H4Cl-4, 186-8°, 526; 2-C6H4CONHQ, -, 526-32; 2-C6H4CONHC6H4(COC6H4C5H11-4)-4, -, 522-4.

IT **4574-72-5P 16362-96-2P**
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of)
RN 4574-72-5 CAPLUS
CN Benzenesulfonic acid, p-(cyanoacetyl)-, ester with N-2-benzothiazolylsalicylamide (7CI, 8CI) (CA INDEX NAME)



RN 16362-96-2 CAPLUS
CN Benzenesulfonic acid, p-acetyl-, ester with N-2-benzothiazolylsalicylamide (8CI) (CA INDEX NAME)



L7 ANSWER 202 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1967:95055 CAPLUS
DN 66:95055
TI 2,3-Dihydro-5-carboxamide-6-methyl-1,4-oxathiin
PA United States Rubber Co.
SO Neth. Appl., 18 pp.
CODEN: NAXXAN
DT Patent
LA Dutch
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	NL 6605525	A	19661027	NL 1966-5525	19660425
<--					
	US 3393202	A	19680716	US 1965-451048	19650426
<--					
	BR 6677408	A0	19730809	BR 1966-177408	19660228
<--					
	BE 679985	A	19661003	BE 1966-679985	19660425
<--					
	IL 25635	A1	19700420	IL 1966-25635	19660426
<--					
	NL 6910431	A	19691027	NL 1969-10431	19690708
<--					
PRAI	US 1965-451048	A	19650426		

GI For diagram(s), see printed CA Issue.
AB The title compds. (I) are prepared by reaction of an α-chloroacetylacetamide or a lower alkyl ester of α-chloroacetylacetic acid with HSC2H4OH. Thus, to 150 g. AcCH2CONHPh in 1 l. C6H6 was added in 1.5 hrs. 72 ml. SO2Cl2, the mixture stirred 0.5 hrs., and filtered to yield 131 g. AcCHClCONHPh (II), m. 136-8°. To 63.5 g. II in 300 ml. C6H6 was added in 2 hrs. <30°, 20.4 g. KOH, 22.2 ml. HSC2H4OH, and 40 ml. MeOH and the mixture stirred 1 hr., filtered, the filtrate concentrated, the residue dissolved in C6H6, acidified with 0.8 g. 4-MeC6H4SO3H, the solution refluxed until 5 ml. H2O separated and concentrated to yield 45.8 g. I (R = NHPh) (III), m. 93-5° (alc.). To 260 g. AcCH2CO2Et was added 270 g. SO2Cl2 in 3 hrs. at 0-5°, the mixture kept overnight, and distilled to yield 300 g. AcCHClCO2Et (IV), b16 88-90°. To 33 g. IV in 200 ml. C6H6 was added in 1.5 hrs. <30°, 13.6 g. KOH, 15 ml. HSC2H4OH, and 30 ml. MeOH, the mixture stirred 1.5 hrs., filtered, concentrated, the residue taken up in C6H6, acidified with 4-MeC6H4SO3H, the solution refluxed until 3.4 ml. H2O separated, washed with H2O, and concentrated to yield 23 g. I (R = OEt) (V), b1 107-10°. To 188 g. V in 50 ml. alc. was added 60 g. NaOH in 400 ml. H2O and the mixture refluxed 0.5 hrs., acidified with HCl, and filtered to yield 134 g. I (R = OH) (VI), m. 180-1° (alc.). To 32 g. VI in 200 ml. CHCl3 was added 16 ml. SOCl2, the mixture refluxed 2 hrs., the solution concentrated, the residue dissolved in C6H6 and 37.2 g. PhNH2 in C6H6 added, to yield after work up 38 g. III. The following I were prepd. by similar methods (R, m.p., or b.p., and % yield given): NHC6H4CO2H-4, 249-51°, 47; morpholino, b2 168-70°, 80; NHNH2, 190-3°, 75; NH2, 172-4°, 50; NHPr-iso, 117-19°, 65; NHCH2CH:CH2, 73°, 66; NHBu, 85-6°, 70; NHBu-iso, 50-1°, 65; NHC12H25, 72°, 64; cyclohexylamino, 127-8°, 77; NHC6H4NO2-4, 139-40°, 25; NHC6H4OEt-4, 120-2°, 50; NHCH2Ph, 93°, 85; NHC6H4CO2H-2, 187-9°, 60; 2-furylamino, 103-4°; 81; N-pyridyl, -, 25; NPr2-iso, b3 119°, 64; NBu2, b12 200°, 40; N(CH2CH:CH2)2, b3 127°, 80; NEt2, b3 132°, 60; NMePh, 11-14°, 72; NHC6H4Cl-4, 130-2° (MeOH), 48; NHC6H4Cl-2, 83-5°, 46; NHC6H4Me-2, 88-9° (MeOH), 81; NHC6H4OMe-2, 123-6° (MeOH), 45; NHC6H4Cl-3, 79-82° (MeOH), 68; NHC6H4Me-4, 95-8° (MeOH), 74; NHC6H4NO2-2, 129-32° (MeOH-Me2CO), 43; NHC6H4NO2-3, 118-20° and 123-5° (MeOH-Me2CO), 60; α-naphthylamino, 125-7° (MeOH), 55; β-naphthylamino, 111-13° (MeOH), 60; NHC6H4Ph-4, 125-7°, 65; NHC6H4Ph-2, 83-6° (MeOH), 57; NHC6H4CO2Me-2, 123-5° (alc.), 44; NHC6H3Me-4,2, 76-8°, 72; NHC6H4OMe-3, 83-4.5°, 65; NHC6H4OH-2, 129-32° (alc.), 61; NHC6H4OH-3, 170-2°, 52; NHNMe2, 122-5°, 52; NHC2H4Cl, 81-3°, 63; ethyleneimino, b1 105°, 59; NHC6H4CF3-3, 70-2°, 61; NHC6H4SMe-2, -, 71; NPhC2H4CN, 87-9°, 60; 2-benzothiazolylamino, 153-4°, 80; NHBu-tert, 48-51°, 78; NHC5H11, 80-2°, 75; NHC6H13, 82-4°, 71; NHC8H17, 74-5°, 84; NHC10H21, 46-7°, 88; NHC16H33, 74-5°, 66; NHC18H37, 79-80°, 74; NHC6H4Et-2, 78-80°, 82; NHC6H4Br-3, 92-3°, 61; NHC6H4Br-4, 119-20°, 86; NHC6H4CO2Et-4, 90-2°, 63; NHC6H4CONH2-2, 186-8°, 57; NHC6H4Ac-3, 117.5-19.5°, 68; NHC6H3Me2-3,2, 101.5-3.5°, 77; NHC6H3Cl2Et2-6,2, 81-3°, 58; NHC6H3MeCl-2,3, 136-8°, 64; NHC6H3Cl2-5,2, 120-2°, 56; NHC6H3Cl2-3,2, 105-7°, 81; NHC6H3Cl2-4,3, 106-8°, 59; NHC6H3Cl2-5,3, 147-9°, 76; NHC6H3MeCl-6,2, 82-4°, 57; NHC6H2Cl3-5,4,2, 166-8°, 70; NEtC6H4Me-2, 57.5-60°, 49. Also prepd. was VII, m. 168°.

IT 14316-44-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 14316-44-0 CAPLUS
CN 1,4-Oxathiin-3-carboxamide, N-2-benzothiazolyl-5,6-dihydro-2-methyl- (8CI, 9CI) (CA INDEX NAME)



L7 ANSWER 203 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1965:463718 CAPLUS
DN 63:63718
OREF 63:11750e-h,11751a-f
TI Purple photographic color couplers
IN Bellone, Domenico; Guzzi, Alberto
PA Ferrania Societa per Azioni
SO 7 pp.
DT Patent
LA Unavailable
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1187478		19650218	DE	19631230
<--					
PRAI	DE		19631230		

AB Color couplers of the general formula p-NCCH2COC6H4SO2R (I) (where R is a mono- or disubstituted amino group or an alkyl group) were prepared When incorporated into a photographic Ag halide emulsion or a developer I produce by the Ag bleaching process purple images absorbing in the range 510-30 mμ. p-H2NC6H4Ac (II) (1272 g.) in 3.6 l. concentrated HCl and 1.2 l. H2O diazotized and added slowly at 5-10° with stirring to 3840 g. SO2 in 1.4 l. HOAc containing 84 g. CuCl, and the mixture stirred at 10° until the gas evolution ceased, yielded 1850 g. p-AcC6H4SO2Cl (III), m. 85-7°. III (20 g.) in 100 cc. EtOH and 100 cc. concentrated NH4OH yielded 15 g. p-AcC6H4SO2NH2 (IV), m. 179-81° (EtOH). IV (15 g.) in 125 cc. AcOH treated on the steam bath with 12 g. Br in 25 cc. AcOH gave 29 g. p-BrCH2COC6H4SONH2 (V), m. 153-5° (EtOH). V (27.8 g.) in 300 cc. EtOH treated 20 min. at 50° with 13 g. KCN in 80 cc. H2O gave p-NCCH2COC6H4SONH2 (VI), m. 166-8°. An exposed Ag halide emulsion developed in a bath containing Na2CO3 20, Na2SO3 0.5, p-Et2NC6H4NH2 1, and VI 1 g. diluted with H2O to 1000 cc., rinsed 5 min., bleached in a bath of K3Fe(CN)6 50, KBr 25, AcONa.3H2O 60, and B(OH)3 5 g. in 1000 cc. H2O, rinsed 10 min., and fixed gave a purple image with an absorption maximum at 514 mμ. III condensed with 2 molar equivs. C8H17NH2 gave p-AcC6H4SO2NHC8H17 (VII), m. 95° (EtOH). VII (31.1 g.) in 300 cc. AcOH with 16 g. Br in 50 cc. AcOH yielded 39 g. (crude) p-BrCH2COC6H4SO2NHC8H17, m. 83-5° (EtOH), which with aqueous alc. KCN yielded p-NCCH2COC6H4SO2NHC8H17 (VIII), m. 121-3° (EtOH). VIII in o-C6H4(CO2Bu)2 added to a Ag halide emulsion, coated onto a support, exposed, developed in a bath containing NH2OH.HCl 1, p-Et2NC6H4NH2 2.8, Na tripolyphosphate 2, Na2CO3 65, Na2SO3 25, and KBr 1.2 g. in H2O, and bleached gave a purple neg. image with an absorption maximum at 512 mμ. p-H2NC6H4SO2NHC8H17 condensed with III yielded p-AcC6H4SO2NHC6H4SO2NHC8H17-p, m. 140-1°, which was converted via p-BrCH2COC6H4SO2NHC6H4SO2NHC8H17-p, m. 137-9°, to p-NCCH2COC6H4SO2NHC6H4SO2NHC8H17-p, m. 160-72°, which yielded purple images absorbing at 510-12 mμ (the absorption maximum in mμ of the purple images produced by the coupler are given in parentheses throughout this abstract). Similarly was prepared I (R = NBu2), m. 79-81°. p-AcC6H4SO2NPh2, m. 125-7°, was converted via p-BrCH2COC6H4SO2NPh2, m. 146-8° to I (R = NPh2) (512), decompose 216°. 2-Aminobenzothiazole in C5H5N with III gave 2-(p-acetylbenzenesulfonamido)benzothiazole, m. 233-5°, which was converted via the 2-(p-BrCH2COC6H4SO2NH) analog, decompose 222-4°, to I (R = 2-benzothiazolylamino) which produces purple images. I was condensed with 3,5-HO2C(C17H35CONH)C6H3NH2, and the product converted to I [R = 3,5-HO2C(C17H35CONH)C6H3NH] (516). IV (5 g.) in 25 cc. C5H5N refluxed 0.5 hr. with 7.6 g. C17H35COCl yielded 11.6 g. p-AcC6H4SO2NHCOC17H35, m. 104-6°, which was converted to I (R = C17H35CONH). III condensed with II gave p-AcC6H4SO2NHC6H4Ac-p (IX), m. 172-4°, which was converted to the purple coupler I (R = p-NCCH2COC6H4NH). II with m-H2NC6H4Ac gave p-AcC6H4SO2NHC6H4Ac-m (X), m. 143-5°, which was converted to I (R = m-NCCH2COC6H4NH). IX (124 g.) in 700 cc. H2O refluxed 24 hrs. with stirring with 1 mole equiv. each of NaOH and C6H13Br, treated again with 1 mole equiv. each of NaOH and C6H13Br, and refluxed 24 hrs. gave p-AcC6H4SO2N(C6H13)C6H4Ac-p, m. 94-6°, which was converted to I [R = N(C6H13)C6H4COCH2CN-p], m. 147-9°. X (205 g.) with C6H13Br yielded 210 g. p-AcC6H4SO2N(C6H13)C6H4Ac-m,m. 84-6°, which was converted via p-BrCH2COC6H4SO2N(C6H13)C6H4COCH2Br-m, m. 90-2°, to I [R = N(C6H13)C6H4COCH2CN-m] (508), m. 159-61°. III condensed with p-aminobenzenesulfonyl-2-thiazolylamide yielded the p-(p-acetylbenzenesulfonylamino) analog, m. 207-9°, which was converted to I [R = p-(2-thiazolylaminosulfonyl)anilino] (512), m. 194-6°. PhOH (20 g.) and 16 g. NaOH in 350 cc. H2O stirred 10 min. at 50° with 44 g. III gave 40 g. p-AcC6H4SO3Ph (XI), m. 85-7° (EtOH). XI (39 g.) with 22.8 g. Br gave 49.4 g. (crude) p-BrCH2COC6H4SO3Ph, m. 100-5° (EtOH), which with aq. alc. KCN yielded I (R = PhO) (512), m. 106°. 1-C10H7OH (72 g.) with III gave p-AcC6H4SO2OC10H7-1, m. 120-1°, which was converted via p-BrCH2COC6H4SO2OC10H7-1, m. 101-3°, to I (R = 1-C10H7O) (512-14), m. 158-60°. Similarly were prepd. I (R = o-PhNHCOC6H4O) (520), m. 126-8°, and I (R = 2C10H7O) (514), m. 115-17°. 2,4-HO(C14H29NHSO2)C6H3CONHPh (48.8 g.), m. 122-4°, and 25 g. III in 500 cc. dioxane treated with stirring with about 40 cc. 10% aq. NaOH, and the resulting ester brominated and then treated with KCN yielded I (R = o-(p-C14H29NHSO2C6H4NHCO)C6H3O] (518), m. 130-2°. o-ClC6H4OH with III gave p-AcC6H4SO2OC6H4Cl-o, m. 77-8.5°, which was converted via p-BrCH2COC6H4SO3C6H4Cl-o, m. 92-4°, to I (R = o-ClC6H4O) (512-14). 2,1-C18H37NHCOC10H5OH (42.7 g.) with III yielded 2,1-C18H37NHCOC10H5O3SC6H4Ac-p, m. 108-10°, which was converted to I [R = 2,1-C18H37NHCOC10H6O] (512-18), m. 100-3°. III with 2,3-HOC10H6CONPh gave 2,3-(p-AcC6H4SO3)C10H6CONPh, m. 174-5°, which was converted via 2,3-(p-BrCH2COC6H4SO3)C10H6CONPh, m. 179-81.5°, to I (R = 3,2-PhNHCOC10H6O) (518-20), m. 235-6°. Similarly were prepd. I [R = 2,1-(p-C14H29NHSO2C6H4NHCO)C10H6O] (515), m. 173-5°, I [R = 2,1-(p-NCC6H4NHCO)C10H6O] (526), m. 186-8°, I [R = 2,1-(p-(p-AmC6H4CO)C6H4NHCO)C10H6O] (522-4), and I [R = o-(2-benzothiazolylaminocarbonyl)phenoxy] (526-32), m. 224-6°.

IT 4574-72-5, Benzenesulfonic acid, p-(cyanoacetyl)-, ester with N-2-benzothiazolylsalicylamide
(preparation of)
RN 4574-72-5 CAPLUS
CN Benzenesulfonic acid, p-(cyanoacetyl)-, ester with N-2-benzothiazolylsalicylamide (7CI, 8CI) (CA INDEX NAME)

L7 ANSWER 203 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 204 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1960:67062 CAPLUS
DN 54:67062
OREF 54:12847a-c
TI Color reproduction in color-photographic multiemulsion materials
IN Riester, Oskar
PA Agfa Akt.-Ges.
DT Patent
LA Unavailable
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1015683		19570912	DE	
<--					
	US 2968556		1961	US	
<--					

AB Filter layers are used containing diffusion-resistant, highly associated rhodacyanines and benzoxacarbocyanines having Ph residues. These filter dyes need not be removed in the further photographic process. The formulas of some dyes are given which are added to the green filter layer, for example: a salt of 5,5'-diphenyl-3,3,9'-triethyloxacarbocyanine gives a sharp absolute maximum at 540 mμ. When a wetting agent is added the maximum is at 525 mμ. A univalent metal salt of anhydro-5,5'-diphenyl-9-ethyl-3,3'-bis(4-sulfobutyl)oxacarbocyanine shows a very narrow absorption in gelatin at 560 mμ. The dyes are added to layers consisting of gelatin, poly(vinyl alc.), starch, or dextrin.
IT 96277-50-8, 2-Naphthamide, N-2-benzothiazolyl-4-(p-diethylaminophenylimino)-1,4-dihydro-1-oxo- (spectrum of)
RN 96277-50-8 CAPLUS
CN 2-Naphthamide, N-2-benzothiazolyl-4-[[p-(diethylamino)phenyl]imino]-1,4-dihydro-1-oxo- (6CI, 7CI) (CA INDEX NAME)



L7 ANSWER 205 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1960:20158 CAPLUS
DN 54:20158
OREF 54:3982g-i,3983a
TI Dye intermediates
IN Davies, Robert R.; Pearson, Kenneth W.
PA Imperial Chemical Industries Ltd.
DT Patent
LA Unavailable
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 808191		19590128	GB	
<--					

AB Bubbling COCl2 into 2-amino-4-hydroxybenzothiazole (I) 60, 32% NaOH (II), 35, and H2O 2125 parts below 30° for 4 hrs., then heating at 40-45° (with addition of II continually to maintain alkalinity to Clayton Yellow), filtration, washing the precipitate with dilute HCl and aqueous Na2CO3, and crystallization from C5H5N gives 1,3-bis(4-hydroxy-2-benzothiazolylamino) urea, C15H10O3N4S2, m. 304°. Heating p-C6H4(COCl)2 11 in PhMe 200 and I 16.6 in C5H5N 100 parts at 90-100° for 20 hrs., cooling, and washing the precipitate with hot dilute Na2CO3 and hot dilute HCl similarly gives a product analyzing C22H14N4O4S2.H2O. Addition of cyanuric chloride 4.7 in Me2CO 40 to I 4.2 in Me2CO 50 and H2O 25 at 8-10°, then H2O 50 and 2N Na2CO3 13 (just acid to Congo Red), stirring 30 min. at 8-10°, 1 hr. at 20-25°, addition of 2N Na2CO3 (5-6 parts, just alkaline to Delta paper) and I 4.2 in Me2CO 40, heating 2 hrs. at 45-50° for 2 hrs., with slow addition of 2N Na2CO3 to maintain alkalinity, then 2N Na2CO3 5 and PhNH2 4.5, refluxing 15 hrs., and distillation of the Me2CO gives a white precipitate Washing this with aqueous Na2CO3 and HCl, and crystallization from EtOCH2CH2OH 300 parts gives a product analyzing C23H16O2N8S2.H2O. Simultaneous addition of fumaroyl chloride 11.4 in CHCl3 60 and 8% NaOH 110 to I 16.6, H2O 500, and 8% NaOH 50 at 30-40°, stirring 1.5 hrs. at the same temperature, washing the precipitate with dilute HCl and dilute Na2CO3, then with boiling MeOH gives a product analyzing for C13H12O4N4S2.
IT 102661-75-6, Terephthalamide, N,N'-bis(4-hydroxy-2-benzothiazolyl)- (preparation of)
RN 102661-75-6 CAPLUS
CN Terephthalamide, N,N'-bis(4-hydroxy-2-benzothiazolyl)- (6CI) (CA INDEX NAME)



L7 ANSWER 205 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L7 ANSWER 206 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1955:3933 CAPLUS
DN 49:3933
OREF 49:759e-i
TI Photographic sensitizers
IN van Dormael, Andre E.; Nys, Jean; de Cat, Arthur
PA Gevaert Photo-Producten N.V.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2680686		19540608	US	

<--
GI For diagram(s), see printed CA Issue.
AB The sensitivity of photographic emulsions containing the customary sensitizing dyes has been increased by adding 30-50 mg./kg. of a compound of the type D·(R)N·(CH:CH)n-1·C:NR', where D is the residue of a 5- or 6-membered heterocyclic ring, n is 1 or 2, R is alkyl, substituted alkyl, aryl, alkenyl, or alkylene, and R' is acyl, substituted acyl, amido, or substituted amido. A supersensitizer typical of this class has been made by heating a mixture of 2 g. 3-methyl-2-iminodihydrobenzothiazole and 0.8 g. Et malonate at 70° for 1 hr. to yield bis(3-methyl-2-benzothiazolinylidene)malonamide, m. 262-3° (from alc.). The following compds. useful as supersensitizers have also been prepared and incorporated into emulsions: from 3-phenyl-2-iminodihydrobenzothiazole in Ac2O, 3-phenyl-2-(acetylimino)benzothiazoline, m. 149.5-50.5° (from alc.); from 3-methyl-2-iminodihydrobenzothiazole (I) and Ac2O, 3-methyl-2-(acetylimino)benzothiazoline, m. 141-2° (from alc.); from I and Et (2-benzothiazolyl)acetate, 3-methyl-2-(benzothiazol-2-ylacetylimino)benzothiazoline, m. 172-3° (from alc.); from I and benzoyl chloride, 3-methyl-2-(benzoylimino)benzothiazoline, m. 156.5-7.5° (from alc.); from I and Et acetoacetate, 3-methyl-2-(acetoacetylimino)benzothiazoline, m. 146-7° (from alc.); from I and urea, 3-methyl-2-(carbamoylimino)benzothiazoline; from 2-aminobenzothiazole and benzoyl chloride, 2-(benzoylimino)benzothiazoline, m. 186-7° (from alc.); from 2-aminonaphthimidazole and benzoyl chloride, 2-(benzoylimino)naphthimidazoline, m. 244-5°; from 2-aminobenzoxazole and benzoyl chloride, 2-(benzoylimino)benzoxazoline, m. 214-15° (from alc.); from I and (p-phenylenedioxy)diacetyl chloride, 1,4-bis(3-methyl-2-benzothiazolinylidenecarbamoylmethoxy)benzene, m. 276-7° (from cyclohexanone.) A mixture of I and 2-(carbethoxymethyl)benzothiazole was refluxed in xylene to give a product, m. 172-3° (from butanol). The latter was converted to its methiodide, m. 253-4° (decompose) which in turn was treated with KOH in EtOH to yield 3-methyl-N-(3-methyl-2-benzothiazolinyldine)-Δ2,α-benzothiazolineacetamide. Procedures are given for using the above supersensitizers in conjunction with the usual sensitizing dyes in photographic emulsions.
IT 5005-14-1, Benzamide, N-2-benzothiazolinylidene-
(preparation of)

L7 ANSWER 206 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 5005-14-1 CAPLUS
CN Benzamide, N-2-benzothiazolyl- (9CI) (CA INDEX NAME)



L7 ANSWER 207 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1951:62732 CAPLUS
DN 45:62732
OREF 45:10606a-f
TI Sulfur dyes of the dioxazine series
IN Robbins, Gordon B.
PA E. I. du Pont de Nemours & Co.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2564381		19510814	US	

<--
AB Sym. N,N'-diaryltriphendioxazinedicarboxamides having thiocyano substituents on the aryl groups are synthesized by condensing an organic polysulfide or a thiocyanoaniline with halogenated triphendioxazinedicarbonyl halides. The products are N,N'-diaryl-6,13-dihalotriphendioxazine-2,9(or 3,10)-dicarboxamide sulfur dyes. The products are characterized by improved purity and tinctorial properties, by virtue of the exact control over the position of the sulfide-vattable polysulfide or SCN groups. The products are, listing in order acid component, amine component, and shade when applied to cotton from a sulfide vat: 6,13-dichlorotriphendioxazine-2,9-dicarboxylic acid (I), 4-thiocyanoaniline, red; I, 2-methoxy-4-thiocyano-5-chloroaniline, red; I, 2,5-dichloro-4-thiocyanoaniline, yellowish red; I, 2,5-dimethoxy-4-thiocyanoaniline, blueish red; I, 2-amino-6-thiocyanobenzothiazole, blueish red; I, 2-amino-4,5-benzo-6-thiocyanobenzothiazole, blueish red; I, 2,2'-diaminodiphenyl disulfide, red; I, 4,4'-diaminodiphenyl disulfide, red; I, N-methyl-4-thiocyanoaniline, light red; 6,13-dichlorotriphendioxazine-3,10-dicarboxylic acid (II), 4-thiocyanoaniline, bright orange; II, 2-methoxy-4-thiocyanoaniline, bright orange; II, 2-methoxy-4-thiocyano-5-chloroaniline, bright orange; II, 2,5-dichloro-4-thiocyanoaniline, yellowish orange; II, 2-methyl-4-thiocyano-5-chloroaniline, yellowish orange; II, 4,4'-diaminodiphenyl disulfide, bright orange; 3,6,10,13-tetrachlorotriphendioxazine-2,9-dicarboxylic acid, 4-thiocyanoaniline (III), red; 6,13-dibromotriphendioxazine-2,9-dicarboxylic acid, III, red; 6,13-dibromotriphendioxazine-3,10-dicarboxylic acid, III, orange; I, 4,4'-diamino-2,2',5,5'-tetrachlorodiphenyl disulfide, yellowish red; I, 4,4'-diamino-2,2'-dichloro-5,5'-dimethyldiphenyl disulfide, red; I, 2,4-dithiocyano-1-naphthylamine, blueish red; I, 2-amino-4-methoxy-6-thiocyanobenzothiazole, blueish red; I, 6,6'-bis(2-aminobenzothiazolyl) disulfide, blueish red; I, 4,4'-diamino-2,2'-dichloro-5,5'-dimethoxydiphenyl disulfide, red; I, 4,4'-diamino-5,5'-dimethyldiphenyl disulfide, yellowish red; I, 2-amino-4-methyl-6-thiocyanobenzothiazole, blueish red. In a typical synthesis 6,13-dichlorotriphendioxazine-2,9-dicarboxylic acid 1, pyridine 0.1, o-C6H4Cl2 26, and SOCl2 3 parts are refluxed 2 hrs. and distilled until the residue boils at 175°. The residue is cooled to 100° and pyridine 2.5 and p-NCSC6H4NH2 1.0 to 1.5 parts are added. The mixture is heated at 125° for 1 hr., cooled, diluted with alc., and the product N,N' - bis(4 - thiocyanophenyl) - 6,13 - dichlorotriphendioxazine-2,9-dicarboxamide is filtered off, washed, and dried.
IT 859322-82-0, 3,10-Triphenodioxazinedicarboxamide, 6,13-dichloro-N,N'-bis(5-thiocyanatonaphtho[1,2-d]thiazol-2-yl)-
(preparation of)

L7 ANSWER 207 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 859322-82-0 CAPLUS
CN 3,10-Triphenodioxazinedicarboxamide, 6,13-dichloro-N,N'-bis(5-thiocyanatonaphtho[1,2-d]thiazol-2-yl)- (5CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L7 ANSWER 208 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1950:31561 CAPLUS
DN 44:31561
OREF 44:6142d
TI Substantive azo dye
PA C I B A Ltd.
SO Addn. to Swiss 245,067 (C.A. 43, 5597g)
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CH 252072		19480916	CH	

<--
AB Reaction of 2 mols. of diazotized 6-ethoxy-2-(4-hydroxy-3-aminobenzamido)benzothiazole with 1 mol. 5,5'-dihydroxy-2,2'-dinaphthylamine-7,7'-disulfonic acid in alkaline solution (20% Ca(OH)2) yields a black powder. This dyes cotton from weakly alkaline solns. to which CuSO4 and Na tartrate have been added in fast, bluish purple shades.
IT 854057-66-2, Benzothiazole, 2-(3-amino-4-hydroxybenzamido)-6-ethoxy-
(azo dyes from)
RN 854057-66-2 CAPLUS
CN Benzothiazole, 2-(3-amino-4-hydroxybenzamido)-6-ethoxy- (5CI) (CA INDEX NAME)



L7 ANSWER 209 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1949:25156 CAPLUS
DN 43:25156
OREF 43:4701c-d
TI N-Substituted 3-hydroxy-2-naphthamide
PA Soc. pour l'ind. chim. a Bale.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CH 225557		19430517	CH	

<--
GI For diagram(s), see printed CA Issue.
AB To 3,2-HOC10H6CO2H 188, 2-amino-6-ethoxybenzothiazole 194, and PhCl 1000 is added PCl3 69 parts at 75° in 1 hr., and the mixture boiled until no more HCl is evolved to produce.
IT 101750-45-2, 2-Naphthamide, N-6-ethoxy-2-benzothiazolyl-3-hydroxy-
(preparation of)
RN 101750-45-2 CAPLUS
CN 2-Naphthalenecarboxamide, N-(6-ethoxy-2-benzothiazolyl)-3-hydroxy- (9CI) (CA INDEX NAME)



L7 ANSWER 210 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1949:24103 CAPLUS
DN 43:24103
OREF 43:4498h-i
TI A nitrogen-containing surface-active agent
PA Soc. pour l'ind. chim. a Bale
SO Addn. to Swiss 225,557
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CH 230409		19431231	CH	

<--
AB N-2-Benzothiazolyl-3-hydroxy-2-naphthamide (I) is prepared from 3-hydroxy-2-naphthoic acid 188, and 2-aminobenzothiazole 150, in C6H5Cl 100 parts at 75°. PCl3 69 parts is added over a period of 1 hr., and the mixture is heated to boiling until evolution of HCl ceases. I ppts. on cooling. I has unusual detergent action on plant fibers.
IT 25829-71-4, 2-Naphthamide, N-2-benzothiazolyl-3-hydroxy-
(preparation of)
RN 25829-71-4 CAPLUS
CN 2-Naphthalenecarboxamide, N-2-benzothiazolyl-3-hydroxy- (8CI, 9CI) (CA INDEX NAME)



L7 ANSWER 211 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1946:20017 CAPLUS
DN 40:20017
OREF 40:3909a-f
TI Amides of 2-aminoarylenethiazoles
IN Henzi, Ernst
PA Soc. pour l'ind. chim. a Bale
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2399026		19460423	US	

<--
AB 2-Aminoarylenethiazoles are treated with aromatic hydroxy carboxylic acids or the corresponding acyl chlorides in the presence of dehydrating agents to form amides. such amides are coupled in the o-position to the OH group of the hydroxy carboxylic acid to diazotized aromatic amino compds. to form azo dyes for various textile materials applicable by the methods in use for ice colors. In the following examples parts are by weight 3-Hydroxy-2-naphthoic acid (I) (188 parts) and 194 parts of 2-amino-6-ethoxybenzothiazole (II) are heated with 1000 parts of PhCl to 75°, 46 parts of POCl3 is added over a period of 1 hr., and the mixture is boiled until no more HCl is evolved. After cooling the precipitated condensation product, 2-(3-hydroxy-2-naphthoylamino)-6-ethoxybenzothiazole (III), is filtered off, excess solvent is removed with steam in the presence of excess NaOAc, and III is filtered, washed and dried. 3-Hydroxy-2-naphthoyl chloride (206.5 parts), 180 parts of 2-amino-6-methoxybenzothiazole (IV) and 1200 parts of PhCl are refluxed with stirring for 12 hrs., cooled, and the condensation product, 2-(3-hydroxy-2-naphthoylamino)-6-methoxybenzothiazole (V), is filtered off. Traces of solvent are removed with steam from the solution made faintly alkaline with Na2CO3. V, m. 300-2°, is filtered off, washed and dried. V is also prepared from I and IV in the presence of PCl3. From 6-hydroxy-m-toluic acid and II in the presence of PCl3 2-(6-hydroxy-m-toluylamino)-6-ethoxybenzothiazole, m. 264-5°, from boiling glacial AcOH, is prepared From 2-hydroxy-3-dibenzofurancarboxylic acid (C.A. numbering) and II in the presence of PCl3 (2-(2-hydroxy-3-dibenzofuranylcarbonylamino)-6-ethoxybenzothiazole) is prepared From bis(2-amino-6-benzothiazolyl) ether and I in the presence of PCl3 bis[2-(3-hydroxy-2-naphthoylamino)-6-benzothiazolyl] ether, m. 304°, is prepared III (36.4 parts) is converted to the Na salt with 150 parts of EtOH, 30 parts of Turkey-red oil and 40 parts by volume of 30% NaOH. The mixture is diluted with 300 parts of water, made faintly acidic with AcOH, and a solution of 25.4 parts of diazotized 2',4-dichloro-2-aminodiphenyl ether is added with stirring. The coupling takes place in o-position to the OH group to form a red dye, m. 300° from PhNO2. Cotton yarn impregnated with a solution containing 1.5 parts of III, 5 parts of Turkey-red oil, 3 parts by volume of 36°B.acte.e. NaOH and 3 cc. of EtOH is developed with a NaOAc solution of diazotized 2-amino-4,4'-dichlorodiphenyl ether to produce an intensive, pure blue-red shade of good fastness. A table of 69 similarly formed azo dyes is given.
IT 101750-45-2, 2-Naphthamide, N-(6-ethoxy-2-benzothiazolyl)-3-

L7 ANSWER 211 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
hydroxy- 854396-28-4, Benzothiazole, 6-ethoxy-2-(2-hydroxydibenzofuran-3-ylcarbonylamino)- 855155-04-3, Benzothiazole, 6-ethoxy-2-(2-hydroxy-5-methylbenzamido)- 855282-14-3, Benzothiazole, 2-(3-hydroxy-2-naphthoylamino)-6-methoxy- 855282-20-1, Benzothiazole, 6,6'-oxybis[2-(3-hydroxy-2-naphthoylamino)- 861089-42-1, 2-Naphthamide, 8-hydroxy-N-(6-methoxy-2-benzothiazolyl)-
(prepn. of)

RN 101750-45-2 CAPLUS
CN 2-Naphthalenecarboxamide, N-(6-ethoxy-2-benzothiazolyl)-3-hydroxy- (9CI) (CA INDEX NAME)



RN 854396-28-4 CAPLUS
CN 3-Dibenzofurancarboxamide, N-(6-ethoxy-2-benzothiazolyl)-2-hydroxy- (4CI) (CA INDEX NAME)



RN 855155-04-3 CAPLUS
CN 2,5-Cresotamide, N-(6-ethoxy-2-benzothiazolyl)- (4CI) (CA INDEX NAME)



RN 855282-14-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

L7 ANSWER 211 OF 211 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 855282-20-1 CAPLUS
CN Benzothiazole, 6,6'-oxybis[2-(3-hydroxy-2-naphthoylamino)- (4CI) (CA INDEX NAME)



RN 861089-42-1 CAPLUS
CN 2-Naphthamide, 8-hydroxy-N-(6-methoxy-2-benzothiazolyl)- (4CI) (CA INDEX NAME)



```
=> => d que l12 sta
L8            27 SEA FILE=CAPLUS ABB=ON  PLU=ON  "STROBEL HARTMUT"/AU
L9            28 SEA FILE=CAPLUS ABB=ON  PLU=ON  ("WOHLFART PAULUS"/AU OR
                 "WOHLFART PAULUS W"/AU)
L10           23 SEA FILE=CAPLUS ABB=ON  PLU=ON  "BELOW PETER"/AU
L11           67 SEA FILE=CAPLUS ABB=ON  PLU=ON  L8 OR L9 OR L10
L12           20 SEA FILE=CAPLUS ABB=ON  PLU=ON  L11 AND (NITRIC OXIDE)

=> d 1-20 bib abs
```

L12 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:898609 CAPLUS
DN 141:366248
TI A preparation of triaza- and tetraazaanthracenedione derivatives, useful as cardiovascular agents
IN Weichert, Andreas; **Strobel, Hartmut; Wohlfart, Paulus;** Patek, Marcel; Smrcina, Martin; Weichsel, Aleksandra
PA Aventis Pharma Deutschland GmbH, Germany
SO Eur. Pat. Appl., 32 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1471066	A1	20041027	EP 2003-9286	20030424
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CA 2523196	AA	20041104	CA 2004-2523196	20040413
	WO 2004094425	A1	20041104	WO 2004-EP3851	20040413
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004248900	A1	20041209	US 2004-829064	20040421
PRAI	EP 2003-9286	A	20030424		
	US 2003-499521P	P	20030902		
	WO 2004-EP3851	W	20040413		

OS MARPAT 141:366248
GI

L12 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB The invention relates to a preparation of triaza- and tetraaza-anthracenedione derivs. of formula I [wherein: A and B are independently selected from N, CH, C-halogen, C-NO2, or C-CN, etc., but A and B are not simultaneously N; R1 is (un)substituted (cyclo)alkyl or alk(en/yn)yl; R2 is H, alkyl, CF3, or (CH2)0-2-(phenyl/imidazolyl), etc.; R3 is (CH2)1-4-(phenyl/imidazolyl/triazolyl) or (CH2)1-4-pyridinyl, etc.; R4 and R5 are independently selected from H, alkyl, CF3, or alkoxy, etc.], useful as cardiovascular agents. The title compds. are useful in the treatment of various disease states including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension, and cardiac insufficiency. They upregulate the expression of the enzyme endothelial **nitric oxide** (NO) synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. For instance, triazaanthracenedione derivative II (activation of eNOS transcription: EC50 = 1.2 μM) was prepared via heterocyclization of 4-tert-butylbenzylamine, Fmoc-L-valine, 2-fluoro-5-nitrobenzoic acid, 2-bromo-1,1-diethoxyethane, and 3-(imidazol-1-yl)propylamine (example 2, no yield data).

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:117248 CAPLUS
DN 140:181465
TI Preparation of acylated arylcycloalkylamines and their use as pharmaceuticals for treatment of cardiovascular disorders
IN **Strobel, Hartmut; Wohlfart, Paulus; Below, Peter**
PA Aventis Pharma Deutschland GmbH, Germany
SO Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1388535	A1	20040211	EP 2002-17587	20020807
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	CA 2494628	AA	20040219	CA 2003-2494628	20030724
	WO 2004014842	A1	20040219	WO 2003-EP8104	20030724
	WO 2004014842	C1	20050428		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1529031	A1	20050511	EP 2003-784056	20030724
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013271	A	20050621	BR 2003-13271	20030724
	JP 2005534706	T2	20051117	JP 2004-526766	20030724
	US 2004082628	A1	20040429	US 2003-636001	20030807
	NO 2005001110	A	20050301	NO 2005-1110	20050301
PRAI	EP 2002-17587	A	20020807		
	US 2002-432312P	P	20021210		
	WO 2003-EP8104	W	20030724		

OS MARPAT 140:181465
GI



I

AB The present invention relates to acylated arylcycloalkylamines of the formula (I) including N-(trans-2-phenylcyclopropyl)carboxamides [wherein R1, R2 = each (un)substituted Ph, 1- or 2-naphthyl, or 5- to 10-membered, aromatic, monocyclic or bicyclic heterocycle containing one or more heteroatoms selected from the group consisting of N, O and S; n = an integer of 1-4]. These compds. upregulate the expression of the enzyme endothelial **nitric oxide** (NO) synthase and can be applied in conditions in which an increased expression of said enzyme or an increased

L12 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
NO level or the normalization of a decreased NO level is desired. They are useful in the treatment of various disease states including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency. The diseases also include for the treatment of stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, peripheral artery occlusive disease, endothelial dysfunction, restenosis, endothelial damage after PTCA, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance or a restricted ability to learn, or for the lowering of cardiovascular risk of postmenopausal women or of women taking contraceptives. For example, N-(trans-2-phenylcyclopropyl)-3-amino-5-methylpyrazine-2-carboxamide and N-(trans-2-phenylcyclopropyl)-2,5-dimethyl-1-(thiophen-2-ylmethyl)-1H-pyrrole-3-carboxamide inhibited the activation of transcription of human endothelial **nitric oxide** synthetase in primary human umbilical vein code cells (HUVEC) with EC50 of 0.060 and <0.01 μM, resp.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:117214 CAPLUS
DN 140:163869
TI Preparation of acylated, heteroaryl-condensed cycloalkenylamines for treatment of cardiovascular disorders
IN **Strobel, Hartmut; Wohlfart, Paulus**
PA Aventis Pharma Deutschland GmbH, Germany
SO Eur. Pat. Appl., 35 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1388342	A1	20040211	EP 2002-17586	20020807
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	CA 2494302	AA	20040219	CA 2003-2494302	20030724
	WO 2004014372	A1	20040219	WO 2003-EP8103	20030724
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1534277	A1	20050601	EP 2003-784055	20030724
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013240	A	20050927	BR 2003-13240	20030724
	JP 2005538124	T2	20051215	JP 2004-526765	20030724
	US 2004092513	A1	20040513	US 2003-632083	20030731
	NO 2005000830	A	20050216	NO 2005-830	20050216
PRAI	EP 2002-17586	A	20020807		
	US 2002-432441P	P	20021211		
	WO 2003-EP8103	W	20030724		

OS MARPAT 140:163869
GI



I



II

AB The title compds. (I) [the ring A = an aromatic 5-membered or 6-membered ring
containing 1 or 2-nitrogen atoms as ring heteroatoms, or an aromatic 5-membered

L12 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ring contg. 1 ring heteroatom which is an oxygen atom or a sulfur atom or 2 ring heteroatoms one of which is a nitrogen atom and the other of which is an oxygen atom or a sulfur atom; R1, R4 = H, each (un)substituted C1-10
alkyl, C2-10 alkenyl, or C2-10 alkynyl, COR9, CONR10R11, CO2R12, CF3, halogens, cyano, NR13R14, OR1, S(O)mR16, SO2NR17R18, NO2; R1 and R4 cannot
be halogen, cyano or NO2 if R1 or R4 is bonded to a ring nitrogen atom; R2, R3 = H, halogens, cyano, (un)substituted C1-10 alkyl, PhCONH, PhSO2-O,
(C1-6 alkyl)-CO, or PhCO, OH, C1-10 alkoxy, PhO, S(O)mR19, CF3, cyano, NO2, C1-10 alkylamino, di(C1-10 alkyl)amino, (C1-6 alkyl)-CONH; but R2 and
R3 cannot be halogen, cyano or NO2 if R2 or R3 is bonded to a ring nitrogen atom; R5 = (un)substituted Ph, naphth-1-yl, naphth-2-yl, a 5-membered to 1 O-membered, arom., monocyclic or bicyclic heterocycle contg. one or more heteroatoms selected from the group consisting of N, O and S; R9 = (un)substituted C1-10 alkyl; R10, R12, R17 = H, (un)substituted C1-10 alkyl; R11, R18 = H, C1-10 alkyl; R13, R14 = H, C1-6
alkyl, each (un)substituted Ph, benzyl, heteroaryl, (C1-6 alkyl)-CO; R16 = (un)substituted C1-10 alkyl, CF3, each (un)substituted Ph or heteroaryl; m
= 0, 1, 2; n = 1, 2, 3] are prepd. These compds. upregulate the expression of the enzyme endothelial **nitric oxide** (NO) synthase and can be applied in conditions in which an increased expression
of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. They are useful in the treatment of various disease states including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension, and cardiac insufficiency. The diseases also include stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary
syndrome, heart failure, myocardial infarction, stroke, peripheral artery occlusive disease, endothelial dysfunction, restenosis, endothelial damage
after PT- CA, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance or a restricted ability to learn, or for the lowering of cardiovascular risk of postmenopausal women or of women taking contraceptives. For example, 2,4-dimethyl-N-(6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-8-yl)benzamide (II) inhibited activation of human endothelial **nitric oxide** synthetase gene cloned in human endothelial cell line with EC50 of 0.054 μM.
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:117213 CAPLUS
DN 140:163868
TI Preparation of acylaminoheteroarenes as upregulators of endothelial **nitric oxide** synthase (eNOS).
IN **Strobel, Hartmut; Wohlfart, Paulus; Below, Peter**
PA Aventis Pharma Deutschland GmbH, Germany
SO Eur. Pat. Appl., 40 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1388341	A1	20040211	EP 2002-17585	20020807
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	CA 2494298	AA	20040219	CA 2003-2494298	20030724
	WO 2004014369	A1	20040219	WO 2003-EP8102	20030724
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1534275	A1	20050601	EP 2003-784054	20030724
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013294	A	20050712	BR 2003-13294	20030724
	JP 2005538123	T2	20051215	JP 2004-526764	20030724
	US 2004110808	A1	20040610	US 2003-634979	20030805
PRAI	EP 2002-17585	A	20020807		
	US 2002-432314P	P	20021210		
	WO 2003-EP8102	W	20030724		

OS MARPAT 140:163868
GI



I

AB Title compds. [I; R1, R4 = H, (substituted) alkyl, alkenyl, alkynyl, Ph, heteroaryl; R2, R3 = H, OH, halo, cyano, alkoxy, PhO, (substituted) alkyl,
PhCONH, etc.; R5 = (substituted) aryl, heteroaryl; X = NR30, S, O, CH:CH, N:CH; R30 = H, (substituted) alkyl, alkenyl, alkynyl], were prepared
Thus,
title compound I (R1-R4 = H; R5 = 4-FC6H4; X = NH) (preparation outlined)

L12 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
activated eNOS transcription with EC50 = 0.028 μM.
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:987083 CAPLUS
DN 141:49
TI Crosstalk between ACE inhibitors, B2 kinin receptor and nitric oxide in endothelial cells
AU Wohlfart, Paulus; Wiemer, Gabriele; Linz, Wolfgang; Schoelkens, Bernward A.
CS Disease Groups Research, Aventis Pharma Deutschland GmbH, Frankfurt/Main, D-65926, Germany
SO ACE Inhibitors (2001), 29-36. Editor(s): D'Orleans-Juste, Pedro; Plante, Gerard E. Publisher: Birkhaeuser Verlag, Basel, Switz.
CODEN: 69EWFQ; ISBN: 3-7643-5982-X
DT Conference; General Review
LA English
AB A review focuses on endothelial aspects of angiotensin converting enzyme (ACE) inhibition, on its interaction with components of the kallikrein-kinin system. ACE degrades bradykinin and kallidin, the N-terminal elongated form of bradykinin. Inhibition of ACE leads to accumulation of both kinin with a subsequent stimulation of endothelial B2
kinin receptors causing the synthesis and release of vasodilator substances such as endothelium-derived hyperpolarizing factor, prostacyclin and nitric oxide. In addition to this basic mechanism, recent results indicate a direct interaction between ACE inhibitors and/or ACE and B2 kinin receptors amplifying this signaling pathway.
RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:708442 CAPLUS
DN 138:55207
TI Red Wine Polyphenols Enhance Endothelial Nitric Oxide Synthase Expression and Subsequent Nitric Oxide Release From Endothelial Cells
AU Leikert, Juergen F.; Raethel, Thomas R.; Wohlfart, Paulus; Cheynier, Veronique; Vollmar, Angelika M.; Dirsch, Verena M.
CS Center of Drug Research, Department of Pharmacy, University of Munich, Munich, Germany
SO Circulation (2002), 106(13), 1614-1617
CODEN: CIRCAZ; ISSN: 0009-7322
PB Lippincott Williams & Wilkins
DT Journal
LA English
AB Background - Population-based studies suggest a reduced incidence of morbidity and mortality from coronary heart disease caused by moderate and
regular consumption of red wine. Endothelial nitric oxide (NO) is a pivotal vasoprotective mol. This study examines the influence of red wine polyphenols on the regulation of endothelial nitric oxide synthase (eNOS) expression and subsequent NO synthesis, focusing on the putative long-lasting antiatherosclerotic effects of red wine. Methods and Results - Treatment (20 h) of human umbilical vein endothelial cells (HUVECs) and of the HUVEC-derived cell line EA.hy926 with a alc.-free red wine polyphenol extract (RWPE) led to a
concentration-dependent (100 to 600 9mg/mL), significant increase in NO release
(up to 3.-fold/HUVEC and 2.0-fold/EA.hy926) as shown by use of the fluorescent probe DAF-2. This effect was corroborated by the [14C]L-arginine/L-citrulline conversion assay in intact EA.hy926 cells. RWPE (20 h, 100 5o 600 μg/mL) also significantly increased eNOS protein levels up to 2.1-fold. Furthermore, we found an increased human eNOS promotor activity (up to 2-fold) in response to red wine polyphenols (18 h, 100 to 600 μg/mL) as demonstrated by luciferase reporter gene assay. Conclusion - We provide conclusive data showing for the first time that a RWPE increases eNOS expression and subsequent endothelial NO release. Increased active eNOS levels may antagonize the development of endothelial
dysfunction and atherosclerosis, a hypothesis that supports the view that red wine indeed may have long-term protective cardiovascular properties mediated by its polyphenols.
RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:637636 CAPLUS
DN 137:185515
TI Preparation of acylated indanyl amines and their use as remedies in upregulation of endothelial nitric oxide synthase
IN Strobel, Hartmut; Wohlfart, Paulus; Safarova, Alena; Walser, Armin; Suzuki, Teri; Dharanipragada, Ramalinga M.
PA Aventis Pharma Deutschland GmbH, Germany
SO PCT Int. Appl., 137 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002064545	A1	20020822	WO 2002-EP1444	20020212
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2437944	AA	20020822	CA 2002-2437944	20020212
	EE 200300369	A	20031015	EE 2003-369	20020212
	EP 1373191	A1	20040102	EP 2002-722067	20020212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002007211	A	20040127	BR 2002-7211	20020212
	CN 1491207	A	20040421	CN 2002-804836	20020212
	JP 2004518719	T2	20040624	JP 2002-564478	20020212
	NZ 527470	A	20050429	NZ 2002-527470	20020212
	US 2003055093	A1	20030320	US 2002-73160	20020213
	ZA 2003005413	A	20040428	ZA 2003-5413	20030714
	BG 108076	A	20050531	BG 2003-108076	20030807
	NO 2003003565	A	20031013	NO 2003-3565	20030812
PRAI	EP 2001-102850	A	20010213		
	WO 2002-EP1444	W	20020212		

OS MARPAT 137:185515
GI

L12 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Title compds. [I; R1-R4 =; A = CH2, CHOH, CH(C1-C3-alkyl); B = CH2, CH(C1-C3-alkyl); R5 = aryl, heteroaryl] are prepared and are useful in the
upregulation of endothelial nitric oxide synthase (eNOS). Title compds. I may therefore be useful for the manufacture of medicaments for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinymetal angina, acute
coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA(percutaneous trans-luminal coronary angioplasty), hypertension, essential hypertension,
pulmonary hypertension, secondary hypertension, renovascular hypertension,
chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes or diabetes complications, nephropathy or retinopathy, angiogenesis, asthma bronchial, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn, or for the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives. Thus, the title compound II was prepared from 2-amino-4-methylindane and 4-fluorobenzoyl chloride, purified
by HPLC and was in vitro tested on human umbilical vein cord endothelial cells for activation effect of eNOS transcription with EC-50(μM) = 6.0 and TIR(max) = 2.80.
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:392358 CAPLUS
DN 137:119060
TI Structural Requirements for Inhibition of the Neuronal Nitric Oxide Synthase (NOS-I): 3D-QSAR Analysis of 4-Oxo- and 4-Amino-Pteridine-Based Inhibitors
AU Matter, Hans; Kotsonis, Peter; Klingler, Otmar; Strobel, Hartmut ; Froehlich, Lothar G.; Frey, Armin; Pfleiderer, Wolfgang; Schmidt, Harald H. W.
CS Molecular Modeling, Aventis Pharma, Frankfurt am Main, 65926, Germany
SO Journal of Medicinal Chemistry (2002), 45(14), 2923-2941
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 137:119060
AB The family of homodimeric nitric oxide synthases (NOS I-III) catalyzes the generation of the cellular messenger nitric oxide (NO) by oxidation of the substrate L-arginine. The rational design of specific NOS inhibitors is of therapeutic interest in regulating pathol. NO levels associated with sepsis, inflammatory, and neurodegenerative diseases. The cofactor (6R)-5,6,7,8-tetrahydrobiopterin (H4Bip) maximally activates all NOSs and stabilizes enzyme quaternary structure by promoting and stabilizing dimerization. Here, we describe the synthesis and three-dimensional (3D) quant. structure-activity relationship (QSAR) anal. of 65 novel 4-amino- and 4-oxo-pteridines (antipterins) as inhibitors targeting the H4Bip binding site of the neuronal NOS isoform (NOS-I). The exptl. binding modes for two inhibitors complexed with the related endothelial NO synthase (NOS-III) reveal requirements of biol. affinity and form the basis for ligand alignment. Different alignment rules were derived by building other compds. accordingly using manual superposition or a genetic algorithm for flexible superposition. Those alignments led to 3D-QSAR models (comparative mol. field anal. (CoMFA) and comparative mol. similarity index anal. (CoMSIA)), which were validated using leave-one-out cross-validation, multiple analyses with two and five randomly chosen cross-validation groups, perturbation of biol. activities by randomization or progressive scrambling, and external prediction. An iterative realignment procedure based on rigid field fit was used to improve the consistency of the resulting partial least squares models. This led to consistent and highly predictive 3D-QSAR models with good correlation coeffs. for both CoMFA and CoMSIA, which correspond to exptl. determined NOS-II and -III H4Bip binding site topologies as well as to the NOS-I homol. model binding site in terms of steric, electrostatic, and hydrophobic complementarity. These models provide clear guidelines and accurate activity predictions for novel NOS-I inhibitors.
RE.CNT 111 THERE ARE 111 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:43353 CAPLUS
DN 136:288538
TI Structural basis for pterin antagonism in nitric-oxide synthase: development of novel 4-oxo-pteridine antagonists of (6R)-5,6,7,8-tetrahydrobiopterin
AU Kotsonis, Peter; Frohlich, Lothar G.; Raman, C. S.; Li, Huiying; Berg, Michael; Gerwig, Rainer; Groehn, Viola; Kang, Yonghan; Al-Masoudi, Najim; Taghavi-Moghadam, Shahriyar; Mohr, Detlev; Munch, Ursula; Schnabel, Joachim; Martasek, Pavel; Masters, Bettie S. S.; Strobel, Hartmut ; Poulos, Thomas; Matter, Hans; Pfleiderer, Wolfgang; Schmidt, Harald H. H. W.
CS Department of Pharmacology and Toxicology, Julius-Maximilians University, Wurzburg, 97078, Germany
SO Journal of Biological Chemistry (2001), 276(52), 49133-49141
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
AB Pathol. nitric oxide (NO) generation in sepsis, inflammation, and stroke may be therapeutically controlled by inhibiting NO synthases (NOS). Here we targeted the (6R)-5,6,7,8-tetrahydro-L-biopterin (H4Bip)-binding site of NOS, which, upon cofactor binding, maximally increases enzyme activity and NO production from substrate L-arginine. The first generation of H4Bip-based NOS inhibitors employed a 4-amino pharmacophore of H4Bip analogous to antifolates such as methotrexate. We developed a novel series of 4-oxo-pteridine derivs. that were screened for inhibition against neuronal NOS (NOS-I) and a structure-activity relation was determined To understand the structural basis for pterin antagonism, selected derivs. were docked into the NOS pterin binding cavity. Using a reduced 4-oxo-pteridine scaffold, derivs. with certain modifications such as electron-rich aromatic Ph or benzoyl groups at the 5- and 6-positions, were discovered to markedly inhibit NOS-I, possibly due to hydrophobic and electrostatic interactions with Phe462 and Ser104, resp., within the pterin binding pocket. One of the most effective 4-oxo compds. and, for comparisons an active 4-amino derivative, were then co-crystallized with the endothelial NOS (NOS-III) oxygenase domain and this structure solved to confirm the hypothetical binding modes. Collectively, these findings suggest (i) that, unlike the antifolate principle, the 4-amino substituent is not essential for developing pterin-based NOS inhibitors and (ii), provide a steric and electrostatic basis for their rational design.
RE.CNT 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:120421 CAPLUS
DN 134:291956
TI NOSIP, a novel modulator of endothelial nitric oxide synthase activity
AU Dedio, Jurgen; Konig, Peter; Wohlfart, Paulus; Schroeder, Christian; Kummer, Wolfgang; Muller-Esterl, Werner
CS Institute for Biochemistry II, University of Frankfurt Hospital, Frankfurt, D-60590, Germany
SO FASEB Journal (2001), 15(1), 79-89
CODEN: FAJOEC; ISSN: 0892-6638
PB Federation of American Societies for Experimental Biology
DT Journal
LA English
AB Production of nitric oxide (NO) in endothelial cells is regulated by direct interactions of endothelial nitric oxide synthase (eNOS) with effector proteins such as Ca2+-calmodulin, by posttranslational modifications such as phosphorylation via protein kinase B, and by translocation of the enzyme from the plasma membrane caveolae to intracellular compartments. Reversible acylation of eNOS is thought to contribute to the intracellular trafficking of the enzyme; however, protein factor(s) that govern the translocation of the enzyme are still unknown. Here the authors have used the yeast two-hybrid system and identified a novel 34 kDa protein, termed NOSIP (eNOS interacting protein), which avidly binds to the C-terminal region of the eNOS oxygenase domain. Coimmunopptn. studies demonstrated the specific interaction of eNOS and NOSIP in vitro and in vivo, and complex formation was inhibited by a synthetic peptide of the caveolin-1 scaffolding domain. NO production was significantly reduced in eNOS-expressing CHO cells (CHO-eNOS) that transiently overexpressed NOSIP. Stimulation with the calcium ionophore A23187 induced the reversible translocation of eNOS from the detergent-insol. to the detergent-soluble fractions of CHO-eNOS, and this translocation was completely prevented by transient coexpression of NOSIP in CHO-eNOS. Immunofluorescence studies revealed a prominent plasma membrane staining for eNOS in CHO-eNOS that was abolished in the presence of NOSIP. Subcellular fractionation studies identified eNOS in the caveolin-rich membrane fractions of CHO-eNOS, and coexpression of NOSIP caused a shift of eNOS to intracellular compartments. The authors conclude that NOSIP is a novel type of modulator that promotes translocation of eNOS from the plasma membrane to intracellular sites, thereby uncoupling eNOS from plasma membrane caveolae and inhibiting NO synthesis.
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:789225 CAPLUS
DN 132:73434
TI Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase
AU Wohlfart, Paulus; Malinski, Tadeusz; Ruetten, Hartmut; Schindler, Ursula; Linz, Wolfgang; Schoenafinger, Karl; Strobel, Hartmut; Wiemer, Gabriele
CS Hoechst Marion Roussel, Frankfurt, Germany
SO British Journal of Pharmacology (1999), 128(6), 1316-1322
CODEN: BJPCBM; ISSN: 0007-1188
PB Stockton Press
DT Journal
LA English
AB In this study we examined the endothelium-dependent effect of YC-1-a benzyl indazole derivative which directly activates soluble guanylyl cyclase (sGC) - on vascular relaxation and nitric oxide (NO) and guanosine-3',5'-cyclic monophosphate (cGMP) in endothelial cells. In preconstricted rat aortic rings with intact endothelium, YC-1 produced a concentration-dependent relaxation. However, the concentration response curve was shifted rightward to higher concns. of YC-1, when (i) the aortas were pre-treated with L-NG-nitroarginine methylester (L-NAME) or (ii) the endothelium was removed. Incubation of bovine aortic endothelial cells (BAEC) with YC-1 produced a concentration-dependent NO synthesis and release as assessed using a porphyrinic microsensor. Pre-incubating cells with L-NAME or with 8-bromo-cGMP decreased this effect indicating that the YC-1 stimulation of NO synthesis is due to an activation of nitric oxide synthase, but not to an elevation of cGMP. No direct effect of YC-1 on recombinant endothelial constitutive NO synthase activity was observed The YC-1 stimulated NO release was reduced by 90%, when extracellular free calcium was diminished. In human umbilical vein endothelial cells (HUVEC), YC-1 stimulated intracellular cGMP production in a concentration- and time-dependent manner. Stimulation of cGMP was greater with a maximum concentration of YC-1 compared to calcium ionophore A23187. Similar effects were observed in BAEC and rat microvascular coronary endothelial cells (RMCEC). When HUVEC and RMCEC were pre-treated with L-NG-nitroarginine (L-NOARG), the maximum YC-1 stimulated cGMP increase was reduced by ≥ 50%. These results indicate, that beside being a direct activator of sGC, YC-1 stimulates a NO-synthesis and release in endothelial cells which is independent of elevation of cGMP but strictly dependent on extracellular calcium. The underlying mechanism needs to be determined further.
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:765564 CAPLUS
DN 132:59345
TI Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension
AU Wallerath, Thomas; Witte, Klaus; Schafer, Stephan C.; Schwarz, Petra M.; Prellwitz, Winfried; Wohlfart, Paulus; Kleinert, Hartmut; Lehr, Hans-Anton; Lemmer, Bjorn; Forstermann, Ulrich
CS Departments of Pharmacology, Johannes Gutenberg University Medical School, Mainz, 55101, Germany
SO Proceedings of the National Academy of Sciences of the United States of America (1999), 96(23), 13357-13362
CODEN: PNASA6; ISSN: 0027-8424
PB National Academy of Sciences
DT Journal
LA English
AB Hypertension is a side effect of systemically administered glucocorticoids, but the underlying mol. mechanism remains poorly understood. Ingestion of dexamethasone by rats telemetrically instrumented increased blood pressure progressively over 7 days. Plasma concns. of Na+ and K+ and urinary Na+ and K+ excretion remained constant, excluding a mineralocorticoid-mediated mechanism. Plasma NO2-/NO3- (the oxidation products of NO) decreased to 40%, and the expression of endothelial NO synthase (NOS III) was found down-regulated in the aorta and several other tissues of glucocorticoid-treated rats. The vasodilator response of resistance arterioles was tested by intravital microscopy in the mouse dorsal skinfold chamber model. Dexamethasone treatment significantly attenuated the relaxation to the endothelium-dependent vasodilator acetylcholine, but not to the endothelium-independent vasodilator S-nitroso-N-acetyl-D,L-penicillamine. Incubation of human umbilical vein endothelial cells, EA.hy 926 cells, or bovine aortic endothelial cells with several glucocorticoids reduced NOS III mRNA and protein expression to 60-70% of control, an effect that was prevented by the glucocorticoid receptor antagonist mifepristone. Glucocorticoids decreased NOS III mRNA stability and reduced the activity of the human NOS III promoter (3.5 kilobases) to ~70% by decreasing the binding activity of the essential transcription factor GATA. The expressional down-regulation of endothelial NOS III may contribute to the hypertension caused by glucocorticoids.
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:595576 CAPLUS
DN 132:102607
TI Late treatment with ramipril increases survival in old spontaneously hypertensive rats
AU Linz, Wolfgang; Wohlfart, Paulus; Schoelkens, Bernward A.; Becker, Reinhard H. A.; Malinski, Tadeusz; Wiemer, Gabriele
CS Hoechst Marion Roussel, DG Cardiovascular Diseases, Frankfurt/Main, D-65926, Germany
SO Hypertension (1999), 34(2), 291-295
CODEN: HPRTDN; ISSN: 0194-911X
PB Lippincott Williams & Wilkins
DT Journal
LA English
AB Spontaneously hypertensive rats (SHR) begin to die from cardiovascular complications at ~15 mo of age. We tested whether chronic ACE-inhibitor treatment would extend the lifespan of such old animals. We also studied cardiac hypertrophy and function, endothelial function and expression, and activity of NO synthase (eNOS). One hundred 15-mo-old SHR were randomized into 3 groups, control (n=10), placebo-treated (n=45), and ramipril-treated with an antihypertensive dose of 1 mg·kg-1·d-1 in drinking water (n=45). Ex vivo expts. were performed after 15 mo (control) and 21 mo, when ~80% of the placebo group had died. Late treatment with ramipril significantly extended lifespan of the animals from 21 to 30 mo. Fully established cardiac hypertrophy, observed in placebo-treated animals and in controls, was significantly reversed by ramipril treatment. In isolated working hearts, a significantly improved function associated with increased cardiac eNOS expression was seen vs. placebo and control hearts. Endothelial dysfunction in isolated aortic rings from control and placebo-treated SHR was significantly improved by ACE inhibition and associated with enhanced NO release. Late treatment of SHR with the ACE inhibitor ramipril extended lifespan from 21 to 30 mo, which is comparable to the lifespan of untreated normotensive Wistar-Kyoto rats. This lifespan extension, probably due to blood pressure reduction, correlated with increased eNOS expression and activity followed by a regression of left ventricular hypertrophy and cardiac and vascular dysfunction.
RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:589097 CAPLUS
DN 131:317316
TI Inhibition of Neuronal Nitric Oxide Synthase by 4-Amino Pteridine Derivatives: Structure-Activity Relationship of Antagonists of (6R)-5,6,7,8-Tetrahydrobiopterin Cofactor
AU Froehlich, Lothar G.; Kotsonis, Peter; Traub, Hermann; Taghavi-Moghadam, Shahriyar; Al-Masoudi, Najim; Hofmann, Heinrich; Strobel, Hartmut; Matter, Hans; Pfleiderer, Wolfgang; Schmidt, Harald H. H. W.
CS Department of Pharmacology and Toxicology, Julius-Maximilians University Wuerzburg, Wuerzburg, 97078, Germany
SO Journal of Medicinal Chemistry (1999), 42(20), 4108-4121
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB The family of nitric oxide synthases (NOS) catalyzes the conversion of L-arginine to L-citrulline and nitric oxide (NO), an important cellular messenger mol. which has been implicated in the pathophysiol. of septic shock and inflammatory and neurodegenerative disease states. NOS can be maximally activated by the ubiquitous cofactor, (6R)-5,6,7,8-tetrahydrobiopterin (H4Bip), and antagonists of H4Bip may be of therapeutic importance to inhibit pathol. high NO formation. The 4-amino substituted analog of H4Bip was reported to be a potent NOS inhibitor. Therefore, we developed a series of novel 4-amino pteridine derivs., anti-pterins, to pharmacol. target the neuronal isoform of nitric oxide synthase (NOS-I). To functionally characterize the pterin/anti-pterin interaction and establish a structure-activity relationship (SAR), we systematically altered the substituents in the 2-, 4-, 5-, 6-, and 7-position of the pteridine nucleus. Varying the substitution pattern in the 2-, 5-, and 7-position resulted in no significant inhibitory effect on enzyme activity. In contrast, bulky substituents in the 6-position, such as Ph, markedly increased the inhibitory potency of the reduced 4-amino-5,6,7,8-tetrahydropteridines, possibly as a consequence of hydrophobic interactions within NOS-I. However, this was not the case for the aromatic 4-amino pteridines. Interestingly, chemical modification of the 4-amino substituent by dialkyl/diaralkylation together with 6-arylation of the aromatic 2,4-diamino pteridine resulted in potent and efficacious inhibitors of NOS-I, suggesting possible hydrophilic and hydrophobic interactions within NOS-I. This SAR agrees with (a) the recently published crystal structure of the oxygenase domain of the inducible NOS isoform (NOS-II) and (b) the comparative mol. field anal. of selected NOS-I inhibitors, which resulted in a 3D-QSAR model of the pterin binding site interactions. Further optimization should be possible when the full length structure of NOS-I becomes available.
RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:574712 CAPLUS
DN 131:252629
TI Interactions among ACE, kinins and NO
AU Linz, Wolfgang; Wohlfart, Paulus; Scholkens, Bernward A.; Malinski, Tadeusz; Wiemer, Gabriele
CS Hoechst Marion Roussel, DG Cardiovascular, Frankfurt/Main, D-65926, Germany
SO Cardiovascular Research (1999), 43(3), 549-561
CODEN: CVREAU; ISSN: 0008-6363
PB Elsevier Science B.V.
DT Journal; General Review
LA English
AB A review, with 183 refs., of data dealing with the interaction of ACE expression/activity, kinins, and NO formation/degradation Data is discussed in relation to mol. and biochem. pathways and pathophysiol. relevance.
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:274361 CAPLUS
DN 129:37597
TI Activation of protein kinase Cα and/or ε enhances transcription of the human endothelial nitric oxide synthase gene
AU Li, Huige; Oehrlein, Silke A.; Wallerath, Thomas; Ihrig-Biedert, Irmgard; **Wohlfart, Paulus**; Ulshofer, Thomas; Jessen, Timm; Herget, Thomas; Forstermann, Ulrich; Kleinert, Hartmut
CS Department of Pharmacology, Johannes Gutenberg University, Mainz, 55101, Germany
SO Molecular Pharmacology (1998), 53(4), 630-637
CODEN: MOPMA3; ISSN: 0026-895X
PB Williams & Wilkins
DT Journal
LA English
AB In primary human umbilical vein endothelial cells (HUVECs), incubation with phorbol-12-myristate-13-acetate (PMA) enhanced basal and bradykinin-stimulated nitric oxide production In the HUVEC-derived cell line EA.hy 926, PMA and phorbol-12,13-dibutyrate stimulated endothelial nitric oxide synthase (NOS III) mRNA expression in a concentration- and time-dependent manner. Maximal mRNA expression (3.3-fold increase) was observed after 18 h. NOS III protein and activity were increased to a similar extent. The specific protein kinase C (PKC) inhibitors bisindolylmaleimide 1 (1 μM), Go 6976 [12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo-(2,3-a]pyrrolo-(3,4-c]carbazole] (1 μM), Ro-31-8220 [3-[1-[3-(amidinothio)propyl-1H-inoyl-3-yl]3-(1-methyl-1H-indoyl-3-yl) maleimide methane sulfonate] (1 μM), and chelerythrine (3 μM) did not change NOS III expression when applied alone, but they all prevented the up-regulation of NOS III mRNA produced by PMA. Of the PKC isoforms expressed in EA.hy 926 cells (α, β1, δ, ε, η, ζ, λ, and μ), only PKCα and PKCε showed changes in protein expression after PMA treatment. Incubation of EA.hy 926 cells with PMA for 2-6 h resulted in a translocation of PKCα and PKCε from the cytosol to the cell membrane, indicating activation of these isoforms. After 24 h of PMA incubation, both isoforms were down-regulated. The time course of activation and down-regulation of these two PKC isoforms correlated well with the PMA-stimulated increase in NOS III expression. When human endothelial cells (ECV 304 or EA.hy 926) were transiently or stably transfected with a 3.5-kb fragment of the human NOS III promoter driving a luciferase reporter gene, PMA stimulated promoter activity up to 2.5-fold. On the other hand, PMA did not change the stability of the NOS III mRNA. These data indicate that stimulation of PKCα, PKCε, or both by active phorbol esters represents an efficacious pathway activating the human NOS III promoter in human endothelium.
RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:509337 CAPLUS
DN 125:168036
TI 1,3-Thiazepine-2-amines and their use as inhibitors of the nitric oxide synthase
IN **Strobel, Hartmut**; Bohn, Helmut; Klingler, Otmar; Schindler, Ursula; Schoenafinger, Karl; Zoller, Gerhard
PA Hoechst A.-G., Germany
SO Eur. Pat. Appl., 24 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 718294	A1	19960626	EP 1995-118404	19951123
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
DE 4444930	A1	19960627	DE 1994-4444930	19941216
JP 08231521	A2	19960910	JP 1995-325903	19951214
CA 2165386	AA	19960617	CA 1995-2165386	19951215
PRAI DE 1994-4444930	A	19941216		

OS MARPAT 125:168036
GI



AB The 1,3-thiazepin-2-amines I [W, X, Y, Z = (un)substituted methine] were disclosed and their uses were claimed for the treatment of diseases related to increased nitrogen monoxide levels. Example compds. are 4,5,6,7-tetrahydro-1,3-thiazepin-2-amine hydrochloride (II) and 1,5-dihydro-2,4-benzothiazepin-3-amine hydrochloride (III). The use of 1,3-thiazepine-2-amines as inhibitors of nitrogen oxide synthase was claimed. These compds. are useful for the treatment or prophylaxis of a pathol. decrease in blood pressure related to septic shock or cancer treatment with cytokines. These compds. were also claimed for the treatment or prophylaxis of inflammatory diseases, such as ulcerative colitis, and for the treatment or prophylaxis of damage related to infarction and tissue reperfusion and for the treatment of graft-vs.-host disease. The use of these 1,3-thiazepin-2-amines for the treatment of nervous system diseases, such as Alzheimer, migraines, and epilepsy was also claimed.

L12 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:417899 CAPLUS
DN 125:67775
TI 2-Amino-1,3-thiazines as nitric oxide synthase inhibitors
IN **Strobel, Hartmut**; Bohn, Helmut; Klemm, Peter; Klingler, Otmar; Schindler, Ursula; Schoenafinger, Karl; Zoller, Gerhard
PA Hoechst A.-G., Germany
SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 713704	A1	19960529	EP 1995-117500	19951107
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
DE 4442116	A1	19960530	DE 1994-4442116	19941125
JP 08239369	A2	19960917	JP 1995-304474	19951122
CA 2163724	AA	19960526	CA 1995-2163724	19951124
PRAI DE 1994-4442116	A	19941125		

OS MARPAT 125:67775
AB Ring-substituted 2-amino-1,3-thiazines are NO synthase inhibitors useful for treatment of diseases characterized by elevated NO levels, e.g. hypotension, rheumatoid arthritis, ulcerative colitis, diabetes mellitus, and transplant rejection. Thus, 2-amino-6-phenyl-5,6-dihydro-4H-1,3-thiazine-HCl was prepared by refluxing 3-amino-1-phenyl-1-propanol with tert-Bu isothiocyanate. Tablets were prepared containing active ingredient 40, lactose 600, corn starch 300, soluble starch 20, and Mg stearate 40 mg.

L12 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:841375 CAPLUS
DN 123:247588
TI Angiotensin II receptor subtype-stimulated formation of endothelial cyclic GMP and prostacyclin is accompanied by an enhanced release of endogenous kinins
AU Korth, Petra; Fink, Edwin; Linz, Wolfgang; Schoelkens, Bernward A.; **Wohlfart, Paulus**; Wiemer, Gabriele
CS PGU Cardiovascular Agents, Hoechst AG, Frankfurt/Main, Germany
SO Pharmaceutical and Pharmacological Letters (1995), 5(3), 124-7
CODEN: PPLEE3; ISSN: 0939-9488
PB Medpharm Scientific Publishers
DT Journal
LA English
AB In cultured bovine aortic endothelial cells angiotensin II (ANG II) enhances the release of endogenous kinins, which is contemporarily associated with increases in nitric oxide (assessed by intracellular cyclic GMP) and prostacyclin. The ANG II-induced cGMP production was inhibited by either the ANG II subtype AT2 receptor antagonists CGP 42112 A and PD 123 177 or the AT1 receptor antagonist MSD L-158,809. In contrast the AT1 receptor antagonists HR 720, S92 0029, S92 0363 and EXP 3174 had no or only minor inhibitory potency. Thus, the ANG II-induced endothelial release of kinins which in turn stimulates endothelial autacoid formation may contribute to the observed vasodilatory effects of ANG II. The ANG II receptor subtype which is responsible for these effects remains unknown.

L12 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:273700 CAPLUS
DN 122:46103
TI Furosemide enhances the release of endothelial kinins, nitric oxide and prostacyclin
AU Wiemer, Gabriele; Fink, Edwin; Linz, Wolfgang; Hropot, Max; Scholkens, Bernward A.; Wohlfart, Paulus
CS Department Clinical Chemie Clinical Biochemie, University Munchen, Munchen, Germany
SO Journal of Pharmacology and Experimental Therapeutics (1994), 271(3), 1611-15
CODEN: JPETAB; ISSN: 0022-3565
PB Williams & Wilkins
DT Journal
LA English
AB Despite a wealth of data, the mechanism of the direct dilator effect of furosemide on the systemic arterial and venous systems is far from being satisfactorily understood. Therefore, the authors investigated whether furosemide is capable of stimulating the production of the endogenous vasodilators nitric oxide and prostacyclin in primary cultured bovine aortic endothelial cells by an enhanced synthesis and release of endothelium-derived kinins. Nitric oxide production was assessed in terms of intracellular guanosine cyclic-3',5' monophosphate accumulation; kinin and prostacyclin release were determined by specific RIAs. Furosemide concentration- and time-dependently increased the formation of nitric oxide and prostacyclin. Maximal increases of both autacoids were already obtained after a 5-min incubation with 3+10-7 to 10-6 mol/L of furosemide. In the same concentration range, furosemide led to an enhanced release of kinins into the supernatant of the cells. This observation was supported by the inhibitory effect of the specific B2 kinin receptor antagonist icatibant (Hoe 140) on the furosemide-induced increase of nitric oxide and prostacyclin. Thus the hemodynamic effects of furosemide, in particular the direct early dilator effect, may be explained in part by an enhanced endothelial synthesis and release of bradykinin and related kinins, which in turn stimulates endothelial autacoid formation via B2 kinin receptor activation.

```
=> d his full

     (FILE 'HOME' ENTERED AT 14:18:59 ON 09 JAN 2006)

     FILE 'REGISTRY' ENTERED AT 14:19:08 ON 09 JAN 2006
L1             STRUCTURE UPLOADED
               D
L2              50 SEA SSS SAM L1
L3            9180 SEA SSS FUL L1

     FILE 'CAPLUS' ENTERED AT 14:20:12 ON 09 JAN 2006
L4             490 SEA ABB=ON  PLU=ON  L3
L5             366 SEA ABB=ON  PLU=ON  L4 AND PY<2003
L6               0 SEA ABB=ON  PLU=ON  L5 AND (NITRIC OXIDE)
L7             211 SEA ABB=ON  PLU=ON  L5 AND PATENT/DT
                   D QUE L7 STAT
                   D 1-211 BIB ABS HITSTR
                   E STROBEL HARTMUT/AU
L8              27 SEA ABB=ON  PLU=ON  "STROBEL HARTMUT"/AU
                   E WOHLFART PAULUS/AU
L9              28 SEA ABB=ON  PLU=ON  ("WOHLFART PAULUS"/AU OR "WOHLFART PAULUS
                   W"/AU)
                   E BELOW PETER/AU
L10             23 SEA ABB=ON  PLU=ON  "BELOW PETER"/AU
L11             67 SEA ABB=ON  PLU=ON  L8 OR L9 OR L10
L12             20 SEA ABB=ON  PLU=ON  L11 AND (NITRIC OXIDE)
                   D QUE L12 STA
                   D 1-20 BIB ABS


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:    8 JAN 2006  HIGHEST RN 871465-69-9
     DICTIONARY FILE UPDATES:   8 JAN 2006  HIGHEST RN 871465-69-9

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     ************************************************************
     *                                                          *
     * The CA roles and document type information have been removed from *
     * the IDE default display format and the ED field has been added,   *
     * effective March 20, 2005.  A new display format, IDERL, is now    *
     * available and contains the CA role and document type information. *
     *                                                          *
     ************************************************************

     Structure search iteration limits have been increased.  See HELP SLIMITS
     for details.
```

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE CAPLUS

FILE COVERS 1907 - 9 Jan 2006 VOL 144 ISS 3
FILE LAST UPDATED: 8 Jan 2006 (20060108/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=>